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Abstract 
Surgery necessitating cardiopulmonary bypass (snCPB) is associated with systemic 
inflammation which can be severe. Systemic inflammation is common in the critically ill, is 
associated with adverse outcome and currently has no specific therapy. Insight into the 
pathogenesis of systemic inflammation may lead to therapies. The receptor for advanced 
glycation end-products (RAGE) may represent a novel target for intervention.  
RAGE is a ubiquitous multi-ligand receptor that is up-regulated in the presence of its ligands. 
Initially characterised as a receptor for glycated proteins, it is also binds the S100 proteins 
and high mobility group box 1 (HMGB1); causing pro-inflammatory responses via NF-κB and 
the MAP kinases. RAGE inhibition has been associated with improved outcomes in animal 
models of infectious and sterile systemic inflammation. 
Of the snCPB patients assessed (n=2440) for relationships between age (associated with 
RAGE up-regulation) with systemic inflammation and clinical outcome, the oldest patients 
met more SIRS criteria in the first 1h and 24h following snCPB than those aged 40-80 y. This 
was accompanied by higher scores of organ dysfunction. Also, plasma levels of RAGE ligands 
and soluble RAGE increased (n=18-120) around surgery with pre-operative levels correlating 
with duration of intensive care. Leukocyte cell-surface and intracellular levels of RAGE were 
assessed and cell surface levels on neutrophils decreased following surgery, possibly 
contributing to the sRAGE levels in plasma. Cytokine release from whole blood increased 
following incubation with RAGE ligands, with a diminished effect on whole blood obtained 
after snCPB, suggesting leukocyte hypo-responsiveness. Finally, genotyping 8 single 
nucleotide polymorphisms in the RAGE, HMGB1 and S100A8 genes in 187 snCBP patients 
indicated statistically significant relationships to clinical outcomes such as impaired 
oxygenation and incidence of acute kidney injury.   
The findings from these investigations, inform understanding of the involvement of the 
RAGE axis in systemic inflammation. 
293 words (<300)  
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1. CARDIAC SURGERY AND THE INFLAMMATORY RESPONSE 
1.1. Cardiac surgery 
1.1.1. Historical perspective 
In the modern era, cardiac surgery is a safe and accepted treatment for a range of 
conditions, with more than 30,000 patients having cardiac surgery per year in the UK alone 
[7, 8]. However, the practice of surgery on the heart is a relatively recent development. 
Prior to the development of effective cardiopulmonary bypass (CPB), cardiac surgery was 
largely confined to a few enthusiasts performing a limited range of procedures with highly 
variable success rates [9, 10]. The limiting factors were movement of the heart and 
overwhelming bleeding if the chambers were opened. The heart-lung machine or 
cardiopulmonary bypass (CPB) was conceived and built by Dr John Gibbon; to provide the 
surgeon with a motionless and bloodless operating field whilst maintaining the supply of 
oxygenated blood to the patient. Gibbon’s machine was first used successfully in an 18 year-
old with an atrial septal defect in 1953 [11]. Unfortunately, Gibbon’s next four patients died 
and he abandoned surgery using CPB. During this hiatus, innovators developed cross-
circulation techniques to treat congenital heart defects in children by connecting them to 
the circulation of their parents, blood group compatibility permitting; which met with 
considerable success [12]. Cross-circulation was superseded by the development of a 
modification of Gibbon’s machine and by the end of 1956 open-heart surgery was being 
offered around the world [13]. The safety of CPB greatly improved over the following few 
decades. Concurrent with this, the range of potential applications of ‘open-heart’ surgery 
increased to include valve repairs and replacement, coronary artery bypass grafting (CABG), 
surgery on the aorta, and correction of congenital defects [10]. 
1.1.2. Modern CPB 
Cardiopulmonary bypass describes the diversion of the patient’s circulation around their 
heart and lungs, into a circuit in which gas exchange occurs and via which newly arterialised 
blood is returned to the patient; a diagrammatic illustration is shown (Figure 1).  
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Figure 1: Highly simplified diagram illustrating key components of the cardiopulmonary bypass circuit 
Prior to the initiation of CPB, the patient is anticoagulated using heparin to prevent 
thrombus formation [14]. The systemic blood is drained from the inferior vena cava via a 
plastic cannula into the venous reservoir. Additional blood enters the CPB circuit from vents 
and suction; systems which collect shed mediastinal blood to reduce blood transfusion 
requirements. Blood is drawn from the reservoir through an oxygenator (which also removes 
carbon dioxide) by a pump, and the temperature is adjusted. Patients are routinely cooled 
during surgery to reduce the metabolic requirements of tissues, including the brain and 
myocardium, that will temporarily be receiving diminished perfusion [15, 16]; they are re-
warmed prior to cessation of CPB. The newly oxygenated blood is passed through a particle 
filter and bubble trap before returning to the patient via a cannula inserted into the aorta at 
an appropriate pressure and flow. The aortic cannula is sited above the level of a clamp 
placed across the aorta which restricts the flow of blood to the aortic root and therefore 
stops blood entering the coronary arteries or flowing back through the aortic valve into the 
left ventricle. During CPB, cardioplegia solution is instilled into the coronary circulation in 
order to minimise myocardial oxygen consumption and reduce the accumulation of toxic 
metabolites. 
Important developments in CPB technology have included the use of circuits and oxygenator 
membranes than are heparin-bonded and bio-compatible, the inclusion of filters, improved 
efficiency of the oxygenators and monitoring such as real-time blood gas analysis and near-
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patient coagulation assessment, controlled hypothermia and re-warming, and advances in 
the performance of the pumps and anticoagulation (and its reversal). 
1.1.3. Complications of snCPB 
Modern surgery necessitating CPB (snCPB) is safe; in the UK those having had a CABG have a 
30-day survival of 98.4% [8]. However, there are many possible complications including 
cerebral or myocardial ischaemia, or bleeding requiring blood transfusion or further surgery. 
There are also complications that develop following progression of the common 
physiological derangements seen in the immediate post-operative period. In the vast 
majority of cases such derangements resolve without consequence and recovery is rapid. In 
a minority, organ failures develop that may lead to death or prolonged illness; which is 
associated with poor functional outcome, low quality of life and increased mortality [17-19]. 
CPB also causes systemic inflammation that is a major contributor to the development of 
acute organ failures [20].  
1.1.4. Systemic inflammation and CPB 
Systemic inflammation due to CPB develops through a variety of mechanisms. Firstly, during 
bypass the heart and lungs are ischaemic. Upon reinstitution of circulation the phenomenon 
of ischaemia-reperfusion injury occurs, resulting in the release of reactive oxygen species 
(ROS) and pro-inflammatory mediators (e.g. cytokines). Secondly, activation of leukocytes, 
platelets, the complement and clotting cascades, and release of other inflammatory 
mediators may occur following the direct contact of blood with the extracorporeal bypass 
circuitry. Thirdly, relative hypoperfusion of the splanchnic bed, both intra- and post- 
operatively, may lead to gut wall ischaemia, an increase in villous capillary permeability and 
translocation of enteral bacteria and bacterial antigens into the systemic circulation (Section 
2.3). Finally, it is recognised that haemolysis occurring in the CPB circuit and following the 
routine suction and transfusion of mediastinal shed blood may contribute to inflammatory 
responses [20, 21]. These mechanisms are illustrated in Figure 2. 
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Figure 2: Diagram illustrating proposed mechanisms in the pathogenesis of systemic inflammation following CPB 
In recent years, cardiac operative procedures have been developed that can take place 
without CPB. However, off-pump coronary artery bypass (OPCAB) has not yet seen its 
theoretical advantages reflected in improved outcomes [22]. A large number of, mostly 
small and uncontrolled, studies have compared different aspects of the inflammatory 
response between traditional CABG and OPCAB techniques. The off-pump technique is 
associated with less elevation of some pro-inflammatory cytokines and acute phase proteins 
in the immediate post-operative period; however, after this time the differences disappear 
and thus are of uncertain significance [23, 24]. By-products of the development of CPB 
technology include ventricular assist devices (VADs) used for severe myocardial failure, and 
extracorporeal membrane oxygenation (ECMO) used for severe respiratory failure. VADs 
now represent possible destination therapy for selected patients with end-stage cardiac 
failure [25] and ECMO can be used as temporary support to facilitate oxygenation during 
reversible severe acute pulmonary failure, as seen during the 2009 H1N1A/Influenza 
pandemic [26, 27]. 
1.2. Sepsis, SIRS and systemic inflammation 
The concept of sepsis is ancient, the word being derived from the ancient Greek word sepo 
(σηπω), which means “I rot” [28]. Hippocrates (460-370BC) recognised fever as a major 
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symptom but it was Celsus (25BC-50AD) who described the four cardinal signs of 
inflammation as: rubor (redness), tumor (swelling), calor (heat) and dolor (pain) [29]. In 
2011, sepsis remains the single most important cause of morbidity and mortality in the 
intensive care unit (ICU). 
Modern use of the term sepsis varied prior to the development of consensus definitions for 
sepsis and its related conditions at a conference of the American College of Chest Physicians 
and the Society of Critical Care Medicine (ACCP/SCCM) in 1991  [1, 30]. The aims of 
standardizing and defining these terms were to enable clinicians and researchers to be more 
consistent in diagnosis, monitoring and treatment and to facilitate research in the 
investigation and management of sepsis and its related conditions. The term ‘systemic 
inflammatory response syndrome’ (SIRS) was introduced to describe the inflammatory 
process common to both sepsis and the similar clinical condition of inflammatory response 
following non-infectious insults such as pancreatitis, CPB, burns injury or trauma. 
SIRS is defined by acute alterations from baseline in two or more physiological parameters 
in the absence of any known cause for the abnormalities. These are temperature, heart 
rate, respiratory rate and white cell count. Sepsis is defined as SIRS due to confirmed 
infection and is clinically distinct from SIRS alone. Progressively more compromising sepsis is 
known as ‘severe sepsis’ when organ dysfunction is present, and ‘septic shock’ when there is 
hypotension resistant to fluid resuscitation (Table 1). Together these conditions are termed 
the sepsis syndromes and the relationships between infection, bacteraemia, sepsis and SIRS 
(and some causes) are demonstrated in Figure 3. 
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Colonisation Presence of micro-organisms with no host response 
Infection Microbial phenomenon characterised by an inflammatory response 
to the presence of microorganisms or the invasion of normally sterile 
host tissue by those organisms. 
Bacteraemia The presence of viable bacteria in the blood 
Systemic 
Inflammatory 
Response Syndrome 
(SIRS) 
The response is manifested by two or more of the following: 
 Temperature > 38°C or < 36°C 
 Heart rate > 90 beats per minute (min) 
 Respiratory rate >20 breaths/min or PaCO2 < 32mm Hg 
(4.3kPa) 
 White blood cell count > 12,000 cells /mm3, < 4,000 
cells/mm3 or >10 % immature (band) forms. 
Sepsis The systemic response to infection.  SIRS with documented infection 
Severe sepsis Sepsis associated with organ dysfunction, hypoperfusion or 
hypotension. Hypoperfusion and perfusion abnormalities may 
include, but are not limited to lactic acidosis, oliguria or an acute 
alteration in mental status. 
Septic shock Sepsis with arterial hypotension despite adequate fluid resuscitation 
along with the presence of perfusion abnormalities. Patients who are 
on inotropic or vasopressor support may not be hypotensive at the 
time that perfusion abnormalities are measured. 
Sepsis induced 
hypotension 
A systolic blood pressure <90mmHg or a reduction of >40 mmHg 
from baseline in the absence of other causes of hypotension. 
Multiple organ 
dysfunction 
syndrome (MODS) 
Altered organ function in an acutely ill patient such that homeostasis 
cannot be maintained without intervention. 
Table 1: Definitions of the sepsis syndromes [1] 
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Figure 3: Relationship between infection, bacteraemia, sepsis and SIRS [1] 
Sepsis is a common problem, affecting more than 750,000 patients in United States each 
year [31]. In the UK, an estimated 31,000 patients were admitted to intensive care units 
(ICUs) with sepsis in 2004 [32].  
A European survey of the prevalence and outcomes of sepsis in the ICU (the SOAP study) 
revealed it to be present on ICU admission in 66% of patients [33]. The commonest sites for 
infection during the ICU stay were lung (68%), abdomen (22%), blood (20%) and urinary 
tract (14%). The overall European ICU and hospital mortality rates were 27% and 36% 
respectively; rates for the UK were 32% and 41%, respectively. Organ failure occurred in 
71% and there was a direct relationship between the number of organs failing and ICU 
mortality rate [33]. 
A further analysis of the SOAP study examined specifically the relationship between SIRS 
criteria and outcome in those with and without infection. In the latter, 82.2% of ICU patients 
had SIRS (≥2 criteria met), with increasing ICU mortality with the number of criteria met: 2 
criteria (10.0%), 3 criteria (19.0%), all criteria (25.0%); there was also an overall increase in 
organ system failure as the number of SIRS criteria increased from two to three but not to 
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four. In those ICU patients with infection on ICU, SIRS was universally present and increasing 
number of SIRS criteria was associated with increased organ failure, prolonged length of 
stay and increased mortality [34]. 
Key findings of an influential review of published cohort studies examining the epidemiology 
of the sepsis syndromes were the very high incidence of SIRS in ICU patients (>50%) and the 
increasing 28-day mortality from SIRS (10%) to sepsis (20-25%) to severe sepsis (20-40%) to 
septic shock (40-70%) [30]. The prognosis of the sepsis syndromes, is also related to the 
nature of underlying disease and the severity of the inflammatory response and its 
sequelae, reflected clinically as shock and organ system failure [30]. 
The ACCP/SCCM definitions have been accepted within the critical care community and 
despite robust criticism and a further consensus conference (2001) have not been revised 
[35, 36]. Criticisms include being overly sensitive and therefore unsuitable as a trial entry 
criterion, not reflecting disease severity, not helping understand pathophysiology, and 
failing to define a distinct pattern of host response to injury [30, 36]. 
1.2.1. Modern management of the sepsis syndromes 
Consensus guidelines on the management of severe sepsis and septic shock were first 
published in 2004 and revised in 2008 [37, 38]. The guidelines are comprehensive and cover 
all aspects of therapy. The least controversial recommendations for initial treatment are for 
the early administration of broad spectrum antibiotics (following drawing blood for culture) 
and intravenous fluids, prompt confirmation of the source of the infection and source 
control measures if appropriate, and use of vasoactive drugs to increase persistently low 
blood pressure following adequate fluid resuscitation. Together these therapies represent 
the key components of optimal ‘supportive’ therapy. Other recommendations include the 
use of early goal-directed therapy, measurement of serum lactate concentration, specific 
haemodynamic targets for resuscitation and time targets for administration of antibiotics 
(<1h from clinical presentation). The revised guideline recommends administration of 
activated protein C to patients with severe sepsis and a high risk of death (in the absence of 
recent surgery) and intravenous hydrocortisone for septic shock when hypotension 
responds poorly to adequate fluid resuscitation and vasopressors. 
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The clinical manifestations of SIRS in the absence of infection may be identical to SIRS of 
infectious origin, and the level of organ support required may be similar. In the absence of 
clinical trial data specifically obtained from non-infected patients, clinical management is 
identical to the ‘supportive’ care described above, with the exception of use of anti-
microbial drugs. 
Despite initially promising pre-clinical studies, no immunomodulatory therapies for the 
treatment of the sepsis syndromes have entered routine clinical practice [39].  
1.2.2. Complications of the sepsis syndromes 
All organ systems are susceptible to dysfunction or failure due to the onset and progression 
of the sepsis syndromes, but only the commonest requiring specific therapy on the ICU will 
be reviewed. These relate to the pulmonary, renal and cardiovascular systems. 
1.2.2.1. Acute lung injury 
Systemic inflammation, whether caused by infection or injury, commonly results in acute 
lung injury (ALI) and its extreme manifestation, the acute respiratory distress syndrome 
(ARDS). A recent prospective study examining risk factors found 6% of patients with sepsis, 
8% with pneumonia and 17.8% with undifferentiated ‘shock’ developed ALI [40].  
ALI is defined by refractory hypoxaemia due to non-cardiogenic pulmonary oedema, in the 
presence of a known predisposing factor. A joint American–European Consensus Conference 
on ARDS formally defined ALI and ARDS as acute severe respiratory distress of sudden 
onset; bilateral infiltrates on frontal chest radiograph, in the absence of left atrial 
hypertension (a pulmonary capillary wedge pressure less than 18mmHg or no clinical signs 
of left ventricular failure); but with severe hypoxemia (assessed by the PaO2/FiO2 ratio, 
PFR)[41]. ALI exists when the PFR is <300mmHg (40kPa) and ARDS when it is <200mmHg 
(26kPa). The definitions have been subject to much debate but have yet to be revised [42]. 
Pathologically, ALI is characterised by alveolar inflammation and injury leading to increased 
pulmonary capillary permeability. The syndrome is known to evolve through exudative, 
inflammatory, and fibroproliferative phases, usually over two to three weeks. The clinical 
consequences are impaired gas exchange with refractory hypoxaemia attributable to 
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ventilation-perfusion mismatch; physiological shunting, atelectasis of lung units, and 
reduced compliance [43].  
The treatment of ALI includes management of the precipitating condition and maintenance 
of acceptable gas exchange without adversely contributing through the application of 
excessive ventilation (ventilator-induced lung injury, VALI). Therefore ‘lung-protective’ 
ventilation with small tidal volumes and appropriate levels of positive end-expiratory 
pressure (PEEP) is the cornerstone of what remains supportive management [44]. 
Conservative fluid replacement is associated with significantly shortened duration of 
mechanical ventilation and intensive care unit stay without increasing non-pulmonary organ 
failures [45]. Early neuromuscular blockade has recently been associated with significantly 
improved mortality, possibly by indirectly minimizing various manifestations of VALI [46]. 
Techniques generally reserved for refractory cases (‘rescue’ therapies) include inhaled nitric 
oxide (NO), placing the patient prone, high frequency oscillatory ventilation (HFOV), and 
ECMO [47]. There is no effective pharmacological intervention for ALI [48]; corticosteroid 
administration remaining controversial [49]. 
The associated mortality has been reported to lie between 15-72% and analyses of change 
in mortality over time are discrepant [50, 51]. Mortality is partly dependent upon the nature 
of the underlying precipitant. 
1.2.2.2. Acute kidney injury 
Acute kidney injury (AKI) is common (36-73%) amongst critically ill patients, measures of 
incidence varying according to which definitions are used and the specific population [52]. 
Sepsis, and particularly septic shock, is the commonest cause of AKI in ICU patients [53]. 
Mortality attributable to AKI, as opposed to the precipitating condition, increases in 
proportion to its severity. Severe AKI necessitates the use of renal replacement therapy 
(RRT) and mortality may be as high as 70-90%. Even small increases in serum creatinine are 
associated with increased mortality [54]. The mechanisms responsible for the increased 
mortality and morbidity risks are elusive [52].  
1.2.2.3. Cardiovascular failure 
The cardiovascular dysfunction that frequently accompanies the sepsis syndromes is 
vasodilatory shock with relative and absolute hypovolaemia, myocardial depression and 
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altered distribution of blood flow. Vasodilatation is due to decreased ability of vascular 
smooth muscle to contract, causing hypotension that may be refractory to standard 
catecholamine therapy. This may be due to endogenous overproduction of NO and 
adrenoceptor desensitization, potentially attributable to high circulating levels of 
catecholamines [55]. There is relative and absolute hypovolaemia such that even after the 
restoration of circulating volume, there remains maldistribution of cardiac output with 
perturbations in microvascular flow [56, 57]. Up to 50% of those with prolonged septic 
shock have myocardial depression, as defined by depressed ejection fraction with 
ventricular dilatation on echocardiography [58]. 
Management of cardiovascular failure relies upon optimisation of intravascular volume 
status, may require use of vasoconstrictor drugs to increase vascular tone and thus systemic 
blood pressure, or the use of positive inotropes to increase cardiac output [57, 59]. The 
optimal means of assessing the circulation, cardiac output and adequacy of resuscitative 
efforts are beyond the scope of this thesis. 
1.2.3. Post snCPB SIRS and sequelae 
Systemic inflammation is common following snCPB; the incidence of SIRS having been 
reported to be between 28% and 63% [60-63].  Complications of post-snCPB SIRS are 
common. In a recent prospective cohort study the incidence of ALI following snCPB was 
10.2% [40], with earlier estimates of the incidence of post-snCPB ARDS of 0.5-2.5% [64-67]. 
The incidence of AKI following snCPB varies by use of definitions, however a recent large 
retrospective study from RBH identified AKI in 25.9% of all patients within the first 7d of 
surgery (AKIN stage 1 or more) [68]; similar studies have demonstrated associations 
between severity of AKI and adverse outcome [69]. 
A common complication following snCPB is cardiovascular failure which is often 
multifactorial in aetiology. Pathological vasodilatation (vasoplegia) is common, with an 
incidence reported to be 5-44%, and may require high doses of vasoconstrictors [70, 71]. 
Post-operative myocardial dysfunction may be due to operative factors, the effects of 
systemic inflammation and the contribution of pre-operative impairment, with an incidence 
reported to be 3.9-9.1%. Operative factors include myocardial ischaemia due to prolonged 
cross-clamp time and inadequate myocardial protection, incomplete revascularisation or 
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graft failure, reperfusion injury, and hypothermia [72-74]. Management of post-snCPB 
myocardial failure may include intra-aortic balloon counter-pulsation, selective pulmonary 
vasodilators, and ventricular assist devices in refractory cases. 
1.2.3.1. Therapeutic approaches 
There are currently no pharmacological interventions that have unequivocally been shown 
to improve clinical outcomes following snCPB. However, this remains a highly sought-after 
goal, reflected in the multitude of current/recent trials registered with clinicaltrials.gov. A 
selection are summarised in Table 2. 
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Redox/nutrition 
 
Inflammation/clotting 
 
Process/technique 
 
N-Acetylcysteine  
 
AP214 (α-melanocyte-stimulating hormone 
analogue)  
Perioperative haemodynamic 
optimization  
 
20% human albumin 
solution  
 
TP10, complement inhibitor  
 
Hypertonic saline with 
hetastarch 
 
Fish oil emulsion  Pexelizumab (monoclonal antibody targeted 
against component 5 of the complement system)  
 
Use of cell-saver vs. non-cell 
saver suction 
 
Selenium peri-op  Lactobacillus probiotic administration pre-
operatively 
sevoflurance vs.propofol 
 
n-3 enriched nutrition 
therapy peri-op 
 
Ulinastatin (protease inhibitor) and Tranexamic 
Acid during CPB  
 
 
Ascorbic acid pre and 
post-op 
 
Atorvastatin pre-op  
 
 
 Peri-op ACE inhibitor or ARB  
 
 
 Bovine Intestinal Alkaline Phosphatase (Anti-LPS) 
peri-op infusion  
 
   
   
Table 2: Summary of registered trials (clinicaltrials.gov on 29/11/10) of interventions for snCPB with markers of systemic 
inflammation as a primary or secondary endpoint. Grouped by putative mechanism of action. 
Many anti-inflammatory therapies have been evaluated as potentially useful adjuncts to 
standard care. Firstly, corticosteroids are used in many acute and chronic inflammatory 
conditions and have multiple actions including suppression of leukocyte-mediated 
inflammation. In the 1960s these were introduced into clinical practice as an anti-
inflammatory prophylactic therapy for post-snCPB SIRS, and there followed a series of 
investigations showing seemingly beneficial effects on levels of circulating mediators and 
organ function but with mixed results on clinical outcomes. To date there remains no 
consensus on their use in this setting [75, 76]. 
Secondly, a non-specific protease inhibitor named aprotinin (trade name Trasylol) was 
incorporated into routine clinical use in cardiac surgery during the 1990s. Its actions were 
mediated by the inhibition of complement activation and fibrinolysis (the break-down of 
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products of coagulation) and it therefore promoted haemostasis and reduced peri-operative 
bleeding.  Additionally it possesses broad anti-inflammatory properties and in vitro data 
suggested it would limit the development of SIRS responses post-operatively [77-81]. 
However, over the following decade reports of increased complications culminated in two 
large multi-centre RCT that found use of aprotinin was associated with significantly 
increased short and long-term mortality [82, 83] and despite a meta-analysis showing 
contrary findings [84], led to withdrawal of the drug. 
Pharmacological strategies that have yet to provide evidence of clinical benefit but remain 
under investigation include anti-oxidants, statins, anti-arrhythmics, complement inhibitors, 
and phosphodiesterase inhibitors. Non-pharmacological treatments that currently have 
insufficient clinical trial data to support their use include leukocyte filtration and endotoxin 
absorption [85-88]. 
1.3. Assessing the severity of systemic inflammation  
There are several methods of measuring the severity of systemic inflammatory response, all 
with specific advantages and limitations. An ideal biomarker would vary in proportion to the 
severity of inflammation and any therapy, be highly specific and sensitive, add independent 
prognostic information, have biological plausibility and potentially identify patient 
subgroups that would benefit from specific interventions. Further desirable characteristics 
would include low cost, rapid results and high reproducibility. 
In the specific context of measuring systemic inflammation following snCPB, an 
International expert committee met and reported in 2008 [89]. In this report the limitations 
of applying standard SIRS criteria were discussed and a division drawn between markers 
likely to be causally involved in the systemic inflammatory process (e.g. levels of circulating 
pro-inflammatory cytokines), and clinical end-points (e.g. ICU length of stay, LOS) or markers 
of organ dysfunction. A recommendation was made that both types are reported with a 
strong emphasis on the clinical end-points, including ICU LOS [89]. 
1.3.1. Clinical assessment 
The parameters assessed when determining SIRS criteria are purposely readily observable 
clinically (temperature, heart rate and respiratory rate) and incorporate one laboratory 
result (white blood cell count). The SIRS criteria were designed to be highly sensitive but not 
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to reflect severity. Therefore, the individual parameters cannot be expected to vary in 
proportion to extent of systemic inflammation, nor should the number of SIRS criteria met 
be considered proportionate to its extent. Furthermore, each of the defining parameters 
can be altered by factors unrelated to systemic inflammation. For example, tachycardia can 
be masked by the use of beta blockers or induced by the use of a cardiac pacemaker, 
tachypnea altered by the use of invasive mechanical ventilation, and the febrile response is 
frequently impaired or obfuscated by concurrent heat losses, deliberate cooling or anti-
pyretic drugs.  
These limitations may restrict the validity of conclusions drawn regarding the extent of 
systemic inflammation based on these parameters in an individual patient. Although when 
considering a large population of patients this is not the case; as previously discussed, in a 
large observational study increased numbers of SIRS criteria met was related to increased 
organ failure and mortality, irrespective of the presence of infection [34]. 
1.3.2. Scoring systems 
Scoring systems have been developed to quantify the severity of illness and extent of organ 
failure. The most widely used is the Acute Physiology and Chronic Health Evaluation 
(APACHE) II score. Simpler systems include Multiple Organ Dysfunction Score (MODS [90]), 
the New Simplified Acute Physiology Score (SAPS II [91]), and Sequential Organ Failure 
Assessment (SOFA [92]) scores. All have been validated in cardiac surgical patients [93-97]. 
The Euroscore has been designed specifically for cardiac surgery; it uses clinical and 
operative variables to predict early mortality and allows risk-adjusted comparison between 
surgical populations [98]. 
Scoring systems are useful for predicting mortality and in some cases, duration of ICU LOS 
and mechanical ventilation, as an indicator of quality of care, by comparing observed with 
predicted outcome, and for benchmarking to aid comparison between ICUs. They are not 
intended to guide individual patient management as calculated probabilities of mortality are 
valid only for populations, not individuals [99, 100]. 
1.3.3. Plasma assays 
CRP, an acute-phase protein, is an exquisitely sensitive systemic marker of inflammation and 
tissue damage. The 99th centile of plasma CRP in healthy adults is 10mg/l. It is produced by 
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hepatocytes, predominantly under transcriptional regulation by IL-6. Synthesis starts rapidly 
following a stimulus, reaching a peak around 48h. The biological role of CRP is to bind a 
range of ligands, autologous and extrinsic, and promote phagocytosis and initiation of the 
complement cascade [101]. The major shortcoming in use of CRP is the delay between the 
onset of inflammatory stimulus and peak plasma levels. 
An elevated white blood cell (WBC) count, or more specifically, neutrophil count, is an 
accepted, simple and established marker of inflammation or infection, but which has major 
limitations to its use as a marker of extent of systemic inflammation. Concurrent bone 
marrow failure or a ‘toxic left shift’ phenomenon (bone marrow stimulation resulting in 
release of immature neutrophil precursors) will reduce the numbers of circulating 
neutrophils in spite of infection. The extent of elevated neutrophil count (neutrophilia) may 
fluctuate during the course of illness or be elevated in the absence of inflammation, by 
procedures such as splenectomy, medications such as corticosteroids or conditions such as 
malignancy. Moreover, neutrophilia is insensitive for discriminating systemic response to 
infection from localised infections [102, 103]. 
A more recently identified marker of inflammation is procalcitonin (PCT); a pro-hormone 
peptide secreted by non-neuroendocrine cells in response to infection or inflammation. 
Levels rise within 2-4h of any stimulus, peaking at 8-24h and remaining elevated as long as 
the inflammation continues. Despite the tendency for PCT to rise massively above minimum 
detectable levels, there are multiple reports of patients with severe inflammatory illnesses 
with serum levels <2ng/ml or even <0.5ng/ml (the indeterminate level of the common 
LUMItest assay). Thus, a lack of sensitivity and specificity limit its clinical use [104].  
Levels of systemic pro- and anti- inflammatory cytokines may be assayed and in the context 
of snCPB have been demonstrated to be raised in numerous studies [105-109]. Circulating 
cytokine levels in patients with sepsis relate to the development of organ dysfunction and 
death [110] and may augment traditional scoring systems [111, 112]. However, no such 
relation to organ failure and outcome has been demonstrated in patients following snCPB 
[113]. Cytokine assays have not entered routine clinical use, probably due to the expense 
and lack of provision of sufficient additional clinically useful information. 
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1.3.4. Cellular assays 
The measurement of cell surface markers on circulating leukocytes through flow cytometry 
can provide detailed information about specific populations of leukocytes and their cellular 
activation and function, and are of established use in the laboratory investigation of 
haematological malignancies and immunodeficiencies [114, 115]. It is also possible to 
measure biomolecules including phosphorylated cell signalling proteins within cells through 
rendering the plasma membrane permeable (permeabilisation) to the antibodies used in the 
preparation for flow cytometry, which can provide mechanistic insight [116]. 
Measures of leukocyte membrane expression are being developed for investigation of the 
sepsis syndromes and associated perturbations in immune status. The extent of immune 
suppression that can follow acute severe systemic inflammation may be assessed by 
measurement of monocyte Human Leukocyte Antigen (HLA) DR expression [117]; levels 
have been associated with development of nosocomial sepsis and death [118] and have 
been used to guide immuno-stimulatory therapy [119]. The analysis of expression of CD64 
(an Fc receptor) and CD35 (a complement receptor) on circulating neutrophils from patients 
can distinguish between bacterial infection, viral infection and sterile inflammation [120]. 
Similarly, quantification of expression of CD69 (human transmembrane C-Type lectin 
protein) on lymphocytes has shown potential to discriminate infectious from injurious 
systemic inflammation [121]. A study of the potential advantages of leukocyte monitoring 
over routine clinical plasma assays of systemic inflammation is currently recruiting, enrolling 
patients following surgical procedures (clinicaltrials.gov NCT01250574).  
A distinct form of cellular monitoring is the measurement of the RNA expression profile of 
leukocytes; this has been described as the ‘riboleukogram’. Characterisation of the 
transcriptional profile of circulating leukocytes in clinical inflammatory conditions has the 
potential to improve diagnostics, particularly differentiation between infectious and non-
infectious SIRS [122-125]. The characterisation could involve examination of expression of 
specific genes of interest, or use gene array chips that analyse the expression of thousands 
of genes. Although only studied in a small number of patients, there are indications that 
onset of infection-specific transcriptional changes may precede the development of clinical 
features, thus permitting earlier diagnosis and treatment [122].  
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1.3.5. Proxy measures 
The length of ICU stay (LOS) in patient populations relates primarily to the need for 
advanced supportive therapies and monitoring. As such, it represents a composite measure 
of organ failures and extent of any inflammatory response. 
1.4. Post-operative SIRS as a model of human systemic inflammation 
To study the onset of systemic inflammation it is necessary to identify patients who can be 
studied prior to its development. Therefore elective surgery is an appropriate model and 
snCPB particularly useful as it is associated with frequent and significant systemic 
inflammation. Since patients are identified when they are well, there are fewer difficulties 
obtaining consent for research participation. Patients undergoing snCPB are routinely 
monitored using arterial and central venous cannulae that facilitate painless acquisition of 
blood samples. 
Patients undergoing snCPB have a range of underlying pathologies, treated with different 
procedures (e.g. CABG versus aortic valve replacement). However, there are many 
similarities including the route of surgical access and the techniques of CPB. The procedures 
are sufficiently similar to induce comparable systemic inflammation, assessed with a range 
of assays [126]. 
2. MECHANISMS OF SYSTEMIC INFLAMMATION 
2.1. Mediators and cytokines 
Cytokines are low molecular weight proteins or glycoproteins that function as intercellular 
messengers. They include interleukins (ILs), interferons (IFNs), tumour necrosis factors 
(TNFs), growth factors, transforming growth factors, colony stimulating factors and 
chemokines. Their synthesis and secretion are highly regulated; they are highly potent and 
have short-lived effects. Their roles are varied and include control of cell proliferation, 
differentiation and metabolism; immune modulation of cytotoxic cells, phagocytic cells, and 
immunoregulatory cells; regulation of acute phase response and fever; and wound healing 
and remodelling. 
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2.1.1. Chemokines 
Chemokines are a subgroup of cytokines that direct the movement of circulating leukocytes 
to sites of inflammation or injury i.e. they are chemotactic. Chemokines and their receptors 
have a standardized nomenclature based on their cysteine-related structures. CC 
chemokines have two adjacent cysteine residues and the group includes monocyte 
chemoattractant protein 1 (MCP-1). The archetypal chemokine IL-8 is in the CXC group, 
characterised by a single amino acid residue between the first two cysteines and is also 
known as CXCL8, paired with its receptor CXCR1. The third group (CX3C) has only one 
member, fractalkine, similarly the fourth only has lymphotactin. 
IL-8 is produced by both neutrophils and monocytes and it has well defined and important 
functions including chemoattraction and neutrophil activation. In patients with septic shock, 
changes in plasma levels of IL-8 are associated with those of other inflammatory mediators 
and to clinical outcome [127, 128]. Elevated circulating levels of IL-8 have been similarly 
demonstrated in other systemic inflammatory conditions including snCPB [129], pancreatitis 
[130] and polytrauma [131]. 
2.1.2. IL-1β 
Classical pro-inflammatory cytokines include IL-1β, IL-6 and TNF-. Interleukin-1β is a 15kDa 
protein secreted by monocytes and macrophages and has the capacity to induce a range of 
genes including those for more cytokines, adhesion molecules and chemokines. IL-1β is 
thought to be partially responsible for some of the classical features of infection or 
inflammation including fever (acting on the hypothalamus) and raised numbers of 
circulating neutrophils (acting on the bone marrow to induce neutrophil production, 
maturation and release)[132]. Recombinant analogues of the naturally-occurring IL-1 
receptor antagonist (e.g. Anakinra) have been shown to be beneficial in patients with 
systemic inflammatory conditions such as rheumatoid arthritis, but not in those with severe 
sepsis [133, 134]. 
2.1.3. IL-6 
IL-6 is a 22-27kDa protein secreted predominantly from immune cells but also by 
endothelial cells and adipocytes. It binds the IL-6 receptor (IL-6R) and through interaction 
with a complex of glycoproteins (gp130), activates pro-inflammatory responses via the 
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MAPK pathways. The IL-6 receptor can disassociate from the cell membrane and continue to 
function as a soluble receptor (sIL-6R), binding IL-6 and then interacting with gp130. The 
importance of this is that IL-6 mediated cellular responses are possible in the wider range of 
cells that possess gp130, but do not endogenously express IL-6R [135]. 
Similarly to IL-1, IL-6 stimulates the febrile response via actions in the hypothalamus. IL-6 
stimulates synthesis of acute phase proteins, including CRP by hepatocytes. In addition to its 
pro-inflammatory actions, IL-6 has anti-inflammatory attributes, suppressing TNF- and IL-
1 and promoting synthesis of IL-1ra and soluble TNF receptor p55. Relative to IL-1 and 
TNF-, IL-6 levels remain elevated in the circulation for longer during systemic 
inflammation.  IL-6 has been described as a cytokine mediating the resolution of acute 
inflammation by balancing pro-inflammatory effects and orchestrating the transition from 
innate to acquired immunity [136]. Antagonism of IL-6 with humanized monoclonal 
antibodies (Tocilizumab) is an effective therapy for rheumatoid arthritis but has not been 
studied in the sepsis syndromes [137]. 
2.1.4. TNF-α 
TNF- is a 17kDa protein produced mostly by monocytes and macrophages. It has 
pleiotropic actions on cellular activity and includes the release of soluble mediators, the 
induction of gene expression, growth inhibitory and cytotoxic effects, and the enhancement 
of proliferation [138]. There are other tumour necrosis factors including TNF-β (also known 
as lymphotoxin-α), lymphotoxin-β and Fas ligand. There is also a family of TNF receptors. 
TNF-α is initially formed as a transmembrane protein cleaved by TNF-α converting enzyme 
(TACE) to release soluble TNF-α, which forms a homo-trimer. It binds the TNFR1 (p55 or 
CD120a) and TNFR2 (p75 or CD120b) receptors, each initiating different intra-cellular 
signalling events. TNFR1/2 are constitutively cleaved by TACE, causing release of soluble 
sTNFR1/2. Levels of the soluble receptors reflect the activation state of the TNF-α/TNF 
receptor system and can be used to monitor the progression of inflammation [139]. 
Soluble TNFR1/2 may compete for plasma TNF-α and reduce cellular TNFR1/2 signalling, 
thereby attenuating inflammatory responses in a negative feedback loop. However, in vivo 
the pathway is far more complex and administration of exogenous sTNFR1/2 has adverse 
effects, possibly by preventing elimination and prolonging the effects of TNF-α [140, 141]. 
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By contrast, TNF-α antibodies have been found to be clinically efficacious in rheumatoid 
arthritis, inflammatory bowel disease and some inflammatory dermatoses [142, 143]. 
Antagonism of TNF-α in the sepsis syndromes has not been successful and this is likely to be 
due to several reasons. Thus,  levels peak very early after the onset of acute illness and are 
already declining when patients present for immuno-modulatory intervention, the selection 
of patients may have been suboptimal, or the early elevations of TNF-α may be a necessary 
and advantageous response promoting appropriate immune cell recruitment and activation. 
2.1.5. SIRS, CARS or both? 
Excessively elevated levels of circulating pro-inflammatory cytokines can be measured in 
patients with SIRS and are implicated in the development of organ failure. Elevated levels of 
anti-inflammatory mediators including IL-10, IL-1ra, and sTNFR1/2 are also detectable 
concurrently. This response has been described as the compensatory anti-inflammatory 
response syndrome (CARS) and was initially thought to succeed SIRS; it is now believed to 
overlap with pro-inflammatory responses. CARS is implicated in the development of a hypo-
responsive immune system (immunoparesis) with the consequent development of 
nosocomial infections. It has been argued that the CARS response is of greater clinical 
significance than SIRS, but in general the pro- and anti- inflammatory responses are equally 
proportionate to the severity of illness [144-147]. 
2.2. Leukocyte responses 
2.2.1. Neutrophils 
Neutrophils are formed in the bone marrow in response to the growth factor granulocyte 
colony-stimulating factor (G-CSF). Following 14-16 days of maturation they are released into 
the circulation and after 4-6h they transmigrate into tissues. After 2-6 days they undergo 
spontaneous programmed cell death, termed apoptosis. During inflammation, large 
increases in the numbers of effective cells are achieved rapidly by the delay of tissue 
apoptosis, the increased release of mature neutrophils from the marrow and the 
mobilization of neutrophils from a marginated pool within the bone marrow sinusoids. 
Apoptosis may be an evolutionarily conserved mechanism for limiting excessive 
inflammation and is delayed in patients with the sepsis syndromes [148, 149]. Conversely, 
augmentation of neutrophil apoptosis is necessary for the resolution of inflammation [150, 
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151]. Following neutrophil apoptosis the shrunken cell remnant is phagocytosed by 
macrophages (efferocytosis), resulting in release of G-CSF. 
Neutrophils are the principal circulating inflammatory cells and in addition to phagocytosis 
they have other important functions. They migrate to inflammatory foci by margination, 
rolling, then adherence and transmigration (via a process termed diapedesis) across the 
endothelium into the tissue. Neutrophils move towards a focus of infection by following 
concentration gradients of chemoattractants, a process termed chemotaxis. Neutrophil 
activation is a two-step process. Priming occurs through interaction with cytokines or 
activated endothelial surfaces. Neutrophil degranulation follows further exposure to 
inflammatory stimulus and aims to destroy invading pathogens through the release of 
preformed granular enzymes and proteins, and production of reactive oxygen species (ROS). 
An unfortunate side effect of neutrophil degranulation is tissue injury mediated via the 
proteases and ROS which damage cells and the extracellular matrix. Tissue injury acts as a 
further stimulus for recruitment of inflammatory cells and a cascade effect results. 
In patients with the sepsis syndromes there are elevated levels of circulating cytokines that 
have been implicated in impairing the ability of circulating neutrophils to migrate to the site 
of infection by reducing neutrophil-endothelium adhesion. The combination of neutrophil 
activation and lifespan extension with failure to appropriately migrate has been implicated 
in the development of organ dysfunction, particularly acute lung injury [152-155]. 
Neutrophils can synthesize and secrete a number of chemokines, including IL-8, growth-
related oncogene-α (GROα), Macrophage Inflammatory Proteins-1α/β (MIP1-α/β), 
Interferon gamma-induced protein 10 kDa (IP-10) and monokine induced by gamma 
interferon (MIG). These cytokines are chemotactic for monocytes, immature dendritic cells, 
T lymphocytes and more neutrophils [156]. 
Microbes or microbial particles that have been opsonised bind to specific receptors on 
neutrophils initiating phagocytosis. Once the opsonised particles have been engulfed within 
a phagosome, intracellular killing takes place. The respiratory burst is the formation of toxic 
ROS and hypochlorous acid within the phagosome. A second mechanism of intracellular 
killing is the fusion of granules rich in hydrolytic and digestive enzymes. 
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Neutrophil extracellular traps (NETs) are extracellular fibres of granule proteins and 
chromatin that bind bacteria and fungi, preventing them from spreading; ensuring a high 
local concentration of antimicrobial agents to degrade virulence factors and kill bacteria 
[157]. 
2.2.1.1. Assessing neutrophil inflammatory status 
Neutrophil function may be assessed by a variety of means. A functional assay involves an 
assessment of alteration in leukocyte function in response to a stimulus. Alterations in 
cytokine secretion represent a simple and accessible functional endpoint. The measurement 
may be the secreted cytokines, or may include the quantity from lysed cells. Common 
methods of quantitation of cytokine protein levels include ELISA or Western blot. To assay 
relative quantity of cytokine mRNA expression, qRT-PCR can be used.  
Proteins that are components of up-stream signalling pathways that progress to changes in 
inflammatory cell function may also be assayed. The mitogen-activated protein kinases 
(MAPK) are commonly studied. These cell signalling pathways link activating stimuli to 
phosphorylation of numerous proteins including transcription factors, cytoskeletal proteins 
and other enzymes. There is an exhaustive array of interconnected and tightly controlled 
intracellular signalling pathways that are activated or deactivated through protein 
phosphorylation. Commonly, investigators compare the expression of phosphorylated to 
total forms of ERK1/2, JNK or p38 in whole cell lysates using Western blotting. 
Dynamic features of leukocyte function may be examined using in vitro assays. Chemotaxis 
may be studied through use of a cell-staining fluorescent dye (such as CFSE), and a potent 
chemo-attractant (such as IL-8) deployed in wells with permeable cell-counting inserts. 
Phagocytosis may be studied through the use of pH-sensitive fluorescent probes. 
Intracellular killing may be studied through the use of fluorescent probes that become 
activated upon oxidation (such as carboxy-H2DCFDA). Neutrophil degranulation may be 
studied with fluorogenic substrates of myeloperoxidase (MPO), a major constituent of the 
azurophilic granules that are released extracellularly during degranulation. 
2.2.2. Monocytes 
Mononuclear phagocytes share many properties with neutrophils and have distinct 
functional properties. Their major functions include phagocytosis, antigen presentation, and 
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immunomodulation. They are formed in the bone marrow from a common myeloid 
progenitor that is shared with neutrophils before they enter the circulation while still 
immature and circulate for several days before entering tissues and differentiating into 
either macrophages or dendritic cells (DCs). They account for 5-10% of circulating leukocytes 
[158].  
Within the circulating population of monocytes there is heterogeneity, and initially they 
were divided into subsets on the basis of their morphology. Their classical appearance is of 
an irregular cell shape with a large kidney-shaped nucleus and cytoplasmic vesicles [159]. 
Differences in chemotaxis, cytokine secretion, respiratory burst, and antigen presentation 
were described. More recently, distinct populations of circulating monocytes have been 
described based upon differences in cluster differentiation (CD) markers. 
Of the many subsets of monocytes, expression of CD14 (a co-receptor with TLR-4 for 
bacterial endotoxin) and CD16 (the immunoglobulin receptor, FcRIII) permits the 
categorization of monocytes. The largest group (80-90%) are CD14+CD16- ‘classical’ 
monocytes; with higher phagocytic activity but lower cytokine expression. By contrast, 
CD14+CD16+ monocytes (~10% of the total) have been characterised as 'pro-inflammatory'. 
They are increased during infections and produce more pro- than anti-inflammatory 
cytokines in response to stimulation [160, 161]. There are many other subgroups defined by 
CD markers and postulated to have divergent functions, with minor subsets having common 
features to macrophages and dendritic cells[162].  
In common with other leukocytes, monocytes are recruited to sites of inflammation by 
margination, rolling, adherence and transmigration. They accumulate more gradually at 
sites of inflammation and persist for longer. Consistent with this, their respiratory burst is 
less extreme. Their microbial killing relies on the formation of ROS and reactive nitrogen 
species (RNS) as well as upon the production of phagolysosomal enzymes. Monocytes have 
the capacity to kill a wider range of microbes than neutrophils. 
During severe sepsis monocytes may become hypo-responsive to inflammatory stimuli and 
turn to producing anti-inflammatory cytokines such as IL-10 and IL-1ra (receptor 
antagonist). In parallel with this, their surface expression of HLA-DR decreases [163]. 
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2.2.2.1. Dendritic cells (DCs) 
DC have a primary role as antigen-presenting cells interacting with T cells and modulating 
their responses. They are present in the blood, the lymphoid tissues, epithelia such as 
mucosa and epidermis, and in the interstitium of organs. Exogenous antigens are 
internalised and then processed for MHC (Major Histocompatibility Complex) presentation. 
The major subsets are myeloid and plasmacytoid DCs, the latter being originally considered 
to arise from a lymphoid lineage [164]. Infections and microbial components accelerate 
differentiation of monocytes into DCs and cause phenotypic changes; migration from 
peripheral sites to lymphoid tissues, up-regulation of antigen presenting molecules, up-
regulation of molecules that interact with T lymphocytes and production of cytokines (IL-12, 
TNFα, IL-10, IL-6, IFN-α/β)[165]. DC regulate which class of effector T cells are induced. 
Naïve CD4+ T cells can differentiate either into T helper 1 cells (Th1) or T helper 2 cells (Th2) 
cells [166]. 
2.2.2.2. Macrophages 
Following their exposure to the environment of the circulation, monocytes selectively 
‘home’ to different tissues to reside. Their functions in the tissue parenchyma alter in 
response to their microenvironment, particularly the presence of inflammatory stimuli or 
microbes. Resident macrophages fulfil a wide variety of roles and are known by different 
names according to tissue: Kupffer cells in the liver, Langerhans cells in the skin, microglial 
cells in the brain, osteoclasts in the bone and histiocytes in connective tissues. 
Macrophages may become polarised in response to their microenvironment. A simplified 
explanation of the types includes a ‘classical’ macrophage type (M1) that is an efficient 
producer of ROS and inflammatory cytokines and participates in Th1 responses. The M2, 
non-classical, macrophage participate in Th2 reactions, promote encapsulation and killing of 
parasites, and promote tissue repair and remodelling [167]. 
2.2.3. Lymphocytes 
There are T (thymus) and B (bone) lymphocytes, and natural killer (NK) cells. T lymphocytes 
can be divided into CD4+ cells, known as helper T cells and CD8+ cells, killer T cells. Helper T 
cells are prolific cytokine producers and are further divided by the type of cytokines they 
produce. Th-1 cytokines promote inflammation and anti-microbial responses, particularly 
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against intra-cellular organisms. Th-2 cytokines include IL-4, -5 and -13, associated with 
promotion of IgE and eosinophilic responses, and also the anti-inflammatory cytokine IL-10. 
A balanced Th-1 and Th-2 response is desirable. B lymphocytes are responsible for the 
production of antibodies, formation of plasma cells and memory B cells - the humoral 
immune response. 
In patients with sepsis, lymphocyte populations are universally and significantly decreased 
and remain so for at least the first 48h [168]. Their function is also impaired with increased 
expression of inhibitory receptors, diminished ex vivo responsiveness, increased Th-2 to Th-
1 ratio, induction of regulatory T cells and increased apoptosis [169].  Inhibition of 
lymphocyte apoptosis is associated with improved outcome in murine models of sepsis 
[170, 171] and has thus been seen as a modifiable response to severe infection with a 
potential therapeutic role [172]. 
T-cell activation affects neutrophils. Experimental data suggest that inadequate CD4+ activity 
produces dysfunctional neutrophils, facilitating bacterial dissemination; and that excessive 
CD4+ activity promotes bacterial clearance but with increased tissue damage [173]. 
Regulatory T cells, characterised by the cell surface marker CD25 and intracellular 
expression of the transcription factor Foxp3, mediate effector T cell responsiveness, as well 
as having the capacity to induce apoptosis of monocytes and neutrophils [174, 175]. 
Furthermore, their numbers increase during sepsis and are implicated in the development 
of T cell hypo-responsiveness [176]. 
2.2.4. DAMPS and PAMPS 
Microbial pathogens and their derived products are potent stimulators of the innate 
immune system. These pathogen-associated molecular patterns (PAMPs) include surface 
molecules such as endotoxin (e.g. lipopolysaccharide, LPS; lipoproteins; outer-membrane 
proteins; flagellin; fimbriae; peptidoglycan, PGN; peptidoglycan-associated lipoprotein; and 
lipoteichoic acid, LTA), and internal motifs released following bacterial lysis (e.g. heat-shock 
proteins, HSP; DNA fragments)[177]. In the host, Toll-like receptors (TLR) and cytoplasmic 
pattern recognition receptors (PRRs) such as NOD1 and NOD2 act as sensors which 
recognize the exogenous noxious stimulis. 
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Tissue damage and cellular necrosis causes an inflammatory response through the release 
of damage-associated molecular patterns (DAMPs) and their detection by pattern 
recognition receptors. DAMPs are usually components of cells that fulfil a distinct role in 
health but when released into the extracellular space due to disruption of the plasma 
membrane, mediate inflammation. DAMPs include HMGB1, DNA, uric acid, IL-1, IL-18, heat 
shock proteins, the S100 proteins and components of the extracellular matrix such as 
hyaluronan and heparan sulfate (Figure 4). 
Together DAMPS and PAMPS have been described as danger signals, or Alarmins. 
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Figure 4: Pathways of Development of systemic inflammation. Overwhelming and dysregulated systemic inflammation 
results from the release of endogenous cellular contents from damaged tissue or dying cells in the form of damage-
associated molecular patterns (DAMPs) or in response to exogenous microbial pathogen-associated molecular patterns 
(PAMPs). Endogenous DAMPs and exogenous PAMPs are recognized by pattern-recognition receptors, such as extracellular 
toll-like receptors or intracellular nucleotide-binding oligomerization domain–like receptors or retinoic acid–inducible 
gene-1–like receptors on cells of the innate immune system, including polymorphonuclear leukocytes and macrophages. 
The abbreviation dsRNA denotes double-stranded RNA, HMGB1 high mobility group box 1, HSP heat-shock protein, LPS 
lipopolysaccharide, ssRNA single-stranded RNA, and TNF tumor necrosis factor. Diagram taken from NEJM [2].  
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2.3. Endotoxin and bacterial translocation 
Endotoxin is a historical term for lipopolysaccharide (LPS), a major constituent of Gram-
negative bacterial cell walls that contributes substantially to bacterial toxicity. Gram-
negative bacteria are those that do not retain crystal violet dye due to the characteristics of 
their cell walls. LPS comprises of a polysaccharide chain that varies between bacterial 
species and a lipid moiety (Lipid A) that shows less variability and is predominantly 
responsible for the pathological effects associated with infection by Gram-negative bacteria.  
LPS is commonly used in vitro as a positive control for activation of inflammatory pathways 
in cells and tissues in culture, and has also been used extensively in studies performed in 
animals and humans in vivo. Intravenous administration of high-dose LPS reproduces the 
clinical features of septic shock in animals. At lower doses in humans, flu-like symptoms 
emerge, accompanied by fever, tachycardia, and mild hypotension [178]. Inhaled LPS has 
been used as a model of direct acute lung injury in humans [179]. 
The phenomenon of bacterial translocation explains how LPS is important in conditions 
other than Gram-negative sepsis. A vast number of live bacteria from >300 species live 
within the lumen of the normal human gut. The passage of these through the epithelial 
mucosa is called bacterial translocation and may have a physiological role in immune 
surveillance [180]. In both infectious and non-infectious systemic inflammatory processes 
there may be both global and regional hypoperfusion leading to increased enteric bacterial 
translocation [181, 182]. Translocated bacteria usually belong to Gram-negative aerobic 
genera such as escherichia, proteus, klebsiella; and thus express endotoxin. The presence of 
bacterial components in the circulation has a potent immunostimulatory effect, exacerbates 
the systemic inflammatory response, and has been implicated in the development of organ 
failure [183].  
In part this mechanism provides justification for the consideration of infectious and non- 
infectious systemic inflammatory states as a continuum rather than distinct pathological 
processes. For example, in non- infectious (or “sterile”) systemic inflammation such as 
complicates haemorrhagic shock, there may be substantial bacterial translocation. The 
immune response to this may be similar to that seen in classical infectious (“non-sterile”) 
systemic inflammation such as that of urinary tract infection. Further evidence in support of 
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this hypothesis is the finding that increased levels of antibodies to endotoxin are associated 
with a decreased incidence of SIRS following non-infectious injury [184, 185]. 
2.3.1. Endotoxin tolerance 
Early experiments demonstrated that animals receiving a low dose of bacterial endotoxin 
had a markedly reduced mortality when re-challenged with a lethal dose; this was termed 
endotoxin tolerance or hypo-responsiveness. Similar decreased responsiveness has been 
demonstrated in terms of cytokine release from LPS-stimulated leukocytes in vitro [178]. 
Endotoxin tolerance is not specific to the action of LPS, and cross-reactivity with other 
exogenous stimuli occurs [186]. 
Early endotoxin tolerance has several potential mechanisms: including the induction of the 
anti-inflammatory cytokine IL-10; altered cell signalling pathways, including several of the 
MAP kinases, and NF-κB; decreased expression of cell-surface receptors such as TLR4; and 
finally via gene silencing of pro-inflammatory pathways [187], an area in which the RAGE 
ligand HMGB1 may have a role [188]. By contrast, late tolerance is mediated through 
antibodies directed against moieties of endotoxin [189].  
Endotoxin tolerance is generally considered to be beneficial rather than a deleterious or 
maladaptive response, protecting the host from excessive inflammation and beneficially 
altering immune responses [189]. Hypo-responsiveness may be a less accurate description 
than tolerance, as not all responses are suppressed; indeed some are enhanced. The exact 
effect of subsequent responses depends upon factors that include the degree of LPS 
exposure [190]. 
2.3.2. Clinical relevance to snCPB 
Levels of endotoxin in the circulation of patients who have undergone snCPB are elevated 
[191-196]. A significant contributor to this observed endotoxaemia is thought to be 
diminished intestinal perfusion and increased mucosal permeability [197, 198]. Therefore, 
leukocytes taken from patients prior to snCPB can be considered LPS-naïve and those taken 
from patients following snCPB can be considered LPS-exposed. In this context, snCPB 
induced an early LPS hypo-responsiveness of whole blood [199-202], and was associated 
with a reduction in LPS-induced IL-8 release from neutrophils sourced from patients 
following snCPB versus healthy volunteers [203]. 
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Given the postulated role of intestinal bacteria in the development of infectious 
complications and organ dysfunction in critical illness and specifically following snCPB, 
sterilisation of the bowel has been considered. Theoretically, the goal would be to 
selectively remove potential pathogenic aerobic bacteria without that of benign anaerobic 
intestinal micro-organisms through the enteral administration of non-absorbable antibiotics 
prior to surgery, termed ‘selective digestive decontamination’, SDD. A small randomised 
controlled trial (RCT) of SDD in snCPB patients did not demonstrate any difference in 
endotoxaemia, cytokine response or clinical complications [195]. One possible contributory 
reason for these findings could be that the bacterial components remained within the 
intestinal lumen and although their viability may have been reduced, their immunogenicity 
was not. SDD has been studied in many different populations of critical ill patients and 
remains a highly contentious area with widely differing degrees of implementation between 
countries and institutions [204-207]. 
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2.4. Genetic variability and outcome from systemic inflammation 
The role of genetic factors influencing the susceptibility to, and progression of, acute and 
chronic systemic inflammatory conditions can be investigated using genetic association. This 
may shed light on the pathways involved in complex disease and identify new targets for 
therapeutic intervention and is achieved by comparison of the distribution of genetic 
markers, such as single nucleotide polymorphisms (SNPs), in genes of interest amongst 
cases and controls.  
SNPs are the common (>1%) single base pair ‘variants’ in the DNA sequence at a particular 
point compared with the ‘common’ sequence. Some SNPs are within the exons, parts of the 
gene that are translated into protein. Among these, non-synonymous SNPs lead to a change 
in amino acid sequence of the resultant protein, whereas synonymous SNPs do not result in 
amino acid change. Other SNPs are in introns and do not directly code for protein but may 
still influence cell function through other means, including so-called intron-mediated 
enhancement [208]. Counter-intuitively, analysis of genetic association studies show that 
non-synonymous SNPs (change in coding) are no more likely to be involved in disease 
mechanisms than synonymous SNPs. Intronic SNPs are less likely to be involved in disease 
mechanisms than extronic SNPs [209]. Synonymous SNPs may affect function through 
alterations in messenger RNA splicing, stability, and structure as well as protein folding 
[210]. 
Haplotypes are combinations of alleles at different loci on the chromosome that are 
transmitted together. They are constructed using knowledge of linkage disequilibrium (LD) 
between markers and offer information about ancestral chromosomes. LD is a mark of 
association between alleles at different loci such that if two SNPs are in LD, they are present 
together more frequently than would be expected by chance (i.e. they are co-inherited). 
Conjoining SNPs into multi-SNP haplotypes may improve the power to assigning a 
phenotype to a genetic region in association studies. A SNP may be associated to a clinical 
phenotype through another SNP that is in LD with it. 
Complex diseases or syndromes are the result of the interplay between genetic and 
environmental factors. The progression of infection to sepsis, to severe sepsis, and to septic 
shock only occurs in a minority of cases; similarly the progression of post-operative SIRS to 
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severe systemic inflammation, to the development of multiple organ dysfunction is rare. 
Although environmental considerations are important, the genetic susceptibility to 
progression of inflammation is also an important determinant. The landmark study that 
initiated investigations in this area determined the causes of death in those who were 
adopted in relation to the causes of death of their biological parents. They found that death 
before the age of 50 in the biological parents resulted in a relative risk of death in the 
adoptees of 5.81 (2.47-13.7, 95% confidence intervals, p<0.001) for infectious causes [211]. 
More recently, a genetic variant in a component of the clotting cascade (factor V Leiden, 
affecting ~5% of the population) that is associated with an increased risk of venous 
thrombosis, has been associated with improved outcome from severe sepsis [212]. 
When the gene of interest is known studies can focus on a ‘candidate’ gene. By contrast, 
non-hypothesis driven studies can study a large number of SNPs on a wide range of genes 
and look for previously unidentified associations that may lead to new investigative 
approaches. Thus a SNP within the RAGE gene (G82S) was recently associated with impaired 
pulmonary function in a genome-wide association study [213]. 
2.4.1. The limitations of genetic association studies 
Genetic association studies are frequently underpowered as sample size calculations may 
not have been performed, or the numbers of recruited patients was less than planned. The 
power of a statistical test is its ability to reject a false null hypothesis. A study that is 
underpowered is at risk of both a type II error, when a null hypothesis is not rejected 
despite being false, and a type I error, when a null hypothesis is rejected when it should not 
be, a ‘false positive’.  
Moreover, when performing multiple statistical tests, it becomes inevitable that some will 
appear to show statistical significance, even in the absence of a true effect and failure to 
compensate for this eventuality increases the risk of false positives. Use of post-hoc 
subgroup analyses increases the chances of detecting a false positive result. 
Publication bias and consequent misleading systematic reviews is a further limitation. 
Publication bias describes the phenomenon of negative results being less likely to be 
submitted for publication, let alone accepted. Thereafter any systematic reviews will only 
have positive papers to analyse leading to false conclusions. 
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Some would argue that complex outcomes, such as duration of ICU stay following snCPB, 
have a vast number of gene-gene and gene-environment interactions and to suppose that 
variation in one gene, however significant it is, will affect this may be overly simplistic and 
reductionist. 
Finally, conducting genetic association studies in different populations may lead to multiple 
reports of contradictory findings, or failure to replicate positive results. This may be 
attributable to the lack of genuine effect or variation in the extent of effect between 
different populations [214].  
2.4.2. Genes of the immune response 
The influence of genetic variability in key components of the immune system (such as 
cytokines, cytokines receptors and intracellular signalling pathway proteins) on outcome in 
patients with the sepsis syndromes has been extensively studied. Unfortunately, a large 
proportion of trials in this area have had methodological shortcomings, and their results 
must be interpreted with caution [215]. Predisposition to sepsis and to the progression of 
sepsis to severe sepsis or septic shock have been the most widely studied aspects of the 
sepsis syndromes but inflammatory responses to snCPB have also been investigated (Table 
3). 
TNF-α is a pivotal pro-inflammatory cytokine with several SNPs affecting gene function, and 
has been studied extensively in relation to critical illness, with inconsistent results [216]. A 
recent study included 854 patients and matched controls and identified an association 
between a SNP in TNF-β (+252) and predisposition to severe sepsis but none between 
several SNPs (in TNF-α and β, IL-1β, IL-6, IL-10 and CD14) and severity of sepsis [217]. A 
systematic review of studies of a promoter region SNP in TNF-α (−308A>G) demonstrated an 
association to predisposition to, but not to severity of, sepsis [218]. 
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Gene SNP Patients Outcome Reference 
TNF- -308G/A 100 No difference in plasma TNF- levels [219] 
TNF- and LT- 
-308G/A and 
+250 respectively 
400 
LT[alpha]+250G/-308TNFG haplotype is associated with 
an increased risk of prolonged mechanical ventilation 
[220] 
TNF- +252G>A 95 
Differences in TNF- and IL-6, cardiovascular support 
requirements and impairments in oxygenation 
[221] 
TNF- -308G/A 98 
AA genotype had higher circulating levels of TNF-α 
postoperatively 
[222] 
 
TNF- -308G/A 250 
Minor allele associated with increased plasma levels but 
no difference in clinical variables 
[223] 
IL-8, IL-6, TNF-α 
-174G>C, -
251A>T, -308G>A 
respectively 
154 
IL-6 (-174GG) and IL-8 (-251AA) associated with higher 
levels of post-op IL-6 and -8 respectively. IL-8 -251AA 
associated with prolonged ventilation and hospital stay. 
[224] 
IL-6, IL-10, TNF-α 
-572, -1082, -308 
respectively 
100 
patients, 
112 
controls 
IL-6 -572 polymorphism was associated with acute lung 
injury after cardiac surgery with cardiopulmonary bypass 
[225] 
IL-6 
-174G>C, -
572G>C, and -
597G>A 
127 
Peak IL-6 levels were significantly higher in carriers of the 
-572C allele than in those of the -572GG genotype and in 
those with genotype -174CC compared with -174G allele 
carriers 
[226] 
IL-6 −174 G>C 111 
-174 G associated with greater IL-6 plasma levels and 
longer ICU and hospital stays 
[227] 
IL-6 −174 G>C 111 
G homozygotes had signiﬁcantly higher IL-6 levels 
postoperatively, worse renal function and prolonged 
mechanical ventilation 
[228] 
IL-10 and TLR-4 Many 156 Haplotype effects on post-operative plasma IL-10 levels [229] 
IL-10 –1082 150 
Minor allele (GG) associated with lower IL-10 plasma 
levels 3h post-CPB 
[230] 
TNF-α, IL-1β, IL-6, I-
10, IL-1ra, ICAM-1, P-
selectin and E-
selectin. 
17 
polymorphisms 
759 
Carriage of minor allele (T) of the E-selectin SNP at +98 
was associated with coagulopathy and increased post-
operative bleeding. ICU LOS not reported. 
[231] 
IL-18 
-607 C/A, -137 
G/C, 8148 C/T 
and 9545 T/G 
658 
Homozygosity for the major (T) allele at 9545 T/G was 
associated with prolonged ICU stay, more severe 
vasodilatation, increased IL-18 and TNF-α levels, with 
decreased IL-10 levels. 
[232] 
Table 3: Studies relating SNPs in genes of the innate immune response and clinical outcomes related to systemic 
inflammation in adult patients who have had snCPB, negative studies not shown. 
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3. THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS (RAGE) 
3.1. Introduction 
3.1.1. History 
Originally characterised in 1992 as a receptor for advanced glycation end-products [233], 
RAGE has since become an area of active research in diverse fields including those relating 
to inflammation, immunity, development, and oncogenesis. Advanced glycation end-
products (AGEs) are modifications of proteins or lipids resulting from non-enzymatic 
glycation or oxidation and are a diverse range of compounds, as are their receptors, each 
being known by several different names. 
3.1.2. Receptors for AGE 
OST-48 (oligosaccharyltransferase-48) is a membrane protein originally considered to have a 
primary role as a glycosyltransferase, but later found to be present on the plasma 
membrane and to bind and internalise AGE [234]; it was originally termed p60 and later 
renamed AGE-R1. 80K-H is an intracellular substrate for protein kinase C but was also later 
found to bind and internalise AGE [234]; it was originally termed p90 and later renamed 
AGE-R2. Galectin-3 is a carbohydrate-binding protein (lectin) of complex composition and 
diverse roles including binding and degradation of AGE [235, 236]; subsequently renamed 
AGE-R3. AGE receptors 1, 2 and 3 may work together as the AGE-receptor complex [237]. 
Macrophage scavenger receptor class A (SRA) is a transmembrane glycoprotein that binds 
oxidized low density lipoprotein (Ox-LDL), but also endocytoses and degrades AGE [238]. 
The defining member of the class B macrophage scavenger receptors is CD36. This 
glycoprotein, in addition to various other ligands, binds and degrades AGE [239]. The protein 
lysozyme also binds AGE and this may adversely affect its antimicrobial properties [240]. 
Finally, the receptors “fasciclin EGF-like, laminin-type EGF-like, and link domain-containing 
scavenger receptor” -1 and -2 (FEEL-1 and -2) may recognize AGEs [241] and are expressed 
in vascular tissues. Further discussion of non-RAGE receptors for AGE is beyond the scope of 
this thesis. In contrast to other AGE receptors, RAGE is a member of the immunoglobulin 
superfamily, and upon ligand inflammatory signalling events are initiated. 
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3.1.3. Structure 
The receptor structure consists of three extracellular domains that participate in ligand 
binding, one V-type (variable) immunoglobulin like domain and two C-type (constant) 
immunoglobulin like domains; a transmembrane domain and a cytoplasmic tail essential for 
intracellular signalling (Figure 5). Different ligands preferentially interact with these 
individual domains [242] and result in different intra-cellular events [243]. It has been 
reported that the V and C1 domains form an integrated structural unit for ligand recognition 
[244]. 
 
Figure 5: Diagrammatic representation of RAGE 
Other immunoglobulin-like receptors include the Fc-γ immunoglobulin receptors, the 
families of receptors named ‘leukocyte immunoglobulin-like receptors’, and the ‘killer cell 
immunoglobulin-like receptor’ [245]; all are involved in mediating the immune response. 
3.1.4. Genesis 
The gene for RAGE (named AGER by the human genome nomenclature committee) is 
located within the gene-dense major histocompatibility class III region on chromosome 6. 
Polymorphisms within the gene and their functional consequences are discussed within 
Section 3.1.6. 
Genetic modified RAGE deleted mice appear phenotypically normal, and are no more 
susceptible to experimental development of diabetes than control mice and breed normally. 
They do however, develop spontaneous pulmonary fibrosis [246] and have abnormal 
osteoclast development causing increased bone mass [247]. 
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3.1.5. RAGE variants 
An exhaustive study of splice variants has attempted to harmonise divergent naming 
conventions and reports of splice variants. Full-length membrane-bound RAGE has several 
splice variants and these are likely to affect ligand-binding and signal transduction [248]. 
However, the finding of novel variants has not been replicated in other laboratories [249, 
250]. 
In addition to splice variants there may be post-translational modifications of RAGE that 
affect ligand binding. The V-type immunoglobulin domain of RAGE has two potential N-
glycosylation sites. N-glycosylation is the enzymatic addition of an oligo- or poly-saccharide 
to a nitrogen molecule within a peptide. Such modifications increased RAGE affinity for 
S100A8/9, S100A12 and HMGB1 [251-253]. 
Genetic variation in the RAGE gene has been related to altered gene function and 
associations have been reported in relation to increase risk of development of diseases and 
in those with diseases, of complications. 
3.1.6. Genetic variation in the RAGE axis 
The human genome nomenclature committee (HGNC) use the name AGER for RAGE. This 
gene has 1492 base pairs and is on chromosome 6p21 in the major histocompatibility (MHC) 
complex locus in the class III region, and is given the Entrez Gene [254]  ID 177. The genomic 
context of the RAGE gene is shown in Figure 6. 
 
Figure 6: RAGE gene (termed AGER) on chromosome 6 and the genomic context 
Once transcribed the resultant messenger RNA (mRNA) includes 11 exons and is illustrated 
in Figure 7. Following splicing and translation the RAGE protein is 404 amino acids in length. 
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Figure 7: RAGE transcript, ENST00000375076. Boxes are exons and lines connecting are introns, boxes are filled if they 
contain coding sequence, and unfilled boxes represent untranslated regions. [image from http://www.ensembl.org/ 
genome browser] 
There are no published investigations of SNPs in the RAGE gene relating to acute 
inflammatory conditions. SNPs affecting the RAGE gene have been studied in association 
with the development of chronic diseases and particularly associated complications thereof. 
The largest literature exists for studies of patients with diabetes (Table 4), with some 
investigations in haemodialysis-dependent patients and those with rheumatoid arthritis 
(Table 5), also in healthy subjects (Table 6). 
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Gene SNP Populations Findings Reference 
RAGE –429 T/C 
Patients with type 2 DM: 106 with and 
109 without retinopathy 
–429 C allele associated with retinopathy and with increased in vitro 
transcriptional activity. 
[255] 
RAGE 
G82S, 1704G/T, 
2184A/G, 
and 2245G/A 
202 Caucasian patients with type 2 DM 
and 169 controls 
G82S and 2245G/A were associated with T2 DM. Complex 
relationships to antioxidant status in those with diabetes 
[256] 
RAGE G82S 
200 Asian Indians, 100 with retinopathy 
and 100 without, 50 unrelated controls. 
G82S was associated with a decreased incidence of retinopathy [257] 
RAGE 
−429 T/C, 
−374 T/A, 
and G82S 
996 Finnish patients with T1 DM 
Less coronary heart disease, acute myocardial infarction and 
peripheral vascular disease in patients with the AA genotype of the 
−374 T/A polymorphism 
[258] 
RAGE −374A 
703 Brazilians with type 2 diabetes (520 
Caucasian- and 183 African-Brazilians) 
−374A allele was associated with a decreased risk of having ischemic 
heart disease in African-Brazilian type 2 diabetic patients 
[259] 
RAGE G82S 
487 type 1 diabetic patients with 
proliferative retinopathy subdivided into 
four groups according to their level of 
renal involvement and in 351 control 
subjects 
G82S associated with advanced nephropathy [260] 
RAGE −374 T/A 
Scandinavians: 867 T1 DM, 2467 T2DM 
and 205 non-diabetic controls 
374 T/A polymorphism was associated with development of diabetic 
nephropathy and was found to be in LD with HLA-DQB1 
[261] 
RAGE Nine SNPs 
Dutch subjects with normal glucose 
metabolism (301), impaired glucose 
metabolism (127), and T2DM (146) 
The minor allele of G82S was strongly associated with lower sRAGE 
levels 
[262] 
RAGE -374 T/A 
1291 Dutch individuals, with normal 
glucose metabolism (44%), impaired 
glucose metabolism (23%) or T2 DM (33%) 
In those with normal glucose metabolism, the -374A allele of the 
RAGE gene is protectively associated with blood pressure and arterial 
stiffness, whereas in individuals with impaired glucose metabolism or 
T2 DM, it is adversely associated with these variables. 
[263] 
RAGE 
−429T/C, 
−374T/A, G82S, 
1704G/T, 
2184A/G, 
2245G/A 
605 Caucasian subjects, some with DM ± 
diabetic nephropathy (DN) 
Significant differences in haplotype frequencies among DM + DN vs. 
DM non-DN and non-DM groups 
[264] 
Table 4: RAGE polymorphisms and incidence of onset and complications of diabetes 
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Gene SNP Populations Findings Reference 
RAGE G82S 
205 Caucasian patients with RA and 169 
matched controls 
G82S associated with increased risk of RA but possibly due to LD with 
HLA-DRB1*0401. Ex vivo monocyte stimulation with S100A12 
demonstrated increased inflammatory signalling in those 
heterozygous for G82S than wildtype. 
[265] 
RAGE 
−429 CC and 2184 
GG 
261 unrelated Caucasian patients on 
chronic HD, 100 healthy controls 
Plasma sRAGE levels were higher in those with −429 CC and 2184 GG, 
and higher for all patients than controls. 
[266] 
Table 5: RAGE polymorphisms and incidence of rheumatoid arthritis, and effect on plasma sRAGE levels in haemodialysis-dependent patients 
 
Gene SNP Populations Findings Reference 
RAGE G82S 
262 infants aged 3-16m and 122 mothers 
of recruited children 
Minor allele of the RAGE gene polymorphism G82S was associated 
with reduced plasma sRAGE (30-40%) in all age groups 
[267] 
RAGE G82S 1676 healthy Koreans 
Minor allele of the RAGE gene polymorphism G82S was associated 
with reduced plasma sRAGE. Heterozygotes were intermediate. 
Additionally plasma levels of TNFα and hsCRP were higher in the SS 
group. 
 
[268] 
Table 6: RAGE polymorphisms and effect on plasma sRAGE levels and inflammatory markers in healthy humans 
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Of the many SNPs within the RAGE gene the most frequently studied are -374 T/A, −429 C/T, 
G82S, 1704 G/T And 2184 A/G. These descriptions of the SNPs are either the position 
relative to the gene and the nucleotide change (i.e. -374 T/A means position 374 before the 
start codon and change of T (thymine) for A (adenine), or the change in amino acid and the 
position within the protein (G82S). The standardised method of described these SNPs is the 
refSNP (rs) number and together with their functional significance are listed in Table 7. 
refSNP 
cluster ID 
numbers 
SNP 
name 
Location Change in 
nucleotide 
(common, 
variant) 
Change in 
amino 
acid 
Functional significance 
rs1800624 -374 T/A Promoter 
region 
 
T to A N/A Increased transcriptional 
activity of RAGE[255] 
rs1800625 −429 T/C Promoter 
region 
 
T to C N/A Increased transcriptional 
activity of RAGE[255] 
rs2070600 Gly82Ser 
G/A 
Ligand binding 
domain – 
exon3 
 
G to A Glycine to 
Serine 
Missense, results in 
damage to structure and 
function of RAGE[269] 
rs184003 1704 G/T Intron 7 
 
G to T N/A  
rs3134940 2184 A/G Intron 8 
 
A to G N/A  
Table 7: SNPs in the RAGE gene that we chose to genotype for. Adenine (A), Cytosine (C), Thymine (T), Guanine (G) 
There have been few genetic association studies of the S100 proteins. Indeed, only S100A8 
has been investigated in the context of the inflammatory dental condition, periodontitis 
[270]. In common with other S100A genes, its gene is on chromosome 1 and is given the 
Entrez Gene [254]  ID 6279. The genomic context of the S100A8 gene is shown in Figure 8. 
 
Figure 8: S100A8 gene on chromosome 1 and the genomic context 
Once transcribed the resultant messenger RNA (mRNA) includes 3 exons and is illustrated in 
Figure 9. Following splicing and translation the RAGE protein is 93 amino acids in length. 
72 
 
 
Figure 9: S100A8 transcript ENST00000368733. Boxes are exons and lines connecting are introns, boxes are filled if they 
contain coding sequence, and unfilled boxes represent untranslated regions 
SNPs of the HMGB1 gene have been studied and although their functional significance at 
the molecular levels remains undetermined, the -1377delA promoter polymorphism in 
HMGB1 was significantly associated with increased risk of delayed mortality in patients with 
SIRS and the 982C>T polymorphism in HMGB1 was associated with significantly higher 
probability of early death due to infection [271]. The gene is on chromosome 13 and is given 
the Entrez Gene [254]  ID 3146. The genomic context of the HMGB1 gene is shown in Figure 
10. 
 
Figure 10: HMGB1 gene on chromosome 13 and the genomic context 
Once transcribed the resultant messenger RNA (mRNA) includes 5 exons and is illustrated in 
Figure 11. Following splicing and translation the HMGB1 protein is 215 amino acids in 
length. 
 
Figure 11: HMGB1 transcript ENST00000339872. Boxes are exons and lines connecting are introns, boxes are filled if they 
contain coding sequence, and unfilled boxes represent untranslated regions 
3.1.7. Signalling 
3.1.7.1. Transduction 
The cytoplasmic tail of RAGE is essential for its role in signal transduction, with its deletion 
exerting a dominant-negative effect [243]. However, the lack of either endogenous kinase 
activity or any known motifs involved in receptor signalling left its mechanism of signal 
transduction unknown until very recently when several mechanisms for RAGE signal 
transduction were proposed (Figure 12). 
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Figure 12: Diagrammatic representation of intracellular signal transduction from RAGE ligation to altered cellular 
function. 
The RAGE cytoplasmic domain was found to interact with Diaphanous-1, a member of the 
formin protein family, which in turn, interacts with mediators of the actin cytoskeleton and 
various signal transduction pathway molecules including the members of the Rho family of 
GTPases, Rac-1 and Cdc42 [272]. 
RAGE forms oligomers on the cell surface and this may be necessary for ligand binding 
[273]; similarly sRAGE [274]. sRAGE and RAGE V-domain can interfere with this process 
inhibiting RAGE dimerization and downstream signalling events [275]. Receptor 
homodimerization is important for signal transduction in other receptor classes such as the 
toll-like receptors [276]. Alternatively, internalisation of the RAGE-ligand complex may be 
important in signal transduction [277]. 
RAGE activation results in the generation of intra-cellular ROS and this is a potent factor 
initiating signal transduction, including the redox-sensitive NF-κB and MAPK pathways [278]. 
In support of this, antioxidants such as N-acetylcysteine and vitamin E, have demonstrated 
inhibition of RAGE-mediated effects [279]. 
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The extracellular signal-regulated kinase-1 and -2 (ERK-1/2) proteins are important 
members of the mitogen-activated protein kinase (MAPK) pathway and have been found to 
interact with the cytosolic tail of RAGE[280]. 
3.1.7.2. Signalling pathways 
An array of intra-cellular signalling pathways has been implicated in the transduction of 
ligand binding to cellular response. The majority of findings from these studies have been 
identified in cells other than leukocytes, from animals other than humans and often in 
transformed cells. The extent to which these findings are generalisable is also challenged as 
different ligand-RAGE interactions result in alternative downstream events. These 
limitations restrict confidence in knowing which pathways are important in human primary 
leukocyte RAGE signal transduction. However, there is sufficient overlap to be able to draw 
some conclusions. 
The most commonly implicated signal pathway is that of nuclear factor κB (NF-κB), a 
complex and highly regulated network of intra-cellular proteins. NF-κB consists of two 
polypeptides (p50 and p65, also known as RelA) and when inactive, resides in the cytoplasm 
in physical association with its inhibitor proteins (the inhibitor–κB or IκB proteins). In 
response to diverse stimuli, including redox changes, the IκB proteins are phosphorylated by 
a complex of protein kinases (The IKKs). Once IκB has been degraded, NF-κB translocates to 
the nucleus where it regulates the expression of hundreds of immune and inflammatory 
genes [281]. 
Secondly, the mitogen-activated protein kinase (MAPK) pathways, c-Jun-NH2-terminal 
kinase/stress-activated protein kinase (JNK/SAPK), p38, and extracellular signal-regulated 
kinases (ERK) have been implicated. These pathways comprise of a complex sequence of 
kinases that rapidly connect single signals to multiple cellular events. They are 
interconnected and incorporate negative feedback loops and redundancy [282]. The MAPK 
pathways lead to activation of transcription factors including NF-κB, specificity protein 1 (Sp-
1), and activating protein-1 (AP1). 
Formation of intracellular ROS may link RAGE activation through initiating the NF-κB 
pathway directly or through the phosphatidylinositol 3′-kinase (PI3K) system to ERK1/2 
[283]. 
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In addition to altered cellular function through activation of transcription factors, protein 
kinases and cytoskeletal changes, there are two important positive feedback loops. Firstly, 
NF-κB promotes further RAGE gene expression [284] and secondly, RAGE activation results 
in increased levels of de novo synthesized NF-κBp65 overriding endogenous negative 
feedback mechanisms and perpetuating the response [285]. Finally, through a less direct 
feedback mechanism, the inflammatory mediator C-reactive protein, increases expression of 
RAGE [286]. 
3.1.7.3. In primary human leukocytes 
There are a paucity of investigations into RAGE signalling that utilise primary human 
leukocytes, partly due to their limited longevity in culture, their reluctance to tolerance 
experimental conditions (such as siRNA techniques) and the necessarily limited quantity of 
material for assays. However, the integral nature of ERK1/2 and NF-κB to RAGE signal 
transduction has been demonstrated in neutrophils in response to HMGB1, AGE and S100B 
[287-289] and the role of ROS has been demonstrated in monocytes in response to AGE 
[290]. 
3.1.8. Soluble RAGE isoforms 
The full-length membrane-bound RAGE protein has been variously described in the 
literature as mRAGE, FL-RAGE, or simply RAGE to distinguish it from the soluble forms of the 
protein that are present in human plasma (Figure 13). The major soluble forms are sRAGE 
(soluble RAGE) and esRAGE (endogenous secretory RAGE). Despite efforts to standardize 
terminology, these terms are used inconsistently in the literature.  
Several studies that have exhaustively studied soluble RAGE isoforms have identified other 
forms in human tissues; potentially the RAGE isoform expressed may depend upon the cell 
type and its environment [248, 291, 292].  
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Figure 13: Diagrammatic illustration of full-length RAGE on the left and the two soluble forms: sRAGE and esRAGE. 
3.1.8.1. sRAGE 
sRAGE is the predominant soluble form in human plasma and is produced by intra-
membrane proteolytic cleavage of full-length RAGE by the membrane metalloprotease 
(MMP) known as ADAM10 (A Disintegrin And Metalloprotease 10)[250, 293]. sRAGE retains 
the extracellular domains but lacks both the transmembrane domain and the cytoplasmic 
tail. 
The full-length RAGE protein is ubiquitous and as the soluble form lacks distinct epitopes, it 
is difficult to distinguish using immunoassays. It is present in the plasma of healthy humans, 
with levels that vary over time and between individuals [294]. By contrast, it is not present 
in the murine circulation [295]. 
Although primary human neutrophils and monocytes have been demonstrated to possess 
mRNA for RAGE and the RAGE protein on their cell surfaces [296-298], there are few 
published data suggesting that leukocytes are a major source of circulating sRAGE [250, 
299]. Circulating sRAGE is largely presumed to originate in the lung which has high basal 
RAGE expression [300, 301]; but another important potential source is the endothelium, 
RAGE being expressed on healthy and diseased human endothelial cells [302]. 
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3.1.8.2. esRAGE 
Endogenous secretory RAGE (esRAGE) is a product of alternative splicing of mRNA resulting 
in a novel stretch of amino acids in the C2-Ig domain, creating an epitope to which specific 
antibodies may be raised. Like sRAGE, it retains ligand-binding but does not have signal 
transduction capacity [303]. 
3.1.9. Differential regulation and expression 
By contrast to the hypothesis of differential regulation and expression, an 
immunohistochemical study of human expression of the two forms of RAGE, using 
antibodies directed against the V-type domain of RAGE, the cytosolic domain of RAGE and 
the C-terminal end of esRAGE, found very similar distributions across a wide range of tissues 
[304]. Similarly, in a large cohort of patients with chronic kidney disease, levels of sRAGE 
correlated very closely with levels of esRAGE [266]. 
Levels of circulating RAGE forms have been variably demonstrated to increase in vivo in 
response to medications including statins (e.g. atorvastatin), thaizolidinediones (e.g. 
pioglitazone), and angiotensin-converting enzyme inhibitors (e.g. perindopril). Supportive in 
vitro work has shown similar results with angiotensin receptor  blockers (e.g.candesartan) 
[299, 305-307]. However, there was no convincing evidence of differential regulation in 
these studies. By contrast, stimulation of human endothelial cells in vitro with distinct AGEs 
differentially enhances expression of RAGE isoforms [308]. 
3.2. RAGE Ligands 
With the exception of advanced glycation end-products, RAGE ligands are all proteins that 
have distinct intra- and extra-cellular properties, and lacking defined secretory signal 
sequences, crossing the plasma membrane through non-classical means [309]. For several of 
these ligands, RAGE is not their exclusive receptor. In a murine model of delayed-type 
hypersensitivity, sRAGE significantly attenuated the inflammatory response both in wild-
type and RAGE-deleted animals [310]. Similarly, sRAGE maintained beneficial anti-
inflammatory effects in a murine endotoxaemia model both in wild-type and RAGE-deleted 
animals [311]. 
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3.2.1. S100 proteins 
These are low-molecular-weight (9-13kDa) calcium-binding proteins with intracellular 
regulatory functions and extracellular effects on inflammatory cell activity. They possess a 
defining N-terminal EF-hand (Figure 14). 
 
Figure 14: Schematic representation of the secondary structure of an S100 protein. Each Ca-binding loop (L1 and L2, in 
the N- and the C-terminal half, respectively) is flanked by α-helices (helices I and II, and helices III and IV for L1 and L2, 
respectively). A linker region (hinge region, H) connects helix II to helix III. Helix IV is followed by a C-terminal extension. 
The hinge region and the C-terminal extension (in grey) display the least amount of sequence homology. An EF hand is the 
helix-loop-helix structure. Reproduced from [3]. 
When intracellular, they mostly exist as anti-parallel homodimers held together by non-
covalent bonds. They regulate the activity of effector proteins across diverse pathways 
including cell growth and differentiation, cytoskeletal maintenance and transduction of 
calcium signalling [3, 312, 313]. They have similarities to the archetypal calcium sensing 
protein calmodulin. The S100 proteins A8/9 and A12 are also known as the calgranulins, 
reflecting their calcium-binding properties, and are highly expressed in granulocytes. 
There are at least 25 identified S100 proteins which are expressed exclusively in vertebrates. 
The majority are of the S100A subfamily and their genes are located on chromosome 1q21. 
S100 genes from other chromosomal regions carry the stem symbol S100 followed by a 
single letter (e.g. S100B). 
S100 proteins are secreted by alternative, rather than classical pathways as they lack the 
relevant signal peptides for the classical endoplasmic reticulum-golgi network. Non-classical 
secretion is typical of DAMPs. The mechanisms by which they are secreted are poorly 
understood. Once in the extracellular space they undergo conformation change and acquire 
oligomeric structures in response to the increased calcium ion concentration. These 
oligomeric structures are important in signalling [314]. Zinc and copper concentrations are 
also important in regulating conformation and therefore signalling [315].  
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Of the S100 proteins, those that have been most studied in relation to acute inflammation 
in humans are S100A8/9, S100A12 and S100B.  
3.2.1.1. S100A8 and S100A9 
S100A8 and S100A9 associate to form the heterodimer known as calprotectin[316]. Other 
names include: A8 as Calgranulin A, or myeloid-related protein-8 (MRP-8), and A9 as 
Calgranulin B or MRP-14. When not in association, they form homodimers and their activity 
is greatly reduced [317]. Calgranulin also exists as heterotetramers and as such sequesters 
Zinc ions [318]. 
S100A8/9 is the most abundant cytoplasmic protein of neutrophils and monocytes (~49% of 
total cytosolic protein) and is released during their activation [319]. Plasma levels in healthy 
humans have been reported across a wide range of values from 58ng/ml to 1000ng/ml 
[320]. 
When extracellular the major role of S100A8/9 is as a potent chemoattractant for 
neutrophils and monocytes and its blockade significantly attenuates inflammatory cell 
migration [321, 322]. In addition, it can cause neutrophil degranulation [323, 324] and has 
been proposed to have inherent anti-microbial properties, possibly as a consequence of its 
zinc sequestering [325-329]. RAGE is an important receptor for S100A8/9, but there is also 
evidence of activity mediated by TLR4-MD2 complex [330-332]. 
Post-translational modifications of these proteins affect their function. S100A8 may be 
modified by S-nitrosylation (addition of -NO to cysteine) or oxidation; S100A9 by S-
glutathionylation (addition of glutathione to a cysteine residue). These modifications 
generate novel anti-inflammatory activities and may function as a negative feedback loop 
[333-335]. By binding ROS they may restrict tissue damage and promote resolution of 
inflammation. 
S100A9 genetically deleted mice live and breed normally. As well as lacking S100A9 protein, 
they also lack S100A8 and therefore the A8/9 heterodimer [336]. 
3.2.1.2. S100A12 
S100A12 has also been known as calgranulin C and extracellular newly identified ligand of 
RAGE (EN-RAGE). It has a high degree of structural homology with S100A9 and is absent in 
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the rodent genome [337]. Like calprotectin, it is constitutively expressed in phagocytes, but 
to a lesser extent (~5% total cytosolic protein) [338]. It binds RAGE on monocytes, 
neutrophils, endothelial cells, macrophages, and lymphocytes [339, 340], provoking pro-
inflammatory responses including chemoattraction and adhesion. S100A12 is susceptible to 
conformational rearrangement in response to altered metal ion concentration; in particular 
the increased extracellular calcium concentration causes formation of S100A12 hexamers, 
greatly increasing their affinity to RAGE [274]. In small cohorts of healthy humans, S100A12 
plasma levels have been found to be between 8 and 75ng/ml [341-344]. 
3.2.1.3. S100B 
The first of the identified S100 proteins was the heterodimer of S100B with S100A1 purified 
from bovine brain [345]. S100B exists within cellular cytoplasm as a homodimer in which the 
two subunits are held together by non-covalent bonds and are arranged in an anti-parallel 
fashion [346]. S100B also forms a variety of oligomeric structures including dimeric, 
tetrameric, hexameric and octameric forms, depending upon calcium ion concentration. The 
oligomeric structure of S100B strongly influences its affinity for RAGE and this is reflected in 
subsequent RAGE activity, with tetrameric forms having greater activity than dimeric forms 
in experimental models [347]. A practical consideration when using S100B experimentally is 
that repeat freeze-thaw cycles may decrease the relative abundance of the more complex 
associations [347].   
The human gene encoding S100B maps to chromosome 21q22.3 and several SNPs have 
been described [348, 349] but without published studies relating to inflammatory diseases.  
S100B is present in the cytoplasm in a wide variety of cells within the nervous, renal, and 
endocrine systems as well as muscle, skin and adipose tissue. Within cells S100B acts as a 
calcium ion sensor protein and upon binding undergoes conformational change, exposing a 
hydrophobic cleft through which dimeric S100B binds to intracellular target proteins. 
Functional effects are diverse and include the regulation of cell proliferation, differentiation 
and shape, calcium homeostasis, protein phosphorylation, transcription, enzyme activity 
and metabolism [346]. 
In monocytes, S100B binds to RAGE and causes pro-inflammatory responses including TNF-α 
and prostaglandin secretion, ROS generation, and promotion of adherence to endothelium 
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[350-352]. In neutrophil-like HL60 cells it promotes ROS generation and in neutrophils, 
enhances chemoattraction and induces expression of pro-inflammatory cytokines [287, 
353]. These functional effects are mediated through changes in the MAPK and NF-κB cell 
signalling pathways. Radioligand studies confirm binding of S100B to RAGE that is blocked 
by the application of sRAGE [339]. 
Extracellular S100B may originate either from secretion or leakage from damaged cells. 
Secretion has been most comprehensively studied in astrocytic multifunctional glial cells, 
within the central nervous system. They release S100B in response to various stimuli 
including pro-inflammatory cytokines and metabolic stress [354, 355]. S100B is secreted 
under normal physiological conditions and plasma levels are high during development, 
decreasing in adults [356-359]. Plasma levels in healthy humans are affected by variation 
within the gene and by adiposity [358, 360, 361]. In a cohort of 200 healthy humans, the 
median level of S100B was 50pg/ml [358]. 
3.2.2. HMGB1 
High mobility group box 1 (HMGB1, previously named HMG1 or amphoterin) is a 25kDa 
nuclear DNA-binding protein that is highly conserved across species and widely distributed 
in all mammalian tissues. Structurally, it is composed of three domains: two homologous 
DNA binding motifs named A box and B box, and a negatively charged C-terminus [362]. 
HMGB1 may exist in its native form or after a variety of post-translational modifications. 
Nuclear HMGB1 may be acetylated in response to inflammatory cell activation resulting in 
HMGB1 passing into the cytosol, prior to packaging into lysozymes and being secreted [363]. 
HMGB1 can exist in oxidised or reduced states (via an intra-molecular disulphide bond) 
which may affect extracellular activity [364]. Indeed, all HMG proteins are subjected to 
extensive post-translational modifications [365] and the extent to which this affects extra-
cellular activity remains to be fully elucidated. 
In the nucleus, HMGB1 binds DNA in a non-specific manner and acts primarily by 
manipulating nucleoprotein complexes to regulate gene transcription and to fluidize 
chromatin by loosening the wrapped DNA-core histone complex [365]. HMGB1 genetically 
deleted mice die shortly after birth from hypoglycaemia, supporting the functional 
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significance of the role of HMGB1 in the transcriptional enhancement of the glucocorticoid 
receptor [366]. 
In a large cohort of healthy humans the mean level of circulating HMGB1 was 1.69±0.04 
ng/ml in males and 1.62±0.04 ng/ml in females; sRAGE levels being independently inversely 
related, and CRP and WBC being (independently) positively related [367]. Anti-HMGB1 
antibodies have been found in the plasma of patients with auto-immune disease and in 
more than one third of patients with septic shock [368, 369]; it is uncertain how this affects 
the accuracy of immunoassays. 
The role of extracellular HMGB1 is contentious; a large body of work suggesting it fulfils a 
cytokine-like role, eliciting pro-inflammatory responses. By contrast, there are data 
suggesting that HMGB1 may have only weak or absent inflammatory activity per se and is 
more likely to function as a molecular chaperone, augmenting the inflammatory responses 
to other mediators.  
3.2.2.1. The case for HMGB1 being a pro-inflammatory mediator 
3.2.2.1.1. Interventional models 
Initially, murine experiments revealed that HMGB1 levels were elevated during sepsis and 
administration of HMGB1 was lethal, and that antibodies to HMGB1 were protective against 
lethal endotoxaemia. Furthermore, they demonstrated that endotoxin caused release of 
HMGB1 from macrophages and levels of HMGB1 were elevated in patients with sepsis 
[370]. These elevations occurred late and persisted far beyond those of the classical 
cytokines; thus HMGB1 was considered to have a larger potential ‘therapeutic-window’ for 
intervention and was described as a late-mediator of sepsis. An inhibitor of HMGB1 release, 
ethyl pyruvate (EP) was shown to have efficacy in reducing mortality in murine 
endotoxaemia and polymicrobial sepsis, even when administered 24h after the onset of 
injury[371]. Later, other inhibitors (anti-HMGB1 antibodies or DNA-binding A box) were also 
shown to be similarly effective in murine models of sepsis even when given late [372]. 
Indeed, a large number of HMGB1-inhibiting reagents have been evaluated in murine 
models of sepsis, (reviewed by Wang et al [373]). In addition to models of sepsis, inhibition 
of HMGB1 was found to be efficacious in experimental acute lung injury, pancreatitis, 
haemorrhagic shock and polytrauma [374-378]. HMGB1-inhibition is particularly attractive 
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as a potential treatment in humans as the therapeutic window is wide and the experimental 
interventions were effective when started after the onset of systemic inflammation; a 
situation akin to the use of antibiotics in patients presenting with sepsis. 
3.2.2.1.2. In vitro data  
Inflammatory stimuli cause monocytes and macrophages to secrete HMGB1 in a non-
classical, leaderless manner [379], an effect that can be attenuated by immunomodulatory 
drugs such as corticosteroids [380]. In response to extra-cellular HMGB1, monocytes show 
altered chemotaxis (spreading), transendothelial migration [381] and release of IL-6, IL-1β 
and TNF-α [382, 383]. HMGB1 also mediates neutrophil adhesion and transmigration across 
endothelium as well as inducing pro-inflammatory cytokine expression [374, 384, 385]. The 
actions of HMGB1 have been shown to be mediated through interaction with RAGE, TLR2, 
TLR4, and TLR9 [386-389]. 
3.2.2.1.3. Patients 
Levels of HMGB1 have been found to be elevated, and in some cases related to clinical 
outcome, in the plasma of patients with acute inflammatory conditions including 
pneumonia, sepsis and septic shock, haemorrhagic shock, disseminated intravascular 
coagulation, falciparum malaria, burns, trauma and severe acute pancreatitis[390-401]. 
Soon after surgery, monocytes exhibit increased HMGB1 expression. Later this is 
diminished, concurrent with elevation in plasma HMGB1 levels, thereby implicating 
monocytes as a source of plasma HMGB1 [383]. 
3.2.2.2. The case against HMGB1 being a pro-inflammatory mediator 
The form of HMGB1 used in early experiments was recombinant and sourced from E. Coli. In 
2007, a pivotal advance suggested that when eukaryotic HMGB1 was appropriately purified, 
it lacked the observed cytokine-like activities [402, 403]. In fact, lesser inflammatory effects 
of native, compared to recombinant, HMGB1 had previously been reported [404]. Affinity 
chromatography revealed that bacterially-derived material, including lipids, were tightly 
bound to HMGB1 and contributed to the observed activity [403]. Thus, in addition to the 
effect of many possible post-translational modifications to HMGB1, there remains the 
important effect of smaller molecules bound to HMGB1 including LPS, IL-1β, IFN-γ, TNF-α 
and fragments of DNA [388, 405, 406]. These findings have altered the view of the scientific 
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community of HMGB1 which is now generally considered to act as a chaperone protein, in 
molecular collaboration with other immuno-stimulatory factors [407, 408]. 
A compelling reason to doubt that inhibition of HMGB1 will offer therapeutic benefit in 
patients is that in a large cohort of patients with severe community acquired pneumonia, 
HMGB1 levels were persistently elevated at hospital discharge [409, 410]. It remains 
possible that anti-HMGB1 therapies will retain efficacy through diminishing the adjuvant 
role of HMGB1 in potentiating inflammatory responses. 
3.2.3. Advanced glycation end-products 
Advanced glycation end-products (AGEs) result from post-translational non-enzymatic 
glycation and oxidation of proteins and lipids and accumulate in diverse biological settings. 
The biochemical reactions leading to the formation of AGEs (Maillard reaction and Amadori 
rearrangement) occur in all tissues and body fluids. The amount of AGE modifications to a 
protein is dependent upon the inherent reactivity of specific amino groups, their 
microenvironment, the glucose concentration, and the half-life of the protein [411]. 
More than a dozen AGE have been found in tissue proteins such as collagen. Adducts 
include Nε carboxyethyl-lysine (CEL) and Nε carboxymethyl-lysine (CML), and crosslinks like 
glyoxal-lysine dimer (GOLD), methlyglyoxal-lysine (MOLD), pentosidine and verperlysines. 
The commonest AGE modification present in human tissue is CML [412, 413]. Albumin is the 
predominant plasma protein, with approximately 30-50g in every litre of plasma and a half-
life of 20 days; it is also a major target of oxidant stress [414]. CML-modified albumin is 
elevated in those with diabetes and is implicated in the development of vascular 
complications [415].  
Clearance of plasma AGEs is achieved predominantly through glomerular filtration and 
therefore chronic kidney disease is associated with raised plasma AGE, including CML-
albumin. Levels correlate to plasma creatinine, and diminish with dialysis and following 
renal transplantation [416-418]. 
AGE accumulation is believed to be a consequence rather than a cause of aging. In humans, 
age-related increases in AGE have been demonstrated in tissues of high extra-cellular matrix 
content with slow, little, or no turnover, including human dura mater, skin and cartilage 
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[419]. Similarly, in nucleated cells with intact metabolic machinery (peripheral T 
lymphocytes) there is a curvilinear increase in the AGE pentosidine with age. This increase is 
potentiated by the presence of end-stage renal disease [420]. The formation of AGEs is 
predominantly endogenous, but they can also be derived from exogenous sources such as 
food and tobacco smoke [421]. Studies of human female twins suggest that the degree of 
plasma CML is largely determined by genetic factors [422]. AGE formation can also occur 
acutely and is facilitated by oxidative stress, acute hyperglycaemia and the actions of 
neutrophil myeloperoxidase [423, 424].  
AGE-modified proteins, including plasma proteins such as albumin, have been shown to 
induce inflammatory responses in leukocytes, mediated via RAGE. CML-albumin has been 
shown to induce an inflammatory response in neutrophils and monocytes, mediated by 
RAGE [287, 297, 425]. AGE both increases surface RAGE expression on monocytes 
experimentally and has been observed to be an independent determinant of the extent of 
monocyte RAGE expression [296, 426]. By contrast, in a cell-free model, AGE was not found 
to bind RAGE [427] and AGEs were not found to induce inflammatory responses in 
peripheral blood mononuclear cells [352]. These discrepant results can be partly explained 
by consideration of the extent of AGE modification. It is simple to generate AGE-modified 
proteins such as albumin experimentally but the degree of glycation may be excessive and 
lack physiological relevance; in vivo glycation modifications are minimal, perhaps one 
modified amino acid per protein [428].  
In support of the pathogenic role of AGE and the pivotal role of RAGE, a recent study 
demonstrated that commercially-available albumin used in the resuscitation fluid ‘human 
albumin solution’, has extensive AGE modifications; furthermore, its use in mice with 
experimental sepsis worsened mortality. Importantly, RAGE-deletion protected mice from 
this effect [429]. 
3.2.4. Amyloid proteins 
Amyloid proteins are insoluble fibrous proteins that are implicated in the pathogenesis of 
diverse conditions including the systemic amyloidoses, Alzheimer’s disease and rheumatoid 
arthritis. Of the varied amyloid proteins, there is evidence of interaction with RAGE for 
serum amyloid A (SAA), transthyretin (TTR) and amyloid β protein [430-433]. The SAA family 
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comprises a number of differentially expressed lipid-binding proteins [434]. Amyloid β 
protein is a short peptide formed by cleavage of the transmembrane glycoprotein named 
amyloid precursor protein (APP) and has a propensity to coalesce to forms fibrils. TTR is a 
55-kDa homotetramer that is physiologically present in the plasma and cerebrospinal fluid 
and binds substances including thyroxine and vitamin A, but also accumulates in systemic 
amyloidoses. SAA has been demonstrated to cause pro-inflammatory responses via RAGE on 
human monocytes and fibroblasts [432, 435].  
RAGE-mediated inflammation due to amyloid β protein neuronal deposition has been 
implicated as a fundamental contributor to the pathogenesis of Alzheimer’s disease [436]. 
Indeed, an early-phase clinical trial of the RAGE inhibitor TTP-488 in patients with 
Alzheimer’s reported a favourable safety profile [437]. 
3.2.5. Integrins 
Integrins are a large family of receptors with functions that include mediation of cellular 
adhesion, either between cells or between the cell and its extracellular matrix. Leukocytes 
express distinct patterns of integrins dependent upon their ontogeny and environment.  
Macrophage-1 antigen (Mac-1) is a heterodimeric integrin consisting of alpha-M and beta-2 
(αMβ2) components, is known as a β-2 integrin and is present on neutrophils, monocytes 
and macrophages and NK cells. The αM component is also known as CD11b or integrin alpha 
M; the β-2 component is also known as CD18 [438]; Mac-1 is also known as complement 
receptor 3 (CR3). 
RAGE has been identified as a counter-receptor for the integrin Mac-1. In an experimental 
model of murine peritonitis, sRAGE diminished neutrophil recruitment. The effect was more 
pronounced when RAGE had been up-regulated. RAGE-deleted mice exhibited diminished 
neutrophil recruitment that was reversed by restoring the expression of RAGE on 
endothelial cells. The RAGE-deleted mice also exhibited decreased macrophage recruitment. 
Further work revealed that Mac-1 bound directly to RAGE, an effect augmented by the 
presence of S100B [439]. Ligation with Mac-1 results in inflammatory responses mediated 
by NF-κB [440, 441]. Furthermore, the chemoattractant properties of HMGB1 may be partly 
attributable to the interaction of Mac-1 and RAGE on neutrophils [442]. 
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3.3. RAGE axis in systemic inflammation 
The role of the RAGE axis has been extensively studied in animal models of acute systemic 
inflammatory conditions, particularly sepsis. More recently, clinical observational studies 
have begun to measure aspects of the RAGE axis in humans with acute systemic 
inflammatory conditions. Interventional trials in this area are yet to be performed. 
3.3.1. Animal models 
3.3.1.1. Sepsis 
Strategies aimed at reducing RAGE-mediated inflammation, explored specifically via the use 
of genetically modified mice or the administration of inhibitors, have shown lethality to be 
reduced in various models of sepsis (Table 8). That most studied has been caecal ligation 
and puncture (CLP), in which significant survival benefit was demonstrated following 
administration of anti-RAGE and anti-HMGB1 antibodies, or after administration of 
pharmacological HMGB1-inhibitors. Similar effects were seen in RAGE-deleted mice [310, 
371, 372, 443, 444]. Importantly, the survival benefits associated with anti-RAGE antibodies, 
anti-HMGB1 antibodies and ethyl pyruvate remain even when they are administered up to 
24h after the CLP procedure [371, 372, 443]. The administration of sRAGE was associated 
with a trend towards improved survival [310]. The efficacy of anti-RAGE strategies is not 
limited to models of intra-abdominal sepsis, but also those employing systemic Listeria 
monocytogenes, intra-nasal Streptococcus pneumoniae or influenza A [443, 445, 446]. 
Targeting relevant ligands to limit RAGE-mediated effects is also associated with 
substantially improved survival and diminished early bacterial dissemination in mice 
genetically deprived of S100A8/9 compared to wild-type, both in systemic endotoxaemia 
and Escherichia coli–induced abdominal sepsis [331, 447]. As discussed in Section 3.2.2, 
inhibition of HMGB1 also showed beneficial effects in murine models of septic and non-
septic systemic inflammation. In addition to anti-HMGB1 antibodies, agents that inhibit the 
release of HMGB1, such as ethyl pyruvate (EP), stearoyl lysophosphatidylcholine, 
intravenous immunoglobulin (IVIG), vasoactive intestinal peptide, ghrelin, and nicotine; or 
those that bind fragments of the HMGB-1 protein (DNA-binding A box), or thrombomodulin 
have all ameliorated adverse inflammatory responses [373]. The substantially reduced 
lethality in RAGE-deleted mice, exposed to AGE-rich human albumin solution as 
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resuscitation fluid in septic shock provides compelling evidence for the centrality of RAGE 
and its ligands [429]. 
Further evidence of the capacity of sRAGE to reduce inflammation and its adverse sequelae 
in acute systemic inflammation was seen when administration of sRAGE reduced end-organ 
damage and levels of pro-inflammatory cytokines and improved mortality in a murine 
systemic endotoxaemia model; effects also seen in RAGE-deleted mice [311]. The 
investigators proposed that LPS binding to RAGE mediated the effect of sRAGE. Alternatively 
sRAGE bound canonical RAGE ligands released in response to endotoxaemia and abrogated 
receptor-mediated inflammatory responses – RAGE-mediated in the wildtype mice and TLR-
mediated in the RAGE-deleted mice. 
3.3.1.2. Non-infective SIRS 
Studies of RAGE inhibition in non-septic systemic inflammation published to date are 
summarised in Table 9. In models of haemorrhagic shock and resuscitation, administration 
of sRAGE attenuated the associated systemic inflammation and RAGE-deleted mice 
exhibited a protected phenotype [448]. Anti-HMGB1 antibodies prevented death and gut 
barrier dysfunction [378]. Use of a resuscitation fluid containing the HMGB1-inhibitor EP 
was associated with complete protection from lethal haemorrhage compared to control 
fluid [449]. 
Anti-HMGB1 antibodies reduced systemic inflammation and end-organ damage following 
bilateral femoral fracture and severe acute pancreatitis (SAP) [376, 377]. EP also limited 
systemic inflammation and improved survival in rat models of pancreatitis, even when given 
12h after onset of SAP [450]. As EP is a small molecule effective at clinically achievable 
concentrations it seems particularly attractive as a pharmacological inhibitor of HMGB1 
release. 
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 Treatment group vs. control group 
Author and year Model 
Mode of RAGE inhibition and 
control 
Indication of altered bacterial 
dissemination 
Organ failure Survival difference 
Yamamoto 
2011[311] 
Intraperitoneal LPS RAGE-deleted, sRAGE Not reported 
Less lung and liver damage 
with sRAGE 
Improved survival in RAGE KO vs. WT 
Improved survival with sRAGE in both RAGE KO and WT 
Van Zoelen 
2010[451] 
Intraperitoneal E.Coli 
RAGE-deleted vs. wildtype 
Increased CFU in peritoneal fluid, blood, 
liver and lungs at 20h 
Worse hepatocellular 
damage 
Not assessed 
Anti-RAGE IgG vs. control IgG 
Increased CFU in peritoneal fluid and 
distant organs at 20h 
No change Not assessed 
Van Zoelen 
2009[445] 
S. pneumoniae 
intranasally 
RAGE-deleted vs. wildtype Decreased CFU in lung, blood and spleen Less lung inflammation Improved survival 
Van Zoelen 
2009[446] 
Influenza A 
intranasally 
RAGE-deleted vs. wildtype Increased clearance of influenza A Not reported Improved survival 
Zhu 2009[444] CLP 
Spermine (inhibitor of HMGB1 
release) vs. control 
Not reported Not reported 
Improved survival when given early and when given late. 
Excessive doses given late worsened survival. 
Table 8 (part I): Summary of major papers assessing effects of RAGE inhibition in murine models of sepsis. sRAGE soluble RAGE, HMGB1 high mobility group box 1, CFU colony forming units, CLP 
caecal ligation and puncture, LPS lipopolysaccharide, IV intravenous. 
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 Treatment group vs. control group 
Author and year Model Mode of RAGE inhibition and control 
Indication of altered bacterial 
dissemination 
Organ failure Survival difference 
Su 2008[452] Intraperitoneal LPS Ethyl pyruvate vs. placebo Not reported No change Worsened survival 
Lutterloh 
2007[443] 
CLP 
RAGE-deleted vs. wildtype 
No change to CFU in liver, spleen and 
peritoneal lavage fluid 
Not reported Improved survival 
Anti-RAGE IgG vs. control IgG 
No change to CFU in liver, spleen and 
peritoneal lavage fluid 
Less lung and gut 
injury 
Improved survival, even when given as a single 
dose 24 hours after CLP 
Listeria monocytogenes IV 
RAGE-deleted vs. wildtype 
No change to CFU in liver or spleen Not reported Improved survival 
Anti-RAGE IgG vs. control IgG 
Vogl 2007[331] 
Intraperitoneal LPS with 
galactosamine 
S100A9-deleted vs. wildtype Not reported Not reported 
Improved survival, returned to normal with IV 
S100A9. 
Liliensiek 
2004[310] CLP 
RAGE-deleted vs. wildtype (and RAGE over-
expressing mutants) 
Not reported Less hypotension 
Improved survival in RAGE-deleted and no change 
in over-expressing mutants. 
sRAGE intra-peritoneal repeat doses vs. vehicle Not reported Not reported Trend towards improved survival. 
Yang 2004[372] 
Anti-HMGB1 vs. control Ig, given 24h after onset No change to CFU in spleen Not reported Improved survival 
Intraperitoneal LPS 
A box subunit of HMGB1 vs. control, given 24h 
after onset 
No change to CFU in spleen Not reported Improved survival 
Ulloa 2002[371] 
Ethyl pyruvate (40mg/kg) vs. placebo, given 
before LPS 
Not reported Not reported Improved survival 
CLP 
Ethyl pyruvate (40mg/kg) vs. placebo, given 
repeatedly from 24h after CLP 
Not reported Not reported Improved survival 
Wang 1999[370] Intraperitoneal LPS 
Anti-HMGB1 IgG intra-peritoneal repeat doses 
vs. control IgG 
Not reported Not reported Improved survival, even when delayed 
Table 8 (part II): Summary of major papers assessing effects of RAGE inhibition in murine models of sepsis. sRAGE soluble RAGE, HMGB1 high mobility group box 1, CFU colony forming units, CLP 
caecal ligation and puncture, LPS lipopolysaccharide, IV intravenous 
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 Treatment group vs. control group 
Author and 
year 
Model 
Mode of RAGE inhibition and 
control 
Indication of altered bacterial dissemination Organ failure Survival difference 
Cai 2009[449] 
Haemorrhagic shock and 
resuscitation 
Ethyl pyruvate vs. none Not reported Not reported 
Dose-dependent, survival 
benefit 
Yang 2006[378] HMGB1 AB vs. control 
Decreased bacterial translocation to mesenteric 
lymph nodes 
Attenuated ileal mucosal hyperpermeability 
Survival benefit (90% vs. 
46%) 
Levy 2007[376] Bony fractures HMGB1 AB vs. control Not reported Attenuated hepatic and systemic inflammation Not assessed 
Sawa 2006[377] 
Severe acute pancreatitis (SAP) 
HMGB1 AB vs. control Increased bacterial translocation to pancreas 
Attenuated pancreatitis and pulmonary and 
renal injury 
Not assessed 
Yang 2008[450] 
Delayed ethyl pyruvate vs. 
control 
Not reported 
Attenuated hepatic, pulmonary and renal 
injury 
Prolonged survival 
Raman 
2006[448] 
Haemorrhagic shock and 
resuscitation 
RAGE-deleted vs. wildtype 
sRAGE vs. sham 
Decreased bacterial translocation to mesenteric 
lymph nodes 
Not reported Not assessed 
Table 9: Summary of major papers assessing effects of RAGE inhibition in murine models of non-septic systemic inflammation. AB antibodies, LPS lipopolysaccharide, KO knockout, WT wildtype, 
LD50 median lethal dose 
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 Condition Measurement Association 
Nakamura 
2011[453] 
ARDS and sepsis 
sRAGE  and HMGB1 levels in 
blood 
sRAGE was independently associated with death 
Jaboudon 
2011[454] 
ARDS ± severe sepsis sRAGE levels in blood sRAGE levels correlated with severity of ARDS, independent of presence of severe sepsis 
Cohen 2010[455] Trauma sRAGE levels in blood 
sRAGE levels were increased early after severe trauma and correlated with the severity of injury, early posttraumatic coagulopathy 
and hyperfibrinolysis, and endothelial cell activation 
Manganelli 
2010[383] 
Major elective surgery 
HMGB1 levels in blood and on 
monocytes 
HMGB1 is increased on monocytes early post-operatively, and then concurrent with increases in plasma HMGB1, decreases. 
Kikkawa 
2010[456] 
Sepsis, major elective 
surgery ± ALI 
sRAGE and S100A12 plasma 
levels 
sRAGE increases in those who do not develop ALI; S100A12 increases more in those that develop ALI. 
Agonstoni 
2010[457] 
snCPB sRAGE levels in blood sRAGE increases following snCPB 
Kohno 2010[458] Aortic snCPB HMGB1 levels in blood Higher HMGB1 was associated with more severe SIRS and a higher incidence of impaired oxygenation 
Calfee 2008[459] ALI/ARDS sRAGE levels in blood Levels associated with severity of illness in all. In subset (high tidal volume arm) correlated with mortality 
Table 10 (Part I): Human studies of the sepsis syndromes relating to measurements of the RAGE axis. BAL broncho-alveolar fluid 
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 Condition Measurement Association 
Payen 2008[460] Recovery from septic 
shock 
Leukocyte gene expression array One of the greatest changes in expression was S100A8 and A12, with plasma S100A8/9 levels changing in parallel 
Bopp 2008[461] Sepsis (and ARDS) sRAGE levels in blood Highest levels in non-survivors 
Kocsis 2009[462] 
Severe acute pancreatitis; 
sepsis 
sRAGE and HMGB1 levels in 
blood 
sRAGE highest in those with sepsis, HMGB1 higher in those with severe, compared to mild pancreatitis 
Makam 2009[463] Cystic fibrosis 
RAGE on neutrophils from 
airways and blood 
Degree of airway inflammation and extent of RAGE expression on airway neutrophils 
Determann 2008[464] Major elective surgery sRAGE levels in blood and BAL Blood levels increased without change in BAL levels 
Wang 1999[370], Sunden-
Cullberg 2005[392] 
Sepsis 
HMGB1 levels in blood 
Levels elevated up to 7 days after admission, without predictable correlation to severity of infection 
Angus 2007[409] 
Community acquired 
pneumonia 
Levels elevated in almost all patients, and although higher circulating HMGB1 were associated with mortality, levels were 
also persistently elevated in those with uncomplicated recovery 
Peltz 2009[400] Trauma Levels elevated as early as one hour after trauma, without relationship to patient outcome 
Alleva 2005[396] 
Infection with Falciparum 
malariae 
Levels elevated at admission to hospital and to a greater extent in non-survivors 
Lantos 2010[397] 
Burn injury >10% body 
surface area 
Levels elevated, with levels correlating to extent of burns and being higher in non-survivors 
van Zoelen 2009[447] 
Severe sepsis 
S100A8/9 levels in blood Levels elevated compared with controls, with levels not correlating to severity of illness. 
Piazza 2007[465] 
S100B levels in blood 
S100B was significantly elevated, no more so in those with cerebral dysfunction 
Korfias 2006 [466] 
Trauma without head 
injuries 
S100B was significantly elevated, in relation to extent of injury and rapidly declined. 
Table 10 (Part II): Human studies of the sepsis syndromes relating to measurements of the RAGE axis. BAL broncho-alveolar fluid 
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3.3.2. Human studies 
3.3.2.1. Sepsis 
Levels of plasma sRAGE have been quantified in observational studies of patients with 
sepsis, in the presence or absence of co-existent ALI/ARDS (Table 10). The first description 
of raised sRAGE in patients with severe sepsis or septic shock was made in a cohort of 
surgical patients; levels were higher than those in controls, and highest in non-survivors. 
Although the presence of ALI/ARDS was not expressly described, both survivors and non-
survivors had oxygenation indices within the defining range for ARDS [461]. A far larger 
cohort of patients with ALI/ARDS, of whom 26% had sepsis as the primary cause, was found 
to demonstrate a correlation between severity of illness (APACHE III score) and plasma 
sRAGE levels [459]. In 20 patients with sepsis (mean APACHE II score of 18.5) sRAGE was 
elevated (2,214±252pg/ml) and correlated positively with plasma HMGB1 levels [462]. No 
description of any relationship to oxygenation was reported. Experimental endotoxaemia 
has been shown to increase levels of plasma sRAGE in healthy volunteers [467]. 
Several recent studies have investigated the relationship between sRAGE and clinical 
parameters in patients with ALI/ARDS and severe sepsis. In patients with both ARDS and 
severe sepsis, sRAGE and HMGB1 levels correlated and were higher in non-survivors, sRAGE 
being an independent predictor of death. No relationship was found between lung injury 
score and sRAGE levels [453]. In another study, levels of plasma sRAGE were compared 
between patients with severe sepsis, severe sepsis with ARDS, ARDS alone and controls. 
sRAGE was found to be elevated in proportion to several markers of ALI/ARDS and without 
difference in levels between those with severe sepsis (without ARDS) and controls [454]. 
Finally, in patients who underwent surgery for abdominal sepsis, some of whom developed 
ALI, plasma sRAGE was higher in those who did not develop ALI, S100A12 higher in those 
who did [456].  
It is difficult to reconcile these contradictory findings. What is clear is that plasma sRAGE 
levels increase in systemic inflammatory conditions, and ALI/ARDS rarely if ever occurs in its 
absence. Additionally, plasma sRAGE levels undoubtedly bear an important relationship to 
alveolar injury, as is discussed in more detail in Section 3.4. 
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Measurement of plasma sRAGE represents only one aspect of the RAGE axis and may not be 
the best gauge of RAGE-axis activity – to date no studies have quantified the extent of RAGE 
leukocyte expression in acute systemic inflammation. However, airway neutrophil RAGE 
expression in patients with chronic airway inflammation was found to be greater than in 
circulating neutrophils [463]. The only other published study of cellular RAGE expression 
was outside the context of acute illness, and demonstrated a positive correlation between 
monocyte RAGE expression and levels of serum AGE [296]. 
Circulating levels of the RAGE ligands (S100A8/9, S100A12, S100B, HMGB1) have been 
shown to be elevated in the plasma of patients with sepsis [341, 370, 392, 447, 460, 465, 
468, 469]. Changes in the expression profile of leukocytes in those recovering from septic 
shock revealed that of the 340 genes studied, some of the greatest changes were in the 
genes for S100A8 and S100A12 and that non-survivors had significantly higher plasma levels 
of S100A8/9 [460]. 
3.3.2.2. Non-infective SIRS 
Levels of plasma sRAGE and RAGE ligands have been quantified in observational studies of 
patients with pancreatitis, burns, trauma, and following major elective surgery. Firstly, 
elective surgical patients undergoing cardiac, thoracic or major abdominal surgery 
demonstrated elevations in plasma sRAGE post-operatively [457, 464, 470]. Those 
undergoing thoracic aneurysm repairs (snCPB) demonstrated elevated levels of HMGB1 
[458]. Secondly, those with pancreatitis also showed elevated plasma sRAGE levels 
compared to controls, but with inverse correlations to disease severity and plasma HMGB1 
levels [462]. Finally, burns and trauma were both associated with increased levels of 
circulating HMGB1 [400]. Levels of HMGB1 were positively correlated with the extent of the 
burn injury and were higher in non-survivors [397]. Levels of sRAGE are elevated very early 
following trauma and positively correlated with the extent of injury, though did not relate to 
mortality [455]. 
Together, these findings indicate that sRAGE levels increase as a consequence of tissue 
damage. To what extent alveolar injury, either attributable to mechanical ventilation (in the 
elective surgery patients), or in response to circulating mediators (in the other patients) was 
relevant is uncertain. 
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3.3.3. Potential role of RAGE inhibition 
Inhibition of RAGE mediated signalling can be achieved through several means. Firstly, 
reduction of the amount of available ligand, either through reduced release or enhanced 
elimination. Agents that inhibitors release of HMGB1 include spermine and ethyl pyruvate. 
Secondly, blockade of RAGE-RAGE ligand interaction has been demonstrated through the 
use of anti-RAGE antibodies, anti-HMGB1 antibodies or excessive quantities of ligand-
binding sRAGE or derivates thereof. Derivates include agents such as TTP-4000, which is a 
fusion protein consisting of the variable region and N-terminal constant domain of RAGE 
mated to the Fc region of human immunoglobin G (Section 9.8.5).  
With few exceptions, inhibition of RAGE in murine models of systemic inflammation has 
been associated with beneficial effects (Section 3.3.1). The question of therapeutic potential 
in various patient groups has been made, but several considerations require discussion.  
Firstly, there is a disconnect between results from murine studies and clinical trials in 
humans. Historically, interventions designed to modulate the immune response in systemic 
inflammation (usually sepsis) have shown promise in animal models but have largely failed 
to replicate this in humans [39, 471, 472]. The reason that RAGE inhibition may have a 
greater chance of demonstrating efficacy compared to previously investigated pathways is 
based on the observation that RAGE inhibitors remain efficacious even when given hours 
after the experimental injury. This is in contrast to the supporting animal studies of the 
largest failed trials of immunomodulation in human sepsis (TNF-α, IL-1ra, PAF antagonists 
[473-475]), all of which involved pre-treatment. 
Secondly, there are specific differences in the RAGE axis between mice and men: unlike in 
humans, sRAGE is not found in mouse plasma [295], and S100A12 is absent from the mouse 
genome [337]. 
Thirdly, and perhaps most importantly, an intact RAGE axis may be necessary for 
antibacterial defence. In a model of bacterial peritonitis, RAGE-deleted mice had enhanced 
bacterial growth, increased bacterial dissemination, and more severe inflammation [451]; 
the effect on mortality or surrogate thereof was not reported. Contradictory findings have 
been reported with RAGE-deleted mice exhibiting diminished bacterial dissemination [445, 
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448]. In non-infectious systemic inflammation treated with anti-HMGB1 antibodies, 
bacterial dissemination has been found to be both reduced [378] and increased [377]. 
Genetic deletion of key components of the innate immune response may result in improved 
outcomes from both endotoxaemia and live bacteria (CD14-deficiency [476]) or worsened 
outcomes from both endotoxin and live bacteria (iNOS-deficiency [477]). Importantly, 
genetic deletion may also result in improved outcomes from endotoxaemia and worsened 
outcomes from live bacteria (MyD88-deficiency [478, 479]). The innate immune response is 
often described as a “double-edged sword”, meaning that it has capacity to help or harm; 
RAGE-mediated inflammation may be necessary to prevent bacterial dissemination but 
should not be excessive and contribute towards mortality. When considering genetic 
deletion models, compensatory changes in the immune system are likely to play a 
significant role but are challenging to evaluate. 
Finally, sRAGE may inherently possess pro-inflammatory capacity.  The interaction between 
RAGE and the Mac-1 integrin resulted in inflammatory activity in murine splenocytes [480]. 
Similarly, when sRAGE was given intra-peritoneally in a murine model of arthritis, the joint 
improved at the cost of increased peritoneal inflammation [480]. Perhaps of greater clinical 
relevance is the recent finding that sRAGE modifies human monocyte behaviour: causing 
recruitment, inducing pro-inflammatory cytokine activation, and promoting survival and 
differentiation [481]. The recombinant source of the sRAGE may be relevant. Indeed it is 
possible that the structure of sRAGE may be responsible for adverse effects rather than the 
inhibition of RAGE per se. In support of this, the small molecule RAGE inhibitor TTP-488 (also 
known as PF-04494700) has shown good initial safety data in early stage trials [437]. 
3.4. RAGE axis in acute lung injury (ALI) 
Systemic inflammation, whether caused by infection or injury, is frequently complicated by 
the development of ALI, and its extreme manifestation, ARDS. The clinical and pathological 
characteristics, defining criteria, and reported mortality rates are discussed in Section 
1.2.2.1. 
3.4.1. RAGE-mediated inflammation is implicated in the pathogenesis of ALI 
RAGE is implicated in ALI both as a marker of alveolar injury and as an important contributor 
to alveolar inflammation. Thus, in rodents with experimental lung injury induced either by 
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intra-tracheal LPS or acid, increased levels of sRAGE in serum and broncho-alveolar lavage 
(BAL) and serum correlate with the severity of insult [482]. In experimental models, BAL 
RAGE levels could distinguish between direct (precipitating factor involves the lung) and 
indirect (precipitating factor does not involve the lung) types of ALI, with raised RAGE levels 
only detectable in the direct lung injury group [483]. However, this finding was not 
replicated in patients with ALI [454]. 
Intra-tracheal administration of HMGB1 induced ALI in mice, thereby implicating RAGE more 
directly in the genesis of ALI. Moreover, the pathological effects of intra-tracheal LPS were 
partially ameliorated by systemic administration of sRAGE or anti-HMGB1 antibodies [374, 
484]. Experimental endotoxaemia in rats induced ALI and increased tissue and circulating 
levels of HMGB1, effects that were aggravated by concurrently induced hyperglycaemia; 
and abrogated when combined with insulin therapy[485]. Experimental murine pulmonary 
ischaemia followed by reperfusion also caused ALI that was ameliorated by pre-treatment 
with sRAGE, and reduced when performed in RAGE deleted mice [486]. In rabbits, 
injuriously high tidal volume ventilation caused ALI and increased HMGB1 content in BAL 
when compared with lower tidal volumes, an effect attenuated by antibodies to HMGB1 
[487]. Together, these data suggest strongly that RAGE plays a fundamental role in 
modulating pulmonary inflammation.  
3.4.2. sRAGE as a biomarker for ALI 
Patients with ALI have increased levels of sRAGE in pulmonary oedema fluid compared to 
those with cardiogenic pulmonary oedema. Moreover, sRAGE levels in oedema fluid were 
100 times higher than plasma levels, supporting the hypothesis that sRAGE is generated in 
the lung [482]. Plasma sRAGE levels from patients enrolled in the influential ARMA trial 
(comparing high versus low tidal volume ventilation for ALI) correlated with the severity of 
illness and of ALI. Once corrected for other dependent variables (including age and severity 
of illness scores), baseline levels of sRAGE in patients randomised to receive high tidal 
volume ventilation correlated with mortality [459]. In a more recent study, extent of 
elevation of sRAGE levels in plasma from patients with ALI, with or without concurrent 
severe sepsis, correlated with markers of lung injury severity (quantified by PFR and Murray 
lung injury score) and radiographic appearance [454]. Another recent study demonstrated 
serum levels of HMGB1 and sRAGE were significantly higher in non-survivors of ARDS 
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compared with survivors; with plasma sRAGE levels being independently predictive of 
mortality [453]. Further observational trials are currently recruiting patients with ALI in 
order to measure RAGE ligands and soluble forms and gain further insight into their 
relationship with clinical parameters (clinicaltrials.gov, NCT01270295). 
Primary graft dysfunction (an ALI-like syndrome) is a common and serious complication of 
lung transplantation. Plasma sRAGE measured shortly after reperfusion correlated with 
adverse short-term outcomes [488]. These results may be partially explained by the 
observation that in isolated perfused human lungs, elevated levels of sRAGE in the airspace 
were associated with impaired alveolar fluid clearance, a measure of epithelial integrity 
[489]. Patients with ARDS have increased levels of S100A12 and A8/9 in their BAL and 
increased S100A12 expression in lung biopsies [343, 490]. Furthermore, inhalation of LPS by 
healthy volunteers increased S100A12 content in BAL [343] and clinical ALI is associated 
with elevated levels of serum S100A12 [456].  
The utility of measuring aspects of the RAGE axis to monitor the contribution of ventilation 
to lung injury has been assessed in several studies. Firstly, patients receiving mechanical 
ventilation for major elective surgery were either randomized to receive lung protective 
(low tidal volume, positive end expiratory pressure, PEEP) or conventional (high tidal 
volume, no PEEP) ventilation. sRAGE was found to be elevated post-operatively irrespective 
of ventilatory strategy [464]. Secondly, in critically ill patients without ALI, BAL levels of 
HMGB1 were greater in those who had undergone long-term (7.6 days mean) mechanical 
ventilation (MV) in comparison to short-term (5 hours mean) MV [491]. Finally, in patients 
undergoing lung resection surgery requiring one-lung ventilation (a major risk for post-
operative ALI) levels of sRAGE did not relate to ventilatory parameters or clinical 
outcomes[470]. 
Despite extensive study of potential biomarkers of ALI none have entered routine clinical 
use [492, 493]; predominantly because they have not demonstrated any clear advantage 
over clinical predictors. An ideal biomarker for ALI would be highly specific and sensitive, 
vary in proportion to the severity of injury and reflect the effect of therapy. It would add 
independent prognostic information, have biological plausibility and potentially identify 
patient subgroups that would benefit from specific therapy. Finally, the assay should be 
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inexpensive, rapid and highly reproducible. Systemic inflammation typically either 
precipitates or complicates ALI, and the utility of plasma sRAGE as a specific biomarker of 
alveolar damage is therefore likely to be limited. 
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4. INFLUENCES ON THE RAGE-AXIS AND OUTCOME FROM ACUTE SYSTEMIC 
INFLAMMATION 
A range of conditions and acquired characteristics affect the RAGE-axis and the acute 
inflammatory response. The same conditions may be associated with adverse outcome from 
acute systemic inflammation. Of particular relevance are conditions associated with 
increased RAGE ligands: old age, diabetes, chronic kidney disease and rheumatoid arthritis, 
the commonest chronic inflammatory arthritis. 
4.1. Old age 
4.1.1. Demographics 
The population of the UK is ageing. Over the last 25 years the percentage of the population 
aged 65 and over increased from 15 per cent in 1984 to 16 per cent in 2009, an increase of 
1.7 million people. The fastest increase has been in the number of those aged 85 and over, 
the “oldest old” (Figure 15). In 1984, there were around 660,000 people in the UK aged 85 
and over, since then the numbers have more than doubled to 1.4 million in 2009. By 2034 
the number of people aged 85 and over is predicted to reach 3.5 million, accounting for 5% 
of the total population [4]. 
 
Figure 15: Population by age in the UK, 1984, 2009 and predicted for 2034 
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4.1.2. Changes in immune status with ageing 
4.1.2.1. Immuno-senescence 
A state of dysregulated immune function is found in the elderly and is termed immuno-
senescence [494, 495]. Table 11 summarises changes in leukocyte function. 
Neutrophils  
Cell number Intact 
Migration Intact endothelial adherence and migration 
Tissue penetration Impaired 
Phagocytosis Intact in healthy elderly 
Production of ROS Enhanced but impaired killing 
NK cells  
Cell number Increased number 
Per cell killing Impaired 
Macrophages  
Phagocytosis Intact 
Killing Impaired 
Cytokines Diminished 
Wound healing Impaired 
T lymphocytes  
Repertoire Diminished, more memory than naïve T cells 
Cytokine response Impaired TH1 response, altered TH2. IL-10 up-
regulated 
Antigen presentation Impaired 
B lymphocytes  
Repertoire More autoantibodies, decreased repertoire 
Antibody response Impaired ability to generate high affinity antibodies 
Dendritic cells  
Migration Impaired  
Cytokine response Hypersecretion of proinflammatory cytokines 
Phagocytosis Impaired 
Table 11: Summary of age-related changes to immune cells, adapted from Castle et al. (2000)  
Immuno-senescence contributes to increased susceptibility to infection, decreased response 
to vaccination, and predisposition to development of malignancy [495-498].  
4.1.2.2. Inflamm-aging  
In addition to a general diminution in the immune response there is a concomitant 
progressive increase in pro-inflammatory status. A state of low-grade chronic inflammation, 
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termed inflamm-aging exists, and may be provoked by a continuous antigenic load and 
stress. It is postulated that this is partly due to incomplete eradication of pathogens and 
continued inflammatory cell signalling [499]. The age-associated low-grade inflammatory 
state is reflected in increased levels of circulating cytokines TNF-α, IL-6, IL-1Ra, sTNFR; and 
acute phase proteins such as CRP and Serum Amyloid A (SAA)[500].  
4.1.2.3. Immuno- responsiveness 
Similar to studies of endotoxin tolerance (Section 2.3.1) there have been ex vivo studies of 
leukocyte response to inflammatory stimuli investigating the effect of the age of leukocyte 
donor on responsiveness. Although data are conflicting [501] the prevailing consensus is 
that there is relative hypo-responsiveness with increased age [502-504]. 
To minimise conflicting immunological studies of older patients the strict SENIEUR protocol 
was developed which classifies only 10–15% of aged subjects (and 75% of young subjects) as 
perfectly healthy and fit [505]. The danger of this approach is that a rigidly defined group of 
“healthy elderly” becomes increasingly irrelevant to a “normal” elderly population with 
advancing age. 
The effect of age on cytokine responses and outcome in animal models of sepsis is rarely 
considered; young animals tend to be chosen for logistical and economic reasons. In a 
murine CLP model, aged animals displayed decreased survival and increased plasma 
cytokines compared to younger counterparts  [506]; similar results have been demonstrated 
in endotoxaemia models [507, 508]. 
Of greater clinical relevance are in vivo observational studies of inflammatory activation and 
cytokine responses. Compared to younger patients, older subjects with pneumonia have 
similar increases in circulating cytokines (IL-1β, IL-6, IL-1ra, sTNFR-I, and IL-10) but a greater 
elevation of TNF-α on the day of initial assessment. One week later the older group had 
persistent elevation of pro- and anti-inflammatory cytokines in comparison to the younger 
group [509]. Similarly, at enrolment to an interventional study of septic shock, those over 
85y had greater levels of TNF-α than younger subjects [510]. In an experimental 
endotoxaemia model, older animals exhibited greater increases in inflammatory cytokines, 
that were also relatively prolonged [511, 512]. Conversely, levels of cytokines during the 
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acute phase of sepsis have also been found to be lower in the elderly group [504] possibly 
explaining  a lower incidence of fever [513] and CRP response [514]. 
4.1.3. Age and the RAGE-axis 
Non-enzmatic glycation reactions occur slowly and relentlessly, leading to gradual 
accumulation of AGEs; episodes of acute systemic inflammation may result in abrupt 
increases in AGE. As discussed in Section 3.2.3, AGE levels in plasma and tissues have been 
related to aging [515]. In the paradigm under consideration within this thesis, such 
accumulated AGEs up-regulate the RAGE-axis and predispose to excessive and perpetuated 
inflammatory responses. However, there are currently few data to suggest that tissue RAGE 
levels increase with age. Thus, levels of RAGE protein (but not mRNA) increase with age in 
human myocardium [516], but not in endothelial cells obtained from peripheral veins [517]. 
4.1.4. Age and outcome from critical illness 
Increased age has been repeatedly associated with adverse outcome from most, if not all 
causes of critical illness; for this reason patient age is a key variable in the majority of 
scoring systems that relate patient characteristics to adverse outcome [91, 98, 518-523]. 
The question is whether this association relates to the changes of aging in themselves, or 
due to other considerations. 
Studies designed to answer this question variably suffer from particular limitations. Firstly, 
failure to consider or precisely correct for all the contributory factors (confounders). For 
example a study of patient outcome following snCPB showed that the incidence of 
myocardial dysfunction (left ventricular systolic dysfunction) increased with age and related 
to increased mortality [524]. Thus, studies that did not assess myocardial function would 
tend to over-estimate the effect of age on mortality. More generally, with advanced age 
there are important confounders that may not be routinely assessed, such as the 
accumulation of co-morbidities, increased use of prescription medications [525] and 
decreased strength and dexterity that may result in increased dependence, associated with 
adverse outcome [526]. 
Comparing patients of different ages and different degrees of severity of illness requires 
consideration of severity of illness, typically through the use of a scoring system. However, 
these are imperfect tools which vary in their sensitivity and specificity [527]. A related pitfall 
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would be to over-correct for age by using an unmodified severity of illness score that 
includes age within it. A simple example of this is the CURB-65 score for community 
acquired pneumonia [522].  
Secondly, when assessing the effect of age on outcomes from an elective intervention such 
as surgery, as opposed to an emergent condition such as sepsis, an important consideration 
is selection bias. Only elderly patients that are deemed likely to benefit are chosen to 
undergo surgical interventions. Further, only a subset of elderly patients who might 
technically benefit will chose to have the surgery – this potentially selects fitter and more 
motivated patients. These selection biases are arguably impossible to correct for and would 
tend to hide any association between age and adverse outcome and may go some way 
towards explaining divergent findings. 
Thirdly, the most commonly used methods of multivariable analysis such as linear or logistic 
regression incompletely eliminate selection factors, or to provide an accurate assessment of 
the effect of the variable of interest being compared after properly adjusting for patient 
differences. The technique of propensity score matching attempts to eliminate these 
limitations [528, 529]. 
Finally, considerations that are difficult to measure. Logically, humans have a limited 
lifespan and those that are elderly have fewer years remaining, therefore the 5y survival 
rate of patients over 85y for anything under consideration will always be less than patients 
who are 55y. There are relevant non-medical factors that differ with age, including access to 
health care, delivery of healthcare and patient care preferences [5]. Related to this, older 
patients are more likely to have considered limitations to their therapy and possess 
advanced directives [530]; and are more likely to have care withdrawn, a relatively common 
practice internationally amongst the critically ill [531].  
It is hypothesised that critical illness triggers a pathophysiological process that persists long 
after discharge when patients have seemingly recovered from acute illness. In older adults, 
there may be an inability to appropriately down-regulate inflammation after resolution of 
initiating injury [532]. Similarly, hospitalization of older persons often results in functional 
decline, despite cure or repair of the condition for which they were admitted [533]. 
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4.1.4.1. Sepsis 
A longitudinal observational study using national discharge data of 10,422,301 adult sepsis 
patients hospitalized between 1979 and 2002 in the United States showed an increased 
incidence of sepsis with age and increased case-fatality (Figure 16). 
 
Figure 16: Incidence (filled circles, left abscissa) and case-fatality (open boxes, right abscissa) for sepsis, adjusted and 
stratified by age deciles. Points represent mean and error bars SEM. Taken from [5]. 
To assess if the observed relationship between age and case fatality was related to age or 
confounding variables, multivariate logistic regression modelling considered age, gender, 
race, source of infection and chronic co-morbid medical conditions (cancer, chronic renal 
failure, congestive heart failure, COPD, coronary artery disease, diabetes, hepatic cirrhosis, 
HIV and hypertension). Age > 65y was independently associated with a 2.3 times higher risk 
of death among patients with sepsis (adjusted OR, 2.26; 95% CI 2.17–2.36). Survivors >65y 
were less likely to be discharged home (54% vs. 76%, p <0.001) [5]. These results mirror 
other observations made in the United States [31] and Singapore [534]. 
As sepsis is not a homogeneous condition, there may be benefit in considering a better 
circumscribed infection, such as pneumonia. A prospective population-based cohort study 
of 3415 patients in Canada examined the association between age and 30-day (short-term) 
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and 1-year (long-term) mortality using Cox proportional hazards regression. The association 
corrected for potential confounders: pneumonia severity, mechanical ventilation, sex, 
functional status, nursing home residence, and having a living will. There was a strong 
statistically significant positive relationship between increased age and increased mortality 
(Table 12) [535]. With each decade increase there was a 24% increase in mortality at 30 
days and 39% increase at 1 yr. This may contrast to previous contradictory reports which 
over-corrected for age when using severity of illness scores that include age. 
 30 day 1 year 
Variable 
 
aHR (95% CI) P aHR (95% CI) P 
Age per decade, yrs 1.24 (1.03–1.49) 0.03 1.39 (1.21-1.60) <0.001 
Age categories, yrs  
<60 1.0 1.0 1.0 1.0 
60-69 0.78 (0.30-2.00) .6 1.14 (0.60-2.18) .7 
70-79 1.79 (0.91-3.51) 0.09 2.62 (1.59-4.31) <0.001 
>80 2.54 (1.21-5.36) 0.01 3.47 (1.99-2.81) <0.001 
Male sex 1.36 (0.78-2.37) .3 1.32 (0.89-1.96) .2 
Functional limitation 2.02 (0.83-4.89) .1 1.60 (0.92-2.81) .1 
Living will 3.08 (1.61-5.90) <0.001 2.00 (1.21-3.32) 0.007 
Nursing home residence 0.71 (0.36-1.42) .3 1.13 (0.71-1.81) .6 
Mechanical ventilation 2.09 (0.87-4.99) .1 1.55 (0.90-2.69) .1 
Modified PSI score (pre 10 points) 1.11 (1.03-1.21) .01 1.12 (1.05-1.19) <0.001 
Table 12: Results of multivariable regression examining increasing age as a correlate of 30 day and 1-yr mortality in ICU 
patients with pneumonia. aHR, adjusted hazard ratio; CI, confidence interval; PSI, Pneumonia Severity Index. Reproduced 
from [535]. aHR emboldened when p<0.05 
4.1.4.2. SIRS 
4.1.4.2.1. snCPB 
This is increasing demand for cardiac surgical procedures in the elderly due to an ageing 
population and the fact that a principle cause of death is cardiovascular pathology, including 
coronary artery disease (CAD). The most common (~70%) snCPB is coronary artery bypass 
grafting (CABG). Although the use of percutaneous coronary intervention (PCI) for 
obstructive CAD has increased, CABG remains the treatment of choice for many types of 
CAD [536]. The second commonest procedure is aortic valve surgery for stenosis, another 
degenerative disease process that increases in incidence with age. One in five patients 
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having CABG are now aged over 75y, and the average age of aortic valve replacement 
patients increased from 61 in 1994 to 68 in 2008 [8]. 
The majority of studies investigating the relationship between age of patient and mortality 
or morbidity following cardiac surgery have found statistically significant, independent 
relationships (Table 13). 
Year Subjects 
Surgery and 
condition 
Statistical 
analysis 
Age associated 
with mortality 
Age 
associated 
with 
morbidity 
Reference 
1991 13,625 CABG LR Yes Yes, Stroke [537] 
2002 31,688 
mitral valve 
replacement 
(MVR) ± 
other 
LR Yes Yes [538] 
2005 7726 snCPB LR Yes 
Yes, stroke 
and re-
operation 
[539] 
2005 1746 CABG LR Yes, >80 
Yes, LOS and 
cost 
[540] 
2008 
122 in each 
group 
CABG PS No 
Yes, AF and 
LOS 
[541] 
2009 3094 snCPB LR 
Yes in those 
>70y 
Higher 
incidence of 
many 
complications 
in those >70y 
[524] 
2009 3683 CABG LR 
Yes, >80 for 
early mortality 
not late 
N/A [542] 
2010 10141 >85y 
CABG or PCI 
for ACS 
LR 
Yes at 60d and 
3y 
N/A [543] 
Table 13: Summary of selection of retrospective observational studies of the relationship between age and outcome in 
cardiac surgery. ACS acute coronary syndrome, RRT renal replacement therapy, LR logistic regression, PS propensity score. 
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4.1.4.2.2. Non-cardiac surgery 
Studies investigating the relationship between age of patient and mortality or morbidity 
following non-cardiac surgery have found statistically significant independent relationships. 
The largest was a multivariate regression database analysis of 594,911 patients having non-
cardiac surgery, in which age was independently associated with mortality [544]. More 
recently, a prospective study of 4158 non-cardiac surgical patients aged 70 years or more 
assessed the relationship between patient factors and mortality at 30 days. Patients in the 
80-89 cohort had an odds ratio of mortality of 2.1 (95% CI 1.6-2.8), p < 0.001; those in the 
90+ cohort OR 4.0 (95% CI 2.6-6.2), p < 0.001) [545]. In two smaller series from California of 
544 patients >70y and 367 patients >80y having non-cardiac surgery, no association 
between age and mortality or morbidity was found [546, 547]. 
4.1.4.2.3. Trauma 
In a retrospective review of trauma registry data collected prospectively on 26,237 blunt 
trauma victims (age ≥65y, n=7,117) the elderly had significantly higher mortality rates after 
stratification by Injury Severity Score (ISS), Revised Trauma Score, and for other pre-existing 
co-morbidities. Age ≥ 65 years was associated with a two- to threefold increased mortality 
risk in mild (ISS < 15, 3.2% vs. 0.4%; < 0.001), moderate (ISS 15-29, 19.7% vs. 5.4%; < 0.001), 
and severe traumatic injury (ISS > or = 30, 47.8% vs. 21.7%; < 0.001) compared with patients 
aged < 65 years. Logistic regression analysis confirmed that elderly patients had a nearly 
twofold increased mortality risk (odds ratio, 1.87; confidence interval, 1.60-2.18; < 0.001). 
Elderly patients also had significantly longer ICU and hospital LOS after stratifying for 
severity of injury [548]. 
Similarly, patients >50y (n = 1,251) had a longer LOS (12.5 versus 8.4 days; p < 0.001) and 
increased mortality (22.1% versus 8.0%; p < 0.001) than those <50y. Age remained an 
independent predictor of mortality when controlling for ISS [549]. 
4.1.5. Conclusions 
Putting aside the considerable, and sometimes unavoidable, limitations, it seems that there 
is a significant relationship between advanced age and adverse outcome. This may be due to 
altered immunity and the inevitable decline in physiological reserve that occurs with age. 
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4.2. Diabetes 
4.2.1. Demographics 
Diabetes in this context refers to both type 1 diabetes, characterised by young onset and 
autoimmune destruction of the β-cells in the pancreas; and type 2 diabetes, characterised 
by later onset, insulin resistance and progressive insulin deficiency due to pancreatic β-cell 
dysfunction. The incidence of both is increasing internationally [550-553]. Prevalence of 
diabetes was 4.3% in the UK and 7% in the US in 2005 [6, 554]. 
Hyperglycaemia is the sine qua non of diabetes and poorly controlled diabetes is typified by 
chronic hyperglycaemia. Acute critical illness is almost invariably associated with 
hyperglycaemia and insulin resistance, even in those without pre-existing diabetes [555, 
556]. As discussed in Section 3.2.3, hyperglycaemia predisposes to formation of AGE 
modifications, particularly when coupled with redox stress. 
4.2.2. Changes in immune status with diabetes 
Alterations in immune status in patients with diabetes has been studied extensively [557] 
and although perturbations in innate and adaptive responses have been demonstrated in 
vitro, to what extent these are clinically relevant remains unresolved [558]. Contrary to 
expectations, attenuated immune function may even be beneficial under some 
circumstances: diabetes having been associated with decreased risk of ALI in those with 
sepsis, compared to those without diabetes [6]. 
Hyperglycaemia is conducive to microbial growth and those with diabetes are generally 
considered to be predisposed to the acquisition of infection. Despite some controversy, this 
relationship has been shown to be robust [6, 559, 560] (Figure 17).  
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Figure 17: Frequency of sepsis cases. Frequency of sepsis cases among patients with diabetes mellitus (DM) and those with 
no diabetes mellitus (non-DM) with a source of infection identified. CV = cardiovascular; GI = gastrointestinal; GU = 
genitourinal; Resp = respiratory; SST = skin and soft tissue. * p < 0.05. Reproduced from [6]. 
4.2.2.1. Innate 
Neutrophil functions including chemotaxis, phagocytosis and intracellular killing are 
significantly impaired during hyperglycaemia, and possibly in associated with its severity 
[561-563]. Indeed, improved gycaemic control may lead to improvements in neutrophil 
function [564]. The ex vivo cytokine response to endotoxin stimulation has been found to be 
impaired in those with type 2 diabetes [565]. 
4.2.2.2. Adaptive 
Defects in the adaptive immune response in those with diabetes are less well described, 
with no consistent defects in cell mediated immunity and normal antibody responses to 
vaccinations [558]. Circulating antibodies are however, subject to AGE-modifications, 
particularly the antigen-binding fragment (Fab) which may affect antigen affinity [566]. 
4.2.3. Diabetes and the RAGE-axis 
RAGE ligands are increased in patients with diabetes. Circulating levels of S100A12 are 
elevated in the plasma of patients with diabetes and relate to Hba1c levels and white blood 
cell count [344]. Plasma CML-albumin is elevated in diabetes and implicated in the 
development of vascular complications [415]. Indeed, a wide range of AGE modifications are 
found in the vasculature and other tissues in those with diabetes [567]. sRAGE plasma levels 
have been shown to be higher in those with diabetes than matched controls [568]. 
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Hyperglycaemia affects circulating leukocytes, with evidence of altered RAGE signalling in 
neutrophils and up-regulation of monocyte membranous RAGE expression [287, 296]. 
Hyperglycaemia up-regulates RAGE, S100A8, S100A12, and HMGB1 expression on human 
endothelial cell expression in vitro [569]. 
The RAGE-axis has a well-established role in the development of diabetic complications 
including retinopathy, nephropathy, neuropathy and atherosclerosis, particularly through 
effects on the vascular endothelium [570-574]. Substantial work has been conducted on the 
role of RAGE in the development of atherosclerosis in diabetes and euglycaemia, but it is 
beyond the scope of this thesis and readers are referred to recent reviews [575-577]. 
4.2.4. Diabetes and outcome from critical illness 
Associations between diabetes and increased morbidity and mortality following critical 
illness could be due to the underlying causes for the diabetes, including obesity [578] (type 
2) or autoimmunity (type 1), the effects of hyperglycaemia and altered immune function; or 
the complications of chronic diabetes including chronic kidney disease and atherosclerosis 
resulting in coronary artery disease [579], peripheral vascular disease and cerebro-vascular 
disease. Lastly, therapies used in the treatment of diabetes, such as insulin, statins and 
glitazones may influence the host response to infection [580]. 
4.2.4.1. Sepsis 
Diabetes traditionally has been considered as a risk factor for the progression of infection 
and subsequent adverse outcome. Recently, an investigation of the influence of diabetes on 
the clinical course of, and outcome from, community acquired pneumonia (CAP) in 3534 
patients was reported [581]. Diabetes was associated with increased severity of illness 
(APACHE III) and severity of pneumonia (PSI) scores, increased incidence of acute kidney 
injury (AKI), and increased mortality at one year. An absence of difference in plasma 
biomarkers of inflammation or coagulation, or cytometric measures of monocyte immune 
status casts doubt on the significance of altered immune function. Deaths due to 
cardiovascular disease and chronic kidney disease were higher among those with diabetes 
(34.4% vs 26.8% and 10.4% vs 4.5% for cardiovascular and kidney disease, respectively). 
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The second commonest infection causing hospitalisation following CAP is urosepsis. Patients 
with diabetes have increased incidence, increased rates of complications and higher 
mortality rates from urinary tract infection than those without diabetes [582, 583]. 
A recent analysis of National Hospital Discharge Survey data from 12.5 million hospital 
admissions with sepsis in the United States confirmed increased rates of infection in those 
with diabetes (for respiratory, urinary, skin and soft tissue and bone infections) but had the 
unexpected finding of decreased organ failure and improved outcome in those with 
diabetes [6]. The authors suggest the lower incidence of respiratory failure observed in 
those with diabetes may be due to protection from ALI/ARDS, consistent with their previous 
findings [584]. Further, they suggest that a blunted immune response may be responsible 
for the decreased incidence of ALI. Alternative explanations include patients with diabetes 
seeking medical attention earlier or an unidentified protective effect of their medications. A 
major limitation of this study is its reliance on coding data and the absence of detailed 
clinical data. 
4.2.4.2. SIRS 
4.2.4.2.1. snCPB 
There have been many studies of the influence of diabetes on outcome from cardiac 
surgery, mostly in patients undergoing CABG. A meta-analysis and systematic review of 
>100,000 patients has recently reported associations between diabetes and increased risk 
of mortality, stroke, renal failure, sternal infection, and blood transfusion [585]. 
4.2.4.2.2. Non-cardiac surgery 
Diabetes is widely considered to be a significant risk factor for adverse outcome following 
non-cardiac surgery, but this not appear to be independent, in that its associated 
complications account for the attributable risk; in particular, coronary artery disease and 
consequent peri-operative myocardial infarction [586, 587]. 
4.2.4.2.3. Trauma 
Early studies found significant associations between diabetes and mortality [588] but more 
recent analyses identified only increased rates of prolonged ICU stay and infectious 
complications [589, 590]. 
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4.2.5. Conclusions 
The increased incidence of infection in those with diabetes may be solely due to 
hyperglycaemia. The extent to which impaired immune responses contribute is uncertain. 
Once systemic inflammation has developed, any progression to death seems to relate more 
to any pre-existing complications of diabetes, rather than immune dysfunction. 
How RAGE-mediated effects of diabetes on the innate immune response contribute to the 
development and progression of systemic inflammation remains uncertain but may be less 
important than the well-established role of the RAGE-axis in the development of diabetic 
complications [574]. 
4.3. Chronic kidney disease (CKD) 
CKD is defined as a structural or functional deficit in the kidneys, manifest by either kidney 
damage detected as excessive urinary protein (proteinuria) with or without a decreased 
glomerular ﬁltration rate (GFR, <60 mL/min/1.73 m2, a measure of kidney function) [591]. 
CKD is divided into stages: 1, normal GFR but intrinsic disease; 2, mild impairment; 3, 
moderate impairment; 4, severe impairment; 5, minimal or absent function, requiring renal 
replacement therapy (RRT), previously known as ‘end-stage renal failure’. 
4.3.1. Demographics 
The prevalence of CKD varies according to which definitions are used, how the renal 
function is measured (or calculated) and whether proteinuria is included. However, CKD 
(stages 3-5) is estimated to affect 5-10% of the adult population in the Western world [592] 
and is growing [593]. 
The commonest causes of CKD are diabetes and hypertension, followed by 
glomerulonephritis.  CKD is associated with an increased risk of death, particularly from 
cardiovascular (CV) causes and although this partly relates to the underlying conditions, 
there is an appreciable excess mortality proportional to the degree of renal impairment 
[594]. The majority of people with mild-to-moderate CKD die from CV disease before 
needing RRT [595].  
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4.3.2. Changes in immune status with CKD 
Biomarkers of inflammation, including classical pro-inflammatory mediators, markers of 
endothelial activation, oxidative stress and coagulation, have been demonstrated 
repeatedly to be elevated in proportion to stage of CKD, when compared to matched 
controls [596-598]. 
Patients with CKD have been shown to have defective leukocyte priming and diminished 
respiratory burst [599, 600], but the effects of CKD on other aspects of the innate and 
acquired immune systems have not been examined in detail. 
4.3.3. CKD and the RAGE-axis 
The RAGE-axis may be important in the development of various types of CKD, not just 
diabetic nephropathy [601]. Of greater relevance to these investigations are the findings of 
increased circulating RAGE ligands, soluble forms, and up-regulated leukocyte RAGE 
expression in CKD. 
Soluble RAGE levels have been noted to be elevated in those with CKD, in proportion to the 
extent of renal impairment, possibly through reduced renal elimination [602, 603]. Levels 
positively correlate with plasma AGE in CKD patients [603]. Similarly, HMGB1 levels in the 
plasma positively correlate with extent of renal impairment [604]. In patients with stage 5 
CKD, S100A12 levels were elevated and associated with all-cause and cardiovascular 
mortality [605]. 
RAGE expression on monocytes is increased in those with CKD, in proportion to the 
abundance of the AGE pentosidine; furthermore, monocyte cytokine response to AGE was 
proportionate to the extent of RAGE expression [606] 
4.3.4. CKD and outcome from critical illness 
The predisposition of patients with CKD to cardiovascular death is highly relevant as critical 
illness may precipitate CV death. CKD is an important risk factor for CV mortality for many 
reasons: there is a high prevalence of co-morbidities; there is abnormal vascular biology 
with endothelial dysfunction; accumulation of phosphate and increased levels of 
parathyroid hormone contributing to vascular calcification, anaemia and left ventricular 
hypertrophy; and increased circulating levels of homocysteine, fibrinogen, and uric acid. 
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Mediations with prognostic benefit are underused and there may be therapeutic nihilism 
associated with these patients [594, 607, 608]. 
Consideration of the relationship between CKD status and adverse outcome from critical 
illness is hampered by the difficulty of correcting for all relevant confounding factors. 
Additionally, the high risk of CV mortality independent of the onset of critical illness will lead 
to bias in any longer-term outcome studies.  
4.3.4.1. Sepsis 
Patients with CKD may be pre-disposed to the development of infection due to a 
combination of factors which include: malnutrition, chronic inflammation, retention of 
uraemic solutes, trace element deficiencies, metabolic abnormalities, relatively higher 
prevalence of chronic urinary sepsis; and in some of those receiving RRT the presence of in-
dwelling catheters or grafts [609]. Indeed, infection is the second commonest cause of 
death after cardiovascular disease in those with stage 5 CKD [609]. Indeed, CKD of all stages 
is associated with increased mortality from infections [610]. Bloodstream infection (BSI) is 
especially common in those with CKD, even in the absence of in-dwelling vascular access 
devices. The risk of acquisition of a BSI relates to degree of renal impairment, as does the 
risk of death [611]. Similarly, the risk of hospitalisation with pneumonia and subsequent 
death relate to severity of CKD [612]. 
4.3.4.2. SIRS 
The most-studied non-infectious cause of SIRS is snCPB. The presence of CKD in such 
patients is invariably associated with higher mortality [607, 613, 614]. 
4.3.5. Conclusion 
CKD is associated with accelerated atherosclerosis contributing to cardiovascular mortality. 
This is the predominant factor determining outcome from acute systemic inflammation. 
However, even non-cardiac all-cause mortality is higher in those with CKD than without 
[610], reflecting the diverse pathological consequences of impaired kidney function. 
The effects of increased activity of the RAGE-axis in CKD on the development and 
progression of systemic inflammation remain uncertain. However, the RAGE-axis is 
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fundamentally important in the development of the accelerated atherosclerosis of CKD that 
accounts for much of the excess adverse outcome. 
4.4. Rheumatoid arthritis 
4.4.1. Demographics 
Rheumatoid arthritis (RA) is a common chronic inflammatory disease with increased 
prevalence with advanced age [615, 616]. Overall, the prevalence of RA in the UK may be in 
decline for women (1.16%) but has remained constant for men (0.44%) since the 1950s 
[617]. Patients with RA suffer from increased cardiovascular morbidity and mortality due to 
accelerated atherosclerosis and premature coronary artery disease [618, 619] believed to 
relate to chronic vascular inflammation. 
4.4.2. Changes in immune status with RA 
Rheumatoid arthritis is a complex, systemic, auto-immune inflammatory disease resulting in 
synovial inflammation and associated damage to articular cartilage and bone [615]. It is 
beyond the scope of this thesis to describe the immunopathology in detail. 
4.4.3. RA and the RAGE-axis 
RAGE ligands are implicated in the development of arthritis, with high level expression of 
S100A12 and S100A8/9 in synovial tissue and elevated plasma levels correlated with disease 
activity and response to therapy [620-624]. sRAGE levels have been found to be suppressed 
in one cohort of patients with RA [625], and unchanged in another [626], both in 
comparison to healthy controls.  
4.4.4. RA and outcome from critical illness 
Patients with rheumatoid arthritis have significantly increased mortality compared to the 
general population, with particularly striking increases in cardiovascular (CV) and infective 
deaths [627]. The increased incidence of CV events in RA patients is independent of 
traditional CV risk factors. A close relationship between markers of systemic inflammation 
and future CV events implicates an inflammatory aetiology in accelerated atherosclerosis 
[619, 628]. 
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4.4.4.1. Sepsis 
Individuals with RA are at increased risk of infection [629]. The increasing use of immune-
suppressive therapy, such as biological disease modifying drugs and oral corticosteroids, 
further increases the risk [630]. The association between RA and susceptibility to infection 
was observed prior to use of immune-suppressive therapy [631]. Sites of infection with the 
highest risk ratios were bone, joints, skin, soft tissues, and the respiratory tract [629]. 
Retrospective observational studies from the 1990s describe high short-term mortality in 
patients with systemic rheumatic diseases admitted to ICU [632], but possibly not 
significantly different from non-selected patients [633]. Another study noted mortality that 
was higher than would be expected from predictive models [634]. Most recently, a matched 
case-control study revealed similar mortality despite lower severity of illness scores [635]. 
Although none of these studies are without significant shortcomings, their conclusions are 
mostly consistent. 
4.4.4.2. SIRS 
Given that patients with RA have a high incidence of macrovascular and microvascular 
atherosclerosis and myocardial infarction is their leading cause of death they might be 
expected to have an increased mortality following CABG surgery. Paradoxically, a large 
retrospective multivariate analysis of hospital in-patient data from the US demonstrated 
improved mortality in patients with RA [636]. There are few studies examining outcome of 
patients with RA and concomitant acute non-infectious critical illness. 
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5. SCOPE OF THIS THESIS 
The work described in this thesis was designed to explore the hypothesis that the RAGE axis 
is an important determinant of systemic inflammation following surgery necessitating 
cardiopulmonary bypass. 
 
Figure 18: Overview of RAGE axis in snCPB with numerals 1 – 5 demonstrating where the specific aims of the thesis lie. 
The specific aims of the work were therefore: 
1: To conduct an analysis of the relationship between the age of patients undergoing snCPB 
and the severity of their systemic inflammatory response, the relationship between these 
variables and adverse clinical outcomes (Section 10). 
2: To characterise levels of relevant RAGE ligands and levels of soluble RAGE forms in plasma 
obtained around snCPB and establish their relationship to relevant clinical variables (Section 
11). 
3: To develop flow cytometric and quantitative reverse transcriptase real-time polymerase 
chain reaction (qRT-PCR) methods to facilitate subsequent measurement of leukocyte RAGE 
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expression at the protein and transcription levels in biological samples from patients pre- 
and post- snCPB (Section 12). 
4: To conduct ex vivo investigations on the inflammatory activity of RAGE ligands on 
leukocytes, the inhibition thereof, and the effect of snCPB on ligand responsiveness (Section 
13). 
5: To investigate genetic variation in select genes relevant to the activity of the RAGE axis 
and their possible influence on outcome from snCPB (Section 14). 
These specific aims are summarized within Figure 18. 
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Methods 
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6. CLINICAL METHODS 
6.1. Patient cohorts 
Cohort A: snCPB patients retrospectively identified between 1/1/2002 and 31/5/2005 at the 
Royal Brompton Hospital (RBH). Patients had routine clinical data collected. The study was 
examined by the Royal Brompton and Harefield NHS Foundation Trust Research Ethics 
Committee and deemed to fall within the remit of ‘service evaluation’ and thereby did not 
require patient consent. Patients within this cohort numbered 2440. Patients were included 
within this cohort if they cardiac surgery following by admission to ICU. Patients were 
excluded if their admission was a re-admission or if records were incomplete or 
unobtainable. 
Cohort B: Patients enrolled in a clinical observational trial studying influence of genetic 
polymorphisms and inflammatory mediators on outcome from snCPB, particularly with 
respect to development of acute lung injury. RBHT ethics committee code 00-033 v1 
(amended 2006); patient consent form and information sheet in the appendix. For the 
majority of the plasma assays the patients had been recruited previously and banked 
specimens were used (n=20). The 20 patients chosen from the larger cohort were chosen at 
random. Banked DNA was used for genotyping. Patients were also prospectively recruited 
for some assays (flow cytometry, qRT-PCR and ex vivo stimulation, n=29). Patients were 
included in this cohort if they were having cardiac surgery involving CPB with patients 
preferentially recruited who were having complex surgery i.e. valve replacement surgery 
and coronary artery bypass grafting or more than one heart valve replaced or repaired. The 
only exclusion was absence of informed consent. 
Cohort C: snCPB patients enrolled in a clinical interventional trial comparing two alternative 
fluids in the cardiopulmonary bypass circuit prior to initiation of CPB. RBHT ethics 
committee code 07/H0712/137); patient consent form and information sheet is in the 
appendix. Patients had been recruited previously and banked specimens of plasma were 
assayed (n=19). The first 19 patients recruited into the study were chosen for these 
analyses. Patients were included in this cohort if they were having cardiac surgery involving 
CPB. Patients with a Euroscore of ≥ 7 were excluded. 
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6.2. Electronic databases 
Each patient admitted to the ICU had clinical, physiological and laboratory data 
automatically entered into an electronic database. In 2009 the clinical information system 
changed from CareVue to IntelliVue Clinical Information Portfolio (ICIP), both provided by 
Philips Healthcare Ltd (Guildford, UK). 
6.3. Measured and recorded variables 
The results of routinely measured laboratory assays were incorporated into the clinical 
information systems and then used in analyses including the calculation of severity of illness 
scores. Such assays included: full blood count (white blood cell count, neutrophil count, 
haemoglobin concentration, platelet count); clotting profiles (international normalised ratio, 
prothrombin time); biochemical profiles (urea, creatinine, sodium, CRP, bilirubin, alanine 
transaminase); and arterial blood gas values, ABG (partial pressure of oxygen, partial 
pressure of carbon dioxide). 
The results of measured physiological variables were also incorporated into the clinical 
information systems and then used similarly. Such measures included: temperature, arterial 
oxygenation saturations, respiratory rate, heart rate, blood pressure, right atrial pressure. 
Details relating to the therapy the patients received were similarly gathered, including 
inspired oxygen concentration, details of mechanical ventilation and vasoactive drug 
therapies; details relating to the operations including type of procedure, CPB time, 
ischaemic time, and volume of blood transfused; details relating to the post-operative 
recovery: duration of ICU stay, duration of hospital stay, vital status (dead/alive). 
Demographic details that were used similarly included age, height, weight, body mass index 
(BMI, kg/m2), ethnicity, and gender. 
In some cases, pre-operative clinical characteristics were gathered from the clinical written 
notes: Presence of diabetes, ischaemic heart disease (IHD), treatment with statin, presence 
of pulmonary hypertension, pre-op creatinine and chronic kidney disease (CKD) stage. 
6.4. Derived variables 
PaO2/FiO2 ratio (PFR) is the result of dividing the partial pressure of oxygen (PaO2) by the 
fraction of inspired oxygen (FiO2). The values used in the original definitions of ALI/ARDS 
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were in mmHg but where kPa are to be used, 1kPa = 7.6 mmHg. The PFR values used in the 
analyses of cohort B were taken from the clinical information system and for every 24h 
period (for example, post-operative day 2, POD2) the PFR used was the lowest (most 
severely impaired) recorded in that period; a PFR was only used if a PaO2 and FiO2 were 
both recorded within an hour of each other. 
The alveolar-oxygen difference (sometimes erroneously termed alveolar-oxygen gradient), 
or D(A-a) is calculated from a simplified formula derived from the alveolar gas equation. 
D(A-a) = Partial pressure of oxygen in the Alveolus (PAO2) − Partial pressure of oxygen in the 
arteries (PaO2). The PaO2 is taken from the ABG and the PAO2 is calculated, assuming a 
respiratory quotient of 0.8. Thus, PAO2 = 100 x FiO2 – PaCO2*1.25. For example, a patient 
breathing 50% oxygen (FiO2 0.5) with a PaCO2 of 5.0 and a PaO2 of 10.0 has a D(A-a) of: (100 
x 0.5 – (5.0*1.25)) – 10.0 = 33.75kPa. A normal value, (100 x 0.21 – (5.0*1.25)) – 12.5 = 
2.25kPa. 
6.5. Definitions and scores 
Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) represent 
diagnoses along the spectrum of a disease process characterised by pathologically increased 
pulmonary alveolar-capillary membrane permeability and the consequent leakage of high 
oncotic pressure fluid into the alveolar space causing refractory hypoxaemia. The criteria 
were defined at a consensus conference [41], all four criteria must be met: 
1. Acute onset of respiratory failure in presence of recognised cause 
2. Diffuse bilateral infiltrates on chest radiograph 
3. Absence of left atrial hypertension (pulmonary artery occlusive pressure *PAOP+ ≤ 18 
mm Hg) or no clinical evidence of left atrial hypertension 
4. Hypoxaemia, defined as PaO2:FiO2 ratio ≤ 300mmHg (ALI) or ≤ 200mmHg (ARDS). In 
SI units: ≤ 40kPa (ALI) or ≤ 27kPa (ARDS). 
Acute physiology and chronic health evaluation (APACHE) II score uses a point score based 
on previous health status, age and 12 routine measures of physiology. The values are 
recorded from the first 24h of assessment. The APACHE II system is most commonly used 
critical illness scoring system in the UK and was initially described in 1985 [518].  
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The Sequential Organ Failure Assessment (SOFA) score is an alternative scoring system that 
can be used to serially quantify extent of organ dysfunction [92]. The score is based on six 
different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal 
and neurological systems. For each organ system a score from 0 to 4 is given, with 4 
representing the most severe organ dysfunction. Thus the total SOFA score ranges from 0 to 
24. The SOFA score was originally designed to predict morbidity in patients with sepsis but 
has been evaluated in many other settings, including assessment of risk of adverse outcome 
following elective cardiac surgery. Initially a single-centre study of 218 patients related 
increased SOFA scores with increased morbidity [97]. In a larger cohort of 857 patients, the 
SOFA score was associated with mortality and morbidity even when assessed in the early 
postoperative period after adult cardiac surgery [96]. Most recently, the discriminatory 
value of four scoring systems was compared in a large cohort and the SOFA score found to 
be inferior to another scoring system, but superior to two others (SAPSII and APACHE II) 
[637]. 
CPB time is the duration that blood is passing from the patient through the cardiopulmonary 
bypass circuit. During this time there is a period when no blood is flowing through the 
pulmonary or coronary circulation and this is the ischaemic time. 
Euroscore is scoring system for the prediction of early mortality in cardiac surgical patients 
on the basis of objective risk factors [98]. Patient-related factors include: age over 60, 
gender, chronic pulmonary disease, extracardiac arteriopathy, neurological dysfunction, 
previous cardiac surgery, serum creatinine >200µmol/l, active endocarditis and critical 
preoperative state. Cardiac factors are unstable angina on intravenous nitrates, reduced left 
ventricular ejection fraction, recent (<90 days) myocardial infarction and pulmonary systolic 
pressure >60 mmHg. Operation-related factors were emergency, other than isolated 
coronary surgery, thoracic aorta surgery and surgery for postinfarct septal rupture.  
Acute Kidney injury (AKI) is the current preferred term for acute renal failure and there are 
two scoring systems for AKI. Acute Dialysis Quality Initiative Group published a consensus 
definition/classification system termed the RIFLE criteria. The Acute Kidney Injury Network 
(AKIN) group modified this system [638]. The analysis of incidence of post-operative AKI and 
its relation to genotypic variation (Section 14.4.2) uses a modification of the AKIN criteria as 
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urine output data was not used in our analyses. Therefore, the following scoring system was 
used (Table 14). 
AKI stage Change in serum creatinine 
1 Increase in serum creatinine; ≥ 26.4 µmol/l or ≥ 1.5- to 2-fold from 
baseline 
2 Increase in serum creatinine; > 1.5- to 2-fold from baseline 
3 Increase in serum creatinine > 3-fold from baseline or serum 
creatinine of ≥ 354µmol/ (with an acute increase 
of at least 44µmol/l); or use of renal replacement therapy 
Table 14: AKI scoring system 
6.5.1. Duration of intensive care therapy and ‘level 3 care’ 
ICU length of stay (ICU LOS) is an important outcome variable for two reasons: firstly, the 
time a patient spends in ICU primarily relates to the degree to which they require advanced 
therapies and monitoring, which is largely proportionate to their severity of illness; 
secondly, a prolonged ICU stay is not benign and is associated with serious adverse 
outcomes including decreased quality of life and increased mortality after hospital discharge 
[639, 640]. 
Hospital administrative database will usually collect ICU LOS and therefore it can be a 
convenient measure to use. However, non-clinical considerations such as availability of 
‘step-down’ bed may be important and compromise the relationship between severity of 
illness and ICU LOS. To overcome this limitation it is possible to analyse electronic databases 
of patient physiological parameters and calculate the duration that they require advanced 
therapies and monitoring. The use of such outcome variables has been encouraged [89]. 
“Level 3 care” duration is such a calculated variable and is derived from the UK Critical Care 
Minimum Data Set (CCMDS), a system used for billing purposes; available online: 
http://www.dh.gov.uk/en/Healthcare/Urgentandemergencycare/DH_4126508 
For the purposes of the study, the ‘level 3 care duration’ was the time in hours that a 
patient required advanced therapies or monitoring at a level that would be usually thought 
of as “intensive care”. Level 3 care is defined as either advanced respiratory, cardiovascular 
or renal support alone, or basic respiratory support in combination with support for at least 
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two other organ systems. In this study we did not consider gastrointestinal or liver support 
parameters. The definitions are shown in Figure 19. 
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Advanced respiratory support 
 Invasive mechanical ventilatory support (excluding mask CPAP or noninvasive methods 
e.g. mask ventilation but including BiPAP or CPAP applied via a tracheal tube). 
 Extracorporeal respiratory support 
Basic respiratory support  
 More than 50% oxygen delivered by face mask.  
 Close observation due to the potential for acute deterioration to the point of needing 
advanced respiratory support. (e.g. severely compromised airway or deteriorating 
respiratory muscle function). 
 Physiotherapy or suction to clear secretions at least two hourly, whether via 
tracheostomy, minitracheostomy, or in the absence of an artificial airway. 
 Patients recently extubated after a prolonged period of intubation and 
 mechanical ventilation, (e.g. more than 24 hours of tracheal intubation) 
 Mask CPAP or non invasive ventilation. 
 Patients who are intubated to protect the airway but needing no ventilator support and 
who are otherwise stable 
Advanced cardiovascular support 
 Multiple intravenous vasoactive and/or rhythm controlling drugs used to support 
arterial pressure, cardiac output or organ perfusion, (e.g. inotropes, amiodarone, 
nitrates). 
 Patients resuscitated after cardiac arrest where intensive therapy is considered clinically 
appropriate. 
 Observation of cardiac output and derived indices (e.g. pulmonary artery catheter, 
lithium dilution, pulse contour analyses, oesophageal doppler). 
 Intra aortic balloon pumping 
Basic cardiovascular support 
 Treatment of circulatory instability due to hypovolaemia from any cause 
 Use of a CVP line for basic monitoring or central venous access to deliver therapeutic 
agents. 
 Use of an arterial line for basic monitoring of arterial pressure or sampling of arterial 
blood. 
 Single intravenous vasoactive drug used to support arterial pressure, cardiac output or 
organ perfusion 
 Intravenous drugs to control cardiac arrhythmias 
 Non-invasive measurement of cardiac output (e.g. echocardiography, thoracic 
impedance) 
Renal support 
 Acute renal replacement therapy (e.g. haemodialysis, haemofiltration etc.) 
Neurological support 
 Central nervous system depression sufficient to prejudice the airway and protective 
reflexes, excepting that caused by sedation prescribed to facilitate mechanical 
ventilation. 
 Invasive neurological monitoring e.g. ICP, jugular bulb sampling. 
 Severely agitated or epileptic patients requiring constant nursing attention and/or 
heavy sedation 
Dermatological support 
 Patients with major skin rashes, exfoliation or burns. (e.g. greater than 30% body 
surface area affected). 
 Use of multiple, large trauma dressings, (e.g. multiple limb or limb and head dressings). 
 Use of complex dressings (e.g. open abdomen or large skin area greater than 30% of 
body surface area) 
 
Figure 19: Level 3 care definitions from UK CCMDS 
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6.6. Operative details 
6.6.1. Induction and maintenance of anaesthesia 
Patients within all cohorts received snCPB at the Royal Brompton Hospital with specific 
management of anaesthesia and cardiopulmonary bypass at the discretion of the attending 
anaesthetist, perfusionist and surgeon. 
6.6.2. CPB 
The extra-corporeal circuit used during CPB consisted of a roller pump, a reservoir, and a 
membrane oxygenator. The circuit was primed with a gelatine solution or human albumin 
solution. Heparin was administered before starting CPB. The pump flow rate was 
~4L/min/m2 and hypothermia (28-32°C) was maintained during CPB. In each patient, the 
myocardium was protected with repeated cardioplegia. Before aortic unclamping, the 
patient was re-warmed. The injected heparin was neutralized by administration of 
protamine sulphate. 
6.7. Patient sample acquisition and preparation 
Healthy volunteers: informed consent was obtained and 30-40ml of venous blood was 
drawn from the non-dominant antecubital fossa with a 20G ‘butterfly’ cannula. The blood 
was mixed with sodium citrate in a 9:1 ratio, and gently mixed to prevent coagulation. 
In experiments using whole blood (WB) the blood was then either used without further 
dilution, or mixed 1:1 with DMEM medium. In experiments using neutrophil suspension the 
blood was further processed as described in Section 7.2.3. 
Patients: following induction of anaesthesia and placement of a radial arterial line, 30-40ml 
of arterial blood was drawn from the arterial line. There was usually no more than 10mins 
between induction of anaesthesia and acquisition of blood. Depending on the specific assay, 
blood was anti-coagulated by addition of sodium citrate, heparin or EDTA. Post-operative 
samples were either obtained as soon after the end of CPB as possible or 2h following the 
end of CPB.  
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7. LABORATORY METHODS 
7.1. General methods 
7.1.1. Centrifugation 
For volumes less than 2ml a fixed angle bench top centrifuge was used either Hawk 15/05 
centrifuge (Sanyo GallenKemp, Etten Leur, Netherlands) or Boeco M-240 R (Hettich, 
Germany) centrifuge. For larger volumes a Hettich Rotina 46R centrifuge was used with 
swing-out buckets (Hettich AG). Centrifugation speeds are quoted as relative centrifugal 
force (RCF or g) or rotor speed in revolutions per minute (RPM) followed by time, 
temperature and brake. 
7.1.2. General cell counting 
Cells were counted under either an inverted phase contrast microscope (CK40, Olympus UK, 
Southend, UK) or a conventional upright microscope (Olympus, CH30, x100-x400 objective) 
using a haematocytometer (improved Neubauer model). The total numbers of cells in each 
of the four (1mm3) larger corner squares were counted.  Cells were included if they were 
entirely within the boundaries of the squares or if they partially overlapped the upper or left 
borders. Appropriate dilutions and repeat counts were undertaken to ensure that the total 
number of cells counted was between 100 and 400.  The total number of cells in suspension 
was estimated using the following formula. 
Total cell count (cells/ml) =  Cell count for four squares  x 104 x dilution factor 
4 
7.2. Cells 
7.2.1. Cell culture of THP-1 cells 
The THP-1 cell line is derived from immortalised blood monocytes from human monocytic 
leukaemia. The cells resemble human monocytes in their morphology, expression of 
membrane antigens and secretory proteins. The cells were purchased from the European 
Collection of Cell Cultures and grown in RPMI 1640 media containing 10% heat inactivated 
fetal calf serum, L-Glutamine, penicillin/streptomycin and incubated at 37oC in 95% air, 5% 
CO2. Cells were maintained at 0.5 - 1 x 10
6 cells/ml. 
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7.2.2. Ex vivo leukocyte models 
Whole blood (WB) contains erythrocytes (red blood cells), leukocytes (white blood cells), 
thrombocytes (platelets), plasma, and plasma proteins. The leukocyte population includes 
neutrophils, monocytes, lymphocytes, eosinophils, and basophils. Use of whole blood for ex 
vivo experimentation requires absolutely minimal processing, only the addition of an 
anticoagulant and optional the addition of culture medium. More importantly than the ease 
of use, WB assays most authentically mimic the in vivo state and thus may be the most 
appropriate milieu in which to study cytokine production in vitro [641] and offer superior 
reproducibility to alternative methods [642]. 
Isolation of leukocyte subsets is cumbersome as it involves multiple stages and importantly, 
it can activate cells and this may cause their ex vivo responses to differ from their in vivo 
responses [642]. Moreover, removal of the possibility of interactions between the 
components of whole blood, further removes the model from physiological relevance. 
7.2.3. Neutrophil isolation 
Following dextran sedimentation to generate a leukocyte rich suspension, granulocytes 
were purified over a discontinuous Percoll plasma gradient [643]. Residual erythrocytes 
were removed by hypotonic lysis. The detailed protocol is outlined in Figures 20 and 21. 
Cells were re-suspended, at 1-2X106cells/ml, in Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% v/v foetal calf serum (containing 100IU/mL penicillin, 100μg/mL 
streptomycin and 2mM L-glutamine). 
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1. Freshly prepare dextran and percoll, place into waterbath with DMEM, and 0.25% and 1.6% 
saline. 
2. Obtain blood into sodium citrate, to final concentration of 10% v/v. 
3. Spin whole blood 300g, 20mins at 20˚C, Acceleration 9, Deceleration 4 
4. Remove all plasma into PRP (platelet rich plasma) falcon and spin 2000g for 20min at 20
o
C 
5. Add 6ml of 6% dextran through 0.45µm filter to blood tube 
6. Top up to 50ml with 0.9% saline 
7. Invert once and leave on bench for 30mins 
8. Take PRP out of centrifuge and put supernatant into new PPP (platelet poor plasma) falcon 
9. After dextran sedimentation there will be two layers: aspirate WBC into 50ml falcon and spin 
300g 7min 
10. Prepare percoll gradient (90% percoll) 
11. 42%: 2.1ml 90% percoll (3 x 700µl), with 2.9ml PPP (3 x 966 µl) 
51%: 2.55ml 90% percoll (3 x 850µl), with 2.45ml PPP (3 x 816.66µl) 
12. 15ml falcon with white needle and 2ml syringe; 3ml 51% percoll then 3ml 42% percoll gently 
layered on top 
13. Take WBC out of centrifuge, white cell pellet and red stain 
14. Remove supernatant (waste), flick to dislodge pellet, add 1ml PPP and pipette up/down (wide 
tip), add 1ml PPP 
15. Add this to gradient, further 200µl of PPP into syringe 
16. Spin gradient 260rcf, 12min, Acc 4, Dec 0 
17. Remove gradient from centrifuge (Figure 21) 
18. Remove top layer and discard monocytes and upper phase 
19. Collect neutrophils into 50ml falcon and add remaining PPP 
20. Spin neutrophils 300rcf, 7min 
21. Remove neutrophils from centrifuge 
22. Discard supernatant, flick tube to dislodge cells 
23. Add 1ml 0.2% saline and pipette up/down x7 (wide tip) 
24. Add 24ml 0.2% saline and invert x10 
25. Top up to 50ml with 1.6% saline, invert once 
26. Spin 300rcf, 7min 
27. Pour off supernatant, flick to dislodge cells and resuspend in medium (2ml FCS, 18ml DMEM) 
28. Count cells (10µl sample and 90µl TURKS stain) 
29. Re-spin and resuspend in medium and desired concentration for experiment 
 
Figure 20: Neutrophil isolation protocol 
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Figure 21: Photographs of Percoll density gradient centrifugation. On the left: A) concentrated leukocyte suspension, lying 
on top of B) two layers of percoll, which are indistinguishable in appearance. On the right, following gentle centrifugation, 
C) monocytes at the interface of two density gradients, and D) neutrophils present at this density interface (hard to 
visualise). 
7.2.4. Neutrophil staining for counting 
At the completion of experimental conditions, the cell suspension was spun at 400g for 
10mins and supernatant aspirated. The remaining cell pellet was re-suspended in PBS prior 
to use of a cytospin to centrifuge the cells onto glass slides. The slides were fixed by air 
drying until staining with May-Grünwald-Giemsa stain prior to mounting with DPX (Figure 
22). Each slide has 2-4 fields photographed and following transfer of the digital images to 
computer the cells are counted. 
Contamination with non-neutrophil cells including eosinophils was consistent with levels 
reported by others (<10%) [643]. Neutrophils spontaneously apoptose in the circulation and 
the isolation technique can precipitate this. Immediately following neutrophil preparation 
there was negligible neutrophil apoptosis, however, after 4h of co-incubation with 
experimental conditions up to 40% of cells had undergone apoptosis. 
A 
B 
C 
D 
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Figure 22: Representative photomicrograph (x65 magnification) of slide stained with May-Grünwald-Giemsa. Arrow 
indicates viable neutrophil, star indicates contaminating eosinophil and arrowhead indicates an apoptotic neutrophil 
7.3. Enzyme immunoassays (ELISA) 
7.3.1. Basic principles 
Enzyme linked immunosorbent assays (ELISA) accurately quantify the presence of soluble 
analytes in a biological sample using specific antibodies directed against antigens of interest. 
In a sandwich ELISA the capture antibody is immobilised on a plate and binds the target 
antigen in solution. ELISA may be purchased in kits that contain all the necessary reagents or 
assay-specific kits can be purchased with the generic parts of the assay purchased 
separately. For the later type of ELISA a description follows and the general cytokine 
sandwich ELISA protocol is described in Figure 23. 
A ‘capture’ antibody is attached to a solid-phase such as the plastic of a 96 well microtitre 
plate by passive adsorption. Surplus antibody is washed away and a blocking buffer 
containing a high concentration of albumin is used to fill excess non specific binding sites. 
Samples are then added to the wells and any antigen present is bound specifically by the 
immobilised primary ‘capture’ antibody. After washing away any unbound substances, a 
second ‘detection’ antibody labelled with biotin and directed at a different epitope on the 
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antigen of interest is added which binds to the now immobilised analyte. After further 
washing, streptavidin horseradish peroxidase (HRP) is added. Streptavidin binds to biotin on 
the detection antibody. Thus, the amount of HRP present is proportionate to the amount of 
antigen in the original sample. Where the secondary antibody is conjugated directly to HRP 
the streptavidin step can be omitted. HRP is quantified by the colorimetric reaction 
following the addition of HRP substrate 3, 3’, 5, 5’ tetramethylbenzidine (Reagent B, BD 
OptEIA) in the presence of hydrogen peroxide (Reagent A, BD OptEIA).  The colour develops 
in proportion to the amount of antigen present in the initial step. The reaction is terminated 
at 20-30mins by acidification. The developed colour is read by a dedicated fluorometer. 
All ELISA reactions used to assay concentration of cytokine within a biological specimen 
were performed in duplicate in neighbouring wells of the same 96 well plate and the assay 
result averaged. Each plate included eight conditions (in duplicate) representing serial 
dilutions of a known concentration of analyte (provided by the manufacturer) and the 
optical density of these wells is used to create a standard curve. ELISA plates were read 
using a Biotek EL800 plate reader and Gen5 (Biotek) software. Data were exported to excel 
and then analysed using GraphPad Prism (v 4.0). The concentration of the analyte was 
calculated by comparing the optimal densities against those from the standard curve using 
appropriate mathematical functions within GraphPad (sigmoidal dose-response curve). 
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General cytokine sandwich ELISA protocol 
Reagents 
Maxisorp 96 well microtitre plates 
Appropriate antibodies (capture and detection), standards and streptavidin-HPR from kit. 
 
Wash buffer  PBS (5 tablet / 1000mls H2O) 
   0.05% Tween 20 (0.5ml/1000mls)  
   pH 7.4. Store 2-8C, use within 30 days. 
 
Blocking buffer  PBS (1 tablet/200mls H2O) 
   1% BSA (2g/200mls) 
   0.05% NaN3 (0.1g/200mls) 
   Store 2-8C, use within 7 days 
 
Reagent  diluent  Tris buffered saline (20mM Trizma base- 1.211g /500ml, 150mM NaCl-  
   4.38g /500ml) 
   0.1% BSA-0.5g/500ml 
   0.05% Tween 20 0.25ml/500ml 
   pH 7.3. Store 2-8C, use within 7 days 
 
Substrate solution 50% Reagent A (H2O2) 
   50% Reagent B (Tetramethylbenzidine) 
   Use immediately 
 
Stop solution  1M H2SO4 
 
Protocol 
1. Coat wells of Maxisorp 96 well microtitre plate with 100l capture antibody.  Seal and incubate 
overnight at room temperature. 
2. Wash each well 3 times with 400l wash buffer.  Invert plate and tap dry on paper towel. 
3. Add 300l/well blocking buffer and incubate for a minimum of 1h at room temperature.  During 
this stage prepare standards and sample dilutions using reagent diluent. 
4. Wash 3 times and tap dry. 
5. Add 100l of control /standard / sample to appropriate wells.  Seal and incubate for 2h at room 
temperature 
6. Wash 3 times and tap dry. 
7. Add 100l/well of detection antibody, seal and incubate for 2hrs at room temperature. 
8. Wash 3 times and tap dry. 
9. Add 100l/well Streptavidin HRP, seal and incubate for 20 mins at room temperature avoiding 
direct light. 
10. Wash 3 times and tap dry. 
11. Add 100l/well substrate solution, seal and incubate for 20mins at room temperature avoiding 
direct light. 
12. Add 50l/well stop solution.  
13. Read O.D. at 450nm (correction of 570nm) within 30mins 
Figure 23: Details of generic ELISA protocol 
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7.4. Multiplex assays 
7.4.1. Principle of electrochemiluminescence (MSD) 
Meso-Scale Discovery (MSD) plates allows the detection of multiple proteins from a single 
biological sample across a wide range of concentrations. Each well of a microplate features 
several micro-spots, each corresponding to a specific analyte (Figure 24). The samples are 
added to the wells and processed very similarly to a standard ELISA. The detection antibody 
is conjugated to a Sulpho-Tag™ group. When the protocol has been completed the plate is 
placed within a plate-reader (MSD Sector) a small electric current is run across each micro-
spot within each well. By electrochemiluminescence, a luminous intensity is generated in 
proportion to the extent the Sulpho-tagged antibody is present and this varies in proportion 
to the quantity of analyte present within each well, Figure 24. A series of dilutions of known 
concentrations of analytes provided a reference and the on-computer software (MSD 
Discovery workbench) calculates the levels of each analyte in each well and exports the data 
to a spreadsheet. 
In addition to measuring multiple analytes simultaneously, the advantage of the MSD 
system is that wide range of concentrations that can be measured without sample dilution – 
a traditional ELISA can measure over 2 to 3 log ranges, the MSD system can measure over 4 
to 5. The main disadvantage of the system is expense. 
 
Figure 24: Cytokine capture antibody is pre-coated on specific spots of a 4-Spot MSD MULTI-SPOT plate.  Calibrator 
solutions or samples are incubated in the MULTI-SPOT plate, and each cytokine binds to its corresponding capture antibody 
spot.  Cytokine levels are quantitated using a cytokine-specific detection antibody labelled with MSD SULFO-TAG reagent. 
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7.4.2. Protocol 
Samples were collected and processed as per the manufacturers’ protocol, Figure 25. 
 
 
 
 
 
 
 
 
 
  
General MSD protocol 
1 Addition of Diluent:  Dispense 25 µL of Diluent 2 into each well. Pipette to the 
bottom of the plate so as to allow the fluid to cover the entire bottom of the well. A 
slight tap may be necessary to allow the fluid to settle to the bottom.  
2 Seal the plate with an adhesive plate seal and incubate for 30 minutes with vigorous 
shaking (300-1000 rpm) at room temperature.  
3 Addition of Sample or Calibrator:  Dispense 25 µL of each Calibrator or Sample 
Solution into a separate well of the MSD plate.   
4 Seal the plate with an adhesive plate seal and incubate for 2 hours with vigorous 
shaking (300-1000 rpm) at room temperature.    
5  Wash and Addition of Detection Antibody Solution:  Wash the plate 3X with PBS + 
0.05% Tween-20.   
6 Dispense 25 µL of the 1X Detection Antibody Solution into each well of the MSD 
plate.   
7 Seal the plate and incubate for 2 hours with vigorous shaking (300-1000 rpm) at 
room temperature.   
8  Wash and Read: Wash the plate 3X with PBS + 0.05% Tween-20. Add 150µL of 2X 
Read Buffer T to each well of the MSD plate.   
9 Analyze the plate on the SECTOR reader. 
 
Figure 25: Protocol for MSD use 
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7.5. Flow cytometry (FC) 
Flow cytometry is a technique that can be used for counting, characterizing, and sorting cells 
suspended in a stream of fluid either by their physical characteristics, or by the extent of 
presence of bound, labelled antibodies or dyes. 
7.5.1. Basic principles of FC 
Cells are processed to allow binding of fluorescently-labelled monoclonal antibodies to the 
cells. Following removal of excess antibodies, the cell suspension is processed such that cells 
pass individually through a series of lasers and paired detectors. The lasers excite the 
fluorescent molecules, which are excited at one range of wavelengths and emit at a second 
range. Filters in front of each of a series of detectors restrict the light that reaches the 
detector to only a small range of wavelengths. Each detector provides a value for the degree 
of fluorescence in that wavelength for each cell. There may be more than ten detectors and 
tens of thousands of cells are typically processed for each experimental condition. The flow 
cytometer machine (LSR II, Becton Dickinson, Oxford, UK) passes the acquired information 
to a microcomputer (Standard PC running FACSDiva software v6.0) that allows the user to 
manipulate how the data is presented. Data may be further analysed ‘off-line’ using 
specialised software such as FlowJo v9.1 (Treestar, Oregon, USA). 
Identification of specific populations of cells is possible through comparison of the 
fluorescence in several channels and the use of ‘gating’ strategies. Extent of fluorescence 
data is usually represented as a histogram with number of events on the y axis and the 
fluorescence along the x axis as a logarithmic scale. If the distribution of fluorescence is 
parametric, then the mean fluorescence intensity (MFI) may be used as a summary statistic 
to represent degree of fluorescence. 
7.5.2. Staining whole blood for FC 
Details of the development of this method are to be found within Section 12.4.1. The final 
protocol that was used is described in Figure 26. 
 
 
140 
 
  
STAINING 
 Obtain 3ml blood into citrate tube (BD Vacutainer
TM
 purple), mix gently 
 Take 1.0ml and add to 10ml of cold PBS/EDTA in 15 ml Falcon tube 
 Spin 400g (10mins 4
o
C), Prepare bead controls 
 Aspirate supernatant 
 Add 10ml PBS/EDTA 
 Spin 400g 
 Aspirate supernatant 
 Top up to 1.0ml volume with PBS/EDTA, gentle mix (resuspended WB) 
 50l into each of the duplicate labelled 2ml eppendorf tubes: 
o RAGE 
o FMO 
o Intracellular RAGE 
o Intracellular FMO 
 Make controls for the live/dead assay by heating 50l of the resuspended WB in 450l of PBS to 90
o
C 
for 5m. Cool, then mix 50l with 50l unheated resuspended WB. 
 Staining: 
o 0.5l of undiluted AB to each tube, 0.5l of undiluted AB to each control for CD14, CD16 and 
Live/dead 
o 0.5l of undiluted Anti-RAGE AB to the RAGE tube and to bead control 
 Give all tubes a very brief vortex then leave on ice in dark for 20mins 
 Add 2ml PBS/ETDA to all tubes 
 Spin 400g  
 Aspirate supernatant, leave about 100ul 
 Add 200ul of PBS to the beads and put in fridge 
 Resuspend all with up to 10x U/D with small wide tip 
 Add 2ml lyse/fix, wait 30mins+ on ice 
 Leave some tubes in the fridge – L/D controls, RAGE, and FMO. With the Intracellular RAGE and 
Intracellular FMO: 
 Spin 600g  
 Aspirate supernatant 
 Add 2ml of perm/wash, gentle u/d, wait 20mins on ice 
 Spin 1500g 5m 
 Aspirate supernatant 
 Add Anti-RAGE AB to RAGE tube 
 Give all tubes a very brief vortex then leave on ice in dark for 20m 
 Add 2ml EDTA-PBS,  Spin 1500g, 5m 
 Aspirate most off, add 2ml lyse/fix, in fridge overnight 
 Next day: wash cells in PBS, Spin, resuspend in 300µl PBS 
ACQUISITION 
 Live cells were distinguished with the cell viability stain 
 Monocytes were characterized on the basis of their CD14 expression and neutrophils on the basis of 
their CD16 expression.  
 At least 10,000 neutrophil events were recorded.  
 Results are expressed as means of fluorescence intensities (MFI) related to the specified population, 
reflecting the RAGE density per cell. 
 
Figure 26: Final flow cytometry staining protocol for whole blood 
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7.6. DNA extraction 
7.6.1. Acquisition 
10mls of peripheral blood was collected from each patient via an indwelling arterial catheter 
into an anticoagulant vacutainer containing sodium citrate. DNA was extracted from the 
blood samples within 24h according to the following protocol.  
Blood was transferred into a 15ml polypropylene tube (Becton Dickinson, UK). 
Centrifugation of the tube at 2,500 rpm for 20 mins at room temperature separated red and 
white blood cells (WBC) from the serum. The buffy coat of WBCs lying between the plasma 
and erythrocyte fractions was aspirated into a new 15ml tube. 10mls of red cell lysis buffer 
(144mM NH4Cl, 1 mM NaHCO3) was added to eliminate contaminating erythrocytes and the 
tubes were inverted several times to ensure complete haemolysis. Each sample was 
centrifuged for 20 minutes at 2,500 rpm, the supernatant was disposed of and red cell lysis 
buffer used to wash the resultant WBC pellet. 
7.6.2. DNA extraction from WBC pellet 
The WBC pellet was immersed in 3 mls of nuclei lysis buffer (10 mM Tris-HCl pH 8.2, 400 
mM, NaCl, 2 mM EDTA pH 8.0). The addition of 1ml of 6M NaCl precipitated proteins and 
2mls of 24:1 Chloroform: Isoamyl alcohol separated the WBC pellet from the DNA. A milky 
solution was formed by agitation of the sample and this was centrifuged for 30 minutes at 
3,000 rpm.  
Three phases were visible after centrifugation; the upper phase containing DNA was 
transferred into a new tube. 10mls of absolute ethanol was added and the tube was 
inverted several times to precipitate the DNA. The DNA was placed in a sterile 1.5ml 
microfuge, suspended in sterile water (Baxter, UK) in aliquots and frozen at -20oC until 
required for SSP-PCR. 
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7.7. Polymerase chain reaction (PCR) 
7.7.1. Basic principle 
The polymerase chain reaction (PCR) enables a selected region of the genome with a known 
DNA sequence to be amplified. Two primers (synthetic oligonucleotides) are designed that 
are complementary to each strand of double stranded DNA that surrounds the region of 
interest. Each strand of DNA is replicated, catalysed by the heat stable enzyme Taq 
polymerase. As the process continues through repeated cycles each newly generated strand 
is used as a template for further replication thus exponentially amplifying the initial DNA 
sequence of interest.  
Each cycle consists of 3 steps: 
1. Denaturation: Samples are heated briefly to 94oC causing disruption of the hydrogen 
bonds between the two strands of DNA resulting in their separation. 
2. Annealing:  Subsequent cooling to 55-65oC in the presence of an excess of the two 
primers allows the primers to bind to the complementary DNA sequences through 
hydrogen bonds. 
3. Extension: Reaction temperature is increased to 72oC, the optimal temperature for Taq 
polymerase to attach to the primer/cDNA segment and extend from the primer by 
adding dNTPs that are complementary to the template in a 5’to 3’ direction. Provided 
there are surplus reagents the amount of target DNA is doubled.  Extension of the 
original template produces strands longer than the target sequence in a linear manner.  
By contrast, amplification of the DNA PCR products only generates DNA of the required 
length. Since these are generated in an exponential manner, after several cycles they 
greatly outnumber the longer sequences. 
4. A final elongation step ensures that any remaining single stranded DNA is fully extended. 
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7.8. Sequence specific primer PCR (SSP-PCR) genotyping  
7.8.1. Principle 
Sequence specific primer PCR (SSP-PCR) uses primers designed with their 3’ end 
complementary to a particular SNP variant and identifies the presence of this variant by PCR 
amplification [644]. Thus, for a single locus, two different PCR reactions detect the two 
allelic variants: one containing a specific primer complementary to one variant, and the 
other containing a specific primer complementary to the other variant in conjunction with a 
consensus primer.  The presence of a PCR product of the expected size indicates the 
presence of the allele in the specimen (Figures 27 and 28). 
 
Figure 27: Diagram illustrating SSP-PCR. This example of a SNP has one variant with a complementary primer with an 
adenine (A) at the locus and the other variant with a guanine (G) – top left of diagram. The consensus primer is the same 
for both. For each patient’s DNA two PCR reactions take place, one with the A primer and one with the G primer. In the 
case of DNA1, the A primer is shown to match and the G primer is shown to mismatch – therefore on the diagram of the 
gel photograph there is a specific band for A but none for G. 
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7.8.2. Primer design 
All primers were designed to work under the same amplification procedures.  For this 
reason, a set of primer design rules were established. Primers were designed optimally with 
a length of 19 to 21 bases, a salt adjusted melting temperature (Tm) of 58 to 61 ˚C, a GC 
content of 45 to 55 % and with no secondary structures (e.g. hairpin loops).  The online 
program oligonucleotide properties calculator was used to determine these conditions: 
http://www.basic.northwestern.edu/biotools/oligocalc.html  
Primers that could potentially form dimers with themselves or with other primers in the 
reaction mix were avoided, having been identified using the program FastPCR: 
http://primerdigital.com/fastpcr.html 
Once designed, primers were checked for specificity using the basic local alignment search 
tool (BLAST): 
http://blast.ncbi.nlm.nih.gov/Blast.cgi  
BLAST is a search tool which looks for matches between the sequence you submit and a 
comprehensive database of all known DNA sequences called GenBank.  This step avoids 
non-specific priming ensuring as far as possible that primers will only anneal to an exact site 
match. 
The oligonucleotides used as primers for each SNP are listed in Table 15. 
Figure 28: Photograph of representative gel showing two heterozygotes, two homozygotes for the first allele and 
two for the second allele. 
 
  Allele  1     2 1     2   1    2      1      2     1     2    1      2    
  Two       Two homozygotes    Two homozygotes 
  heterozygotes      2nd allele            1st allele 
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Reference Variant Specific primer 
complementary to SNP 
Consensus primer 
rs1800624 WT CTG TTG TCT GCA AGG GTG CAT AGG TTG GAA GTG TGA TGG GT 
 variant CTG TTG TCT GCA AGG GTG CAA 
rs1800625 WT C AGG AGA GAA ACC TGT TTG GAA TAA AGA TCC GGG CAG GAC TG 
 variant AGG AGA GAA ACC TGT TTG GAG    
rs2070600 WT GCT CGT GTC CTT CCC AAC A GCC CTC ATG GGC CAA GGC TG 
 variant GCT CGT GTC CTT CCC AAC G 
rs184003 WT AGG TAG GGT GAA CCA TAA CTA T TGA CAG CAC GGC TTT CCT G 
 variant AGG TAG GGT GAA CCA TAA CTA G 
rs3134940 WT CGC GCC CAG CCG TCT GTC CCA CCC ATT CCA GCC ACG 
 variant CGC GCC CAG CCG TCT GTT 
rs3806232 WT GAA TGG ATA TAG CCC TTG GCA GGA GGT AGG AGA AGC GGA AA 
 variant GAA TGG ATA TAG CCC TTG GCG 
rs3795391 WT GGG CAG TAC GCA GAG GAC GAG TGA GGC AGG GAT AAG GA 
 variant A GGG CAG TAC GCA GAG GAT 
rs1060348 WT CGA TAC TCA GAG CAG AAG AGG TGT CCA ATG CAT CAC AGA AA 
 variant CGA TAC TCA GAG CAG AAG AGA  
Table 15: Oligonucleotides used as primers for each SNP 
Primers were manufactured by Invitrogen in nanomolar quantities.  Stock solutions of 
primer were prepared by adding DEPC-treated water to give a resultant concentration of 
1nmol.l-1 (1mM).  Stock solutions were stored at -20C. 
7.8.3. SSP-PCR amplification 
10µl of oil was added to each well in a 96 well plate and 5 µl of primer mix was dispensed 
into the oil. The primer mix contained two pairs of primers; one pair for a sequence specific 
reaction and one pair for an internal positive control reaction to validate the results. Each 
well received 8 µl of DNA/PCR reaction mix containing TDMH (1X NH4 buffer, 300 µM of 
each dNTP, 2 mM MgCl2) 0.08 µg DNA and 0.32 units Taq DNA polymerase (Bioline UK). The 
plate was sealed with a Thermowell sealer (costar) and secured in an MJ Research PTC-200V 
Thermal Cycler machine. SSP-PCR was performed with the following cycling parameters: 
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1 minute at 96oC; 4 cycles of 20 seconds at 96oC; 45 seconds at 75oC; 25 seconds at 72oC; 20 
cycles of 25 seconds at 96oC, 50 seconds at 65oC, 30 seconds at 72oC, 3 cycles of 30 seconds 
at 96oC, 60 seconds at 55oC, 90 seconds at 72oC, 10 minutes at 5oC. 
Control primers were multiplexed (mixed in the same reaction well and amplified 
simultaneously) into each PCR in order to confirm that amplification was successful.   
7.8.4. Gel electrophoresis 
 1.5% agarose gel was prepared using 0.5 X Tris Borate EDTA (TBE) buffer, stained with 20µl 
of SYBRSafe (Invitrogen). On completion of SSP-PCR, 10µl of orange G loading Buffer 
(glycerol, 0.5x TBE, orange G) was added to the PCR product in each well of the 96-well 
plate. 25 µl of PCR product and orange G was then loaded into each well of the gel. 
Electrophoresis was carried out at 200V for 20 minutes. The gel was visualised under 
ultraviolet light (UV, 320nm) light; resultant amplicons were photographed and digitally 
recorded using the alpha digidoc system. Any equivocal results were repeated. 
The stringent conditions outlined in this section ensured amplification using the SSPs 
occurred only with an exact primer match.  Therefore, the presence of a specific allele was 
scored by observing an amplicon of the expected size in association with a control PCR 
product. The absence of a specific allele was scored by observing only a control PCR 
product. Through careful design, all primers worked optimally at the same conditions. It was 
therefore possible to ‘phototype’ several SNPs simultaneously in one DNA sample. 
7.8.5. Reading the gels 
The images of the gels were read by two independent observers and any discordance or 
uncertainty was resolved by re-typing. For each SNP, for each patient their genotype was 
entered into anonymised excel spreadsheet for later analysis. 
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7.9. Quantitative reverse transcription real-time polymerase chain reaction 
(qRT-PCR) 
Reverse transcription PCR describes the use of PCR following the conversion of coding 
information from RNA to DNA, reverse transcription (RT). The RT-PCR described within this 
thesis is a two-stage process, although an integrated process is possible. Prior to RT, the 
mRNA must be isolated from the DNA, protein and other cellular components. 
7.9.1. mRNA isolation from leukocytes 
Total ribose nucleic acid (RNA) was extracted from leukocytes using the phenol-chloroform 
extraction method [645]. Cell suspension (either whole blood or isolated neutrophils) was 
thoroughly mixed 1:3 with TRI Reagent™ (Invitrogen). TRI reagent combines phenol and 
guanidine thiocyanate in solution. The later denatures proteins including RNAses that might 
otherwise cause RNA degradation. The samples can be stored in TRI reagent at -80oC until 
processing. The RNA extraction relies upon phase separation and upon addition of 
chloroform (200µl for every 1ml) and following centrifugation (120g for 15mins at 4oC), the 
RNA becomes dissolved in the upper aqueous phase (Figure 29). Addition of isopropanol 
results in precipitation of the RNA. Following centrifugation and aspiration of the 
supernatant, the RNA pellet is washed in 75% ethanol. The supernatant is discarded and the 
RNA pellet air-dried prior to addition of RNAse-free water to dissolve the RNA prior to RT. 
 
 
Figure 29: Diagrammatic illustration of phenol extraction method 
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7.9.2. Reverse transcription 
7.9.2.1. Basic principle 
The isolated RNA isolated must be non-specifically transcribed into complementary DNA 
(cDNA) prior to PCR. Mature mRNA has a chain of adenosine nucleotides on the 3’ end – this 
is known as the Poly-A tail. The RT primer used in this thesis is an oligo-(dT) that, by 
complementarity, hybridizes with the poly-A end of mRNA. Polymerization starts from this 
primer, and proceeds until a complete cDNA transcription of the mRNA has formed. 
7.9.2.2. Protocol 
 
 
  
Reagents: 
RT buffer (x5)  250nM Tris HCl pH 8.3, 375nM KCl, 15mM HgCl2 
DTT    0.1M 
dNTP   10mM dATP, dCTP, dGTP and dTTP (For 200l: 20l of each    
   each at 100mM + 120l DEPC H2O) 
OligoDT   12-18 
RNasine   0.5U/l 
RTase   200U/l 
DEPC H2O Dissolve  DEPC in 200mls distilled H2O, leave on agitator in water bath at 37C 
over night, autoclave once DEPC is dissolved completely. 
Ice 
 
Reverse Transcription mixture buffer (for 1 sample): 
RT buffer (x5) 2.8l, DTT 2l, dNTP 10mM 2l, DEPC H2O 1.7l, RNAsine 0.5l, RTase 1l. 
 
Protocol 
1. Turn heat blocks on to 37C and 65C in advance. 
2. For each sample dilute 0.6g mRNA in 7l DEPC H2O 
3. Add 1l Oligo DT to each sample 
4. Incubate at 65C for 10 mins followed by 5 minutes on ice 
5. Add 10l of reverse transcription mixture buffer to each sample 
6. Incubate at 37C for 1 hour 
7. Incubate at 65C for 5 mins 
8. Store at -20C 
 
 Figure 30: Protocol for cDNA preparation by Reverse Transcription 
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7.9.3. Principles of real-time PCR 
Real time PCR enables quantification of PCR product as the amplification process proceeds. 
Based on conventional PCR it has the advantage that it allows more accurate, quantitative 
measurements of PCR product concentrations after each cycle using the incorporation of a 
fluorescent dye or oligonucleotide probe.  The simplest and most cost-effective method is to 
add a fluorescent DNA binding dye such as SYBR Green into the reaction mixture. SYBR 
Green fluoresces when it binds to the minor groove of the double stranded DNA. SYBR 
Green emits a low signal when in solution but a much higher signal when bound to DNA. 
Thus, as the reaction proceeds there is a corresponding increase in signal intensity (Figure 
31).  
 
Figure 31: The basic principle of real-time PCR using SYBR green 
Individual reactions are characterised by the PCR cycle at which fluorescence first rises 
above background levels. It is at this point that PCR amplification becomes exponential, 
termed the threshold cycle (Ct). The more target present in the starting material the lower 
the Ct. The correlation between fluorescence and the amount of amplified product enables 
quantification of target molecules over a wide range. Figure 32 shows an example graph of 
fluorescence plotted against time/cycle.  
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Figure 32: The progress of the reaction is monitored by tracking the increase in fluorescence over time. Each coloured 
line represents one condition/reaction/tube within the machine. The x axis is cycle number and the y axis is 
fluorescence intensity. The red horizontal line represents the threshold. It can be seen that the first black line crosses 
the threshold earlier than the other lines, this indicates it had a greater quantity of cDNA specific for the primer in that 
tube than the other samples had of their respective primers. 
7.9.4. qRT-PCR protocol 
20μl PCR reactions were set up in duplicate in 0.1 ml Thermo-PCR tubes, containing SYBR 
Green PCR Master Mix, forward primer, reverse primer, template cDNA and RNAse free 
water and loaded into the PCR machine (Rotor-Gene 6000, Corbett). The loading volume of 
reagents and samples were based on duplicate measurements for each sample. Preparation 
of reagents and materials are shown in and details of cycling conditions (Figures 33 and 34). 
 
 
 
 
 
 
 
 
 
 
Reagents: 
cDNAs (15l cDNA from RT of 1.2g RNA + 345l H2O) 
SYBR Green  
Primer mix (20M) 
DEPC H2O 
Keep all reagents on ice 
 
Protocol 
1. For new primers reconstitute with TE [10 mM Tris-HCl (pH 8.0), 1 mM EDTA] and 
vortex 
2. Calculate total volume of SYBR green and primer mixture to make a master mix 
according to sample number (N)  
3. Add  SYBR green (10xNx1.1) to primer mix (2xNx1.1) and vortex for each gene. 
4. Aliquot 12l of Sybr/Primer and 8l of cDNA into each PCR tube. Performed in 
duplicate. 
5. Load the tubes into the rotor of the PCR machine (Rotor-Gene 6000).  Set up the 
running program and start amplification procedure 
Figure 33: Details of qRT-PCR protocol 
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7.9.5. Quantification of gene expression 
Under identical cycling conditions, all primer sets worked with similar efficiencies to obtain 
simultaneous amplification in the same run. The choice of reference genes is discussed 
within Section 12.5.1. HPRT1, GUSB and RPL13 were chosen; the gene of interest was RAGE. 
Analysis of relative expression and CT values was with rotor-gene software (v 1.7), followed 
by use of Excel software to implement the delta delta CT method [646] to compare the 
difference between post-snCPB and pre-snCPB expression of RAGE relative to the mean 
change in reference genes. Relative transcript abundance is expressed as ΔCt value (ΔCt = Ct 
reference – Ct target), with higher ΔCt values indicate higher transcript abundances, and 
negative ΔCt values represent genes that are less expressed compared with the reference 
gene. The fold-change of the transcript levels in post versus control can be estimated by 
2ΔΔCt, where ΔΔCt values are calculated as ΔCtpost – ΔCtpre. Positive 2ΔΔCt values indicate 
up-regulation, negative values indicate down-regulation of a target gene. 
7.9.6. Melt Curve 
The melt curve is a post PCR analysis tool that is used to ensure the specificity of amplified 
products. End products are incubated through a range of increasing temperatures. The 
amplicon (specific PCR product resulting from amplification of the region of sequence 
targeted by the PCR primers) is melted from a double stranded to single stranded state. At 
low temperatures the DNA is double stranded and a high fluorescence is recorded; at high 
temperature the strands dissociate and low fluorescence is detected due to release of the 
dye. Melt curves are presented as a derivative plot showing rate of change of fluorescent 
signal. The x axis represents temperature and the y axis the negative derivative (rate of 
PCR was carried out over 45 cycles using the following conditions: 
Step   Temperature  Time 
Initial Denaturing  95
o
C   15 mins  
Denaturing  94
o
C   20 sec 
Annealing  60
o
C   20 sec  
Extension  72
o
C   20 sec 
Final Extension  72
o
C   15 sec 
Figure 34: Details of PCR cycling conditions 
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change) of fluorescence (F) with respect to temperature (T), shown as dF/dT (Figure 35).  
The melting temperature depends on the length of DNA, sequence and G:C content.  The 
peak of the plot represents the melting point (Tm) at which 50% of the DNA is single 
stranded. More than one peak indicates more than one amplified product. Primer dimers 
denature into single strands at high temperatures. 
 
Figure 35: A representative melt curve, temperature (x axis) versus the rate of change of fluorescence (F) with respect to 
temperature (T), shown as dF/dT (y axis). 
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8. STATISTICAL METHODS 
8.1. Data processing 
Data were entered in Excel spreadsheets prior to statistical analysis using PRISM v4.0 
(GraphPad software, La Jolla, CA, USA) or SPSS v17.01 (IBM, Somers, NY, USA). 
8.2. Data presentation and analysis 
Data are presented as mean and standard error of the mean (SEM), or median (interquartile 
range, IQR) for non-parametric data. For each dataset the distribution was determined using 
the Kolmogorov-Smirnov test. The statistical tested used for individual experiments are 
outlined as the results are presented. Statistical significance was defined at the 95% level. 
Statistical tests used are presented in Table 16. 
Distribution Groups Paired Test 
Parametric 2 N t- test 
Non-parametric 2 N Mann Whitney U (MWU) 
Parametric >2 N ANOVA with Bonferroni correction 
Non-parametric >2 N Kruskal-Wallis test (KWT) with Dunn’s multiple 
comparisons test (DMCT) correction 
Parametric 2 Y Paired t-test 
Non-parametric 2 Y Wilcoxon matched pairs test (WMPT) 
Parametric >2 Y Repeated measures ANOVA with Bonferroni 
correction 
Table 16: Statistical tests used according to dataset distribution and number of groups 
Contrary to standard methodology but to more clearly demonstrate statistical relationships, 
the mean and SEM were charted in preference to the median and IQR for some non-
parametric variables in Section 10; appropriate non-parametric statistical analyses were 
performed. 
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8.3. Correlations 
If data were parametric in distribution, Pearson’s correlation was used; if non-parametric, 
Spearman’s rank correlation. In both cases, a value is stated for r (degree of correlation) and 
p (statistical significance), r values of >0.3 or <-0.3 are considered significant when 
associated with a p value of <0.05. 
8.4. Binary logistic regression 
To assess relationship between continuous variables and binary outcomes binary logistic 
regression was used. Continuous variables were necessarily parametric in distribution and 
were this not the case, a Log10 transform was used. Statistical relationship of variables to 
outcome was initially assessed individually and if p<0.10 then these variables were used in 
the multivariate analysis. For each analysis, odds ratio, 95% confidence intervals and p 
values were presented. 
In the presentation of the data, for each outcome, 0 indicates absence of the outcome and 
the mean and standard deviation for the relevant clinical variable are shown, 1 indicates 
presence of outcome and similarly the mean and standard deviation are shown. A variable 
that, in multivariate analysis, has 95% confidence intervals that do not span 1.0 will have a p 
value of less than 0.05 is considered to be have an independent relationship with the 
outcome under consideration. An odds ratio of less than 1.0 equates to reduced risk and 
greater than 1.0, increased risk. 
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9. MATERIALS 
9.1. General reagents 
Bovine Serum Albumin  A7030 Sigma Aldrich 
Dextran 31392 Sigma Aldrich 
Distilled water - MilliporeTM water 
purification system 
ELISA substrate reagents A and B, OptEIA 555214 BD  
Endotoxin free water W50-100 Lonza  
Ethidium Bromide - Sigma Aldrich 
Ethylenediaminetetraacetic acid (EDTA)  03690 Sigma Aldrich 
Goat Serum  G9023 Sigma Aldrich 
Methanol - Merk 
Microcentrifuge tubes - Fisher 
Normal Human Serum - Invitrogen 
Percoll 17-0891-02 GE Healthcare 
Perm/wash buffer 554723 BD 
Phosflow Lyse/Fix Buffer 558049 BD 
Phosphate buffered saline D8537 Sigma Aldrich 
Sodium Azide - Sigma Aldrich 
Sodium chloride S7653 Sigma Aldrich 
Sodium Citrate S5770 Sigma 
Triethylamine (TEA) solution - Sigma Aldrich 
Trizma base T6066 Sigma Aldrich 
Trizol reagent 15596-018 Sigma 
Tween 20 P1379 Roche 
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9.2. Equipment 
EL800 plate reader with Gen 5 (Biotek) software  Biotek 
LSRII  BD 
RG-6000 RT-PCR machine  Corbett 
 
9.3. Antibodies  
Target Host 
species 
Monoclonal/Polyclonal and 
conjugate 
Code Producer 
RAGE Rabbit Polyclonal, none Ab37647 Abcam 
Rabbit 
IgG 
Goat Polyclonal, FITC Ab6717-1 Abcam 
Isotype Rabbit Polyclonal, none ab37415 Abcam 
RAGE Mouse Monoclonal, none MAB5328 Millipore 
Mouse 
IgG 
Goat Polyclonal, FITC DAM1487570 Millipore 
Isotype Mouse Monoclonal, none MABC004 Millipore 
RAGE Mouse Monoclonal, none sc-80652 Santa Cruz 
Mouse 
IgG 
Goat Polyclonal, FITC sc-2010 Santa Cruz 
CD16 Mouse Monoclonal, PerCP 302030 BioLegends 
CD16 Mouse Monoclonal, pacific blue 558122 BD 
CD14 Mouse Monoclonal, PE-Cy7 557742 BD 
TLR-4 Mouse Monoclonal, PE FAB14781P R&D 
TLR-9 Mouse  Monoclonal, PE IMG-305D Imgenex, San 
Diego, CA 
S100B Mouse Monoclonal (blocking) ab11179 Abcam 
Isotype Mouse Monoclonal, none ab18447 Abcam 
TLR-2 Mouse  Monoclonal (blocking) MAB2616 R&D 
RAGE Mouse Monoclonal (blocking) MAB11451 R&D 
TLR-4 Mouse Monoclonal (blocking) D077-3 MBL 
 
157 
 
9.4. Antibody related 
Compbeads, anti-mouse Ig 552843 BD 
IgG labelling kit: Zenon™ labelling kit with 
Alexa-fluor 488 
 Invitrogen 
Lightning linkTM – APC kit conjugation kit 705-0005 Innova Bioscience, 
Cambridge, UK 
Live/Dead FITC kit V13242 Invitrogen 
 
9.5. Cells and cell culture 
Dulbecco’s modified eagle’s medium D6546 Sigma Aldrich 
Foetal calf serum - Invitrogen 
Glutamine - Invitrogen 
Penicillin Streptomycin - Invitrogen 
RPMI medium R8758 Sigma Aldrich 
THP-1 - European Collection of Cell 
Cultures 
 
9.6. qRT-PCR 
5xFirst strand buffer Y02321 Invitrogen 
DEPC  - Gibco 
dNTP (dATP, dCTP, dGTP and dTTP, 
100mM) 
088k6003 Sigma Aldrich 
DTT Y00147 Invitrogen 
Micropipettes  Gilson 
M-MLV Reverse transcriptase 28025-013 Invitrogen 
M-MLV RT M531a Invitrogen/Promega 
Oligo(dT)12-18 18418-012 Invitrogen 
OligoDT12-18 58862 Invitrogen 
PCR tubes- capped 0.1ml - Corbett 
Quantitect Primer assay: HPRT QT00059066 Qiagen 
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Quantitect Primer assay: RAGE QT00000119 Qiagen 
Quantitect Primer assay: TLR-4 QT01670123 Qiagen 
RNasine, 0.5U/l N261B Promega 
RNeasy Kit 74106 Qiagen 
RT buffer - Invitrogen 
SYBR green PCR kit  Qiagen 
 
9.7. ELISA and related 
Calprotectin (S100A8/9) ELISA CAL0100 NovaTec 
Immunodiagnostica GmbH 
CML-albumin ELISA   
esRAGE UM-100901 B Bridge, CA, USA 
HMGB1 ELISA - Shino-test, Kanagawa, 
Japan 
Human IL-8 HK310 Hycult, Netherlands 
Human proinflammatory-7 Ultra-sensitive 
plate 
K15008C-1 Meso Scale Discovery, 
Gaithersburg 
IL-8 duoset DY208 R&D 
Quantikine sRAGE ELISA DRG00 R&D 
Rapid Endotest - Lonza 
S100A12 CY-8058 Circulex, Nagano, Japan 
S100B RD192030100R Biovendor, Czech republic 
 
9.8. Recombinant proteins 
9.8.1. S100B 
A recombinant human S100 β-chain (RC790, Randox) comprises a 91 amino acid fragment 
(2-92) corresponding to processed S100 β-chain and is expressed in E. coli with an amino 
terminal hexahistidine tag, necessary for affinity chromatography purification. It was not 
certified endotoxin-free. 
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9.8.2. S100A12 
A partial recombinant human protein, produced using the in vitro Wheat Germ expression 
system for Novus Biologicals (Littleton, CO 80160) under license from CellFree Sciences Co., 
Ltd of Japan. Supplied by Abnova. H00006283-Q01 
9.8.3. LPS 
Lipopolysaccharide (LPS), was provided by my colleague Dr Susanna Leaver, following 
extensive purification and validation. The LPS was purchased from a commercial 
manufacturer (Sigma, L2880) prior to the availability of highly purified LPS. The LPS was 
derived by hot phenolic extraction from Escherichia coli (serotype 055:B5) and this may 
leave residual non-LPS contaminants. It was therefore further purified using a phenol 
extraction method and quantified using Limulus amoebocyte lysate (LAL) assay performed 
commercially by BioWhitaker, Verviers, Belgium. 
9.8.4. HMGB1 
A recombinant human protein synthesised in murine myeloma cell line (NS0-derived), 
purchased from R&D (Catalogue number 1690-HM-025). Certified endotoxin free <1.0 EU 
per 1µg of the protein. The method of purification was not specified. 
9.8.5. sRAGE 
A recombinant human protein (Prospec, Israel) produced in HEK (Human Embryonic Kidney) 
cells as a single, glycosylated, polypeptide chain containing 331 amino acids and having a 
molecular mass of 35.2 kDa. It is fused to a Flag tag at C-Terminus and purified by 
proprietary chromatographic techniques. It was not certified endotoxin-free. 
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9.8.6. TTP-4000 
A protein provided as a research donation from Transtech Pharma; it is a fusion protein 
containing the variable region and N-terminal constant domains of RAGE mated to the Fc 
region derived from human IgG (Figure 36). It was not certified endotoxin-free. 
 
Figure 36: Diagrammatic representation of how TTP-4000 relates to the IgG, RAGE, and sRAGE biomolecules 
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10. THE RELATIONSHIP BETWEEN SIRS AFTER SNCPB AND AGE 
10.1. Introduction 
Advanced age is associated with adverse outcomes from a variety of clinical conditions 
associated with SIRS, including infection and following snCPB (as described in Section 4.1). 
However, the relationship between age and the severity of systemic inflammation 
consequent upon snCPB has not been characterised. Thus, significant changes in immune 
function occur with age, and heightened inflammatory responses have been demonstrated, 
exemplified by positive associations between age and levels of circulating inflammatory 
cytokines during sepsis [509, 510]. Secondly, oxidative modifications to long-lived 
biomolecules occur with age, and these advanced glycation end-products are ligands for 
RAGE. There is therefore justification for exploring the hypothesis that accumulation of 
RAGE ligands may contribute to age-related changes in immune function, predisposing to 
greater inflammatory responsiveness which is reflected in adverse outcomes for elderly 
patients displaying an acute systemic inflammatory response to the stimulus of snCPB. 
Unfortunately, optimal clinical and other parameters that might quantify the extent of 
systemic inflammation are undefined; patients displaying such a reaction to snCPB typically 
fulfilling several SIRS-defining criteria. However, these were not designed to quantify 
systemic inflammation, but rather as defining criteria. Thus, fulfilling three defining criteria 
for SIRS does not infer that the extent of a systemic inflammatory response is more severe 
than if only two were met.  Whilst retrospective observational studies have shown that 
meeting more SIRS criteria is associated with worse outcome from both infectious and non-
infectious acute systemic inflammatory conditions (Section 1.2) [34, 647], the relationship 
between the number of SIRS criteria fulfilled and outcome in patients undergoing snCPB has 
not been reported. Partly this may be because of significant limitations to using standard 
SIRS criteria to assess systemic inflammation in these patients. Indeed, body temperature is 
influenced by cooling for cardiopulmonary bypass, heart rate by pacing, respiratory rate by 
mandatory invasive ventilation, and white blood cell count by haemodilution. By contrast, 
meeting two or more SIRS defining criteria after snCPB is common (estimated to be 28-
63%); the variables under consideration are therefore almost universally present in a given 
population. Moreover, proposals have been made concerning the best way to report 
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systemic inflammation following snCPB in the form of a combination of causal inflammatory 
markers known to be associated with adverse sequelæ, such as circulating inflammatory 
cytokines; and evidence of at least one clinical end-point of organ injury, such as organ 
failure scores or ICU length of stay (LOS) [89].  
Increased numbers of circulating white blood cells (leukocytosis) and more specifically 
neutrophils (neutrophilia) are non-specific markers of inflammation and incorporated into 
the some severity of illness scores (including APACHEII [518]). Both excessively high (>12 
X109/l) and low (<4X109/l, leucopenia) leukocyte counts are defining criteria for SIRS 
although leucopenia is often attributable to immunosuppressant therapies or bone marrow 
failure; both uncommon following snCPB. CRP is an acute-phase protein under 
transcriptional control by IL-6 and rises rapidly following a stimulus, peaking around 36-48h. 
It is routinely measured in the critically ill as an inflammatory marker but has limited 
prognostic value, particularly as an isolated measurement [648]. 
The SOFA and APACHE II scores are derived from routinely collected clinical variables and 
quantify different aspects of severity of illness, and have been validated in relation to 
adverse outcome in cardiac surgical patients [94, 96]. SOFA score reflects the extent of 
organ dysfunction and does not include age as a variable. APACHE II includes age and 
information regarding chronic health status. 
The duration of time that a patient spends on an ICU or the length of stay (LOS), relates 
primarily to the need for advanced supportive therapies and monitoring. As such, it 
represents a composite measure of organ failures and extent of inflammatory response. 
Prolonged ICU has serious implications as it is associated with poor functional outcome, low 
quality of life and increased mortality [17-19].  
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10.2. Aims and objectives 
The analyses reported within this chapter were aimed at determining the relationship 
between the age of patients undergoing snCPB and the severity of their systemic 
inflammatory response, and whether such an association has influence upon clinical 
outcome. The specific objectives were: 
i. To demonstrate the relationship between patient age and SIRS criteria, as a measure 
of extent of systemic inflammation; and patient age and SOFA score, as a measure of 
organ dysfunction. 
ii. To determine the relationship between patient age and leukocytosis and levels of 
CRP, as measures of systemic inflammation. 
iii. To establish the relationship between patient age and duration of ICU stay (ICU LOS). 
iv. To assess predictors of fatal outcome or prolonged ICU LOS. 
10.3. Specific methods 
Patients admitted to the Adult Intensive Care Unit following elective cardiac surgery 
between 1st Jan 2002 until 31st May 2005 at the Royal Brompton Hospital were 
retrospectively identified as part of a related study (termed ‘Cohort A’). The study was 
examined by the Royal Brompton and Harefield NHS Foundation Trust Research Ethics 
Committee and deemed to fall within the remit of ‘service evaluation’ and thereby did not 
require patient consent.  
The characteristics of the patients, their operations and subsequently clinical course 
including physiological and laboratory data were extracted from electronic databases 
(Section 6.2). Admissions with conditions unrelated to cardiac surgery, re-admissions and 
those in whom electronic data was incomplete were excluded.  Patients had undergone  
coronary artery bypass-graft (CABG), valvular surgery (Valve), CABG with valve surgery 
(CABG & Valve), or other. The influence of age on systemic inflammation was considered 
within the surgical categories to avoid confounding by surgery type. Within the surgical 
category ‘CABG and Valve’ there were very few patients aged less than 40 years and the 
group was merged with that of the 40-60 year cohort for analysis. 
To determine the number of SIRS criteria fulfilled physiological data were assessed in one 
hour epochs. Standard SIRS criteria were used with the following modifications: immature 
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forms of leukocyte were not considered, as this information was not available; axillary 
temperatures were increased by 0.5oC and core temperatures were not adjusted as 
recommended[649]. SOFA and APACHE scores were calculated as described in Section 6.5. 
ICU LOS was defined as the duration (in hours) between admission and discharge from ICU. 
10.3.1. Data analysis  
Data were entered in Excel spreadsheets prior to statistical analysis using PRISM v4.0 
(GraphPad software, La Jolla, CA, USA) and SPSS v17.01 (IBM, Somers, NY, USA). 
Patients were allocated to one of 4 groups: <40 (young), 40-60 (middle aged), 60-80 (old), 
>80 (oldest) years. When divided by quartile the relative abundance of patients between 60 
and 80 years reduced the age difference between the groups; an approach employed by 
others in studies attempting to relate age to inflammatory response [510]. The distribution 
of scores was compared between groups using ANOVA with Bonferroni correction for 
multiple comparisons when data were parametric; and with the Kruskal Wallis Test with 
Dunn’s Multiple Comparison Test when non-parametric. The Kolmogorov-Smirnov test was 
used to determine the distribution of each variable. For some non-parametric variables, the 
mean and standard error of the mean were charted in preference to the median and 
interquartile range, in order to more clearly demonstrate statistical relationships. Binary 
logistic regression is explained in Section 8.4. To assess possible relationships between 
potential predictors of adverse outcome and survival, binary logistic regression analysis was 
conducted. 
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10.4. Results 
10.4.1.1. Age of patients 
 
Figure 37: Histogram of ages of patients in the cohort with a parametric curve superimposed for reference. N=2440. 
Data from 2440 patients of the total cohort of A were analysed. The median age was 67 
years and the mean 65.3 years. There were 103, 532, 1603 and 202 patients in the young, 
middle aged, old and oldest groups respectively. The distribution of age was therefore non-
parametric in distribution (Kolmogorov-Smirnov test p<0.0001) (Figure 37).   
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10.4.2. Description of patients 
Population 
 
CABG 
n = 1425 
 
Valve 
n=763 
 
CABG and Valve 
n=252 
 
 
Age, years (median, IQR) 67, 60-73 65, 53-74 72, 65-78 *** 
WBC, x109/L (median, IQR) 11.8, 9.4-15 12.2, 9.5-16 12.2, 9.3-15  
CRP, mg/L (median, IQR) 72, 55-91 67, 50-88 74, 65-78 *** 
APACHE II (median, IQR) 15, 12-18 15, 12-18 17, 14-20 *** 
ICU Length of stay (days, IQR) 1, 0.8-1.9 1.6, 0.9-2.9 1.8, 0.9-3.8 *** 
ICU mortality (number, %) 22, 1.54% 22, 2.88% 12, 4.76% *** 
Table 17: Demographics, markers of systemic inflammation, severity of illness and outcome. Groups were compared 
using the Kruskal Wallis test with Dunn’s Multiple Comparison Test correction, *** p<0.001 for comparisons between each 
group with the others. CABG (n=1425) Valve (n=763) Valve & CABG (n=252). 
The distribution of ages within each of the surgical categories differed significantly (Table 
17), p<0.001 for all comparisons. There was no difference between the groups in 
distribution of white blood cell count measured within the first 24h of surgery. There were 
significant differences in CRP within the first 24h of surgery between the groups; the Valve 
& CABG group having the highest CRP, followed by the CABG group, and the valve group 
(p<0.001 for all comparisons). APACHE II was highest in the Valve and CABG group and 
similar in the two remaining (p<0.001 for valve and CABG vs. either CABG or valve) groups. 
These differences between the surgical categories justify consideration of the relationships 
between age and other variables within categories, as opposed to consideration of the 
entire cohort together. 
Consistent with expectations, the ICU LOS and mortality were highest in the valve & CABG 
group, followed by the valve group, and were lowest in the CABG group. Overall, LOS was 
short (median one day), although many patients had prolonged ICU LOS with 456 patients 
(18.7%) staying more than 3 days.  
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Figure 38: SOFA score by operative category. Bar graph showing distribution of SOFA score in the three surgical categories: 
CABG (n=1425) Valve (n=763) Valve & CABG (n=252). Data are presented as median values with bars indicating IQR. Groups 
were compared using the Kruskal Wallis test with Dunn’s Multiple Comparison Test correction, *** p<0.001 for 
comparisons between each group with the others. 
As seen in Figure 38, the SOFA score was highest in the Valve & CABG group, followed by 
the Valve group, and was lowest in the CABG group (p<0.001 for all comparisons). 
10.5. Incidence and severity of SIRS 
10.5.1. For all patients 
SIRS criteria met 
 
Proportion of patients 
 Within 1h Within 24h 
0 7.13% 0.04% 
1 35.31% 3.80% 
2 42.97% 38.53% 
3 13.64% 45.59% 
4 1.05% 12.05% 
≥2 57.66% 96.17% 
Table 18: Proportion of patients meeting SIRS criteria within 1h and 24h of admission to ICU. 
As seen in Table 18, on the basis of meeting 2 or more defining criteria, 57.66% of patients 
in the total cohort had SIRS within the first hour following snCPB and 96.17% within the first 
24h. 
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10.5.2. SIRS criteria in relation to age of patient and type of surgery 
 
Figure 39: SIRS criteria in the first hour (left) and in the first 24h (right) for patients in the three operative categories, 
split into age groups. Data are presented as mean values with bars indicating SEM, although non-parametric in distribution 
(Section 8.2). Kruskal Wallis test with Dunn’s Multiple Comparison Test correction, * p<0.05, ** p<0.01, *** p<0.001. CABG 
(n=1425) Valve (n=763) Valve & CABG (n=252). 
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Statistially significant differences in the distribution of the maximum number of SIRS criteria 
met within the first 1h and 24h were seen (Figure 39). A common pattern was seen across 
the 3 surgical groups in terms of the maximum number of SIRS criteria met in the first hour. 
Higher mean numbers of criteria were met with increased age, a finding most apparent in 
the CABG group (p<0.001 for all comparisons). By contrast, a different pattern was seen in 
the distribution of SIRS criteria met within the first 24h, a non-linear, ‘U-shaped’ relationship 
emerging with the oldest (>80y) and youngest(<40y) cohorts having a higher number, which 
reached statistical significance in the CABG (p<0.001) but not the valve group. The 
numerically smallest group, Valve & CABG, showed no significant differences between age 
groups. 
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10.5.3. SOFA score in relation to age of patient and type of surgery 
 
Figure 40: SOFA scores in the first 24h for patients in the three operative categories, split into age groups. Data are 
presented as median values with bars indicating IQR. Kruskal Wallis test with Dunn’s Multiple Comparison Test correction, 
*** p<0.001. CABG (n=1425) Valve (n=763) Valve & CABG (n=252).  
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Statistically significant differences in the distribution the SOFA score was seen across 
surgical categories, with an association between higher SOFA scores and increased age 
(Figure 40). In the CABG and Valve groups this was significant (p<0.001 for all comparisons). 
The smallest group, Valve & CABG, showed no significant differences between age groups.  
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10.5.4. CRP and WBC in relation to age of patient and type of surgery 
 
Figure 41: Markers of systemic inflammation, CRP (left) and WBC (right) for patients in the three operative categories, 
split into age groups. Data are presented as median values with bars indicating IQR. Kruskal Wallis test with Dunn’s 
Multiple Comparison Test correction, * p<0.05, ** p<0.01, *** p<0.001. CABG (n=1425) Valve (n=763) Valve & CABG 
(n=252).  
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As seen in Figure 41, statistically significant differences in the distribution of CRP and white 
blood cell count (WBC) were seen. In both the CABG and Valve groups, increasing age was 
associated with decreasing WBC and CRP, which was significant in the CABG patients 
(p<0.001 for all WBC, p<0.05 for >80 vs. 40-60 CRP). 
In the Valve group CRP was significantly lower in the >80 group than the <40 (p<0.05) or 40-
60 groups (p<0.001). Similarly, the CRP was significantly lower 60-80 group than the 40-60 
group (p<0.01). The WBC was significantly lower in the >80 than <40 groups (p<0.05). The 
numerically smallest group, Valve & CABG, showed no significant differences between age 
groups. 
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10.5.5. ICU LOS in relation to age of patient and type of surgery 
 
Figure 42: Duration of intensive care stay (ICU LOS) for patients in the three operative categories, split into age groups. 
Data are presented as median values with bars indicating IQR. Kruskal Wallis test with Dunn’s Multiple Comparison Test 
correction, * p<0.05, *** p<0.001. CABG (n=1425) Valve (n=763) Valve & CABG (n=252). 
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ICU LOS was statistically significantly different by age, particularly in the CABG group, 
p<0.001 for comparisons between all groups (Figure 42). ICU LOS increased with age, with 
the exception of the <40y group who also had prolonged LOS. The same trend was seen in 
the valve group, and reached statistical significance for ICU LOS in those >80 vs. 40-60 
(p<0.05). The numerically smallest group, Valve & CABG showed no significant differences 
between age groups. 
10.5.6. Determinants of outcome in mixed cohort of snCPB patients 
 Outcome For fatal outcome 
 Survived 
Mean(std) 
Died 
Mean(std) 
Univariate analysis 
Odds Ratio, 95% CI 
P Multivariate analysis 
Odds Ratio, 95% CI 
P 
Age 65.1(12.3) 71.8(9.8) 1.064 (1.03-1.10) 0.000 1.042 (1.01-1.07) 0.008 
CRP 74.7(34.6) 70.1(38.6) 0.996 (0.99-1.01) 0.358   
WBC 12.8(5.9) 15.8(6.6) 1.035 (1.01-1.06) 0.004 0.997 (0.96-1.03) 0.856 
Max SIRS in 1h 1.65(0.8) 2.01(0.8) 1.677 (1.22-2.31) 0.001 0.971 (0.67-1.40) 0.877 
Max SIRS in 24h 2.64(0.7) 3.40(0.7) 4.588 (3.03-6.96) 0.000 2.950 (1.75-4.98) 0.000 
SOFA score 5.9(2.1) 10.0(2.6) 2.068 (1.82-2.35) 0.000 1.894 (1.64-2.19) 0.000 
ICU LOS 2.8(5.9) 10.8(21.9) 1.051 (1.03-1.07) 0.000 1.000 (0.98-1.02) 0.990 
Table 19: Binary logistic regression analysis relating potential predictors of adverse outcome to vital outcome. N=2440. 
Out of the study cohort of 2440 patients 56 (2.2%) died (Table 19). All the variables 
considered excluding CRP were statistically significantly associated with death (p<0.05). 
When analysed together to assess which were independently associated with an increased 
risk of death, in addition to age, maximum number of SIRS criteria fulfilled in the first 24 
hours (odds ratio 2.95, 95% confidence intervals 1.75-4.98, p = 0.000) and SOFA score (odds 
ratio of 1.89 95% confidence intervals 1.64-2.19, p = 0.000) emerged as significant (Table 
19). 
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 Outcome For >1d ICU LOS 
 < 1d 
Mean(std) 
>1d 
Mean(std) 
Univariate analysis 
Odds Ratio, 95% CI 
P Multivariate analysis 
Odds Ratio, 95% CI 
P 
Age 64.5(11.6) 66.1(13.0) 1.010 (1.00-1.02) 0.002 1.000 (0.99-1.01) 0.999 
CRP 74.5(29.4) 74.7(38.7) 1.000 (1.00-1.00) 0.908   
WBC 12.3(4.8) 13.5(6.9) 1.045 (1.03-1.06) 0.000 1.009 (1.00-1.03) 0.356 
Max SIRS in 1h 1.63(0.81) 1.71(0.85) 1.122 (1.02-1.23) 0.019 0.937 (0.83-1.06) 0.287 
Max SIRS in 24h 2.53(0.70) 2.78(0.73) 1.597 (1.43-1.79) 0.000 1.432 (1.23-1.67) 0.000 
SOFA score 5.1(1.9) 6.9(2.2) 1.564 (1.49-1.64) 0.000 1.604 (1.52-1.69) 0.000 
Table 20: Binary logistic regression analysis relating potential predictors of adverse outcome to greater than 1 day ICU 
LOS. N=2440. 
The relationship between potential determinants and the binary outcome of greater than, 
or less than 1 day of ICU stay was assessed similarly (Table 20). ICU LOS is a continuous 
variable and may be best analysed as such [650], however dichotomizing is a common and 
accepted method of statistical analysis [651]. An ICU LOS of 1 day was the median and 
greater than, or less than, the median was used to dichotomize. All the variables considered 
excluding CRP were statistically significantly associated with an ICU LOS of greater than 1 
day, p<0.05. When re-analysed together to assess which were independently associated 
with an increased risk of >1d ICU LOS, maximum number of SIRS criteria fulfilled in the first 
24 hours (odds ratio 1.43, 95% confidence intervals 1.23-1.67, p = 0.000) and SOFA score 
(odds ratio of 1.60, 95% confidence intervals 1.52-1.69, p = 0.000) emerged as significant.  
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10.6. Discussion 
The specific aims of the studies described in this chapter were fourfold. First, to 
demonstrate any relationship between patient age and SIRS criteria, and patient age and 
SOFA score. Second, to determine the relationship between patient age and markers of 
systemic inflammation, specifically WCC and CRP. Third, to establish the relationship 
between patient age and ICU LOS. Finally, to identify any predictors of fatal outcome or 
relatively prolonged ICU LOS.  
In addressing these issues, data of general importance emerged. Thus, almost all (96%) 
patients enrolled met two or more SIRS criteria in the first 24h following snCPB, thereby 
calling into question the usefulness of the description. Similar findings have been reported 
in surgical ICU patients with an incidence of 93% [652]. Moreover, only a small minority 
(2.2%) of patients post snCPB developed severe manifestations of systemic inflammation 
and progressed to multiple organ dysfunction syndrome (MODS) and death.  A definition 
that was less sensitive but which predicted this subset of patients could be of greater clinical 
utility. The term 'severe SIRS' has been used in such circumstances , based either on the 
presence of 3 or more SIRS criteria, or 2 or more in association with a high severity of illness 
score, such as APACHE II [653, 654]. Alternatively, refinements to the SIRS criteria, 
particularly cumulative consecutive hours scoring great than 2 or 3 criteria, have been 
developed by others and show improved discriminatory capacity for adverse outcome after 
snCPB [655].  
Beyond these general results, in addressing the first study objective, a complex relationship 
was revealed between patient age and number of SIRS criteria met within the first 1h and 
up to 24h. In the first hour a consistent pattern of increasing SIRS with age was seen in all 
surgical groups. Up to 24h, there was a non-linear, ‘U-shaped’ relationship, the oldest (>80y) 
and youngest (<40y) cohorts having a higher number of SIRS criteria in the CABG group. The 
same pattern was seen in the valve group although without statistically significant increased 
SIRS at 24h in the >80y group compared to the other groups. No such pattern was seen in 
the numerically smallest group (Valve & CABG).  Statistically significant increases in SOFA 
scores were seen with increasing age. Secondly, a consistent pattern was seen across all 
surgical categories, increasing age being associated with decreasing WBC and CRP. Thirdly, 
ICU LOS increased with age, with the exception of the <40y group who also had prolonged 
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LOS. Finally, two variables were independently associated with both mortality and 
prolonged ICU LOS: maximum number of SIRS criteria fulfilled in the first 24 hours and SOFA 
score. 
A primary aim of these analyses was to demonstrate the relationship between patient age 
and markers of systemic inflammation. Compared to those aged between 40 and 80 years, 
the oldest patients (>80y) had higher SIRS criteria and SOFA scores but with lower CRP and 
WBC counts. SIRS criteria and SOFA scores had strong relationships to mortality and 
prolonged ICU stay in contrast to the lack of relationship of CRP and WBC.  
Older patients may have a relatively exaggerated inflammatory response reflected in their 
higher SIRS and SOFA scores which could contribute to adverse outcomes. However, there 
are several alternative explanations. Firstly, the number of SIRS criteria met could have been 
higher in elderly patients due to the preference of treating physicians for cardiac pacing and 
ventilation settings. Thus, the elderly are at increased risk of developing perioperative atrial 
fibrillation and this may be ameliorated through prophylactic pacing [656]. Secondly, the 
SOFA score may be higher due to the incidence of other co-morbidities with age, such as 
chronic kidney disease. Age influencing physician preference in maintaining a higher arterial 
pressure requiring the use of higher doses of vasoactive drugs would also affect the score.  
The lack of agreement between increased SIRS and SOFA score versus decreased WBC and 
CRP in those >80y compared to other groups is unexpected. Generally, one would expect 
inflammatory markers, such as WBC and CRP, to parallel changes in scores of inflammation 
and organ dysfunction in this setting. The most likely explanation is that CRP and WBC 
within the first 24h following snCPB do not represent a genuine reflection of systemic 
inflammatory state. CRP takes more than 24h to reach its peak following rise in the 
cytokines that lead to its synthesis and the WBC count early after snCPB will have had any 
increased production and decreased elimination counterbalanced by the haemodilution that 
occurs during CPB. Alternatively, SIRS criteria, SOFA score and ICU LOS are higher in the 
oldest group through mechanisms that are independent of systemic inflammation. 
The patients over 80y in this study might not be representative of their age cohort. Not all 
patients with coronary or valvular heart disease in their 80s would agree to undergo snCPB. 
Therefore these patients represent a selected group who were referred and accepted for 
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snCPB. A 2009 UK report suggests that the average age of patients having snCPB continues 
to rise [8]. Indeed, by comparison with patients from the previous decade at the same 
institution, this cohort demonstrated increased age and APACHE II score, but unchanged ICU 
LOS and mortality [657]. 
Compared to patients between 40 and 80 years, younger patients (<40) had higher SIRS 
scores up to 24h, but lower SOFA scores with high WBC and CRP. This may reflect a 
propensity to mount a greater inflammatory response without the concomitant 
development of organ dysfunction, possibly reflecting increased physiological reserve. 
Alternately, younger patients may have a different range of co-morbidities and be confined 
to specific procedure groups. CABG operations vary in their complexity but are more 
homogeneous than ‘valve surgery’ as an operative category. The majority of younger 
patients in the ‘valve surgery’ group are likely to suffer from adult congenital heart disease, 
and to have a high incidence of pulmonary hypertension and previous sternotomy which are 
both associated with an increased incidence of peri operative complications. 
The shortcomings of the SIRS criteria will always emerge in patients requiring intensive care, 
in that they present with physiological perturbations amenable to intervention – the heart 
rate and respiratory rate are examples. In these circumstances the decision to employ 
cardiac pacing or mechanical ventilation may reflect the choice of the treating physician 
rather than the severity of underlying systemic inflammation.  
Other important limitations to these analyses should be mentioned. First, the data were 
collected prospectively although analysed retrospectively. Second, in a small number of 
cases, important data in the electronic record were missing. Third, the use of 1h epochs was 
necessary for analysis but could potentially lead to inaccurate calculation of SIRS criteria. 
Fourth, the proportion of patients within this cohort who received ‘off-pump’ cardiac 
surgery is not precisely known but is estimated to be 5%. Fifth, a group of patients with low 
risk for complicated recovery from CABG were not included within this cohort as only those 
who required ICU admission postoperatively were included. Sixth, the population was 
recruited from a single tertiary/quaternary referral centre admitting 1200 patients to ICU 
per annum; this casemix may not be comparable to that of other units. Finally, the absence 
of any estimation of the contribution of pre-operative co-morbidities, the severity of the 
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underlying condition necessitating requiring surgery and intra-operative details such as the 
duration of CPB, to the development of SIRS criteria, SOFA score and outcomes is a 
significant deficiency.  Further, a technical limitation to the use of SIRS criteria in this study 
is that WBC values in this study were mostly obtained pre-operatively. In ‘uncomplicated’ 
patients blood counts might not be drawn and analysed until the day following surgery. In 
some a sample was analysed soon after their return from theatre; WBC values were higher 
in these samples. Unlike other variables, WBC is relatively infrequently sampled and this can 
result in artefact. Similarly, the blood that was analysed for CRP and WBC was not taken at a 
uniform time following the operation which introduced variability. 
The statistically significant relationship between the age of patient and the number of SIRS 
criteria met in the first 24h following surgery was informative but has limited clinical 
relevance for individual patients. The difference in SIRS scores between age groups were 
numerically very small. 
10.7. Conclusion 
In this population, the oldest patients met more SIRS criteria in the first 1h and 24h 
following snCPB than those aged 40-80 y. This was accompanied by higher SOFA scores, 
reflecting more severe organ dysfunction. Meeting SIRS criteria in the first 24h and SOFA 
score predicted adverse outcomes. Overall, these findings are supportive of the paradigm of 
excessive systemic inflammatory responses contributing towards organ failure and death. In 
support of our initial hypothesis, patients over 80y exhibited higher SOFA scores and 
number of SIRS criteria met in the first 24h than patient between 40 and 80, possibly 
reflecting predisposition to more severe inflammatory response. Future work in this area 
should involve the conduct of a prospective study looking at relationship between age and 
outcome. A homogeneous population, with similar indications for identical surgical 
procedures and with similar co-morbidities, but from across a spectrum of ages; with clinical 
management standardized before, during and after snCPB would be ideal. There are obvious 
limitations to this approach, not least the prolonged recruitment time if conducted in a 
single centre. A multi-centre study would make standardization of care difficult. Whether it 
is age per se or age as a reflection of cumulative morbidities and loss of physiological 
reserve that affects outcome is unclear. In any event the chronological age of the patient at 
the time of any operative intervention does not represent the optimal measure of 
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senescence. A similar study would have greater value if paired with measures of biological 
aging and cell senescence. Thus, it has been postulated that senescence-associated 
attenuations in physiological function are caused by molecular oxidative damage, such as 
AGE modifications [658]. Others have shown that the length of regions of repetitive DNA on 
the ends of chromosomes (telomeres) diminishes with age, and that the rate of decrease in 
length can be affected by lifestyle factors and affects the onset of age-associated diseases 
[659]. Measuring macromolecular modifications and telomere length, or a surrogate thereof 
[660] could therefore add value to such an investigation. 
The systemic inflammatory response syndrome (SIRS) is a useful concept which permits the 
identification of patients with more severe responses to their underlying condition, be it 
infection or injury, using simple and easily quantified parameters. However, when 
considering patients with more severe systemic inflammation, or following highly invasive 
surgery leading to ongoing physiological perturbations necessitating organ support, the use 
of the standard defining criteria has important limitations. The extent to which the RAGE 
axis contributes towards predisposition to excessive systemic inflammation is 
undetermined. Indeed, neither the abundance of the major ligands of RAGE nor the soluble 
receptor has been studied around snCPB in detail. 
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11. RELEASE OF LIGANDS AND SOLUBLE RAGE AROUND SNCPB 
11.1. Introduction 
In the previous chapter a relationship was demonstrated between advanced age and 
increased number of SIRS defining criteria and severity of organ failure (SOFA score) 
following snCPB. Furthermore, the maximum number of SIRS criteria and SOFA score in the 
first 24h following snCPB were statistically significantly related to mortality and prolonged 
ICU LOS. 
The RAGE-axis may be up-regulated in response to chronic stimulation [285] and conditions 
that result in increased RAGE ligands, such as advanced age, have been associated with 
adverse outcome from critical illness (Sections 3.2.3 and 4.1). It is undetermined to what 
extent up-regulation of the RAGE-axis may contribute to predisposition to excessive 
inflammatory response. 
The majority of RAGE ligands are damage-associated molecular pattern (DAMP) 
biomolecules and are released during tissue injury, such as occurs during snCPB. Ligands 
that have been particularly implicated in causing inflammatory responses in humans include 
three of the S100 proteins (S100B, S100A12, S100A8/9), HMGB1 and CML-albumin (Section 
3.2). 
The precise role of soluble RAGE (sRAGE) levels in plasma and their relation to tissue levels 
of the full membrane-spanning RAGE protein is uncertain in humans. sRAGE levels may vary 
in proportion to membrane levels, therefore acting as a gauge of RAGE-axis activity. 
Alternatively, sRAGE may act as a competitive antagonist binding RAGE ligands and 
preventing them from interacting with the cellular RAGE thus abrogating cell signalling 
events (Section 3.1.8).  
sRAGE has been demonstrated to be elevated following elective general and pulmonary 
surgery, in ALI, sepsis and following snCPB [457, 461, 464, 470]. The elevations in plasma 
sRAGE following pulmonary surgery did not relate to clinical outcomes, although the sample 
size was small (n=30) [470]; similarly the elevations following snCPB were not related to 
duration of CPB, no comparison to clinical outcomes were described, and the sample size 
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was small (n=20) [457]. Patients with severe sepsis or septic shock were found to have 
elevated plasma sRAGE, with a positive association with mortality. However the 
interpretation of this association is limited by the co-existence of severe oxygenation 
impairment in this patient cohort, suggesting co-existent ALI/ARDS [461]. Plasma sRAGE was 
related to mortality in those with ALI who received high tidal (12ml/kg) volume ventilation 
but not those who received ‘lung protective’ ventilation [454, 459]. esRAGE is a soluble form 
of RAGE that is synthesised without a transmembrane domain, with an alternative C' 
terminal, and is believed to have the same ligand binding capacity without signal 
transduction. Measurement of plasma esRAGE levels in acute systemic inflammation has not 
been previously reported and paired analyses with sRAGE (allowing calculation of shed 
RAGE) are rare.  
Elevations in the levels of RAGE ligands following snCPB have been described, mostly in 
small cohorts with limited comparison to operative factors (such as duration of CPB) and 
clinical outcomes: HMGB1 [458, 661], S100B [662], and S100A8/9 [663-665]. 
11.2. Aims and objectives 
To characterise the levels of relevant RAGE ligands and levels of soluble RAGE forms in 
plasma obtained around snCPB and their relationships to clinical variables. 
Specific objectives: 
i. Assay plasma obtained from patients around snCPB for S100B, S100A12, S100A8/9, 
CML-Albumin, HMGB1; and the soluble RAGE forms sRAGE and esRAGE 
ii. Look for statistical relationships between assays and clinical variables 
11.3.  Specific methods 
Patients presenting for snCPB at the Royal Brompton Hospital were approached and 
informed consent was obtained on the day prior to surgery. Blood samples were taken 
around snCPB as described in Methods (Section 6.7) and plasma isolated and stored at -80oC 
until analysis. Samples were obtained from patients in cohorts B and C, as defined in the 
methods section (Section 6.1). 
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Commercially available ELISA kits were used for all assays (Methods and Materials, Section 
9.7) except endotoxin and CML-Albumin measurement. Endotoxin testing was performed by 
Lonza at their European endotoxin testing centre in Belgium. The CML-albumin 
measurement was performed by MicroCoat Biotechnologie GmbH using a custom ELISA 
technique. To calculate parts per million (PPM) of CML-albumin, the measured amount of 
total albumin (clinical laboratory) was divided by the measured amount of CML-albumin. All 
assays were conducted in duplicate and the mean result used. 
A wide range of clinical variables were collated and relevant variables compared to assay 
results. The clinical variables, how they were measured, and their derived scores are 
described in methods (Section 6.3). Scoring systems used include Multiple Organ 
Dysfunction Score (MODS [90]), the New Simplified Acute Physiology Score (SAPS II [91]), 
and the Sequential Organ Failure Assessment (SOFA [92]) score. 
Data were entered in Excel spreadsheets prior to statistical analysis using PRISM v4.0 
(GraphPad software, La Jolla, CA, USA) and SPSS v17.01 (IBM, Somers, NY, USA). 
11.3.1. Statistical methods 
Samples were assayed at two times from the same individual and are thus paired, if 
parametric in distribution, a paired t test was used and mean/SEM displayed; if non-
parametric, Wilcoxon Matched Pairs Test (WPMT) was used and median/IQR displayed. 
For assessment of relationship between assays and each other or clinical variables; 
correlations were performed: if parametric in distribution, Pearson’s correlation is used and 
if non-parametric Spearman’s rank correlation. In both cases, a value is given for r (degree 
of correlation) and p (statistical significance), r values of >0.3 or <-0.3 are considered 
significant when associated with a p value of <0.01. 
Binary logistic regression was used to assess which variables independently influence post-
operative outcomes. Dependent variables are required to be parametric in distribution and 
need to relate to a binary outcome (i.e. prolonged ICU: yes/no). To permit this some 
variables required a log10 transformation (Creatinine, BMI, and both sRAGE and S100A8/9 
pre- and post-op) and binary outcomes were derived from continuous thus: duration of 
level 3 care was dichotomised into greater than median (L3_LONGER, yes/no), or 4th quartile 
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(L3_LONGEST, yes/no); similarly hospital LOS was dichotomised into greater than median 
(Hosp_LONGER, yes/no), or 4th quartile (Hosp_LONGEST, yes/no); PaO2:FiO2 ratio (PFR) less 
than median (PFR_worse) or 1st quartile (PFR_Worst); acute kidney injury at any time in first 
week (AKI, y/n); finally vital outcome (dead/alive). 
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11.4. Results 
11.4.1. Changes in ligands and their correlates 
11.4.1.1. S100B levels were elevated post-snCPB 
 
Figure 43: Concentration of S100B in plasma from patients (n=2) pre-, immediately, 2h, 6h and 24h post snCPB. 
Concentrations of S100B were measured in plasma collected from patients pre-, immediately, 2h, 6h and 24h post snCPB. 
To inform the choice of optimal time-point to measure the ligands and soluble RAGE forms 
in a larger number of patients, analysis of assays was conducted in two randomly-selected 
‘pilot’ patients from Cohort B. Pre-operatively levels were barely detectable, peaked at the 
end of the operation, remained elevated at 2h and then continued to decline (Figure 43). 
The 2h time point was chosen and levels assayed in a larger number of patients (Figure 44). 
 
Figure 44: Concentration of S100B in plasma from patients pre and post-snCPB. Concentrations of S100B were measured 
in plasma collected from patients (n=36, cohorts B&C) pre- and 2h post-snCPB. Data are presented as median values with 
bars indicating IQR. Groups were compared using a Wilcox Matched Pairs Test; ***p<0.001 
Pre-operative levels were undetectable in 26 of the 36 samples and low in the remainder. 
The lower limit of detection of the assay was 15pg/ml. 2h following snCPB levels were 
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significantly elevated with a median value of 280pg/ml (IQR 191-430pg/ml), p<0.001. There 
were no statistically significant correlations with clinical parameters. 
11.4.1.2. S100A12 levels were elevated post-op 
 
Figure 45: Concentration of S100A12 in plasma from patients (n=2) pre-, immediately, 2h, 6h and 24h post snCPB. 
Concentrations of S100A12 were measured in plasma collected from patients pre-, immediately, 2h, 6h and 24h post 
snCPB. 
The levels of S100A12 for the two ‘pilot’ patients at five times are shown above (Figure 45). 
Pre-operatively levels were undetectable and remained low at the end of the operation, 
peaking 2h later and remaining elevated at 6h and 24h. The lower limit of detection of the 
assay was 56pg/ml. The 2h time-point was chosen and levels assayed in a larger number of 
patients (Figure 46). 
 
Figure 46: Concentration of S100A12 in plasma from patients pre and post-snCPB. Concentrations of S100A12 were 
measured in plasma collected from patients (n=39, cohorts B&C) pre- and 2h post-snCPB. Data are presented as median 
values with bars indicating IQR. Groups were compared using a Wilcox Matched Pairs Test; ***p<0.001 
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Levels of plasma S100A12 significantly increased from a median 11.4ng/ml (IQR 0.0-21.5) to 
a median of 77.80 (IQR 40.8-112.0), p<0.001. 
Age of the patient and pre-op S100A12 levels  Spearman’s r=0.34, p=0.03 
Duration of CPB and ischaemia with post-operative 
S100A12 levels 
Spearman’s r=0.73 p<0.0001 for both 
Post-op A12 levels and A8/9 levels Spearman’s r=0.76 p<0.0001 
Table 21: Correlations between plasma levels of S100A12 and assays/clinical variables. (n=39, cohorts B&C). 
A positive correlation was seen between pre-operative levels of S100A12 and the age of the 
patient and strong positive associations between duration of CPB and post-operative levels 
of S100A12. S100A12 was also highly correlated to levels of S100A8/9 (Table 21). 
11.4.1.3. S100A8/9 levels were elevated post-op 
 
Figure 47: Concentration of S100A8/9 in plasma from patients (n=2) pre-, immediately, 2h, 6h and 24h post snCPB. 
Concentrations of S100A8/9 were measured in plasma collected from patients pre-, immediately, 2h, 6h and 24h post 
snCPB. 
The levels of S100A8/9 for the two ‘pilot’ patients at five times are shown above (Figure 47). 
Pre-operatively levels were low, becoming elevated by the end of the operation and only 
slowly declining. The 2h time-point was chosen and levels assayed in a larger number of 
patients (Figure 48). 
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Figure 48: Concentration of S100A8/9 in plasma from patients pre and post-snCPB. Concentrations of S100A8/9 were 
measured in plasma collected from patients (n=39, cohorts B&C) pre- and 2h post-snCPB. Data are presented as median 
values with bars indicating IQR. Groups were compared using a Wilcox Matched Pairs Test; ***p<0.001 
Levels of plasma S100A8/9 were statistically significantly elevated from a median of 
0.6mg/ml (IQR 0.5-0.8) to 4.0mg/ml (IQR 3.0-6.4mg/ml), p<0.001. S100A8/9 was also 
measured in a larger number of patients from cohort B (n=130) and a similar relationship 
was demonstrated: 0.4mg/ml (IQR 0.2-0.6) to 2.3mg/ml (IQR 1.7-3.1), p<0.0001. 
A statistically significant positive correlation between duration of CPB (and ischaemic time) 
and post-operative levels of plasma S100A8/9 was demonstrated, Pearson’s r=0.57, 
p=0.0001 for both. No relationship between the age of the patients and their levels of post-
operative S100A8/9 was seen. 
11.4.1.4. CML-albumin levels were elevated post-op 
 
Figure 49: Concentration of CML-albumin in plasma from patients pre and post-snCPB. Concentrations of CML-albumin 
were measured in plasma collected from patients (n=19, cohort C) pre- and 2h post-snCPB. Data are presented as mean 
values with bars indicating SEM. Groups were compared using a paired t test; ***p<0.001. 
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Levels of plasma CML-albumin were statistically significantly elevated from a median of 
13.9ppm (IQR 12.0-17.1ppm) to 23.7ppm (IQR 17.0-27.3ppm), p<0.001 (Figure 49).  
11.4.1.5. HMGB1 levels are elevated post-op 
 
Figure 50: Concentration of HMGB1 in plasma from patients (n=6, cohort B) pre-, immediately, 2h, 6h and 24h post 
snCPB. Concentrations of HMGB1 were measured in plasma collected from patients pre-, immediately, 2h, 6h and 24h post 
snCPB. Data are presented as mean values with bars indicating SEM. Repeated measures ANOVA p>0.05 for all 
comparisons. 
The levels of HMGB1 for six patients randomly selected from cohort B and levels measured 
at five times are shown above (Figure 50). Pre-operatively levels were low, becoming 
elevated by the end of the operation and only slowly declining with a possible late increase 
in levels at 24h. The 2h time-point was chosen and levels assayed in a larger number of 
patients (Figure 51). 
 
Figure 51: Concentration of HMGB1 in plasma from patients pre and post-snCPB. Concentrations of HMGB1 were 
measured in plasma collected from patients (n=25, 6 from cohort B & 19 from cohort C) pre- and 2h post-snCPB. Data are 
presented as median values with bars indicating IQR. Groups were compared using a Wilcox Matched Pairs Test; **p<0.01 
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Levels of HMGB1 significantly increased (Figure 51) and similar to the relationships seen 
between post-operative levels S100A12 and A8/9 to duration of CPB, HMGB levels were 
positively associated with duration of CPB (Pearson’s r=0.48, p=0.04). 
11.4.1.6. Endotoxin was not detectable in plasma 
Endotoxin levels have been reported to be elevated during and following snCPB [191-196]. 
Plasma was obtained from 3 patients pre-, during and post-snCPB (cohort B); following heat 
treatment and suitable dilution (according to Lonza instructions), samples were sent to 
Lonza’s European endotoxin testing facility in Belgium. Lonza used the highly sensitive 
kinetic chromogenic LAL method and no endotoxin was detected in any of the samples. 
11.4.1.7. Patient characteristics and assays 
 Assay With the co-
morbidity 
 
Mean ±standard 
deviation, n 
Without 
 
 
Mean ±standard 
deviation, n 
P value 
(t test) 
Diabetes 
Pre-op S100A8/9 1023.9±419.4, 5 636.4±296.6, 30 0.02 
Pre-op CML-alb 11.0±2.5, 3 15.1±3.2, 16 0.05 
Pulmonary 
hypertension 
Pre-op S100A8/9 968.0±477.3, 7 622.4±262.7, 28 0.01 
Pre-op CML-alb 18.4±3.4, 4 13.4±2.6, 15 0.005 
Ischaemic heart 
Disease 
Change in S100A12 32.8±86.8, 18 122.5±129.7, 18 0.02 
Table 22: Patient characteristics and relationship to assay values. Pulmonary hypertension (PHT) was determined on pre-
operative echocardiography. Diabetes when treated with insulin or oral hypoglycaemic agents; Ischemic heart disease 
(IHD) when undergoing CABG or having had either CABG or percutaneous coronary intervention. Diabetes/S100A89 data 
was obtained from patients in cohorts B&C, unknown status in 4; CML-albumin from cohort C, no missing data. 
PHT/S100A89 data was obtained from patients in cohorts B&C, unknown status in 4; CML-albumin from cohort C, no 
missing data. IHD data was obtained from patients in cohorts B&C, no missing data. 
Levels of ligands were related to clinical characteristics and the positive findings are shown 
above (Table 22). Patients with diabetes (either treated with insulin or oral hypoglycaemic 
agents) had statistically significantly higher levels of S100A8/9 pre-operatively, and lower 
levels of CML-albumin pre-operatively. Those with pulmonary hypertension (detected on 
pre-operative echocardiography) had statistically significantly higher levels of S100A8/9 pre-
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operatively, and higher levels of CML-albumin pre-operatively. Those with ischaemic heart 
disease (either presenting for, or having previously had coronary artery revascularisation) 
had statistically significantly lesser increment in S100A12 levels between pre- and post- 
operation. 
Comparisons of assay values without significant findings were also performed between 
other groups: LV function (from pre-op echo; normal, mildly impaired or moderately 
impaired), pre-op use of HMG-CoA reductase inhibitors (statins) and renal function as 
assessed by creatinine clearance. 
11.4.1.8. Correlates between clinical characteristics and outcomes 
 Spearman’s correlations 
Age and Hospital LOS  r=0.47, p=0.003 
CRP (48h) and Hospital LOS r=0.46, p=0.004 
SOFA score and ICU LOS r=0.51, p=0.001 
SOFA score and hospital LOS r=0.52, p=0.001 
SAPSII score and hospital LOS r=0.38, p=0.017 
MODSII score and ICU LOS r=0.43, p=0.007 
MODSII score and hospital LOS r=0.44, p=0.005 
Table 23: Correlations between clinical characteristics and outcomes, n=39 (cohort B&C). 
Positive associations were seen between scores of severity of illness (SOFA and MODSII) and 
ICU LOS. Hospital LOS was positively associated with age, CRP (at 48h post-op), SOFA score, 
SAPSII score and MODS II score (Table 23). 
 
  
194 
 
11.4.2. Changes in soluble RAGE forms and their correlates 
11.4.2.1. sRAGE measured around snCPB 
 
Figure 52: Concentration of sRAGE in plasma from patients (n=6, cohort B) pre-, immediately, 2h, 6h and 24h post snCPB. 
Concentrations of sRAGE were measured in plasma collected from patients pre-, immediately, 2h, 6h and 24h post snCPB. 
Data are presented as mean values with bars indicating SEM. Repeated measures ANOVA, ** p<0.01. 
The levels of sRAGE for six ‘pilot’ patients at five times are shown above (Figure 52). Pre-
operatively levels were low, becoming elevated by the end of the operation and slowly 
declining until less than pre-operative by 24h. Levels at 6h and 24h were statistically 
significantly decreased when compared to levels immediately following CPB, p<0.01 ANOVA 
with Bonferroni correction. The 2h time-point was chosen and levels assayed in a larger 
number of patients (Figure 53). 
 
Figure 53: Concentration of sRAGE in plasma from patients pre and post-snCPB. Concentrations of sRAGE were measured 
in plasma collected from patients (n=39, cohorts B&C) pre- and 2h post-snCPB. Data are presented as paired symbols. 
Groups were compared using a Wilcox Matched Pairs Test; ***p<0.001 
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Levels of sRAGE in plasma statistically significantly increased from a median of 1116pg/ml 
(IQR 907-1853pg/ml) to 1908pg/ml (IQR 1189-2478pg/ml), p<0.001. Data are presented as 
paired pre- and post-snCPB values to demonstrate how the majority increment but a small 
number decline. In a larger number of patients (n=130, from cohort B) sRAGE was measured 
in paired pre- and post-snCPB plasma and similar results were seen with a median of 
1054pg/ml (IQR 717-1760pg/ml) incrementing to 1897pg/ml (IQR 1129-2641pg/ml), 
p<0.001. Plasma samples from patients obtained pre-, post- and also intra- CPB were 
obtained (n=13, cohort B) and the measured levels of sRAGE are presented (Figure 54). 
 
Figure 54: Concentration of sRAGE in plasma from patients pre-, intra- and immediately post-snCPB. Concentrations of 
sRAGE were measured in plasma collected from patients (n=13, cohort B) pre-, intra- and immediately post-snCPB. Data 
are presented as mean values with bars indicating SEM. Repeated measures ANOVA, ***p<0.001, ** p<0.01. 
sRAGE levels were statistically significantly higher intra- (6177±4653pg/ml) than pre- 
(1749±1546pg/ml), p<0.001, and higher post- (4098±2778pg/ml) than pre, p<0.001. 
11.4.2.2. shed RAGE from esRAGE and sRAGE 
Plasma from 19 of the 39 patients with sRAGE measured (Figure 53, from cohort C) also had 
esRAGE measured and the difference between represents shed RAGE, these data are 
presented below (Figure 55). 
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Figure 55: Concentration of soluble RAGE forms in plasma from patients pre- and 2h post-snCPB. Concentrations of 
sRAGE and esRAGE were measured in plasma collected from patients (n=19, cohort C) pre-, and 2h post-snCPB. Shed RAGE 
levels were calculated from the difference between sRAGE and esRAGE. Data are presented as mean values with bars 
indicating SEM. paired t test ** p<0.01. 
As discussed previously, sRAGE was statistically significantly increased, in contrast esRAGE 
was not, from 530±299pg/ml to 653±337pg/ml, p=0.06. Shed RAGE was statistically 
significantly increased, from 747±408pg/ml to 1133±400pg/ml, p<0.01. There was a tight 
correlation between shed RAGE and esRAGE both pre-operatively (Pearson’s r=0.90 
p<0.0001) and post-operatively (Pearson’s r=0.90 p<0.0001). 
11.4.2.3. Correlations 
Levels of soluble RAGE forms were related to clinical characteristics and the positive 
findings, and important negatives, are shown below (Table 24). Unless otherwise specified, 
39 patients were studied (Cohorts B&C). 
Pre-op sRAGE and age of patient Spearman’s r=0.18 p=0.25 
Pre-op sRAGE and Diabetes MWU p>0.05 
Pre-op sRAGE and Creatinine clearance Spearman’s r=0.21 p=0.19 
Pre-op sRAGE and ICU LOS Spearman’s r=0.35 p=0.03* 
Pre-op sRAGE and hospital LOS Spearman’s r=0.25 p=0.12 
Post-op sRAGE and post-op CML-albumin Pearson’s r=0.73 p<0.001***  (n=19, cohort C) 
Delta sRAGE and PFR post-op Pearson’s r=0.36 p=0.03* 
Table 24: Correlations between plasma levels of sRAGE pre- and post-operatively and assays/clinical variables, n=39. 
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The lack of statistically significant association between the age of the patient and the levels 
of sRAGE (either pre- or post-) was also seen in a larger cohort (n=127 from cohort B, 
Spearman's r=0.21, p=0.01). A strong positive correlation was found between post-op levels 
of sRAGE and CML-albumin Pearons’s r=0.73, p<0.001, n=19 from cohort C. 
The observation of a positive correlation between pre-op sRAGE and ICU LOS (Spearman’s 
r=0.35, p=0.03) was investigated further in a larger cohort (Section 11.4.3). The positive 
correlation between change in sRAGE levels (delta sRAGE) and the PaO2:FiO2 (PFR) Pearson’s 
r=0.36, p=0.03, was not replicated in the larger cohort (n=127, Spearman's r=0.12 p=0.19). 
11.4.2.4. Patient characteristics and assays 
 Assay With the co-
morbidity 
 
 
Mean ±standard 
deviation, n 
Without 
 
 
Mean ±standard 
deviation, n 
P value 
(t test) 
Impaired LV 
function 
Pre-op sRAGE 2618.4±1012.0, 5 1262.3±744.3, 34 0.01 
Pulmonary 
hypertension 
Pre-op esRAGE 820.6±317.5, 4 451.9±249.0, 15 0.02 
Ischaemic heart 
Disease 
Post-op esRAGE 477.9±260.8, 11 892.8±283.9, 8 <0.01 
Table 25: Patient characteristics and relationship to assay values. Impaired LV function and pulmonary hypertension were 
determined on pre-operative echocardiography. Ischemic heart disease when undergoing CABG or having had either CABG 
or percutaneous coronary intervention. 
Levels of soluble RAGE forms were related to clinical characteristics and the positive findings 
are shown (Table 25). Patients with impaired left ventricular function (on pre-operative 
echocardiography) had statistically significantly elevated levels of sRAGE pre-operatively 
(p=0.01). Those with pulmonary hypertension (on pre-operative echocardiography) had 
statistically significantly elevated levels of esRAGE pre-operatively (p=0.02). Those with 
ischaemic heart disease (either presenting for, or having previously had coronary artery 
revascularisation) had statistically significantly diminished levels of esRAGE post-operatively 
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(p<0.01). Neither renal function as assessed by creatinine clearance nor pre-op use of HMG-
CoA reductase inhibitors (statins) had a relationship with assay values. 
11.4.3. Pre-op sRAGE and ICU LOS 
The relationship between pre-op sRAGE and ICU LOS was further investigated patients from 
Cohort B with paired pre- and 2h post- CPB plasma (n=124 from 127, due to missing data in 
3). In preference to using ICU LOS, duration of Level 3 care was used as a more specific 
indicator of severity of post-operative SIRS (Methods Section 6.5.1). 
ICU LOS (hours) was longer than L3 care duration (hours) reflecting the extent to which non-
clinical factors influence ICU LOS (Table 26). 
 Mean Median 
Level 3 care (hours) 11h1m 7h59m 
ICU LOS (hours) 22h11m 15h37m 
Hospital LOS (days) 11.7d 9.0d 
Table 26: Comparison of level 3 care to ICU LOS and hospital LOS. The mean value was greater than the median for all 
measures due to skewing effect of the uncommon patient with a very prolonged length of stay. N=124. 
For the purposes of illustrating the relationship between sRAGE and L3 care, the cohort was 
split into quartiles of pre-op sRAGE and plotted against duration of L3 care (Figure 56). 
 
Figure 56: Difference in duration of level 3 care between quartiles of pre-op plasma sRAGE. Plasma sRAGE was measured 
in 124 patients and patients were split into quartiles of sRAGE, corresponding duration of level 3 care charted. Data are 
presented as median values with bars indicating IQR. Groups were compared using the Kruskal Wallis Test with Dunn’s 
Multiple Comparison’s test, *p<0.05, ** p<0.01, *** p<0.001. n=124. 
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The correlations between sRAGE measurements and duration of stay (Table 27). 
 N Pre-op sRAGE Post-op sRAGE (2h) 
Duration of L3 care, hours (ICU) 124 r =0.3, p<0.001* r =0.2, p<0.05 
Hospital stay (days) 124 r =0.32, p<0.001* r =0.26, p<0.05 
Table 27: Assessment of correlation between sRAGE levels and duration of stay using Spearman’s rank correlation 
To optimally assess the relationship between pre-op sRAGE and clinical outcomes binary 
logistic regression was performed. Clinical variables (or assays) and their statistical 
relationship to the outcome variable are tabulated in the following tables (28-33) with one 
outcome of interest per table. The variables assessed including age, duration of aortic cross-
clamp time (ischaemic time), marker of renal function (Log creatinine), indicator of obesity 
(Log body mass index, BMI), sRAGE measurements (Log), S100A8/9 measurements (Log) and 
Euroscore (Log). Euroscore is a risk stratification score that relates to risk of death. 
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 ICU(L3) Longer (>median)  
 No 
Mean(std) 
Yes 
Mean(std) 
Univariate analysis 
Exp(B) 95% CI 
p Multivariate analysis 
Exp(B) 95% CI 
p 
Age 68.4 (12.1) 70.2 (8.6) 1.02(0.98-1.05) 0.340   
Ischaemic time 85.9(29.1) 95.7(31.1) 1.01(1.00-1.02) 0.072 1.00(0.99-1.02) 0.326 
Log Creatinine 1.97(0.1) 1.97(0.1) 1.55(0.83-29.0) 0.768   
Log BMI 1.43(0.1) 1.42(0.1) 0.34(0.00-26.55) 0.624   
Log sRAGE pre-op 2.97(0.3) 3.13(0.3) 6.38(1.78-22.90) 0.004 7.97(1.13-56.39) 0.038 
Log sRAGE post-op 3.20(0.3) 3.30(0.3) 3.38(0.87-13.09) 0.079 0.43(0.05-3.71) 0.443 
Log S100A8/9 pre-op 2.67(0.23) 2.70(0.3) 1.63(0.35-7.67) 0.534   
Log S100A8/9 post-op 3.34(0.2) 3.42(0.2) 10.62(1.42-79.50) 0.021 6.20(0.75-51.0) 0.090 
Log Euroscore 0.73(0.2) 0.77(0.2) 2.21(0.45-10.80) 0.327   
Table 28: Multivariate binary logistic regression considering relationship between clinical and assay results to longer duration of L3 care. Log sRAGE pre-op is the only statistically significant result. 
N=124. 
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 ICU(L3) Longest (4
th Quartile)  
 No 
Mean(std) 
Yes 
Mean(std) 
Univariate analysis 
Exp(B) 95% CI 
p Multivariate analysis 
Exp(B) 95% CI 
p 
Age 68.2(11.3) 72.7(7.2) 1.05(1.00-1.09) 0.047 1.04(0.99-1.10) 0.141 
Ischaemic time 89.6(30.5) 93.6(30.0) 1.00(0.99-1.01) 0.523   
Log Creatinine 1.97(0.11) 1.98(0.14) 1.22(0.04-39.1) 0.910   
Log BMI 1.43(0.08) 1.40(0.08) 0.18(0.00-3.80) 0.141   
Log sRAGE pre-op 3.02(0.28) 3.14(0.36) 3.92(0.94-16.40) 0.061 3.74(0.66-21.25) 0.136 
Log sRAGE post-op 3.22(0.25) 3.31(0.30) 3.38(0.67-17.01) 0.140   
Log S100A8/9 pre-op 2.65(0.25) 2.76(0.26) 6.35(0.90-45.00) 0.064 3.19(0.38-26.73) 0.284 
Log S100A8/9 post-op 3.36(0.18) 3.45(0.20) 15.04(1.52-149.30) 0.021 5.67(0.34-95.40) 0.228 
Log Euroscore 0.75(0.24) 0.74(0.24) 0.80(0.13-4.74) 0.802   
Table 29: Multivariate binary logistic regression considering relationship between clinical and assay results to longest duration of L3 care. N=124. 
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 Hospital Longer (>median)  
 No 
Mean(std) 
Yes 
Mean(std) 
Univariate analysis 
Exp(B) 95% CI 
p Multivariate analysis 
Exp(B) 95% CI 
p 
Age 67.7(11.7) 70.5(9.5) 1.03(0.99-1.06) 0.141   
Ischaemic time 83.3(26.3) 96.7(32.2) 1.02(1.00-1.03) 0.015 1.01(0.99-1.03) 0.253 
Log Creatinine 1.98(0.12) 1.96(0.11) 0.39(0.21-7.31) 0.530   
Log BMI 1.43(0.08) 1.42(0.83) 0.62(0.01-48.2) 0.829   
Log sRAGE pre-op 2.97(0.28) 3.12(0.30) 5.76(1.62-20.4) 0.007 5.09(0.52-49.9) 0.162 
Log sRAGE post-op 3.18(0.27) 3.30(0.25) 6.69(1.64-27.3) 0.008 2.02(0.17-23.9) 0.576 
Log S100A8/9 pre-op 2.63(0.22) 2.72(0.27) 4.93(0.95-25.7) 0.058 4.05(0.70-24.5) 0.128 
Log S100A8/9 post-op 3.36(0.17) 3.40(0.19) 2.34(0.35-15.7) 0.380   
Log Euroscore 0.73(0.27) 0.76(0.20) 1.52(0.32-7.26) 0.601   
Table 30: Multivariate binary logistic regression considering relationship between clinical and assay results to longer duration of hospital care. N=124. 
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 Hospital Longest (4
th Quartile)  
 No 
Mean(std) 
Yes 
Mean(std) 
Univariate analysis 
Exp(B) 95% CI 
p Multivariate analysis 
Exp(B) 95% CI 
p 
Age 68.4(11.4) 71.3(8.3) 1.03(0.99-1.07) 0.165   
Ischaemic time 85.1(25.5) 103.8(36.8) 1.02(1.01-1.03) 0.003 1.01(0.99-1.0) 0.186 
Log Creatinine 1.97(0.12) 1.97(0.12) 0.95(0.38-23.9) 0.976   
Log BMI 1.43(0.08) 1.41(0.08) 0.11(0.00-14.1) 0.375   
Log sRAGE pre-op 3.00(0.29) 3.16(0.29) 6.61(1.64-26.6) 0.008 18.9(1.22-392.0) 0.035 
Log sRAGE post-op 3.22(0.26) 3.31(0.26) 4.16(0.92-18.9) 0.065 1.3(0.06-27.74) 0.865 
Log S100A8/9 pre-op 2.65(0.22) 2.74(0.31) 4.71(0.76-29.4) 0.097 1.8(0.21-14.32) 0.601 
Log S100A8/9 post-op 3.35(0.17) 3.45(0.19) 19.6(2.16-177.9) 0.008 11.9(0.60-237.2) 0.105 
Log Euroscore 0.75(0.25) 0.75(0.19) 1.04(0.19-5.62) 0.965   
Table 31: Multivariate binary logistic regression considering relationship between clinical and assay results to longest duration of hospital care. Log sRAGE pre-op is the only statistically significant 
result. N=124. 
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 PFR Worse (<median)  
 No 
Mean(std) 
Yes 
Mean(std) 
Univariate analysis 
Exp(B) 95% CI 
p Multivariate analysis 
Exp(B) 95% CI 
p 
Age 67.9(12.1) 70.8(8.6) 1.03(0.99-1.06) 0.124   
Ischaemic time 89.0(27.6) 92.3(33.2) 1.00(0.99-1.02 0.549   
Log Creatinine 1.98(0.11) 1.96(0.12) 0.21(0.01-4.05) 0.299   
Log BMI 1.42(0.08) 1.43(0.08) 1.41(0.18-109.9) 0.876   
Log sRAGE pre-op 3.01(0.28) 3.08(0.32) 2.15(0.66-7.01) 0.204   
Log sRAGE post-op 3.22(0.26) 3.27(0.27) 2.33(0.62-8.82) 0.213   
Log S100A8/9 pre-op 2.66(0.25) 2.69(0.26) 1.49(0.32-6.95) 0.611   
Log S100A8/9 post-op 3.39(0.21) 3.37(0.16) 0.67(0.10-4.36) 0.670   
Log Euroscore 0.74(0.24) 0.76(0.23) 1.31(0.28-6.22) 0.735   
Table 32: Multivariate binary logistic regression considering relationship between clinical and assay results to worse PFR post-operatively. N=124. 
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 PFR Worst (1
st Quartile)  
 No 
Mean(std) 
Yes 
Mean(std) 
Univariate analysis 
Exp(B) 95% CI 
p Multivariate analysis 
Exp(B) 95% CI 
p 
Age 69.1(11.3) 69.7(8.8) 1.01(0.97-1.04) 0.771   
Ischaemic time 88.9(28.2) 94.8(35.5) 1.01(0.99-1.02) 0.334   
Log Creatinine 1.97(0.12) 1.98(0.12) 2.23(0.09-58.6) 0.630   
Log BMI 1.42(0.07) 1.44(0.09) 14.87(0.11-2048) 0.283   
Log sRAGE pre-op 3.04(0.28) 3.07(0.36) 1.46(0.39-5.43) 0.575   
Log sRAGE post-op 3.25(0.26) 3.23(0.29) 0.85(0.20-3.71) 0.833   
Log S100A8/9 pre-op 2.68(0.25) 2.68(0.27) 0.98(0.18-5.56) 0.980   
Log S100A8/9 post-op 3.37(0.20) 3.40(0.15) 2.64(0.32-21.5) 2.643   
Log Euroscore 0.74(0.23) 0.77(0.24) 1.81(0.30-10.8) 0.518   
Table 33: Multivariate binary logistic regression considering relationship between clinical and assay results to worst PFR post-operatively. N=124. 
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Multivariate binary logistic regression analyses demonstrated that levels of pre-operative 
sRAGE (transformed to Log10) were independently associated with an ICU LOS of greater 
than median (odds ratio of 7.97 with 95% confidence intervals of 1.13-56.39, >19.1 hours, 
"ICU_LONGER") and with being in the 4th quartile of hospital LOS (odds ratio of 18.9 with 
95% confidence intervals of 1.22-392.0, >13 days, "HOSP_LONGEST"). The PFR calculated 
from PaO2 and FiO2 in the first 24h immediately following snCPB did not relate to any of the 
considered characteristics. 
11.4.4. Inflammatory markers and snCPB 
11.4.4.1. CRP 
C-reactive protein is routinely measured in ICU patients. Levels measured in 39 patients 
(from cohorts B&C )at 24h were 58 (41-92) mg/L, and 48h were 173 (132-216) mg/L, 
p<0.001 (Figure 57). 
 
Figure 57: Levels of CRP in patients at 24h and 48h following snCPB. Plasma CRP was measured in 39 patients ()cohorts 
B&C). Data are presented as median values with bars indicating IQR. Groups were compared using the Wilcoxon Matched 
Pairs test, *** p<0.001 
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11.5. Discussion 
11.5.1. RAGE ligands 
All measured RAGE ligands statistically significantly increased and the extent of increase of 
S100A12, S100A8/9 and HMGB1 was in proportion to the duration of cardiopulmonary 
bypass. Different S100 proteins appeared to show different temporal release patterns with 
S100B levels falling sharply after their initial increase in comparison to S100A8/9 and 
S100A12 levels that stayed elevated. 
S100B plasma levels have been extensively studied as a marker of injury to the blood-brain 
barrier due to snCPB and in this context have been repeatedly reported to be elevated post-
CPB [662] with levels correlating to duration of CPB in some studies [666]. As S100B is 
released from many injured tissues and there have been inconsistent associations between 
measured levels and neuropsychological outcomes, its use as a cerebral-injury biomarker 
remains controversial [667-669]. S100B has been found to be elevated in the plasma of the 
critically ill and a positive association with plasma lactate levels (and SOFA score) has led to 
the hypothesis that tissue hypoperfusion may result in S100B release [670]. Traumatic injury 
and non-cardiac operative surgery have been associated with rapid and short-lived increases 
in plasma S100B levels [466]. 
S100A12 plasma levels around snCPB have not been previously reported but an increase in 
gene expression for S100A12 (and S100A8) in circulating leukocytes has been demonstrated 
4h following CPB [671]. S100A8/9 has been demonstrated to be elevated following snCPB in 
several small studies [663-665]. However, the strong positive associations between duration 
of CPB and levels of post-operative S100A8/9 and S100A12 are not previously described and 
may reflect a number of factors. Release of S100A12 could plausibly be due to 
cardiopulmonary ischaemia, systemic hypoperfusion and consequent reperfusion injury, or 
duration of CPB as an indirect marker of surgical trauma. The inter-relationship between 
S100A12 and S100A8/9 may indicate a shared aetiology of release, perhaps release from 
neutrophils, in contrast to S100B levels which may solely source from injured tissues. The 
correlation between S100A12 levels pre-op and the age of the patient has not been 
previously described and is weak and may be artefactual. S100A8/9 was higher in those 
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patients with diabetes and although this has not been previously reported, increased levels 
of S100A12 have been [344]. 
HMGB1 has been demonstrated to be released by leukocytes in response to surgery with 
maximal release at 24h [383], in contrast to victims of polytrauma with peak levels at 2-4h 
[400]. These different temporal relationships may reflect the two modes of release. The 
finding of elevated levels of HMGB1 and their positive correlation to duration of CPB is novel 
and is most likely to indicate release from tissue damaged during snCPB. HMGB1 
measurements from six patients over a more prolonged time showed a possible second 
peak of release that may reflect immune signalling. Levels of HMGB1 measured in six 
patients around snCPB have very recently been reported by others in abstract form; 
elevations following surgery were also found [661]. In a study of 20 patients undergoing 
elective thoracic aortic aneurysm repair (requiring some form of cardiopulmonary bypass in 
all cases), HMGB1 levels peaked at day two and remained elevated; levels did not correlate 
with duration of CPB but a greater peak HMGB1 elevation was associated with more severe 
SIRS and a higher incidence of impaired oxygenation [458]. 
Acute AGE formation is facilitated by oxidative stress, acute hyperglycaemia and the actions 
of neutrophil myeloperoxidase, all conditions present during snCPB. Elevation in levels CML-
albumin is not previously described in relation to snCPB. 
In contrast to some published reports we were unable to detect any endotoxin within the 
plasma of our patients either pre-, during- or post- CPB. Severity of illness scores variably 
correlated with duration of stay outcomes, as did the levels of CRP at 48h. 
11.5.2. Soluble RAGE 
Pre-operative levels of sRAGE did not differ between patients with diabetes than those 
without, neither did it relate to their age nor renal function. However, of the 39 patients, 
only 5 had diabetes. There were large variations in pre-snCPB sRAGE levels and this may be 
partially explained by the range of conditions within the cohort: ischaemic heart disease 
requiring revascularisation and/or valvular heart disease requiring repair or replacement. 
Those undergoing valve surgeries had higher sRAGE levels and may have been more likely to 
have a degree of heart failure than those having coronary revascularisation. Although 
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clinical measures of heart failure were not assessed, plasma sRAGE levels (and HMGB1) 
have been reported to be elevated in those with heart failure [672, 673].  
The levels of pre-operative sRAGE correlated with the duration of ICU stay and this was 
investigated further in a larger cohort of patients (n=124). Binary logistic regression revealed 
pre-op sRAGE was independently related to longer L3 care time and longest hospital stay. In 
preference to using ICU LOS we calculated the duration of Level 3 care, as a more specific 
indicator of severity of post-operative SIRS. Level 3 care duration was always shorter than 
ICU LOS. Levels of plasma sRAGE measured prior to surgery were more closely related to 
prolonged recovery from acute systemic inflammation (duration of level 3 care) and from 
overall hospital admission (time to hospital discharge) than variables including the age of 
the patient, a score of their operative risk (Euroscore), and the duration of 
pulmonary/myocardial ischaemic time (component of total CPB time). This striking finding 
can be explained if plasma sRAGE levels reflect tissue RAGE levels and therefore 
predisposition to excessive RAGE-mediated systemic inflammation following systemic 
inflammatory stimulus (snCPB). The systemic inflammation resulting in organ dysfunction or 
failure necessitating organ support is reflected in duration of level 3 care. 
sRAGE levels statistically significantly increased during CPB and 2h post-CPB compared to 
pre-op levels. esRAGE levels also increased but did not reach statistical significance. Shed 
RAGE was very highly correlated with esRAGE. Elevation of sRAGE levels following snCPB 
had not been described until very recently [457]. During CPB, the pulmonary circulation is 
not receiving a flow of blood and the marked elevation of sRAGE levels at this time would be 
consistent with sRAGE sourcing from the systemic circulation. This is of particular interest as 
many authorities propose that circulating sRAGE predominantly sources from the 
pulmonary alveolar epithelial cells. During CPB the bronchial circulation continues to receive 
a variable supply of blood [674] and considering that it may anastamose as distal as the 
terminal bronchioles [675], it may make a small contribution to drainage of the alveolar 
epithelium. To what extent the bronchial circulation may be responsible is hard to know. 
This finding has not been previously described. 
Levels of sRAGE and esRAGE were tightly correlated at all times and in all patients, either 
suggesting a commonality of regulation, contrary to accepted dogma, or suggesting a lack of 
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specificity of the enzyme immunoassays. In a large cohort of patients with chronic kidney 
disease, levels of sRAGE and esRAGE have been demonstrated to correlate very closely 
[266]. An absence of difference between antibodies directed towards the extracellular V 
domain of human RAGE (sRAGE) and the C-terminal (esRAGE) has been previously observed 
[304]. Assuming differential regulation of esRAGE and shed RAGE (the difference between 
sRAGE assay and esRAGE assay) then the increase in esRAGE being modest (25%) and the 
increase in shed RAGE more substantial (51%) suggests that the contribution of esRAGE to 
ligand quenching is minor in comparison to that of RAGE shed from plasma membranes. 
The strongly positive correlation between post-op sRAGE and CML-albumin is consistent 
with the concept of RAGE ligands stimulating cleavage of sRAGE. This correlation has also 
been found in other studies [262]. 
The positive association between the change in sRAGE (delta sRAGE) and the PaO2:FiO2 
ratio (PFR) immediately post-operatively seen in the cohort of 39 patients lost statistical 
significance when analysed in the larger cohort. Pulmonary dysfunction following snCPB is 
both common and multi-factorial, and although subclinical ALI is common, clinically evident 
ALI is not. The lack of relationship between initial post-operative PaO2:FiO2 ratio and sRAGE 
level is therefore not surprising.  
An important limitation to these investigations is the absence of standardisation of peri-
operative care. In common with the majority of similar observational cohort studies, the 
specific management by the anaesthetist, perfusionist and cardiac surgeon was not 
protocolised and thus was likely to differ between patients. The anaesthetic induction 
agent, neuromuscular blocking agent, choice of maintenance agent, and fluid resuscitation 
strategy all have potential to modulate systemic inflammatory responses. Given the 
purported role of sRAGE as a marker of alveolar injury and the potential for intra-operative 
ventilation to contribute to the incidence of ALI post-operatively, it would have been 
preferable to have a uniformly applied ventilatory strategy. Important variables pertaining 
to the role of the perfusionist and the extra-corporeal circuit include the choice of priming 
solution. This may influence systemic inflammatory responses and particularly the content 
of plasma AGE in those who received albumin (approximately half of those in which AGE 
was measured, cohort C). Furthermore, the degree of intra-CPB hypothermia and the 
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manner in which it was reversed may also be of relevance. Finally, the maintenance 
medications taken by the patients prior to snCPB (such as aspirin) certainly have the 
potential to influence inflammatory response and the absence of information about all pre-
operative medication represents a shortcoming of this study. 
There are limitations to the application of simple statistic correlations between clinical and 
biochemical parameters. The greater the number of comparisons between variables, the 
greater the risk of finding positive associations though chance alone. A correlation may be 
highly statistically significant but only be weak in extent; there is no consensus on what level 
of correlation is considered ‘strong’ or ‘weak’. 
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11.6. Conclusion 
We have demonstrated substantial increases in circulating levels of the five best-
characterised ligands for RAGE, with a strong relationship between severity of surgical injury 
(duration of CPB) and extent of S100 protein release; elevations in levels of circulating 
soluble RAGE forms, maximal during surgery; and a robust relationship between pre-
operative levels of sRAGE and duration of requirement of intensive care. 
Plasma sRAGE deserves further study as a biomarker for systemic inflammatory response to 
tissue injury and as such, could offer superior risk stratification of patients presenting for 
major elective surgery than current methods. Plasma sRAGE likely reflects shedding from 
many cell types, possibly including leukocytes. Thus, measuring membrane-bound RAGE on 
circulating leukocytes will compliment these findings. 
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12. LEUKOCYTE RAGE EXPRESSION AROUND SNCPB 
12.1.  Introduction 
In the previous chapter it was shown that levels of plasma sRAGE increase during and 
following snCPB. It was also shown that levels of RAGE ligands increase in the plasma, some 
in proportion to the duration of snCPB (Section 11.4.1). The cellular origin of plasma shed 
RAGE in humans has not, previously, been described. One possible source is leukocytes, 
with elevated levels of RAGE ligands in plasma causing up-regulation of leukocyte RAGE and 
subsequent shedding of the RAGE ectodomain. Levels of plasma sRAGE were independently 
related to prolonged duration of critical illness and therefore show promise as a biomarker 
for systemic inflammatory response to tissue injury (Section 11.4.2). Membrane-bound 
RAGE on circulating leukocytes potentially represents a complimentary assay of pro-
inflammatory RAGE-axis activity and may therefore be a superior biomarker. 
Relationship between RAGE expression on circulating leukocytes and concentration of RAGE 
ligands in chronic conditions has been described previously. Thus, in patients with diabetes, 
monocyte RAGE expression correlated with serum AGE; similarly, in patients with chronic 
kidney disease, monocyte RAGE expression correlated with serum AGE [296, 606]. RAGE 
expression on neutrophils obtained from patients with exacerbations of cystic fibrosis was 
assessed using flow cytometry and was increased in the airway in comparison to the 
circulation [463], but no other studies have reported leukocyte RAGE expression in acute 
inflammation. Measurement of RAGE at the mRNA level has not, previously, been reported 
in human primary leukocytes. 
By contrast, RAGE expression has been studied in THP-1 cells, a monocyte cell line derived 
from peripheral blood of a 1 year-old patient with acute monocytic leukaemia [676]. Such 
immortalised cells retain some characteristics of their cellular origin (monocytes) but may 
lose or gain features related to their neoplastic transformation. At the time of starting these 
experiments, it had been shown by others that RAGE mRNA was present in THP-1 cells and 
RAGE protein levels on these cells were increased in response to AGE, an effect blocked by 
anti-RAGE antibodies [298]. Furthermore, AGE up-regulated NF-κB signalling and pro-
inflammatory cytokine secretion, an effect blocked by competitive antagonists [677]. RAGE 
protein had not been identified on the cell surface of THP-1 cells but had been on 
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monocytes and tissue macrophages [678-680]. It was later observed that expression of 
RAGE protein on the cell surface was limited [250] and RAGE expressed on the plasma 
membrane was predominantly shed. Most recently, further evidence of an intact RAGE 
pathway has been observed in THP-1 cells: with S100B causing pro-inflammatory cytokine 
release [681] and signalling events triggered by AGEs and blocked with anti-RAGE antibody 
[682] or small interfering RNA to RAGE [683]. 
The very significant disadvantage of experimenting with immortalised cell lines such as THP-
1 cells is that the findings may not be replicated in the equivalent human primary cells. 
Thus, alteration in RAGE-mediated signalling events and in surface RAGE expression that are 
demonstrated in THP-1 cells may not be reproducible in human primary monocytes.  
Measuring changes in abundance of receptors and other biomolecules on the cell surface is 
a useful research tool and flow cytometric determination of leukocyte membrane 
expression is being developed for diagnostic and prognostic purposes (Section 1.3.4). 
Moreover, in some cases, measures obtained from membrane expression profiles are 
superior to plasma assays, for example the ratio of expression of monocyte membrane-
bound TNF-α protein to its receptor TNFR was shown to correlate with scores of organ 
dysfunction better than plasma levels in ICU patients [684]. 
With regard to the RAGE axis, others have shown that neutrophil RAGE expression can be 
detected by flow cytometry [463]. Similarly, other putative RAGE ligand receptors such as 
TLR-4 and TLR-9 have been studied in other patient cohorts [685, 686]. However, neither 
RAGE nor TLR-9 have been quantitated in leukocytes pre- and post-snCPB. Alterations in the 
expression of the LPS receptor TLR-4 during surgery have been reported with inconsistent 
results [200, 685, 687, 688]. TLR4 receptor down-regulation during snCPB could be an 
important contributory factor to endotoxin tolerance. Toll-like receptor 9 (TLR-9) is an 
intracellular receptor for DNA and as such plays a role in detection of ‘foreign’ bacterial and 
viral DNA, but also responds to cellular DNA. The response to cellular DNA may be 
important in detection of damage to tissues in the host organism but has also been 
implicated in auto-immune diseases such as systemic lupus erythematosus. In this context, 
interaction between HMGB1 and DNA, RAGE and TLR-9 responses have been shown to 
augment immune signalling in antigen presenting cells [388]. Release of HMGB1 into the 
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circulation during snCPB has been demonstrated (Section 11.4.1) and tissue damage causing 
release of cellular DNA into the circulation is likely. 
12.2. Aims and objectives 
To develop flow cytometry (FC) and qRT-PCR assays to facilitate subsequent analysis of 
cellular RAGE before and after snCPB at both the protein and transcript levels. 
Specific objectives: 
i. To develop a FC assay of cell surface RAGE expression on leukocytes in whole blood. 
ii. To develop and optimise quantitative reverse transcriptase real-time PCR measure of 
RAGE expression relative to stable reference genes. 
iii. To obtain blood from patients around the time of snCPB and perform FC measurements 
for RAGE, TLR-4 and TLR-9; to extract mRNA from leukocytes (either as buffy coat or 
isolated subsets). 
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12.3. Specific methods 
12.3.1. Protocol 
Patients presenting for snCPB at the Royal Brompton Hospital were approached and 
informed consent was obtained on the day prior to surgery. Samples were obtained from 
patients in Cohorts B, as defined in the methods section. Blood was obtained (pre-op) within 
10m of induction of anaesthesia and initiation of invasive ventilation. The sample was split 
into small aliquots (3ml) for FC and a large aliquot (30ml) for leukocyte preparation. The 
samples were processed for flow cytometry and mRNA extraction as per Methods (Sections 
7.5.2 and 7.9.1). Following cessation of CPB, blood was obtained similarly (post-CPB) and 
within 30 mins after cessation of CPB. On the first post-operative day, the cells prepared for 
flow cytometry were washed and re-suspended prior to reading on the cytometer. 
12.3.2. Flow cytometry 
General principles of flow cytometry are discussed in Section 7.5. The development of the 
specific protocol used to stain whole blood for surface and intracellular RAGE follows in 
Section 12.4.1 and the complete protocol is presented in Section 7.5.2. 
In brief, whole blood was obtained and the cellular constituents washed in an excess of PBS 
(with 0.5% EDTA). The cells were re-suspended in PBS to the original volume and 0.5µl of 
each undiluted antibody added to each 50µl of cell suspension; incubation was for 20 mins 
at 4oC in the dark. For each condition, one pair of samples was stained with the RAGE 
conjugated antibody and one pair without; permitting comparison between stained and the 
so-called FMO which will have no specific staining. Staining conditions were performed in 
duplicate and results averaged to account for variability in the assay. All samples were 
stained with the following markers: CD14, CD16 and the Live/Dead™ green assay, thereby 
permitting identification of leukocyte subsets and exclusion of dead cell events. Following 
staining, cells were washed in PBS prior to addition of excess a fix/lyse buffer that caused 
hypotonic lysis of erythrocytes and fixation that stabilised the staining and allowed 
acquisition at a later time. For intracellular staining the cells were then washed and 
permeabilized prior to a second round of staining, for those that were not for further 
staining they were washed and stored at 4oC in the dark until acquisition. 
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12.3.3. qRT-PCR 
General principles of qRT-PCR are discussed in Section 7.9.3. The development of the 
specific protocol used follows in Section 12.5.1 and the complete protocol is presented in 
Section 7.9.4. 
In brief, the whole blood was either processed to isolate leukocyte subsets or minimally 
processed to isolate the buffy coat. The buffy coat is the total leukocyte population, 
identified at the interface between plasma and erythrocytes following density gradient 
centrifugation. The cellular suspensions were mixed in a 1:3 ratio with TRI reagent, following 
vigorous mixing, were stored at -80oC. At a later time, samples were thawed and the further 
stages of choloform-phenol extraction (Section 7.9.1) resulted in a small volume of RNA 
dissolved in water. Following measurement of RNA concentration, 0.6µg of RNA was reverse 
transcribed resulting in cDNA formation (Section 7.9.2). Using primers specific for RAGE and 
the reference genes HPRT1, RPL13 and GUSB, qRT-PCR reactions were conducted. Data 
analysis took place using Rotor-gene 6000 (Corbett) and using the delta-delta-CT formula in 
Excel (Microsoft, Redmon, USA). 
 
  
218 
 
12.4. Results of flow cytometry 
12.4.1. Development of flow cytometry protocol  
12.4.1.1. Indirect staining 
Antibodies directed against human RAGE with a directly conjugated fluorochrome were not 
available; therefore an indirect staining protocol was adapted from manufacturer’s 
protocols. Indirect staining uses an unconjugated primary antibody directly against the 
epitope of choice (RAGE) and following a period to allow antibody capture, the excess 
antibody is washed off and then a secondary antibody added (Figure 58). The secondary 
antibody is usually directly against the Fc portion of IgG in the animal species in which the 
primary antibody was raised. The theoretical advantage of this method is increased 
sensitivity as each primary can be bound by several secondary antibodies thus amplifying 
the signal. However, the major disadvantage is the increased background, non-specific, 
staining. A goat anti-RAGE antibody from Abcam (Cambridge, UK) was used with an anti-
goat IgG-FITC conjugate.  
 
Figure 58: Indirect antibody staining 
To determine the extent to which staining is specific for the epitope of interest it is common 
to compare the staining with a negative control. For an indirect protocol the negative 
control could be staining due to a primary isotype control (with secondary) or to secondary 
only. An isotype antibody is directed against an irrelevant epitope and any binding should be 
non-specific. A secondary antibody in the absence of any primary should result in very little 
staining (i.e. an Anti-goat IgG antibody will not bind to any part of a human monocyte). 
219 
 
Important variables within a staining protocol include the non-specific blocking content of 
the wash buffer (and/or a discrete blocking step), the conditions of the staining steps, the 
order of fixing/staining, the option of fixing the cells and at what conditions. 
12.4.1.2. Experiments to determine optimal antibody concentration 
THP-1 cells (2.5 x105) were subjected to experimental conditions and then stained for RAGE 
prior to analysis (staining protocol 1, Figure 59). Experimental conditions included LPS 
(400ng/ml) or HMGB1 (400ng/ml) for 18 hours – both intended as positive controls.  
Four different concentrations of primary antibody and three different concentrations of 
secondary antibody were used (Figure 60). The cells were not fixed and were analysed soon 
after the final wash stage. 
 
Figure 59: Experimental protocol. Cells were resuspended in medium before experimental conditions, which took place in 
a CO2 incubator at 37
o
C. Fixing was in 1% paraformaldehyde and either took place directly after experimental conditions or 
prior to analysis. Cells were resuspended in PBS with 1% BSA until the final resuspension prior to analysis which was in 
FACSflow™ solution 
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Figure 60: Fluorescence intensity (MFI) charted against increasing concentrations of primary antibody (x axis) and 
secondary antibody (different plots, 0, 2, 5 10 g/ml). THP-1 cells were stimulated with LPS (400ng/ml) prior to staining 
for FC. 
12.4.1.3. Experiments to determine specificity of antibody 
Despite differing experimental conditions (to maximise RAGE expression) and many 
modifications to the staining protocol, the extent of staining obtained with the isotype 
control (IC) antibodies was indistinguishable from the RAGE-specific antibodies. Staining for 
both was greater than that for the secondary antibody alone. Conditions used to maximise 
RAGE staining may have been suboptimal but even in the absence of stimulation, RAGE 
should be detectable as basal levels. 
To minimise background staining, particularly when working with cells that express 
immunoglobulin receptors (such as THP-1 [689]) it is important to block non-specific 
binding. 1% bovine serum albumin in the phosphate buffered saline was being used but may 
have been inadequate. Normal human serum (the cells were human) or goat serum (the 
secondary antibody was a goat antibody) were tried without improvement.  
Failure to detect specific RAGE staining on the THP-1 cells was attributed to the lack of 
sufficient specificity for RAGE of the Abcam antibody and the possibility that THP-1 cells do 
not express RAGE on their cell surface. A presentation at conference (3rd International 
DAMPS, Endokines and Alarmins symposium, Pittsburgh, 2008) and publication [250] 
suggested that THP-1 cell surface expression of RAGE was limited. 
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12.4.1.4. Whole blood staining protocols 
Whole blood (WB), offers a more analogous system to the in vivo state and is readily 
obtainable from healthy volunteers. A schematic demonstrating the WB staining protocol is 
shown (Figure 61). Cells can be fixed prior to primary staining or after primary staining. The 
fixing solution also lyses erythrocytes. An alternative primary antibody (rabbit anti-RAGE, 
Millipore/Fisher) was used. 
 
Figure 61: Revised experimental protocol. 100μl of whole blood plated out. Experimental conditions took place in a CO2 
incubator at 37
o
C. Fixing was in BD FACSLyse solution and either took place directly after experimental conditions or after 
primary antibody staining. Cells were resuspended in PBS with 1% BSA until the final resuspension prior to analysis which 
was in FACSflow™ solution. 
Additional changes included S100A12 (500ng/ml) to up-regulate RAGE and blocking with 
50% pooled normal human serum/matched donor serum. Pooled human immunoglobulin 
was not attempted as the IgG content of pooled serum was greater. 
Despite these modifications, the signal attributable to membrane RAGE was almost 
indistinguishable when primary antibody was compared to IC. Furthermore, there was 
evidence of increased fluorescence in the absence of primary or isotype control antibody, 
possibly due to neutrophils binding the secondary antibody. On isolated occasions the 
results from the flow cytometric assay were as intended, Figure 62. However this result was 
not achieved consistently. 
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Figure 62: Histogram of fluorescence intensity (x axis, FL1 Log) and cell counts (y axis) representative of desired results. 
In the absence of any primary antibody there should be minimal fluorescence (green line); in the presence of an isotype 
control primary and a fluorescent secondary there should be background staining (blue); with primary antibodies present 
and unstimulated cells there should be increased fluorescence (purple); and finally with primary antibodies present and 
stimulated cells there should be maximal fluorescence (red). 
To circumvent the background staining, an alternative to indirect staining protocols was 
found – antibody labelling technology. An IgG labelling kit (Invitrogen Zenon™ labelling kit 
with Alexa-fluor 488) was used: the anti-RAGE primary is incubated with a fluorophore-
labelled Fc-specific anti-IgG Fab fragment which binds the Fc portion of the primary 
antibody. Excess binding fragment is neutralised by addition of excess IgG then the primary 
antibody-conjugate is ready for use.  
Additional changes included the use of a cell marker antibody to improve discrimination of 
neutrophils events from non-neutrophil events. Selecting neutrophils based on expression 
of characteristic markers is superior to using purely physical characteristics as assessed by 
forward scatter/side scatter. An anti-CD16 fluorochrome-conjugated antibody was 
purchased. A flow cytometry facility with improved infrastructure and support was used. To 
distinguish flow cytometry events related to intact cells from cell remnants, cell viability 
assays were planned. 
However, the assay did not achieve sufficiently reproducible quantitation of membrane 
RAGE expression. Work from investigators at the Herzenberg Laboratories, Stanford 
University was published at this time and included the first description of a flow cytometic 
assay for membrane RAGE performed on whole blood [463] (Figure 63). A visit to the lab 
was arranged and following the trip a protocol was developed (Section 7.5.2). 
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Figure 63: Histograms of RAGE expression on neutrophils from 3 representative patients with inflammatory airways 
disease (filled black airway neutrophils, filled grey circulating neutrophils), compared to unstained control (unfilled). 
Image adapted from paper by Stanford group ([463]). 
12.4.1.5. Stanford protocol 
The protocol includes membrane staining and intracellular staining; to stain proteins within 
the cell the membrane must be permeabilized using saponin. A stage was introduced prior 
to the intracellular staining whereby the cells are fixed and the erythrocytes lysed. To 
improve discrimination of leukocyte subsets a large array of cluster differentiation (CD) 
markers are available. CD16 is characteristically on neutrophils and CD14 on monocytes. A 
cell viability marker that is unaffected by the fixation process was used (Invitrogen 
Live/Dead). Bead controls were introduced to help calibrate the flow cytometer to improve 
intra-assay comparability. To avoid the problems of background staining a protein 
conjugation kit was used (Innova Lightning linkTM) with a well characterised anti-RAGE 
antibody (Santa Cruz). This allowed a single staining stage. Lastly, whole blood was used but 
the non-cellular components were washed away prior to staining and the cells re-suspended 
in cold PBS. 
12.4.1.6. Reporting fluorescence 
When reporting the fluorescence intensity for an experimental sample it is standard practice 
to express in relation to a control sample staining. In order of increasing complexity: the  
fluorescence intensity can be used without comparator; the fluorescence intensity can be 
compared between the stained sample and the unstained, where the unstained could be 
either the secondary antibody alone or a sample without antibody in the fluorescent 
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channel of interest (fluorescence minus one, FMO); the fluorescence intensity can be 
compared between the stained sample and an identically treated sample apart from the 
substitution of an isotype control antibody for the primary antibody. There is no consensus 
within the flow cytometry community and the details are beyond the scope of this thesis 
(readers referred to reviews [690, 691]).  
Within this thesis all reported measure of extent of staining are given as the mean 
fluorescent intensity (MFI) and relate to the difference in MFI between the sample with 
relevant antibody present and the FMO; all measures were taken in duplicate and averaged. 
12.4.1.7. Gating strategy 
Acquisition of flow cytometry data provides a huge amount of information that needs to be 
logically represented to extract the relevant information. This may be achieved through 
successive ‘gating’ populations of events until the events of interest can be measured in 
isolation. In this case we wish to select live (L/D low) neutrophils (CD16+CD14-), Figure 64 
for details. 
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Figure 64: Gating strategy for selective consideration of live neutrophils. Dead cells were not considered by excluding 
events that were either excessively small (low forward scatter) or had excessive staining in the FL1 channel that 
corresponded to high staining for the live/dead marker [as dead cells lack of membrane integrity and bind more of the 
marker (top left)]. The second gate shown (top right) was around neutrophils which had high values in the Pacific Blue 
channel, corresponding to the CD16 marker, and low values in the PE-Cy7 channel, corresponding to the CD14 marker. The 
histogram shown (bottom left) represents the range of fluorescence intensities in the gated population, it is parametrically 
distributed and can be expressed as a mean fluorescence intensity (MFI) which appears to be 10
3
, or 1000. 
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12.4.2. RAGE protein expression on leukocytes around snCPB 
The extent of RAGE expression upon the surface and within circulating neutrophils and 
monocytes was compared (Figure 65).  
12.4.2.1. Differences in RAGE expression between leukocyte populations 
 
Figure 65: Expression of RAGE on surface (left) and intracellular (right) of neutrophils and monocytes from blood 
obtained pre-operatively. Blood was obtained pre-operatively (n=8) and stained for RAGE using a standardized protocol. 
Extent of staining is shown as the mean fluorescence intensity (MFI). Data are presented as mean with bars indicating SEM. 
Unpaired t tests, p>0.05 for both. 
The extent of monocyte surface RAGE expression (mean MFI 2296±2463) was not 
significantly different from that on neutrophils (mean MFI 501±232; p=0.06). Likewise, 
intracellular monocyte RAGE expression (mean MFI 8533±3774) was not significantly 
different from that in neutrophils (mean MFI 12480±5144; p>0.05), as seen in Figure 65. 
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12.4.3. Difference between intracellular and membrane staining 
The expression of RAGE was compared between the surface and the intracellular space of 
neutrophils and monocytes (Figure 66). 
 
Figure 66: Expression of RAGE on surface (s) and intracellular (i) of neutrophils (left) and monocytes (right) from blood 
obtained pre-operatively. Blood was obtained pre-operatively (n=8) and stained for RAGE using a standardized protocol. 
Extent of staining is shown as the mean fluorescence intensity (MFI). Data are presented as mean with bars indicating SEM. 
Unpaired t tests, ** p <0.01 for both. 
 
Figure 67: Overlay of two histogram representing distribution of fluorescence intensity for APC (RAGE) on cells staining 
for surface staining (red) and permeabilized cells for intracellular staining (blue) 
For both cell types the quantity of intra-cellular RAGE protein was greater than the surface 
expression (unpaired t test p<0.01), Figures 66 and 67.  
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12.4.4. Changes related to snCPB 
The change in extent of RAGE expression upon the surface of circulating neutrophils was 
compared pre- and post-snCPB (Figure 68, left). Similarly, the extent of RAGE expression 
within the circulating neutrophils was compared pre- and post-snCPB (Figure 68, right). 
 
Figure 68: Expression of RAGE on surface (left) and intracellular (right) of neutrophils from blood obtained pre- and post-
snCPB. Blood was obtained pre- and post-snCPB (n=8) and stained for RAGE using a standardized protocol. Extent of 
staining is shown as the mean fluorescence intensity (MFI). Data are presented as mean with bars indicating SEM. Paired t 
tests, * p <0.05. 
Expression of RAGE on the surface of neutrophils fell significantly following snCPB (mean 
MFI pre 501±232 vs. post 346±172, p=0.025); there was no change in the extent of 
intracellular RAGE expression, mean pre MFI 12480±5144 vs. post 15850±5144, Figure 68. 
The change in extent of RAGE expression upon the surface of circulating monocytes was 
compared pre- and post-snCPB (Figure 69, left). Similarly, the extent of RAGE expression 
within the circulating monocytes was compared pre- and post-snCPB (Figure 69, right). 
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Figure 69: Expression of RAGE on surface (left) and intracellular (right) of monocytes from blood obtained pre- and post-
snCPB. Blood was obtained pre- and post-snCPB (n=8) and stained for RAGE using a standardized protocol. Extent of 
staining is shown as the mean fluorescence intensity (MFI). Data are presented as mean with bars indicating SEM. Paired t 
tests, p >0.05 for all. 
Expression of RAGE on the surface of monocytes did not change significantly following 
snCPB (mean MFI pre 2296±2463 vs. post 4749±5251, p=0.08). Likewise, there was no 
change in the extent of intracellular RAGE expression (mean MFI pre 8533±3774 vs. post 
7242±6233), Figure 69. 
12.4.5. Expression of Toll-like receptors 
12.4.5.1. TLR-4 
Levels of expression of TLR-4 were not consistently detectable on neutrophils or monocytes. 
12.4.5.2. TLR-9 
TLR-9 is an intracellular toll-like receptor and levels of expression were measured in 
neutrophils and monocytes pre-snCPB (Figure 70). 
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Figure 70: Expression of intracellular TLR-9 within neutrophils (left) and monocytes (right) from blood obtained pre-
snCPB. Blood was obtained pre-snCPB (n=8) and stained for TLR-9 using a standardized protocol. Extent of staining is 
shown as the mean fluorescence intensity (MFI). Data are presented as mean with bars indicating SEM. Unpaired t test, 
*** p <0.001. 
Expression of intracellular TLR-9 pre-operatively was higher on monocytes (mean MFI 
1543±522) than neutrophils (mean MFI 684±508), p<0.001, Figure 70. 
The change in extent of TLR-9 expression within neutrophils was compared pre- and post-
snCPB (Figure 71). Similarly, the extent of TLR-9 expression within monocytes was compared 
pre- and post-snCPB (Figure 72). 
 
Figure 71: Expression of intracellular TLR-9 within neutrophils from blood obtained pre- and post-snCPB. Blood was 
obtained pre- and post-snCPB (n=8) and stained for TLR-9 using a standardized protocol. Extent of staining is shown as the 
mean fluorescence intensity (MFI). Data are presented as mean with bars indicating SEM. Paired t test, p >0.05. 
Expression of intracellular TLR-9 was not statistically significantly different between pre- and 
post- snCPB in neutrophils (mean MFI pre 460±89 vs. post 684±508, p>0.05), Figure 71. 
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Figure 72: Expression of intracellular TLR-9 within monocytes from blood obtained pre- and post-snCPB. Blood was 
obtained pre- and post-snCPB (n=8) and stained for TLR-9 using a standardized protocol. Extent of staining is shown as the 
mean fluorescence intensity (MFI). Data are presented as mean with bars indicating SEM. Paired t test, p >0.05. 
Expression of intracellular TLR-9 was not statistically significantly different between pre- and 
post- snCPB in monocytes; mean MFI pre 8533±3774 vs. post 7242±6233, p>0.05, Figure 72. 
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12.5. Measurement of RAGE mRNA in leukocytes around snCPB using qRT-
PCR 
12.5.1. Method development - reference gene experiments 
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) allows 
quantification of levels of mRNA from cells or tissues and is described in detail (Section 7.9). 
Levels are necessarily expressed in relative terms. For each sample analysed by the real-time 
PCR machine and software, a result is given as a CT value which corresponds to the cycle 
number at which the fluorescence emission exceeds a fixed threshold. The higher the initial 
amount of DNA, the sooner accumulated product is detected in the PCR process, and the 
lower the CT value. Errors and inconsistencies in measurement and pipetting can result in 
different amounts of mRNA entering the reverse transcription reaction, and this may be 
compounded by different efficiencies of reverse transcription, resulting in variability in 
amount of cDNA going into the PCR reaction. Thus the results of PCR may vary according to 
initial amount of mRNA (the signal) but also due to unwanted variability (noise). To minimise 
the noise, experiments were conducted in duplicate and were compared to reference gene 
expression. 
Reference gene expression remains constant under experimental or clinical conditions. 
However, traditional reference genes (β-actin and GAPDH) may vary unacceptably and give 
rise to erroneous results [692]. To ensure that the selected reference genes are unaffected 
and remain relatively constant, the chosen reference genes will have been validated for the 
cells and experimental conditions under consideration. Several candidates genes were 
identified as being suitable for use in monocytes and neutrophils [693, 694] (Table 34). 
ACTB β-actin 
B2M β-2-microglobulin 
CSF3 Colony stimulating factor 3 
GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 
GUSB - Glucuronidase 
HPRT1 Hypoxanthine phosphoribosyltransferase 1 
RPL13A 60S ribosomal protein L13a 
RPL32 60S ribosomal protein L32 
SDHA Succinate dehydrogenase complex subunit A 
Table 34: Potential reference genes 
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Blood from three patients pre- and post- snCPB was obtained and neutrophil and monocyte 
populations isolated. Primers were obtained for seven potential reference genes: SDHA, 
B2M, RPL13, GUSB, CSF3, HPRT1, and ACTB. qRT-PCR was conducted for each sample in 
duplicate (both values used) and Ct values obtained for neutrophils and monocytes (Figures 
73 and 74). 
 
Figure 73: Neutrophil expression of reference genes. Neutrophils were isolated from patients pre- and post-snCPB, qRT-
PCR for reference genes (SDHA, B2M, RPL13, GUSB, CSF3, HPRT1, and ACTB) was performed and box and whisker plot of 
percentage change in CT values are shown, comparing pre- to post-snCPB mRNA expression of reference genes in 
neutrophils (n=3 in duplicate with both values used). 
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Figure 74: Monocyte expression of reference genes. Monocytes were isolated from patients pre- and post-snCPB, qRT-PCR 
for reference genes (SDHA, B2M, RPL13, GUSB, CSF3, HPRT1, and ACTB) was performed and box and whisker plot of 
percentage change in CT values are shown, comparing pre- to post-snCPB mRNA expression of reference genes in 
neutrophils (n=3 in duplicate with both values used). 
Together these graphs demonstrate the large extent that reference gene expression 
changes. Of the seven reference genes, HPRT1, RPL13 and GUSB had the least variability 
(Table 35) and were chosen for future experiments. 
Mean % variability HPRT1 RPL13  GUSB 
Neutrophil 6.9% 10.7% 16.9% 
Monocyte 4.1% 4.1% 0.5% 
Table 35: Mean percentage variability of the three best reference genes for neutrophils and monocytes 
 
  
235 
 
12.5.2. Expression of RAGE mRNA in leukocytes from patients around snCPB 
12.5.2.1. Isolated leukocyte populations 
Neutrophils and monocytes were isolated from patients pre- and post-snCPB (Section 7.2.3). 
The fold-change in quantity of mRNA for RAGE in relation to changes in reference genes was 
determined in neutrophils and monocytes (Figure 75). 
 
Figure 75: Fold change in expression of RAGE relative to reference genes in neutrophils and monocytes relating to 
snCPB. Neutrophils and monocytes were isolated from patients pre- and post-snCPB (n=4, measured in duplicate and mean 
value charted) and using qRT-PCR their fold-change in expression of RAGE relative to reference genes was calculated. Data 
are presented as mean with bars indicating SEM, paired t test p>0.05. 
The fold-change in expression of RAGE mRNA relative to the mean change in three 
reference genes was 2.1±1.6 in neutrophils and 1.4±0.9 in monocytes. Although 
methodologically superior, this method does not permit traditional statistical analysis in this 
instance. An alternative means of analysis allows such statistical testing and relies upon 
comparative estimates of mRNA content through comparison of the expression relative to 
the standards; the results from this analysis are presented in Figure 76. 
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Figure 76: Expression of RAGE relative to reference genes in neutrophils (left) and monocytes (right) relating to snCPB. 
Neutrophils and monocytes were isolated from patients pre- and post-snCPB (n=4, measured in duplicate and mean value 
charted) and using qRT-PCR their expression of RAGE relative to reference genes was calculated. Data are presented as 
mean with bars indicating SEM, paired t test p>0.05. 
When analysed using comparative estimates of mRNA content these differences did not 
reach statistical significance, p >0.05. 
12.5.2.2. Buffy coat 
Buffy coat was isolated from patients pre- and post-snCPB (Section 12.3.3). The fold-change 
in quantity of mRNA for RAGE in relation to changes in reference genes was determined 
(Figure 77). 
 
Figure 77: Fold change in expression of RAGE relative to reference genes in leukocytes relating to snCPB. Leukocytes in 
buffy coat were obtained from patients pre- and post-snCPB (n=5, measured in duplicate and mean value charted) and 
using qRT-PCR their fold-change in expression of RAGE relative to reference genes was calculated. Data are presented as 
mean with bars indicating SEM. 
The fold-change in expression of RAGE mRNA relative to the mean change in three 
reference genes was 23.2±32.8 in cells from the buffy coat. 
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Results from the alternative method of analysis are presented in Figure 78. 
 
Figure 78: Expression of RAGE relative to reference genes in leukocytes relating to snCPB. Neutrophils and monocytes 
were isolated from patients pre- and post-snCPB (n=5, measured in duplicate and mean value charted) and using qRT-PCR 
their expression of RAGE relative to reference genes was calculated. Data are presented as mean with bars indicating SEM, 
paired t test p>0.05. 
When analysed using comparative estimates of mRNA content these differences did not 
reach statistical significance, p >0.05. 
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12.6. Discussion 
The first specific objective was to develop an assay of cell surface RAGE expression on 
leukocytes in whole blood using flow cytometry. Performing the staining in whole blood as 
opposed to processing to remove non-leukocyte components was intended to shorten the 
duration of the protocol and more importantly, avoid activating the leukocytes through 
isolation procedures prior to staining [695, 696]. This objective was met after protracted 
systematic experimentation and having sought assistance from international experts. 
Significant problems encountered during the development of the methods were lack of 
antibody specificity and high levels of non-specific staining; use of THP-1 cells, that were 
later found not to express RAGE; uncertainty regarding optimal conditions to up-regulate 
expression of RAGE; and lack of manufactured primary conjugated antibody and issues 
related to consequent indirect staining techniques which were resolved when antibody 
conjugation was used.  
Quantification of extent of staining with flow cytometry requires correction for background 
staining. As discussed in section 12.4.1.6, there is no consensus on the optimum method of 
performing this correction. Consistent with the method adopted from the Stanford group, 
the raw value of mean fluorescence intensity (MFI) had the ‘fluorescence-minus one’ (FMO) 
value subtracted. The FMO represents background staining. By contrast, some authorities 
recommend the use of an isotype control antibody and the subtraction of this MFI instead 
of the FMO. It is not possible to know how the use of an isotype control antibody might 
have affected the results of the assays reported within this thesis. 
The second objective was to develop and optimise quantitative reverse transcriptase real-
time PCR measures of RAGE expression relative to stable reference genes. qRT-PCR results 
are expressed in relation to changes in standard “reference” genes and if these genes vary 
in response to the experimental conditions (or clinical interventions) then the results may 
be erroneous [692, 697]. Having established which reference genes varied the least around 
snCPB the assay was used to measure the extent of change in RAGE mRNA expression. 
Initial plans included a study of the expression of cellular RAGE expression within a large 
cohort of patients around snCPB and use of these data to gain insight into the regulation of 
RAGE expression and its relation to sRAGE and esRAGE levels in the plasma; to assess the 
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relation to measures of systemic inflammation, related organ dysfunction, and clinical 
outcomes. Unfortunately these objectives could not be met as experimental methodology 
took considerably longer to develop than anticipated and thus, the sample size was too low 
to permit these detailed analyses. 
Nonetheless, these data represent the first account of alterations in the expression of 
leukocyte RAGE due to acute systemic inflammation in humans. RAGE expression on 
circulating leukocytes was previously related to the abundance of RAGE ligands in chronic 
conditions. Having shown increased RAGE ligands during snCPB, increased leukocyte RAGE 
expression following snCPB was anticipated. 
Contrary to these expectations, the extent of RAGE expression on circulating neutrophils 
significantly decreased. Plasma soluble RAGE levels increase in acute inflammatory 
conditions, including snCPB, and a large proportion of soluble RAGE is believed to result 
from cleavage of the full-length membrane bound form. Data presented in this chapter are 
consistent with the idea that RAGE expression on circulating neutrophils decreased due to 
increased shedding, concomitantly increasing plasma sRAGE levels.  
Which leukocytes are the predominant sources of sRAGE in plasma? No statistically 
significant difference in surface RAGE expression between monocytes and neutrophils was 
observed. This is in contrast to the recent observation of greater RAGE expression on 
neutrophils than monocytes in the circulation of mice [311]. In humans, neutrophils are 
present in a far greater number than monocytes and thus, are likely to represent the major 
source of sRAGE. In recently published work, very low plasma sRAGE levels were reported in 
patients with neutropenic sepsis [454] supporting this conjecture. 
TLR-9 expression was consistently measurable within the cytoplasm of neutrophils and 
monocytes and was present to a greater extent on monocytes than neutrophils. 
Comparative expression of TLR-9 at the protein level has not been previously reported but 
mRNA for TLR-9 was reported to be equivalent between neutrophils and monocytes [698]. 
Expression of TLR-9 was not significantly altered by snCPB but the small sample size might, 
at least in part, contribute to the lack of statistical significance.  
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The assessment of expression of mRNA for RAGE in leukocytes in relation to reference genes 
showed increases associated with snCPB. In retrospect, in order to establish statistical 
significance of the fold-changes it would have been ideal to collect blood from a matched 
control group at two similar times to the pre- and post-snCPB; then compare the fold 
change between the two times between the two groups. An alternative method of showing 
statistical significance is to compare the estimated amount of RNA for RAGE (relative to 
reference genes) at each time and compare using a paired t test; results from this method 
are shown and although they do not reach statistical significance it is easily appreciated that 
they might if the sample size were larger. The fold-change result stems from the use of the 
‘delta delta CT method’ which is mathematically more appropriate and as it does not rely on 
the standard curve, potentially less susceptible to variation [699]. 
12.7. Conclusion 
RAGE is expressed on human neutrophils and monocytes and snCPB was associated with a 
significant decrease in RAGE protein on neutrophils, possibly relating to shedding of the 
ectodomain increasing soluble RAGE in the plasma. snCPB was associated with increased 
expression of mRNA for RAGE. Consistent with this, intracellular RAGE protein was higher 
post-operatively, though with such a low sample size and high degree of assay variability, 
this did not reach statistical significance. 
As the relationships between leukocyte RAGE and soluble RAGE, and between leukocyte 
RAGE and systemic inflammation and the consequence thereof, remain incompletely 
understood, future work might include a prospective observational study. The study could 
recruit patients with systemic inflammation (± lung inflammation) and detailed clinical 
characterisation combined with sampling of plasma and cells would contribute to our 
understanding of these questions. Populations of interest would include those having 
snCPB, but also acute lung injury and acute sepsis/septic shock. Cells that could be used for 
flow cytometric measurement of RAGE could include circulating leukocytes and also airway 
leukocytes and peripheral venous endothelial cells [700, 701]. A further quantity of blood 
could be obtained for RNA extraction and subsequent analysis of the ‘riboleukogram’ with 
gene expression arrays (Section 1.3.4); also DNA could be extracted for genetic 
polymorphism analysis. 
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Thus far we have established that systemic inflammation is an important determinant of 
outcome from snCPB, RAGE ligands including S100B and S100A12 are released during snCPB 
and that leukocytes express RAGE. The inflammatory potential of RAGE ligands on human 
leukocyte populations and the potential to inhibit these responses will be investigated in the 
following chapter.  
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13. EX VIVO ASSESSMENT OF PRO-INFLAMMATORY EFFECTS OF RAGE 
LIGANDS 
13.1. Introduction 
In the previous chapters it was established that systemic inflammation is an important 
determinant of outcome from snCPB (Section 10); RAGE ligands including S100B, S100A12, 
and HMGB1 are released during snCPB (Section 11); and that leukocytes express RAGE 
(Chapter 12). However, the extent to which RAGE ligands might activate leukocytes, 
triggering cytokine release that could contribute to the systemic inflammatory response, has 
not been well-investigated.  
Thus, in this chapter, the pro-inflammatory effects of the RAGE ligands S100B, S100A12, and 
HMGB1 on leukocytes, specifically cytokine release, and the efficacy of a range of putative 
inhibitors will be determined. Whilst the effects on RAGE ligands has been investigated in 
various cell types and with different means of inhibition evaluated (Table 36), there have 
been few studies of the effects of RAGE ligands on leukocyte inflammatory responses in 
whole blood models or primary human neutrophils. The efficacy of inhibition of RAGE-
mediated responses in reducing cytokine release has yet to be demonstrated in these 
models. 
Of the two models, whole blood (WB) models offer distinct advantages over the use of 
isolated leukocyte subsets, not least for ease and efficiency of screening multiple 
experimental conditions. Moreover, leukocyte isolation techniques cause activation of 
sensitive cells such as neutrophils, thereby affecting the inflammatory state of the 
leukocytes prior to experimental conditions. Finally, the WB model is more clinically 
analogous as the actions of RAGE ligands on leukocytes in vivo occur in whole blood, not on 
isolated cells (Section 7.2.2).  
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Human cell types RAGE ligand Inhibition Endpoint Reference 
Monocytes 
THP-1 
Mono-Mac 6 
AGE, S100B Anti-RAGE 
antibody 
Superoxide production increased with 
S100B, reduced with anti-RAGE 
[350] 
Monocytes 
THP-1 
 
AGE, S100B Anti-RAGE 
antibody 
COX2 expression and adherence to 
SMC increased with S100B, blocked 
with anti-RAGE 
[351] 
Peripheral blood 
mononuclear cells 
S100B - TNF-α release in response to S100B [352] 
Neutrophils S100B - Concentration-dependent release of 
TNF−α, IL−6, and IL−8 
[353] 
Neutrophils 
HL-60 
S100B - Superoxide production increased [287] 
Human pulmonary 
microvascular 
endothelial cells 
HMGB1 sRAGE IL-8 release increased by HMGB1 and 
the effect was diminished with sRAGE 
[702] 
Chondrocytes AGE-modified 
albumin 
sRAGE and 
siRNA for 
RAGE 
Increased IL-6 and IL-8 mRNA 
expression, the effect was diminished 
with sRAGE/siRNA RAGE 
[703] 
THP-1 
Monocytes 
Neutrophils 
S100A12 - Promotes chemotaxis [340] 
Monocytes S100A12 sRAGE Promotes chemotaxis, inhibited by 
sRAGE 
[339] 
THP-1 
Monocytes 
 
S100A12 - No cytokine release [704] 
Cord-blood derived 
mast cells 
S100A12 RAGE 
peptide42-59 
IL-8, IL-6, TNF-α release increased, 
inhibited by RAGE peptide 
[705] 
Whole blood and 
monocytes 
HMGB1, AGE-
modified 
albumin 
alpha7 agonist 
GTS-21 
TNF-α and IL-1β release increased, 
inhibited by GTS-21. IL-8 and IL-6 not 
increased. 
[706] 
Whole blood HMGB1 Anti-TLR-4 IL-8 release increased with HMGB1, 
inhibited by anti-TLR4 (not anti-RAGE) 
antibodies 
[387] 
Table 36: Studies of effects of S100B, S100A12 or HMGB1 on pro-inflammatory effects on human cells and their 
inhibition, with focus on cytokine release, preferentially including leukocyte studies. 
Nevertheless, WB and isolated neutrophil assays were utilised for the experiments 
presented in this chapter to allow comparison between the two models. The main cytokine 
measured was IL-8 because, as discussed (Section 2.1.1), it is an archetypal chemokine, 
produced by neutrophils and monocytes. The functions of IL-8 include chemoattraction and 
neutrophil activation, and it is raised in plasma of patients following snCPB [707]. However, 
for comparison other cytokines were also determined; IL-1β, IL-10, IL-6, IL-8 and TNF-α. 
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Also, cytokine release from WB of healthy volunteers (HV) was compared to that released 
from WB from patients undergoing CPB to determine how release might change as a 
consequence of snCPB. 
13.2. Aims and objectives 
The investigations reported within this chapter aim to compare the effects of the RAGE 
ligands S100B, S100A12 and HMGB1 on release of cytokines from whole blood and isolated 
neutrophil suspensions from healthy volunteers and where possible patients undergoing 
CPB. 
Specific objectives: 
i. To compare the effects of RAGE ligands (S100B, S100A12 and HMGB1) on leukocyte 
cytokine release in 2 models: whole blood and isolated neutrophils obtained from 
snCPB patients and from healthy volunteers (HV). 
ii. To determine the effect of snCPB on responsiveness to S100B in comparison to 
anticipated endotoxin hypo-responsiveness. 
iii. To investigate the effect of putative inhibitors on this cytokine release 
iv. To establish the pattern of cytokine release in response to RAGE ligands 
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13.3. Specific methods 
Patients presenting for snCPB at the Royal Brompton Hospital were approached and 
informed consent was obtained on the day prior to surgery. Blood samples were taken 
around snCPB as described in Methods (Section 6.7) and plasma isolated and stored at -80oC 
until analysis. Samples were obtained from patients in Cohorts B, as defined in the methods 
section. 
Following whole blood acquisition or neutrophil isolation (Section 7.2.3) cell suspensions 
(250µl) were incubated with or without stimuli/inhibitors in 96-well plates for 4h; where 
possible, assay conditions were set up in duplicate. Cells were centrifuged (400g, 4oC, 10 
mins), supernatant aspirated and placed in a new microplate for storage at -20oC until assay. 
ELISA assays were always carried out in duplicate and the mean value used. In selected 
experiments, the cell pellet remaining after removal of the supernatant was re-suspended 
and cytocentrifuged (450g, 3 mins) onto slides and air-fixed prior to staining (Section 7.2.4),  
photographed and  the cell number counted. 
When presenting results, the number of samples (n) was either the number of individuals, 
or the number of measurements in total from fewer individuals, for example 8 
measurements from 4 individuals. Where the number of samples equals the number of 
individuals, it is written as n=x; conversely where the number of measurements is used from 
a lesser number of individuals, it is written as n=x from y. This is justifiable as the cells are 
not clonal and therefore each experimental result valid per se. This compromise was arrived 
at due to the expense of experiments and/or limited number of cells available.  
The sequence of adding ligands, inhibitors and cell suspensions could impact on the findings. 
Addition of all three components (cells, inhibitors and ligands) simultaneously was deemed 
neither clinically analogous to a treatment, nor providing optimum conditions for inhibitors 
to act (A, Figure 79). Addition of inhibitors to the ligands prior to addition of cells might 
increase the effectiveness of the inhibitor, particularly if the inhibitor is thought to bind 
directly to the ligand (B, Figure 79). Finally, adding the inhibitor following the addition of 
stimulus to cell suspensions (C, Figure 79) was deemed most clinically analogous to a 
therapy. Thus, unless otherwise stated, inhibitors were co-incubated with stimuli for 1h 
prior to addition of both to cell suspensions (B, Figure 79). 
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Figure 79: Three methods of combining stimulus, inhibitor and cell suspensions. A represents adding the stimulus and 
inhibitor at the same time to the already-plated-out cell suspension ‘co-incubation’; B represents combining the stimulus 
and inhibitor together for a duration prior to addition to cell suspension ‘co-pre-incubation’; C represents adding the 
stimulus, then the cell suspension, then the inhibitor, ‘treatment’. 
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13.4. Results 
13.4.1. Healthy volunteers 
13.4.1.1. S100B caused release of IL-8 from WB and neutrophils from healthy 
volunteers 
Initial experiments suggested that the optimum duration of incubation to assess IL-8 release 
was 4h. Earlier time points (30 or 60 mins) did not provide equivalent range of cytokine 
release and later times (24h) showed substantially elevated cytokine release (>15,000pg/ml 
of IL-8 in the absence of stimuli) without experimental stimuli making it impossible to assess 
effects of stimuli/inhibitors.  
 
Figure 80: IL-8 release from whole blood in response to S100B. WB was obtained from healthy volunteers (n=6) and 
incubated with S100B (0.1-2.0µg/ml) or negative control for 4h. IL-8 content of supernatant was measured with ELISA. Data 
are presented as mean with bars indicating SEM. ANOVA with Bonferroni correction * p<0.05, ** p<0.01, *** p<0.001. 
IL-8 levels at 4h in supernatants of whole blood were elevated when S100B was present and 
increases were concentration-dependent (Figure 80). IL-8 levels were undetectable in the 
absence of stimulus, increased with 0.1µg/ml of S100B to 145±163pg/ml, with 1.0µg/ml to 
763±265pg/ml (p<0.01) and further still with 2.0µg/ml to 1113±590pg/ml IL-8 (p<0.001)  
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Figure 81: IL-8 release from neutrophils in response to S100B. Neutrophils were isolated from healthy volunteers (n=6) 
and suspended at 1x10
6
/ml prior to incubation with S100B (0.1-2.0µg/ml) or negative control for 4h. IL-8 content of 
supernatant was measured with ELISA. Data are presented as mean with bars indicating SEM. ANOVA with Bonferroni 
correction * p<0.05. 
Similar results were seen in isolated neutrophil suspensions (as seen in Figure 81). Mean IL-8 
levels in the absence of stimulus were 112±205pg/ml, with 0.1µg/ml of S100B 
449±300pg/ml and 1241±789pg/ml and 1601±1146pg/ml of IL-8 with 1.0 and 2.0µg/ml, 
respectively. 
The quantities of IL-8 released from WB and neutrophils are not directly comparable as the 
neutrophil concentration in WB was not determined.   
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13.4.1.2. Lack of inhibition of S100B-stimulated IL-8 release 
 
Figure 82: IL-8 release from neutrophils in response to S100B with inhibitor. Neutrophils were isolated from healthy 
volunteers (n=8 from 4) and suspended at 1x10
6
/ml prior to addition of the combined S100B (0.1µg/ml) and inhibitor 
(having been co-incubating at 37
o
C for >1h). IL-8 content of supernatant was measured with ELISA. Data are presented as 
mean with bars indicating SEM. ANOVA with Bonferroni correction p>0.05 for all. PBS phosphate buffered saline, sRAGE 
(0.5µg/ml), TTP (1µg/ml), mAB to RAGE (1µg/ml), AB to S100B (1µg/ml) or isotype control antibody (1µg/ml). 
In experiments conducted on both WB and isolated neutrophils and despite several protocol 
modifications, alterations in concentrations, and adding components in different sequences, 
there was no consistent statistically significant reduction in IL-8 release following co-
incubation of S100B with any putative inhibitors. Representative data from select neutrophil 
experiments are shown (Figure 82). 
S100B was used at 0.1µg/ml in these experiments and those described in section 13.4.2 
onwards. Figures 81 and 82 do not show a significantly increased quantity of IL-8 released in 
response to S100B at this concentration in comparison to the negative control. However, in 
allied experiments without the dose range but with higher sample numbers, this 
concentration was consistently found to induce a significantly different release of IL-8 than 
negative control. Furthermore, it is of greater clinical relevance than higher concentrations, 
being closer to levels observed in vivo, and maximised the number of experiments that 
could be performed for a given quantity of expensive recombinant protein. 
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13.4.1.3. S100A12 caused release of IL-8 from WB and neutrophils from 
healthy volunteers 
 
Figure 83: IL-8 release from whole blood in response to S100A12. WB was obtained from healthy volunteers (n=4 from 2) 
and incubated with S100 A12 (0.01-1.0µg/ml) or negative control for 4h. IL-8 content of supernatant was measured with 
ELISA. Data are presented as mean with bars indicating SEM. ANOVA with Bonferroni correction ** p<0.01, *** p<0.001. 
IL-8 levels in the supernatant of whole blood were significantly increased with S10012; 
increases were concentration-dependent (Figure 83). IL-8 was undetectable in the absence 
of stimulus and with 0.01µg/ml of S100A12. With 0.1µg/ml the mean IL-8 release was 
236.9±101pg/ml (P<0.01) and with 1.0µg/ml 2157±1040pg/ml (p<0.001)  
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Figure 84: IL-8 release from neutrophils in response to S100A12. Neutrophils were isolated from healthy volunteers (n=4 
from 2) and suspended at 1x10
6
/ml prior to incubation with S100 A12 (0.01-1.0µg/ml) or negative control for 4h. IL-8 
content of supernatant was measured with ELISA. Data are presented as mean with bars indicating SEM. ANOVA with 
Bonferroni correction *** p<0.001. 
A similar profile of IL-8 release from isolated neutrophil suspensions (Figure 84) to that from 
whole blood was seen, but the amounts were less.  Thus, basal release was 42±28pg/ml of 
IL-8  increasing to  55±40pg/ml with 0.01µg/ml, 139±16pg/ml with 0.1µg/ml but only 
reaching significance from basal with  542±133pg/ml IL-8 release with 1.0µg/ml (p<0.001).  
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13.4.1.4. Lack of Inhibition of S100A12-related cytokine release  
 
Figure 85: IL-8 release from neutrophils in response to S100A12 with inhibitor. Neutrophils were isolated from healthy 
volunteers (n=6 from 3) and suspended at 1x10
6
/ml prior to addition of the combined S100A12 (0.1µg/ml) and inhibitor 
(having been co-incubating at 37
o
C for >1h). IL-8 content of supernatant was measured with ELISA. Data are presented as 
mean with bars indicating SEM. ANOVA with Bonferroni correction p>0.05 for all. PBS phosphate buffered saline, sRAGE 
(0.5µg/ml), TTP (1µg/ml), mAB to RAGE (1µg/ml). 
In experiments conducted on both WB and isolated neutrophils and despite several protocol 
modifications, alterations in concentrations, and adding components in different sequences, 
there was no consistent statistically significant reduction in IL-8 release following co-
incubation of S100A12 with any putative inhibitors. Representative data from select 
neutrophil experiments are shown (Figure 85). 
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13.4.1.5. HMGB1 does not cause release of IL-8 
 
Figure 86: IL-8 release from neutrophils in response to S100A12. Neutrophils were isolated from healthy volunteers (n=6 
from 3) and suspended at 1x10
6
/ml prior to incubation with PBS (negative control) vs. HMGB1 at 0.5µg/ml, S100B (B) at 
0.1µg/ml vs. both s100B and HMGB1 (B+H), S100A12 (A) at 0.1µg/ml vs. both S100A12 and HMGB1 (A+H). IL-8 content of 
supernatant was measured with ELISA. Data are presented as mean with bars indicating SEM. Unpaired t test correction 
p>0.05 for each pair. 
In contrast to the findings with S100B and S100A12, HMGB1 did not alter release of IL-8 
from neutrophils of healthy volunteers (Figure 86). As it has been suggested that HMGB1 
may lack inherent pro-inflammatory activity, but might augment effects of other mediators, 
HMGB1 was co-incubated with S100B and S100A12, but no significant change in IL-8 release 
compared with S100B or S100A12 alone was seen. 
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13.4.1.6. LPS caused concentration-dependent release of IL-8 in WB 
 
Figure 87: IL-8 release from whole blood in response to LPS. WB was obtained from healthy volunteers (n=4 to 8, from 2 
to 4) and incubated with LPS 1x10
-10
 g/L (0.1pg/ml) to 1x10
-3
 g/L (1µg/ml) for 4h. IL-8 content of supernatant was measured 
with ELISA. Data are presented as mean with bars indicating SEM.  
LPS was used as a positive control in experiments and exhibited a concentration-dependent 
release of IL-8 from whole blood (Figure 87). 
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13.4.2. Patients pre/post snCPB 
Whole blood was obtained from ten snCPB patients pre- and post-CPB and co-incubated 
with S100B/controls following 1h co-incubation with putative inhibitors or controls. 
13.4.2.1. Effect of S100B (with and without inhibitors) on IL-8 release pre- vs. 
post-snCPB 
 
Figure 88: IL-8 release from whole blood obtained pre-snCPB in response to stimuli in the presence or absence of 
putative inhibitors. WB was obtained from patients pre-snCPB (n=18 from 9) and incubated with S100B (0.1µg/ml), LPS 
(1ng/ml) or negative control (PBS) for 4h in the presence/absence of inhibitors sRAGE (1µg/ml, SR) or TTP-4000 (1µg/ml, 
TTP) that had been co-incubating at 37
o
C for >1h with the S100B or LPS respectively. IL-8 content of supernatant was 
measured with ELISA. Data are presented as mean with bars indicating SEM. ANOVA with Bonferroni correction p>0.05 for 
effect of inhibitors on IL-8 release. 
S100B (0.1µg/ml) increased IL-8 release in comparison to PBS; LPS (1ng/ml) caused a greater 
release of IL-8 compared to S100B. Co-incubation with putative inhibitors sRAGE (1 µg/ml) 
and TTP (1 µg/ml) did not significantly alter IL-8 (Figure 88), p>0.05. 
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Figure 89: IL-8 release from whole blood obtained post-snCPB in response to stimuli in the presence or absence of 
putative inhibitors. WB was obtained from patients post-snCPB (n=18 from 9) and incubated with S100B (0.1µg/ml), LPS 
(1ng/ml) or negative control (PBS) for 4h in the presence/absence of inhibitors sRAGE (1µg/ml, SR) or TTP-4000 (1µg/ml, 
TTP) that had been co-incubating at 37
o
C for >1h with the S100B or LPS respectively. IL-8 content of supernatant was 
measured with ELISA. Data are presented as mean with bars indicating SEM. ANOVA with Bonferroni correction p>0.05 for 
effect of inhibitors on IL-8 release. 
In blood obtained from patients post-snCPB, the amount of IL-8 released in response to 
S100B or LPS was decreased (Figure 89), Also, neither sRAGE nor TTP decreased IL-8 
production from WB. 
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Figure 90: IL-8 release from whole blood in response to identical stimuli but comparing pre- vs. post- snCPB. WB was 
obtained from patients pre- and post-snCPB (n=18 from 9) and incubated with S100B (0.1µg/ml), LPS (1ng/ml) or negative 
control (PBS) for 4h. IL-8 content of supernatant was measured with ELISA. Data are presented as mean with bars 
indicating SEM. Paired t test ** p<0.01. 
When IL-8 release pre and post bypass were compared, directly, release post-CPB was 
significantly decreased following stimulation with either LPS (P<0.01) or S100B (P<0.01), 
Figure 90. 
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13.4.2.2. Decreased cytokine release with S100B following snCPB 
In samples obtained from 3 patients IL-6, IL-8, TNF-α, IL-1β, and IL-10 were measured using 
the MSD system. Measurements were in duplicate on supernatants from whole blood, 
obtained pre- and post-CPB, following 4h of experimental conditions. 
 
Figure 91: IL-6 and IL-8 release from whole blood in response to S100B or negative control pre- (graphs on left) and post- 
snCPB (graphs on right). WB was obtained from patients pre- and post-snCPB (n=18 from 9) and incubated with S100B 
(0.1µg/ml) or negative control (PBS) for 4h. IL-8 content of supernatant was measured with ELISA. Data are presented as 
mean with bars indicating SEM. Unpaired t test ** p<0.01. 
In WB obtained pre-snCPB, levels of IL-6 and IL-8 were elevated following stimulation with 
S100B, in comparison to stimulation with PBS, p<0.01. By contrast, in WB obtained following 
snCPB, levels of IL-6 and IL-8 were non-significantly elevated following stimulation with 
S100B, in comparison to stimulation with PBS (Figure 91). 
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Figure 92: TNF-α, IL-1β or IL-10 release from whole blood in response to S100B or negative control pre- (graphs on left) 
and post- snCPB (graphs on right). WB was obtained from patients pre- and post-snCPB (n=18 from 9) and incubated with 
S100B (0.1µg/ml) or negative control (PBS) for 4h. IL-8 content of supernatant was measured with ELISA. Data are 
presented as mean with bars indicating SEM. Unpaired t test ** p≤0.01. 
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In WB obtained pre-snCPB, levels of TNF-α, IL-1β and IL-10 were elevated following 
stimulation with S100B, in comparison to stimulation with PBS (p≤0.01). By contrast, on WB 
obtained following snCPB, levels of TNF-α and IL-1β were non-significantly elevated 
following stimulation with S100B, in comparison to stimulation with PBS (Figure 92). IL-10 
levels were high following snCPB, irrespective of stimulating conditions with S100B or PBS, 
Figure 92. 
 
Figure 93: IL-6 and IL-8 release from whole blood in response to identical stimuli but comparing pre- vs. post-snCPB. WB 
was obtained from patients pre- and post-snCPB (n=18 from 9) and incubated with S100B (0.1µg/ml) or LPS (1ng/ml) for 
4h. IL-8 content of supernatant was measured with ELISA. Data are presented as mean with bars indicating SEM. Paired t 
test ** p<0.01. 
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Figure 94: TNF-α, IL-1β or IL-10 release from whole blood in response to identical stimuli but comparing pre- vs. post-
snCPB. WB was obtained from patients pre- and post-snCPB (n=18 from 9) and incubated with S100B (0.1µg/ml), LPS 
(1ng/ml) or PBS (IL-10 only) for 4h. IL-8 content of supernatant was measured with ELISA. Data are presented as mean with 
bars indicating SEM. Paired t test ** p<0.01. 
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Comparing cytokine release due to identical experimental conditions but using whole blood 
acquired post- compared to pre-snCPB, statistically significant decreases in response to both 
S100B and LPS were seen (Figures 93 and 94), p<0.01 for all.  
IL-10 levels in the post-op whole blood supernatants were uniformly high post-snCPB, 
irrespective of stimulation/inhibiting conditions (without stimulus: 1.17±0.3pg/ml pre vs. 
129.8±28.7pg/ml post). This probably reflected high levels in the plasma of the patients 
following snCPB. 
The negative control (PBS) was not associated with significant cytokine release and the 
positive control (LPS at 1ng/ml) was associated with a relatively large release of all 
measured cytokines: Mean values pre-snCPB, IL-6 11254±3833 pg/ml, IL-8 8923±1262 
pg/ml, TNF-α 12765±4683 pg/ml, IL1-β 636±295 pg/ml, IL-10 47.62±23.6 pg/ml. 
Supernatant of WB incubated with HMGB1 (20ng/ml) for 4h showed no difference in levels 
of cytokines compared to supernatant incubated with negative control, Figure 95. 
 
Figure 95: Extent of cytokine release from whole blood (pre-snCPB) in response to HMGB1. WB was obtained from 
patients pre- snCPB (n=6 from 3) and incubated with HMGB1 (10ng/ml, black) or negative control (PBS, grey) for 4h. 
Cytokine content of supernatant was measured with MSD. Data are presented as mean with bars indicating SEM. Paired t 
test p>0.05 for all. 
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13.4.2.3. Lack of efficacy of TTP-4000 at reducing S100B-mediated cytokine 
release from WB obtained pre- and post-snCPB 
 
Figure 96: Extent of cytokine release from whole blood (pre-snCPB) in response to S100B following co-incubation with 
TTP-4000 (black) or PBS (negative control, grey). WB was obtained from patients pre- snCPB (n=6 from 3) and incubated 
with S100B (0.1µg/ml) for 4h following co-incubation with TTP-4000 (black) or PBS (negative control, grey). Cytokine 
content of supernatant was measured with MSD. Data are presented as mean with bars indicating SEM. Paired t test 
p>0.05 for all. 
 
Figure 97: Extent of cytokine release from whole blood (post-snCPB) in response to S100B following co-incubation with 
TTP-4000 (black) or PBS (negative control, grey). WB was obtained from patients post- snCPB (n=6 from 3) and incubated 
with S100B (0.1µg/ml) for 4h following co-incubation with TTP-4000 (black) or PBS (negative control, grey). Cytokine 
content of supernatant was measured with MSD. Data are presented as mean with bars indicating SEM. Paired t test 
p>0.05 for all. 
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For each of the four archetypal pro-inflammatory cytokines, and for the anti-inflammatory 
cytokine IL-10, the pre-incubation of TTP-4000 (1µg/ml) compared to negative control (PBS), 
with S100B (0.1µg/ml) for 1h prior to co-incubation in whole blood for 4h, was not 
associated with a significant difference in release either pre- (Figure 96) or post- (Figure 97) 
snCPB, p>0.05 for all. 
The TTP-4000 inhibitor was not associated with significant cytokine release in the absence 
of stimulus, with mean IL-8 release of 37.1±20.7 versus 39.3±23.2 for PBS (n=6 from 3), 
p>0.05; similar lack of difference from negative control was seen for IL-6, TNF–α, IL-1β and 
IL-10. 
13.4.3. Assessment of S100B for contamination 
The S100B used was a recombinant protein manufactured in Escherichia coli (Randox 
Laboratories) and was not certified endotoxin-free. The failure to eliminate the possibility of 
bacterial contamination has caused incongruous and conflicting results in related areas of 
investigation (Section 3.2.2). Therefore it was necessary to establish to what extent, if any, 
LPS might contribute to the S100B response. The S100A12 and HMGB1 were certified free 
from endotoxin contamination. sRAGE was not formed in bacterial cells. TTP was not 
certified free from endotoxin but did not elicit any inflammatory responses. 
13.4.3.1. Polymyxin did not diminish IL-8 response 
 
Figure 98: IL-8 release from whole blood in response to S100B in the presence or absence of polymyxin B (PMX). WB was 
obtained from healthy volunteers (n=4) and incubated with S100B (1µg/ml) for 4h in the presence or absence of polymyxin 
B (0.1µg/ml or 10µg/ml). IL-8 content of supernatant was measured with ELISA. Data are presented as median with bars 
indicating IQR. Kruskal Wallis test, p>0.05. 
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Figure 99: IL-8 release from neutrophils in response to S100B in the presence or absence of polymyxin B (PMX). 
Neutrophils were isolated from healthy volunteers (n=8 from 4) and incubated with S100B (0.1µg/ml) for 4h in the 
presence or absence of polymyxin B (0.1µg/ml). IL-8 content of supernatant was measured with ELISA. Data are presented 
as median with bars indicating IQR. Mann Whitney U test, p>0.05. 
Had the cytokine-releasing attributes of the S100B been due to endotoxin contamination 
then the IL-8 release from the cells incubated without polymyxin (PMX) would have been 
expected to be higher that that from cells incubated with PMX. No significant difference was 
seen in WB or neutrophil suspension, p>0.05 (Figures 98 and 99). 
13.4.3.2. Endotoxin assay 
S100B (1mg/ml) was diluted in Lonza’s endotoxin-free water to reach the minimum testing 
volume (500µl) and placed into endotoxin-free glass vials and the most accurate available 
test, the kinetic chromogenic LAL assay, was conducted at Lonza’s European endotoxin 
testing centre. Endotoxin contamination was measured to be 2810 European Units/ml. 
Having considered the dilution, the S100B 1mg/ml solution was estimated to have 16860 
EU/ml. One Endotoxin Unit (EU) has the endotoxin activity of 0.2 ng of reference Endotoxin 
Standard. The extent of contamination may be expressed as 3.372 µg/ml endotoxin in a 
1mg/ml solution, or 0.34%. 
13.4.3.3. Comparing known with estimated endotoxin 
To further validate the results of the external test, the cytokine release between whole 
blood and isolated neutrophils exposed to either S100B, or the amount of LPS that should 
be within that quantity of S100B was compared; using the estimated degree of 
contamination provided by Lonza. 
266 
 
  
Figure 100: IL-8 release from whole blood in response to LPS vs. S100B. WB was obtained from healthy volunteers (n=4 
from 2) and incubated with LPS 1x10
-6
 g/L or S100B (2.96x10
-4 
g/L) for 4h. IL-8 content of supernatant was measured with 
ELISA. Data are presented as mean with bars indicating SEM. Unpaired t test, *** p<0.001. 
 
Figure 101: IL-8 release from neutrophils in response to LPS vs. S100B. Neutrophils were isolated from healthy volunteers 
(n=4 from 2) and incubated with LPS 1x10
-6
 g/L or S100B (2.96x10
-4 
g/L) for 4h. IL-8 content of supernatant was measured 
with ELISA. Data are presented as mean with bars indicating SEM. Unpaired t test, * p<0.05. 
Had the cytokine-releasing attributes of the S100B been entirely due to endotoxin 
contamination and the assay accurate, the amounts would have been expected to be 
similar; had the S100B had inherent pro-inflammatory activity above and beyond any LPS 
contamination then the release from S100B would have been predicted to be greater. 
However, in this case the LPS was associated with significantly more release of IL-8 (Figures 
100 and 101). This is likely to be due to inaccurate estimation of endotoxin contamination 
and/or increased potency of our LPS relative to reference LPS.  
13.4.3.4. S100B-stimulated cytokine release profile 
Had the cytokine-releasing properties of the S100B be attributable to contaminating LPS 
then the pattern of cytokine release would be identical to that due to pure LPS. However, 
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S100B provokes a substantially different pattern with S100B having the greatest release of 
IL-8 then IL-6 then TNF-α, the complete opposite of LPS with TNF-α > IL-6 > IL-8 (Table 37). 
Cytokine S100B, pg/ml LPS, pg/ml 
IL-1β 55.03 635.77 
IL-6 1,275.56 11,253.62 
IL-8 1,492.26 8,923.44 
IL-10 7.05 47.62 
TNF-α 1,119.43 12,765.38 
Table 37: Mean cytokine levels in supernatant from whole blood (n=3) obtained pre-operatively and co-incubated with 
either S100B (100ng/ml) or LPS (1ng/ml) for 4h. 
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13.5. Discussion 
13.5.1. Effect of RAGE ligands 
Our first specific objective was to compare the effects of the RAGE ligands S100B, S100A12 
and HMGB1 on cytokine release in two models, WB and neutrophils. The RAGE ligands 
S100B and S100A12 resulted in release of the pro-inflammatory cytokine IL-8 from whole 
blood and neutrophil suspensions in a concentration-dependent manner. Whole blood and 
neutrophil assays invariably showed similar patterns of response. 
S100B was used as there is strong evidence that it binds to RAGE [339], has pro-
inflammatory activity in leukocytes [287, 350-353], and is known to be increased in the 
plasma of patients following snCPB. Although RAGE-mediated inflammatory signalling is 
likely to result in the release of a range of mediators including IL-8, until very recently this 
had only been shown in human endothelial cells and chondrocytes [702, 703]. One report of 
concentration -dependent release of IL-8 from neutrophils in response to S100B measured 
by Western Blot has previously been was published in abstract form. No attempts at 
inhibition were reported [353].  
S100B-induced inflammatory response investigations in leukocytes have been 
predominantly performed in cell lines. Neutrophil-like cells (HL-60) were used to investigate 
the effect of hyperglycaemia and S100B on oxidative burst and the effects of MAPK 
signalling inhibitors [287]; monocyte-like cells (THP-1) and primary human monocytes 
showed  increased expression of cyclo-oxygenase enzymes (enzymes with pro-inflammatory 
products) in response to S100B and AGE. Successful inhibition experiments with anti-RAGE 
antibody and NF-κB and MAPK pathway inhibitors were performed in THP-1 cells [351]. 
S100A12 was also used on the basis of strong evidence of ligation to RAGE, pro-
inflammatory activity in leukocytes [339, 340] and is increased in the plasma of patients 
following snCPB. S100A12 has not been previously shown  to induce IL-8 release from 
leukocytes, indeed there was a lack of IL-8 release shown in a study of THP-1 cells [704]. 
Others have shown a chemo-attractant effect diminished by the presence of sRAGE [339, 
708].  
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Concentrations of S100A12 and S100B used in these experiments (mostly 0.1 µg/ml but up 
to 2µg/ml) were higher than those measured in plasma samples from patients post-snCPB 
but were similar to, or significantly less than, amounts described in the literature.  In 
defence of this, levels at sites of inflammation are far higher than those found in the 
circulation and these experiments are models to facilitate experimental investigations 
rather than attempts to accurately recreate the in vivo state. 
In our models, the HMGB1 neither induced IL-8 release alone or in combination with S100B 
or LPS. As discussed (Section 3.2.2), the inflammatory activity of HMGB1 is controversial. 
HMGB1 was used both at concentrations close to those observed clinically (10ng/ml), and at 
higher concentrations (0.5µg/ml). By contrast, others have shown induction of IL-8 release 
in WB when used at 5µg/ml. This effect was not found to be inhibited by anti-RAGE 
antibodies, but by anti-TLR-4 antibodies used at 100µg/ml [387]. The same investigators 
used HMGB1 at 1.15 µg/ml and demonstrated release of TNF-α from human monocytes, 
with inhibition by the selective cholinergic agonist GTS-21 [706]. In both these studies the 
HMGB1 was recombinant but not of bacterial origin. Therefore, we might have used 
insufficient HMGB1 to induce cytokine release from WB or neutrophils. However, responses 
induced by very high concentrations of HMGB1 and their inhibition by extremely high 
concentrations of inhibitors bear little relevance to the clinical state and therefore lack 
translational relevance. 
13.5.2. Hypo-responsiveness 
The second objective was to investigate -responsiveness of leukocytes before and after 
snCPB. Leukocytes were hypo-responsive to S100B in terms of cytokine release (IL-1β, IL-6, 
IL-8, and TNF-α) from whole blood obtained post compared with pre- snCPB. This has not 
been previously described. Also,  findings of leukocyte LPS hypo-responsiveness concur with 
previous findings showing that ex vivo cytokine production is suppressed early after the 
onset of CPB [199, 202].  
Postulated mechanisms of endotoxin tolerance include the effects of increased circulating 
anti-inflammatory cytokines. Increased expression of the anti-inflammatory cytokine IL-10 
was shown however the sample size was insufficient to robustly investigate any relationship 
between extent of IL-10 release and degree of change in cytokine response to S100B or LPS. 
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Another potential mechanism that has been implicated is altered NF-κB subunit 
composition. In an endotoxin tolerance model conducted using a leukocyte cell line (Mono-
Mac-6) a shift from p50/p65 heterodimers to p50 homodimers resulted in impaired ability 
to transcribe mRNA for pro-inflammatory cytokines [709, 710]. As NF-κB is a major RAGE 
signal transduction pathway, such changes might also mediate the S100B tolerance 
observed.  
In support of the hypothesis that excessive leukocyte-mediated inflammatory responses 
contribute to organ failure, pre-operative ex vivo production of the pro-inflammatory 
cytokine IL-6 was previously correlated with impaired post-snCPB oxygenation [202]. By 
contrast, ex vivo endotoxin hypo-responsiveness in an undifferentiated group of surgical ICU 
patients was associated with prolonged ventilation [711]. The latter findings are likely to 
reflect the deleterious effects of immunoparesis and its relationship to nosocomial 
infections and consequent prolonged critical illness. 
13.5.3. Inhibition 
The third objective was to investigate the effect of putative inhibitors on cytokine release. In 
this regard, S100B and S100A12-mediated cytokine release from either whole blood from 
healthy volunteers and patients, or neutrophil suspensions from healthy volunteers could 
not be inhibited using the protocols utilised in this study. The failure to inhibit RAGE-
mediated cytokine release in whole blood and isolated neutrophils could be ascribed to 
problems with the models and/or the inhibitors.  
Firstly, the models employed were human leukocytes ex vivo as WB or suspension of 
isolated neutrophils. None of the putative inhibitors used in this study have previously been 
used in whole blood models, or neutrophil suspensions. Certainly, pre-clinical efficacy data 
of the synthetic sRAGE analog (TTP-4000) comes from murine, in vivo studies.  
Secondly, the inhibitors; there are no published studies of inflammation-suppressing effects 
of sRAGE on human leukocytes. In fact, following reports of sRAGE induced production of 
inflammatory cytokines from murine splenocytes [480], studies on human monocytes 
reported induction of IL-6, TNF-α by recombinant (endotoxin-free) sRAGE [481]. Both sRAGE 
and TTP-4000 should bind S100B and S100A12 with high affinity and prevent binding to 
cellular RAGE, thus abrogating RAGE-mediated IL-8 secretion. TTP-4000 is a synthetic sRAGE 
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analogue and would have been expected to have similar inhibitory effects to sRAGE (Section 
9.8.5). The monoclonal antibody to RAGE should bind and block interaction with its ligands; 
the antibody to S100B should similarly bind to S100B and prevent interaction with RAGE. 
The possible reasons for the failure of these agents include failure to bind their targets; 
failure to eliminate binding to cellular RAGE; or the presence of inherent pro-inflammatory 
activity. The latter possibility is unlikely as sRAGE and TTP in isolation did not increase IL-8 
released compared with negative control. 
In general terms, mediator-binding proteins may vary in their capacity to block mediator-
receptor interaction depending upon factors including the relative concentrations of binding 
proteins and mediator; indeed, there are examples of the opposite effect occurring with 
inhibitors both prolonging the duration of mediator activity and having agonist activity 
[712].  
The sRAGE from Prospec was a human recombinant protein produced in HEK (Human 
Embryonic Kidney) cells as a single, glycosylated, polypeptide chain containing 331 amino 
acids and having a molecular mass of 35.2 kDa. It is fused to a Flag tag at C-Terminus and 
purified by proprietary chromatographic techniques. Investigators have previously found 
reduced inhibition of RAGE-mediated inflammation when using recombinant sRAGE compared 
to tissue-derived sRAGE due to differences in glycosylation that affect ligand binding [252, 
253]. Therefore, the dissimilarities between this protein and endogenous human sRAGE may 
significantly affect its ability to bind ligand. Furthermore, structural differences may affect its 
ability to interact with membrane-bound RAGE, another hypothesised mechanism by which 
sRAGE could interfere with RAGE-mediated signal transduction [275]. Finally, despite adhering 
to manufacturer’s guidance on storage, there is evidence that sRAGE degrades into several 
peptide species during storage [713] and this might also affect activity. Alternatively, sRAGE 
could have bound the S100B but ineffectively inhibited its binding to membrane-bound RAGE 
protein. Similarly, the investigational drug TTP-4000 might lack affinity or unsuccessfully block 
interaction with the receptor. 
The S100B antibody was synthesised in the murine peritoneal cavity and is provided at 80-90% 
purity. As a mixture of monoclonal antibody to S100B and undetermined murine proteins it 
may offer more pro-inflammatory stimuli than inhibitory effect. Although it was shown to be 
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effective at inhibiting human RAGE-S100B interactions, the model used was very different, 
specifically, cultured rectal epithelial cells from patients with ulcerative colitis and assessment 
of  the reduction in protein production of inducible nitric oxide synthetase after 24h [714]. 
The HMGB1 used was sourced from R&D (catalogue number 1690-HM) and derived from a 
murine myeloma cell line, with a predicted molecular mass of 24.9kDa. This is dissimilar to 
endogenous human HMGB1 (Molecular mass 30kDa) and is likely to have different or 
absence post-translational modifications (Section 3.2.2) which might account for the 
absence of effect demonstrated. 
13.5.4. Cytokine release pattern 
The final objective was to establish the pattern of cytokine release from WB obtained from 
patients pre- and post-snCPB in response to RAGE ligands. In a limited number of patient 
samples we measured release of IL-6, IL-8, TNF-α, IL-1β, and IL-10 in response to 
stimulation. The pattern of cytokine release from whole blood from patients pre- and post- 
snCPB differed in response to S100B compared to LPS. The S100B used is of recombinant 
bacterial origin and therefore likely to have a degree of LPS contamination, however this is 
difficult to accurately quantify. Any contaminating LPS is unlikely to account for the 
observed activity for several reasons: firstly, the pattern of cytokine release differs from that 
observed for LPS; secondly, the cytokine response is unaltered following co-incubation with 
the LPS-binder polymyxin. 
13.5.5. Future work 
There are many options for taking this work forward. Firstly, other effects of RAGE ligands 
on leukocyte function (chemotaxis, phagocytosis, intracellular killing) could be investigated. 
Further inhibition experiments with pharmacological agents might include short peptide 
sRAGE fragments [713], inhibitors of cell signalling pathways, or inhibition of toll-like 
receptors. Also, it would be essential to establish that  RAGE-inhibitory effects of some of 
the putative antagonists could be established in models that have been better 
characterised, such as alveolar epithelial cell lines (A549s, [715]) or endothelial cells 
(HUVECs [716]). 
Although the advantages of using primary cell lines are considerable, characterisation of the 
responses in leukocyte cell lines including THP-1 for monocytes, HL-60 for neutrophils would 
273 
 
facilitate siRNA experiments to knock-down RAGE, TLR-2 and TLR-4 to determine which has 
the greater effect on S100 protein-mediated responses. Also, larger numbers of cells could 
be used which would facilitate collection of mRNA for qRT-PCR. Although siRNA techniques 
are possible in primary leukocytes and have been used to knock-down RAGE in monocytes 
[290], experience from our laboratory suggests that the techniques are difficult to 
reproduce consistently. 
13.6. Conclusion 
S100B and S100A12 are DAMPs released during tissue injury or infection. Such proteins 
cause secretion of canonical inflammatory cytokines from neutrophils. In the context of 
localised release this will cause acute inflammation and may be beneficial in leading to 
resolution of injury or infection. However, when high levels are present in the circulation, 
disseminated activation and recruitment of inflammatory cells is likely to be 
disadvantageous. The data presented within this chapter supports the hypothesis that 
release of the RAGE ligands, S100B and S100A12, during snCPB has pathophysiological 
significance. 
Successful inhibition of RAGE-mediated leukocyte cytokine release was elusive in our 
investigations and has yet to be demonstrated by other investigators but might yet prove to 
be valuable therapy. 
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14. GENETIC POLYMORPHISMS IN THE GENES FOR RAGE AND ITS LIGANDS 
14.1. Introduction 
Activation of the RAGE-axis predisposed patients to excessive systemic inflammation, 
manifest as prolonged ICU LOS (Section 11). The extent of systemic inflammation was 
related to adverse outcome, including death (Section 10). Leukocytes expressed RAGE and 
possibly contribute to circulating sRAGE (Section 12). RAGE ligands were released during 
snCPB and caused pro-inflammatory responses in leukocytes (Section 11 and 13). This 
chapter describes investigations into the role of genetic variation in the RAGE-axis and how 
genetic variants may be associated with more severe systemic inflammation and organ 
dysfunction following snCPB. 
Variation in the genes of the inflammatory response has been investigated in the context of 
post-snCPB SIRS with mixed results (Section 2.4). SNPs affecting expression of pro-
inflammatory cytokines such as IL-6, IL-8 and TNF-α have been related to greater elevations 
in circulating levels of cytokines post-operatively than their allelic variants [222, 224, 226]. 
These elevated cytokines were variably related to adverse clinical outcomes such as 
impaired oxygenation, impaired renal function, prolonged ventilation, and prolonged ICU 
and hospital LOS [220, 225, 227, 228]. More generally, elevated levels of circulating 
inflammatory cytokines were associated with adverse outcome [110]. 
The RAGE gene has been studied in relation to onset of diabetes and the development of 
diabetic complications (Section 3.1.6). However, there are very few studies that investigated 
the role of genetic variation in the RAGE gene in chronic inflammatory disease; and none in 
acute critical illness. One particular study showed associations between SNPs in the HMGB1 
gene and adverse outcome from SIRS [271]. 
Previous genetic association studies of RAGE genes have identified SNPs which bear 
functional significance and also some candidate SNPs that could potentially have 
implications on outcomes from acute critical illness. These studies pave the way for the 
investigation of genetic variation in the genes of the RAGE axis and their influence on 
outcome from snCPB, as an exemplar of acute critical illness. 
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14.2. Aims and objectives 
The studies reported within this chapter aimed to investigate genetic variation in select 
genes of the RAGE axis and their influence on outcome from snCPB. 
Specific objectives: 
i. To select appropriate SNPs in the RAGE, S100A8 and HMGB1 genes, then design 
primers for these SNPs and test them using the SSP-PCR technique 
ii. To clinically characterise a large cohort of snCPB patients and genotype their DNA 
using SSP-PCR 
iii. To verify genotype and distribution 
iv. To measure sRAGE and S100A8/9 in the plasma of patients in the cohort 
v. To analyse the relationship between genotype and clinical outcomes, initially using 
data mining 
14.3. Specific methods 
14.3.1. Genes of the RAGE axis 
These investigations focus on RAGE and in particular its ligands HMGB1, S100B, S100A8/9, 
S100A12 and AGEs. As AGE modifications do not result from gene products the influence of 
genetic variability is limited.  
The National Center for Biotechnology Information maintains a SNP database 
(www.ncbi.nlm.nih.gov/SNP) which was used to determine the nucleic acid sequences of 
the SNP, necessary for primer design. The Ensembl project (www.ensembl.org) and SNPper 
(snpper.chip.org) provided further detailed information. 
On the basis of published reports and choice of genotyping methodology, 8 SNPs were 
selected for analysis, Table 38.  
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Gene refSNP 
cluster ID 
numbers 
SNP 
name 
Location Change in 
nucleotide 
(common, 
variant) 
Change in 
amino 
acid 
Functional significance 
RAGE 
rs1800624 -374 T/A 
Promoter 
region 
 
T to A N/A 
Increased transcriptional 
activity of RAGE[255] 
rs1800625 −429 T/C 
Promoter 
region 
 
T to C N/A 
Increased transcriptional 
activity of RAGE[255] 
rs2070600 
Gly82Ser 
G/A 
Ligand binding 
domain – 
exon3 
G to A 
Glycine to 
Serine 
Missense, results in damage to 
structure and function of 
RAGE[269] 
rs184003 1704 G/T 
Intron 7 
 
G to T N/A 
Unknown function but with 
clinical associations (diabetes) 
rs3134940 2184 A/G 
Intron 8 
 
A to G N/A 
Unknown function but with 
clinical associations (diabetes) 
S100A8 
rs3806232  5’ near gene C to T N/A 
Unknown function but with 
clinical associations 
(periodontitis[270]) 
rs3795391 - Intron C to T N/A 
Unknown function but with 
clinical associations 
(periodontitis[270]) 
HMGB1 rs1060348 982C/T Exon 2 C to T None 
Unknown function [717] but 
with clinical associations[271] 
Table 38: SNPs in the RAGE axis that were genotyped. Adenine (A), Cytosine (C), Thymine (T), Guanine (G) 
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From the 5 SNPs of the RAGE gene studied, there were eight possible haplotypes, based on 
computationally calculated haplotypes [718], Table 39.  
HAPLOTYPE 
 
-429T/C -374T/A G82S 1704G/T 2184A/G 
1 T T G G A 
2 C T G G G 
3 T A G G A 
4 C T G G A 
5 T T G G G 
6 C T - - G 
7 C T G - - 
8 T A G - - 
Table 39: Construction of 8 haplotypes from the variants for the 5 SNPs of interest 
Further details of the primer design and methods of genotyping are in Methods (Section 
7.8). 
14.3.2. Clinical variables 
187 UK Caucasian patients undergoing snCPB (Cohort B) were genotyped for the eight SNPs 
listed in Table 40. Clinical parameters relating to the severity of the inflammatory response 
and degree of organ dysfunction were collected: hospital and intensive care unit length of 
stay (ICU LOS), duration of level 3 care, neutrophil and white blood cell (WBC) count, C-
reactive protein (CRP), PaO2:FiO2 ratio and alveolar-arterial oxygen difference. Additional 
clinical variables include plasma levels of sRAGE, S100A8/9; analysis of ten pro-inflammatory 
cytokines is current. 
14.3.3. Data mining 
Data regarding genotype, clinical outcomes and sRAGE and S100A8/9 assays were entered 
into an Excel (Microsoft) spreadsheet. Data were imported into KnowledgeStudio 4.1 
(Angoss Software, Guildford, UK); a decision tool used to ‘data mine’ or extract previously 
unknown information from large databases. 
Data mining was necessary to efficiently analyse the possible combinations of comparisons. 
For example, for each of the SNPs (8), there are several permutations (5) of genotype and 
allelic distribution, and each of these must be compared to each of the clinical outcomes (9) 
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at each of the times (4); representing over 1000 analyses. RAGE haplotypes were also 
compared to outcome variables.  
Prior to the data mining processing, the variables were appropriately categorised. Of the 
data mining tools available within KnowledgeSTUDIO (decision trees, neural networks, 
clustering algorithms and affinity analysis methods) the ‘decision tree’ tool was the most 
appropriate and was used to investigate the relationship between several independent 
variables and one dependant variable.  
Variables of interest were individually selected as the dependant variable and the in-built 
algorithm (KnowledgeSEEKER) was run to identify a list of correlated variables. The lists of 
potentially related variables were further investigated by selecting them as the dependent 
variable and verifying that the relationships remained. KnowledgeSTUDIO was used as a 
preliminary step in the analysis of databases to select variables for further traditional 
statistical analysis using PRISM v4.0 (GraphPad software, La Jolla, CA, USA) and SPSS v17.01 
(IBM, Somers, NY, USA). 
14.3.4. Statistical methods 
There remain unresolved issues relating to statistical analysis of genetic association studies, 
particularly how to correct for the risk of false positive results stemming from the use of 
multiple comparisons. Purely as a function of statistical testing and the use of a P value of 
≤0.05 as signifying significance, analysing associations with a large number of SNPs, and/or 
with a large number of outcomes will inevitably result in false positives. One way of 
circumventing this is the Bonferroni method, in which the threshold P value is divided by the 
number of tests. However, this may be overly conservative and stringent. Although there 
have been many suggested methods, there is no consensus on which is optimal [719]. 
Despite recognition of the risk of false positive findings, given the uncertainties of correction 
for multiple comparisons, genetic association studies are particularly susceptible to 
publication bias – with strongly positive results finding their way into press more easily than 
negative results. Within this thesis the Bonferroni method is used, the p value acquired from 
comparisons between variable of interest and genotype is multiplied by the number of SNPs 
of that gene that were typed for. 
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The influence of genetic associations on complex disease is usually small with odds ratios of 
<2.0 and therefore single studies with several hundred participants are usually 
underpowered [720, 721] and even sizeable studies may fail to detect associations, resulting 
in a substantial risk of false negative results [719]. 
14.3.5. Data presentation 
As described above, there are a vast number of possible combinations of genetic and clinical 
data. The data displayed and/or commented on represents the highlights - positive results 
and important negatives. 
The genetic variation of a gene within a study population should not differ from the 
variation found in other populations. It is standard practice to compare the observed 
genotypic and allelic distribution to that found by other investigators in order to confirm the 
maintenance of what is known as Hardy–Weinberg equilibrium. The distributions found by 
other investigators are stored within the online repository, the HapMap project; this aims to 
create a complete haplotype map (HapMap) of the human genome. Of the populations 
selected for inclusion in the HapMap project the most phylogenetically similar to the 
patients included within our cohort (Caucasian patients in London) are either from U.S. 
residents of northern and western European ancestry (CEU), or Tuscans in Italy (TSI). When 
there were more than one set of HapMap CEU data, either the largest sample size, or the 
most recently submitted were used. 
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14.4. Results 
14.4.1. Single nucleotide polymorphisms in the RAGE gene 
14.4.1.1. Genotypic distribution 
The distribution of genotypes and alleles in the cohort studied and that recorded within the 
HapMap project are shown in Table 40.  
rs1800624 
(-374) 
 HapMap-CEU TSI Observed 
Genotype 
AA 0.017 
- 
0.02 
AT 0.271 0.27 
TT 0.712 0.71 
Allele 
A 0.153 0.15 
T 0.847 0.85 
 
rs1800625  HapMap-CEU TSI Observed 
Genotype 
CC 0.017 0.034 0.04 
CT 0.300 0.239 0.27 
TT 0.683 0.727 0.70 
Allele 
C 0.167  0.17 
T 0.833  0.83 
 
rs2070600 
(G82S) 
 HapMap-CEU TSI Observed 
Genotype 
AA 0 0 0 
AG 0.233 0.023 0.1 
GG 0.767 0.977 0.9 
Allele A 0.117  0.05 
 
 G 0.883  0.95 
rs184003 
(1704) 
 HapMap-CEU TSI Observed 
Genotype 
GG 0.966 0.750 0.87 
GT 0.034 0.296 0.13 
TT 0 0.037 0 
Allele 
G 0.983  1.00 
T 0.017  0.13 
 
rs3134940  HapMap-CEU TSI Observed 
Genotype 
AA 0.700 0.727 0.59 
AG 0.280 0.239 0.36 
GG 0.020 0.034 0.05 
Allele 
A 0.840  0.95 
G 0.160  0.41 
Table 40: The observed distribution of genotype and allele for 5 SNPs of the RAGE gene compared with those recorded 
in on-line databases of genomic distribution for two populations of relevance (CEU and TRI). 
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The observed distribution of RAGE genotypes was comparable to the distributions recorded 
in online repositories of genetic epidemiological data, as shown in Table 40. A χ2 test 
confirmed Hardy-Weinberg equilibrium, p<0.05. i.e. the observed frequencies of each 
genotype were not statistically significantly different to those expected. 
14.4.1.2. Relationship to endpoints 
14.4.1.2.1. Clinical 
14.4.1.2.1.1. Systemic inflammation 
Graphical representation of selected relationships between genotype distribution within 
SNPs of the RAGE gene and markers of systemic inflammation (neutrophil count and CRP) 
are presented in Figures 102, 103, and 104). 
 
Figure 102: Neutrophil counts in post-snCPB patients, grouped by RAGE G82S-A carriage status on each post-operative 
day (POD). snCPB patients were genotyped and comparison of neutrophil counts made between those carrying the minor 
allele (A, grey, n=17) and those without the minor allele (no A, black, n=168). Data are presented as median with bars 
indicating IQR. Mann Whitney U test * pc<0.05. 
As seen in Figure 102, there was a consistent trend towards a lower neutrophil count in 
those with the minor (A, in grey) allele and at post-operative day 2 (POD2) this became 
statistically significant: minor allele carrier’s median neutrophil count 7.6 (IQR 5.8-9.0) x109/l 
versus 8.9 (IQR 7.2-12.0) x109/l in those without, pc=0.026.  
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Figure 103: CRP in post-snCPB patients, grouped by RAGE G82S-A carriage status on each post-operative day (POD). 
snCPB patients were genotyped and comparison of CRP made between those carrying the minor allele (A, grey, n=17) and 
those without the minor allele (no A, black, n=168). Data are presented as median with bars indicating IQR. Mann Whitney 
U test pc>0.05 for all. 
As seen in Figure 103, the levels of CRP measured immediately post-operatively (POD0), and 
on each of the following days, were not statistically significantly different between those 
patients carrying the minor allele and those without. 
 
Figure 104: CRP in post-snCPB patients, grouped by RAGE -374 genotype on each post-operative day (POD). snCPB 
patients were genotyped and comparison of CRP made between those with AA genotype (in white, n=7), AT genotype (in 
grey, n=62) and TT genotype (in black, n=106). Data are presented as median with bars indicating IQR. Kruskal Wallis test 
with Dunn’s Multiple Comparison test * pc<0.05. 
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As seen in Figure 104, there was a pattern of those homozygous for the minor allele (AA, 
shown in white) having lower CRP at each time considered. At POD1 this reached statistical 
significance: median CRP in those genotyped AA 39 (IQR 24-48) mg/L, vs. AT 67 (IQR 49-91) 
mg/L, vs. TT 63 (IQR 46-94) mg/L, pc=0.02 for both comparisons. 
14.4.1.2.1.2. Pulmonary dysfunction  
Graphical representation of selected relationships between genotype distribution within 
SNPs of the RAGE gene and markers of pulmonary dysfunction (PFR and D(A-a)) are 
presented in Figures 105 and 106. 
 
Figure 105: PFR in post-snCPB patients, grouped by RAGE G82S-A carriage status on each post-operative day (POD). 
snCPB patients were genotyped and comparison of PFR made between those carrying the minor allele (A, grey, n=17) and 
those without the minor allele (no A, black, n=168). Data are presented as mean with bars indicating SEM. Unpaired t test 
p>0.05 for all. 
As seen in Figure 105, there was a trend towards a lower PFR in those with the minor (A) 
allele but at no point did this result become statistically significant.  
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Figure 106: D(A-a) in post-snCPB patients, grouped by RAGE G82S-A carriage status on each post-operative day (POD). 
snCPB patients were genotyped and comparison of D(A-a) made between those carrying the minor allele (A, grey, n=17) 
and those without the minor allele (no A, black, n=168). Data are presented as median with bars indicating IQR. Mann 
Whitney U test p>0.05 for all. 
As seen in Figure 106, no statistically significant differences or apparent trends were seen. 
14.4.1.2.1.3. Length of stay 
A relationship between RAGE genotype and the composite endpoint of ICU LOS was of 
primary importance within these investigations. Data mining did not identify any statistically 
significant relationships with the exception of possible relationship between a 1704-T RAGE 
variant and prolonged advanced respiratory support. 
 
Figure 107: Hours of advanced cardiovascular support in post-snCPB patients, grouped by RAGE 1704-T carriage status. 
snCPB patients were genotyped and comparison of hours of advanced cardiovascular support made between those 
carrying the T allelic variant (grey,n=6) and those not (black, n=74). Data are presented as median with bars indicating IQR. 
Mann Whitney U test p>0.05. 
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As seen in Figure 107, those carrying the minor variant at 1704 (T, in grey) had a median 
duration of requiring CV support of 27.7 (IQR 19.0-208) hours vs. those without the minor 
variant 37.3 (IQR 20.0-65.5) hours, p>0.05. Therefore the possible association was found not 
to have statistical significance. 
14.4.1.2.2. Plasma assays 
Graphical representation of relationships between G82S genotype and sRAGE levels pre- 
and post-snCPB are presented in Figures 108. 
14.4.1.2.2.1. RAGE axis 
 
Figure 108:  Plasma sRAGE levels in patients pre- and post snCPB, grouped by RAGE G82S genotype. snCPB patients were 
genotyped and comparison of sRAGE levels made between those carrying the A allelic variant of the G82S SNP (grey, n=17) 
and those not (black, n=168). Data are presented as median with bars indicating IQR. Mann Whitney U test p>0.05. 
As seen in Figure 108, pre-operative plasma levels of sRAGE were lower in those patients 
carrying the minor allelic variant, median(IQR): 1030(522.0-1318) pg/ml vs. 1092(724-1763) 
pg/ml. The effect was more pronounced post-operatively, median(IQR): 1365 (633.7-2794) 
pg/ml vs. 1937 (1284-2681) pg/ml. However, the differences did not meet statistical 
significance. 
14.4.1.2.2.2. Cytokine 
The relationships between genotype distribution within SNPs of the RAGE gene and 
cytokines are yet to be determined. Mulitplex assays for IL-6, IL-8, IL-10, MCP-1, TNF-α, TNF-
β, GRO, Eotaxin, VEGF and IP-10 are ongoing. 
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14.4.2. Single nucleotide polymorphisms in the S100A8 and HMGB1 genes 
14.4.2.1. Observed allelic frequencies 
S100A8 
rs3806232 
(1) 
 HapMap-CEU TSI Observed 
Genotype 
CC 0 0.034 0.02 
CT 0.224 0.284 0.22 
TT 0.776 0.682 0.76 
Allele C 0.112  0.24 
 T 0.888  0.98 
 
rs3795391 
(2) 
 Pilot.1.CEU TSI Observed 
Genotype 
CC 
unknown 
0.034 0.02 
CT 0.273 0.24 
TT 0.693 0.74 
Allele C 0.111  0.26 
 T 0.889  0.98 
Table 41: The observed distribution of genotype and allele for 2 SNPs of the S100A8 gene compared with those recorded 
in on-line databases of genomic distribution for two populations of relevance (CEU and TRI). 
Linkage disequilibrium analysis revealed the two SNPs rs3795391 and rs3806232 in the 
S100A8 gene to be in tight linkage disequilibrium and therefore co-inherited. Our 
observations were consistent with this. 
HMGB1 
rs1060348  MITOGPOP6 TSI Observed 
Genotype 
CC 0.864 - 0.97 
CT 0.045  0.03 
TT 0.091  0 
Allele C 0.886  1.00 
 T 0.114  0.03 
Table 42: The observed distribution of genotype and allele for one SNP of the HMGB1 gene compared with those 
recorded in on-line databases of genomic distribution of the MITOGPOP6 population (mixed population including Asian 
ancestry). 
The observed distribution of S100A8 and HMGB1 genotypes was comparable to the 
distributions recorded in online repositories of genetic epidemiological data, as shown in 
Tables 41 and 42. A χ2 test confirmed Hardy-Weinberg equilibrium, p<0.05. 
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14.4.2.2. Relationship to endpoints 
14.4.2.2.1. Clinical 
14.4.2.2.1.1. Systemic inflammation 
Data mining did not identify any potential relationships between genotypic variants of the 
S100A8 or HMGB1 genotypes and white blood cell count, neutrophil count or CRP. 
14.4.2.2.1.2. Pulmonary dysfunction 
 
Figure 109: PFR in post-snCPB patients, grouped by S100A8 (rs3806232) genotype on each post-operative day (POD). 
snCPB patients were genotyped and comparison of PFR made between those carrying the minor C allele (white, n=47) and 
those not (black, n=138). Data are presented as mean with bars indicating SEM. Unpaired t test * pc<0.05. 
As seen in Figure 109, carriers of the minor allele (white) had lower PFR (equating to worse 
oxygenation) on post-operative days 1 and 2, reaching statistical significance at post-
operative day 3; mean PFR for minor allele carriers 160±73mmHg vs. 232±86mmHg, p<0.05. 
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Figure 110: D(A-a) in post-snCPB patients, grouped by S100A8 (rs3806232) genotype on each post-operative day (POD). 
snCPB patients were genotyped and comparison of D(A-a) made between those carrying the minor C allele (white, n=47) 
and those not (black, n=138). Data are presented as mean with bars indicating SEM. Unpaired t test ** pc<0.01. 
 POD0 POD1 POD2 POD3 
CT/CC 47 45 22 10 
TT 138 129 41 26 
Table 43: Numbers of patients on each day in the two groups: Those with carriage of the minor C allele and those 
without. 
As seen in Figure 110, carriers of the minor C allele (white) had higher D(A-a) (equating to 
worse oxygenation) on post-operative days 1 and 2, although not statistically significantly, 
but reached statistical significance at post-operative day 3: mean D(A-a) for minor allele 
carriers was 33.9±20.3kPa vs. 20.5±10.0kPa, p=0.01. 
On each passing day a proportion of patients will have recovered sufficiently to have been 
extubated or even left ICU and therefore the numbers in each group diminish, as can be 
seen in Table 43.  
When comparing the total duration of advanced respiratory support (in hours) between the 
TT [median (IQR): 15.8 (11.5-21.7)] and CT/CC groups [median (IQR): 16.3(8.5-19.7)], there 
was no significant difference (p>0.05 MWU).  
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14.4.2.2.1.3. Renal dysfunction 
Renal dysfunction following snCPB is associated with adverse patient outcome, even when 
mild [69]. Clinical assessments of renal dysfunction included changes in plasma creatinine 
but of greater clinical relevance is the need for renal replacement therapy or the worse 
acute kidney injury (AKI definitions in Section 6.4) score within the first week. The 
distribution of worst AKI scores within the first week against S100A8 genotype (Figure 112) 
showed dissimilarity. 
 
 
Figure 111: Histogram of distribution of post-snCPB acute kidney injury (AKI) score grouped by carriage of the minor C 
allele at S100A8 (rs3806232). snCPB patients were genotyped and comparison of worse AKI score in the first week post-
snCPB compared between those with the minor allele (Not_TT, top image) and those without (TT, lower image) 
This pair of histograms (Figure 111) demonstrate the distribution of worst AKI scores in the 
first week following snCPB, with the top figure (Not_TT) representing those carrying the 
minor allele and the lower figure, those homozygous for the major variant (TT). 
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To investigate this further, the worst AKI score was entered into a contingency table and 
Fisher’s exact test calculated (Table 44). 
Worst AKI score in 
first week 
Fisher’s exact test p 
value 
≥1 0.4809 
≥2 0.0421* 
≥3 1.0000 
Table 44: Table of p values from the Fisher’s exact test comparing distribution of AKI between the two groups: not_TT 
and TT. 
Patients carrying the minor allele had a statistically significantly greater incidence of AKI of 
greater than or equal to stage 2 (an increase of 200-300% in serum creatinine from baseline) 
than those with the TT genotype.  
14.4.2.2.1.4. Length of stay 
Data mining did not identify any potential relationships between genotypic variants of the 
S100A8 or HMGB1 genotypes and duration of Level 3 (ICU) or hospital stay. 
14.4.2.2.2. Plasma assays 
14.4.2.2.2.1. Plasma levels of S100A8/9 
 
Figure 112:  Plasma S100A8/9 levels in patients pre- and post snCPB, grouped by carriage of the minor C allele at S100A8 
(rs3806232). snCPB patients were genotyped and comparison of S100A8/9 levels made between those carrying the C allelic 
variant (grey, n=29) and those not (black, n=96). Data are presented as mean with bars indicating SEM. Unpaired t test 
p>0.05. 
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No relationship was found between S100A8 genotype and levels of circulating S100A8/9 
either pre-operatively: mean levels of minor allele carriers 484.2±378.7pg/ml vs. 
449.9±385.9pg/ml; or post-operatively 2915±1486pg/ml vs. 2561±1234pg/ml, p>0.05 
(Figure 112). 
14.4.2.2.2.2. Cytokine 
The relationships between genotype distribution within SNPs of the S100A8 and HMGB1 
genes and cytokines are yet to be determined. Multiplex assays for IL-6, IL-8, IL-10, MCP-1, 
TNF-α, TNF-β, GRO, Eotaxin, VEGF and IP-10 are ongoing. 
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14.5. Discussion 
Our primary hypothesis was that genetic variation within the RAGE axis would influence 
clinical outcomes from snCPB, particularly duration of requirement for level 3 care; a more 
specific marker than ICU LOS. Accordingly, SNPs were identified in the RAGE, S100A8 and 
HMGB1 genes. Furthermore, the DNA of a large cohort of snCPB patients was genotyped 
using SSP-PCR. The distribution of studied genotypes was found to be consistent with those 
reported in the Hapmap database. However, none of the genetic variations studied showed 
statistically significant relationships to prolonged duration of ICU or hospital stay. 
Nonetheless, there were notable relationships found between the RAGE and S100A8 SNPs 
with other end-points, which will be discussed.  
Before discussing the positive findings it is important to explain why we should not accept 
the null hypothesis – that there is no relationship between genetic variation in the RAGE 
axis and outcome from snCPB. This study did not recruit sufficient numbers of patients to be 
adequately powered to confidently accept or reject the null hypothesis. This shortcoming is 
common in such trials, with the majority of trials assessing genetic variation in inflammatory 
genes and their effect on outcomes from sepsis recruiting no more than 200 patients [215]. 
Of the SNPs studied here, the G82S variant of RAGE was arguably the most likely to have an 
association with clinical outcome given the repeated associations of G82S genotype with 
plasma sRAGE levels and predisposition to inflammatory conditions. Unfortunately, as in 
other studies, the low prevalence (5%) of the minor allele of the G82S SNP might have 
compounded the effect of small sample size [722]. The duration of requirement for level 3 
care reflect the extent of respiratory, cardiovascular, neurological and renal dysfunction and 
the effects of variation in one inflammatory pathway would have to be very large to 
significantly influence this. As the extent of the effect is likely to be small, a very large 
sample size would be required. For example, it has been estimated that for a study assessing 
the influence of candidate SNP on outcome from septic shock to be suitably powered it 
would need to recruit 2000 patients [216]. 
14.5.1. RAGE 
Polymorphisms in the RAGE gene were related to differences in systemic inflammation, as 
assessed by neutrophil count and CRP (Figures 102-104). Being heterozygous for the 
293 
 
functional RAGE G82S minor allele (genotype AG) was associated with lower neutrophil 
counts post-operatively, reaching statistical significance at day 2 post-operatively. No 
patients were homozygous for the minor allele of G82S.  
The RAGE G82S SNP (rs2070600) has a common and a minor variant; the later is associated 
with a change in amino acid glycine to serine within the ligand-binding domain of RAGE. The 
82Serine variant is associated with enhanced ligand affinity and up-regulated RAGE 
signalling with hyper-responsiveness to S100A12 resulting in increased pro-inflammatory 
signalling and cytokine secretion in monocytes [265]. Carriage of this minor allele has been 
associated with increased risk of type 2 diabetes, development of nephropathy in patients 
with existing diabetes and retinopathy, and increased risk of rheumatoid arthritis; as well as 
relatively lower levels of plasma sRAGE in several populations [256, 260, 265, 267, 268].  
The association between carriage of G82S SNP with lower neutrophil count was therefore 
unexpected. As the G82S minor variant has been associated with increased inflammatory 
signalling, the development of RAGE-mediated complications and low sRAGE levels, we 
might have expected an association with increased inflammatory markers. Neutrophilia 
reflects increased neutrophil formation as well as prolonged lifespan from delayed 
apoptosis, a mechanism proposed to mediate tissue damage in systemic inflammation. The 
relatively less elevated neutrophil counts associated with the G82S SNP following snCPB 
may reflect a diminished response.  
The crucial question when interpreting these data is; to what extent does neutrophilia vary 
in proportion to inflammation? Extent of leukocytosis (or neutrophilia) has not been 
assessed in isolation in relation to outcome from systemic inflammation but is an integral 
part of prognostic severity of illness scores such as APACHE II [518]. On a population basis 
there may be a strong relationship between leukocytosis and outcome but in individuals, a 
higher WBC does not necessarily indicate a more severe infection. Indeed the SIRS criteria 
have high, or low, WBC as defining criteria. Furthermore, very high WBC counts are more 
likely to be due to non-infectious or inflammatory conditions [723]. 
Those who were homozygous for the minor allele for the RAGE promoter region SNP (-374) 
had a lower CRP at day 1 post-operatively but not on other days (Figure 104). This SNP has 
been associated with increased transcriptional activity of the RAGE gene and with the 
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abolition of a nuclear protein binding site, the functional significance of which is unclear 
[255].  
The physiological delay of 24-36h between inflammatory stimulus and peak concentration 
of CRP means that the levels on post-operative day 1 may represent the best indicator of 
initial inflammatory response to surgery. Levels of plasma CRP do not necessarily correlate 
with RAGE ligands such as S100A8/9 [724] and therefore the RAGE axis might function in 
parallel and independently to the inflammatory axis reflected in CRP levels. The lack of 
relationship between CRP and neutrophil count during the first 24h and either the vital 
outcome or ICU LOS demonstrated in Section 10.5.6, suggests that they are not the optimal 
variables to be used as a measure of systemic inflammation. Studies of the predictive value 
of CRP for adverse outcome in patients with systemic inflammation suggest that isolated 
measurements have some value but are inferior to serial measurements [648].  
Plasma sRAGE levels has been reported to be lower in healthy subjects carrying the minor 
allelic variants at G82S and although the levels were lower both pre- and post- operatively in 
these patients, these differences were not statistically significant (Figure 108). It is possible 
that the association between G82S and lower sRAGE levels and lower WBC counts are 
related but this requires further investigation. 
The small numbers of patients who were carriers of the minor variants combined with a 
large degree of variability of sRAGE values post-operatively might have contributed towards 
the lack of statistical significance. There were no associations between SNPs in the RAGE 
gene and post-operative pulmonary function or duration of ventilation.  
14.5.2. S100A8 and HMGB1 
Polymorphisms in the S100A8 gene were related to differences in pulmonary and renal 
dysfunction. The minor allelic variants of the S100A8 genes were consistently associated 
with impaired oxygenation as assessed by PFR and A-a difference, becoming statistically 
significant on day 3 post-operatively. There were no significant differences between the 
measured levels of S100A8/9 either pre- or post-operatively between the genotypes. 
The S100A8 SNPs are in strong LD and can be considered together. Neither are in coding 
regions of the S100A8 gene with rs3806232 lying in the promoter region and rs3795391 in 
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an intron, yet they may still exert influence over gene function (Section 2.4). There are no 
studies of these SNPs in Caucasian populations and the associations from other populations 
(Chinese [270]) may not be valid in Caucasians. These SNPs were chosen as the only SNPs in 
the S100A8 gene with association with an inflammatory condition, albeit the minor allele 
with reduced incidence of aggressive periodontitis. The reported study included small 
numbers of patients, did not report power calculations, made multiple comparisons without 
appropriately statistical correction and the findings are yet to be replicated. Given the lack 
of robust data to suggest whether the S100A8 minor allele was associated with greater or 
lesser inflammatory activity, we had no expectations regarding any associations between 
carriage of the minor allele and outcomes following snCPB.  
Post-snCPB oxygenation impairment is multi-factorial and includes non-inflammatory 
sequalae such as cardiogenic pulmonary oedema, bronchospasm and pleural collections. 
However, snCPB induces lung inflammation on a spectrum from subclinical lung injury to 
ARDS [725, 726]. The chosen measures of oxygenation are both accepted and clinically 
useful but are interrelated. PFR reflects extent of hypoxaemia for a given concentration of 
inspired oxygen and the alveolar-arterial oxygen difference indicates the severity of 
impairment of the alveolar membrane function. A potentially superior measure would have 
been the ‘oxygenation index’ – a measure of oxygenation impairment that is specific for 
ventilated patients as it incorporates the mean airway pressure, which broadly reflects how 
much effort is being put into ventilation [727].  
During the successive days following snCPB, an increasing proportion of patients have 
recovered sufficiently to be extubated and discharged from the ICU; such patients do not 
have oxygenation data and were not represented within the analysis. The difference in 
oxygenation by genotype only reached significance by post-operative day 3, when the 
numbers in the groups had significantly decreased (26 vs. 10 carrying the minor allele). The 
mean incidence of ARDS post-snCPB is 5 days, therefore the differences in oxygenation at 
these later times might relate more to the influence of inflammatory responses than during 
the earlier times [726]. Perhaps the most clinically significant measure of pulmonary 
dysfunction is duration of mechanical ventilation and there was no statistically significant 
difference in this measure between the genotypes. 
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There was an association between minor allelic variants of the S100A8 genes and a higher 
incidence of acute kidney injury (AKI) of stage 2 or worse in the first week (an increase of 
200-300% in serum creatinine). AKI following snCPB is associated with increased mortality, 
even if it does not require renal replacement therapy [728, 729]. Indeed, AKI complicating 
admission to ICU for any cause is associated with adverse outcome in proportion to stage 
[52, 730]. The main contributory determinants of AKI post-snCPB are cellular ischaemia and 
systemic inflammation. Furthermore, S100A6 and S100B have been implicated in the 
pathogenesis of experimental AKI [731]. 
The minor alleles of these S100A8 SNPs are associated with impaired oxygenation following 
snCPB and we hypothesise that this could be due to increased pulmonary inflammation due 
to altered S100A8/9-mediated effects. Although plasma levels did not vary (Figure 112), 
pulmonary levels (perhaps via broncho-alveolar lavage, BAL sampling) may have. Similarly, 
the increased risk of AKI may relate to aberrant inflammatory signalling within the injured 
kidney.  
No associations were found between the HMGB1 SNP studied (rs1060348) and clinical 
outcomes. This is likely to be due to the low prevalence of the minor variants of this SNP 
within the cohort, with only 6 heterozygous and no homozygous. The SNP is in a coding 
region (exon 4) but not associated with a change in the protein structure. However, it is in 
close LD with a SNP in the promoter region (−1615 A/G SNP, 1412125)[717] and despite not 
being a known binding or splice site, may affect transcriptional activity of HMGB1. The 
minor allele of the HMGB1 SNP has been associated with increased number of SIRS criteria, 
greater organ failure and impaired oxygenation in 239 patients on an adult ICU. In the same 
study a promoter variant (-1377delA) was associated with inferior longer-term (4y) 
outcome. 
There are significant limitations to genetic association studies (Section 2.4.1) and of 
particular relevance to these investigations are those that stem from a small sample size, 
such as risk of type  and II errors. 
14.5.3. Future work 
In order to avoid false positive associations and falsely accept the null hypothesis a 
significantly larger sample size would be necessary. To facilitate this, the study could be 
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extended to all types of major surgery. Studying patients at higher-risk for the development 
of organ dysfunction, such as those with diabetes, chronic kidney injury and of increased 
age might increase the sensitivity of the study. Using more sensitive markers of organ 
dysfunction would also be advantageous. In order to ascertain the role of the S100 proteins 
in pulmonary and renal inflammation during and following snCPB, acquisition of clinical 
samples such as BAL and urine would be informative. 
Alternatively the systemic inflammatory response to infection could be studied in patients 
with sepsis, perhaps in a cohort similar to the GenoSept study. This International study has 
recruited patients with sepsis and septic shock from across Europe and intends to identify 
novel candidate genes which are then used in genetic association epidemiological studies of 
sepsis related adverse outcomes [732].  
The SNPs considered in this study were selected from a far larger range of possibilities and 
we were restricted by our choice of genotyping technology (SSP-PCR). Given the 
opportunity, further SNPs of the RAGE, S100A8 and HMGB1 genes could have been 
assessed, in addition to SNPs in the genes for S100A12, and S100B. 
14.6. Conclusion 
Genetic association studies have the potential to offer valuable insights into pathogenesis of 
diseases states. However, for the findings to be reliable and reproducible the studies need 
to be large. The risks of false positive associations and accepting the null hypothesis are 
significant and cannot be overlooked.  
The complexities of the immune response to injury should not be underestimated and for a 
study of this size, even if a genetic variation has a potent and profound effect within the 
pathway of interest, it is hard to demonstrate. This is particularly the case when the 
outcome is a clinical outcome such as duration of requirement for intensive care that 
reflects many processes, of which only a proportion will relate to extent of systemic 
inflammatory response. 
The role of genetic variation in the RAGE axis in clinical response to acute inflammatory 
insult, such as snCPB, is an unexplored area, as are the functional significance of many of the 
SNPs studied. The associations identified within this study are supportive of the hypothesis 
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that the RAGE axis is important in determining extent of systemic inflammatory response 
and may play an important role in the development of organ dysfunction.   
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Concluding remarks 
Summary of results 
The relationship between systemic inflammation following snCPB and the age of the patient 
had not been previously investigated. Extent of systemic inflammation was assessed using 
C-reactive protein, neutrophil count and the number of SIRS-defining criteria fulfilled within 
the first hour or first 24h. Extent of organ dysfunction was assessed with the SOFA score and 
ICU LOS was used as a surrogate of severity of illness. The largest patient group was those 
who underwent CABG, and also represents the most homogeneous surgical category. In this 
surgical category, the mean number of SIRS-defining criteria was significantly higher in the 
>80y group compared with the 40-60y or 60-80y groups both in the first hour and the first 
24h. Similarly, the SOFA score and ICU LOS were significantly higher in the >80y group 
compared with the 40-60y or 60-80y groups. However, these markers of increased systemic 
inflammation, organ dysfunction and severity of illness were not reflected in higher CRP or 
WBC; in fact, these were significantly lower in the >80y group than the younger groups. 
These incongruous findings may be reconciled either through acknowledgement that CRP 
and WBC within the first 24h do not represent a genuine reflection of systemic 
inflammatory state; or that SIRS criteria, SOFA score and ICU LOS are higher in the oldest 
group through mechanisms that are independent of systemic inflammation. However, 
considering all the patients who had snCPB, the maximum number of SIRS criteria in the first 
24h and the SOFA score were demonstrated to be independently associated with risk of 
mortality and prolonged ICU LOS, itself an undesirable outcome. This clearly supports the 
paradigm of excessively severe systemic inflammatory responses contributing towards 
organ failure and death. 
To what extent might the RAGE-axis participate in, determine the extent of, and outcome 
from, the acute systemic inflammatory response? RAGE ligands are damage-associated 
molecular pattern (DAMP) biomolecules and are released during tissue injury, such as occur 
during snCPB. The release of some RAGE ligands following snCPB has been reported by 
others in small series without detailed comparison to clinical characteristics [661, 663-666]. 
Soluble RAGE levels in plasma have been demonstrated to be elevated in patients with 
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acute systemic inflammatory conditions and were recently reported in a small cohort of 
patients following snCPB [457]. However, reports have not featured paired assays of sRAGE 
with esRAGE, have not studied large groups of patients and have not measured levels of 
sRAGE during CPB. We demonstrated significant elevations in plasma levels of S100B, 
S100A8/9, S100A12, HMGB1 and CML-albumin, with a strong relationship between severity 
of surgical injury (duration of CPB) and extent of S100 protein release – supporting the 
concept of surgery and CPB resulting in release of RAGE ligands. sRAGE plasma levels bore a 
strikingly consistent relationship to esRAGE levels – casting doubt on the prevailing 
understanding of differential regulation. The maximal extent of sRAGE abundance in the 
plasma was observed during CPB, a time when the lungs are solely dependent on the 
bronchial circulation for perfusion – casting doubt on the current dogma of the pulmonary 
alveoli representing the predominant source of sRAGE in the circulation. In the chronic 
state, plasma sRAGE levels may reflect extent of RAGE-mediated signalling and thereby 
propensity to RAGE-mediated inflammation. Thus, in patients prior to snCPB the levels were 
found to have a robust relationship to duration of requirement of intensive care post-snCPB. 
Plasma sRAGE could represent a biomarker for systemic inflammatory response to tissue 
injury and as such, could offer advantages over current methods of risk stratification for 
patients presenting for major elective surgery. 
Having demonstrated elevations of RAGE ligands and soluble RAGE in the plasma following 
snCPB we sought to determine the expression of leukocyte RAGE expression both at the 
level of transcription and protein. Membrane-bound RAGE on circulating leukocytes could 
represent a more direct assay of pro-inflammatory RAGE-axis activity. Development of a 
reproducible method for the quantitative assay of RAGE on live leukocyte populations of 
whole blood was facilitated by collaboration with a group with an established protocol. The 
extent of RAGE expression on neutrophils was shown to decrease following snCPB. Extent of 
intracellular RAGE expression was high relative to membrane expression, but was not 
demonstrated to significantly alter following snCPB. Change in expression of RAGE when 
measured at the level of transcription, and in relation to the expression of reference genes, 
was non-significantly increased in neutrophils, monocytes and buffy coat when comparing 
post-snCPB to pre-snCPB. Together these findings indicate that snCPB affects the regulation 
of leukocyte RAGE. It seems probable that RAGE ligands up-regulate RAGE expression and 
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following RAGE protein expression on the cell surface, there is cleavage of the extracellular 
domain resulting in increased sRAGE levels paired with decreased RAGE on leukocytes. 
To investigate the effects of RAGE ligands on leukocyte inflammatory responses and how 
snCPB may alter these, samples were obtained from healthy volunteers and patients for ex 
vivo experiments. Stimulation of both whole blood and isolated neutrophils with S100B and 
S100A12 resulted in a concentration-dependent release of the archetypal chemokine IL-8. 
We were unable to demonstrate pro-inflammatory responses or augmentation of such 
responses with HMGB1. Pre-incubation of either the cells or the ligands with either a 
recombinant sRAGE protein or an experimental analogue (TTP-4000) was not associated 
with any diminution of cytokine release. Similarly, use of anti-S100B or anti-RAGE antibodies 
was not associated with diminution of cytokine release. Endotoxin tolerance has been 
reported to occur following snCPB and in addition to replicating this phenomenon we 
demonstrated tolerance to S100B. Identical stimulation of whole blood obtained post- 
versus pre-snCPB with S100B resulted in significantly lower release of the pro-inflammatory 
cytokines IL-1β, IL-6, IL-8, and TNF-α.  
Genetic variation in the genes of the inflammatory response has been associated with 
altered levels of pro-inflammatory cytokines and adverse clinical outcomes following snCPB. 
Although the RAGE gene has been studied in relation to development of diabetes and its 
complications, there had been no studies in acute critical illness. In order to investigate the 
hypothesis that genetic variation within the RAGE axis would influence clinical outcomes 
from snCPB, the DNA of a large cohort of snCPB patients was genotyped for genes of the 
RAGE axis using SSP-PCR. Of the studied genetic variations in the genes for RAGE, S100A8 
and HMGB1 there were no significant associations with prolonged duration of ICU or 
hospital stay. Unfortunately, the study did not recruit sufficient numbers of patients to be 
adequately powered to confidently accept or reject the null hypothesis and therefore we 
cannot conclude that there is no relationship between genetic variation in the RAGE axis 
and outcome from snCPB. Carriage of the G82S SNP within the RAGE gene was associated 
with lower neutrophil counts post-operatively than the common variant. Homozygous 
carriage of minor variant of the promoter -374 of the RAGE gene was associated with a 
lower CRP on the first post-operative day. The clinical significance of these relationships is 
uncertain. The association between the minor variant of an S100A8 SNP with impaired 
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oxygenation and acute kidney injury post-snCPB could indicate the influence of RAGE-
mediated inflammation on the development of organ dysfunction. 
Clinical relevance 
Increased age predisposes to adverse outcomes from a range of acute systemic 
inflammatory conditions including snCPB. The novel finding of an association between 
number of SIRS criteria met within the first 24h and both mortality and prolonged ICU LOS 
supports the concept of systemic inflammation being an important influence on outcome. 
Immune responses are altered with advanced age but the extent to which these alterations 
are important in the evolution of acute systemic inflammation and development of 
complications remain undetermined. Similarly, the extent to which increased abundance of 
RAGE ligands and up-regulation of the RAGE axis contributes is unknown. 
RAGE ligands are elevated in the plasma following a range of acute systemic inflammatory 
conditions including snCPB, and also at sites of localised inflammation. S100 proteins and 
HMGB1 are archetypal DAMPs and, as such, are released from injured or inflamed tissues. 
The measurement of RAGE ligands as biomarkers of specific tissue injury or inflammation 
has entered clinical practice with varying degrees of adoption: S100B has yet to become a 
standard of care in brain injury [733], S100A8/9 has a well recognised role in inflammatory 
bowel disease [734], and use of plasma S100A12 assays remains highly specialised in some 
arthritides and auto-immune diseases [735].  
The measurement of sRAGE has been proposed as a marker of acute lung injury and several 
studies have reported its use in this context [454, 459, 482]. Close correlations between 
physiological and radiographic markers of ALI with sRAGE levels, combined with ex vivo 
experimental data from human lungs, provides particularly compelling evidence for the role 
of sRAGE as a marker of alveolar damage [454, 489]. Major limitations include the lack of 
specificity and the differences in measured values between control populations [294, 454].  
The novel finding of a statistically significant relationship between pre-snCPB plasma levels 
of sRAGE and prolonged duration of level 3 care is potentially of great clinical significance. 
The levels of pre-snCPB sRAGE were more closely related to prolonged recovery from acute 
systemic inflammation (duration of level 3 care) and to overall hospital admission (time to 
hospital discharge) than variables including the age of the patient, a score of their operative 
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risk (Euroscore), and the duration of pulmonary/myocardial ischaemic time (component of 
total CPB time). Measurement of sRAGE pre-operatively could be incorporated into clinical 
practice, improving provision of accurate prognostic information for patients and identifying 
those requiring closer monitoring, or even those who might benefit from RAGE inhibition.  
The physiological function of sRAGE in humans remains to be determined. The meaning of 
elevated levels of sRAGE may depend upon the clinical situation. In the setting of acute 
critical illness, elevated sRAGE levels could stem from several sources including injured 
alveoli with their constitutively high levels of membrane-bound RAGE being shed, activated 
inflammatory cells up-regulating RAGE and shedding the ectodomains, and other, as yet 
unidentified sources that may include the vascular endothelium. Outside the setting of 
acute critical illness, elevated sRAGE levels probably reflect the ‘tone’ of the RAGE-axis, that 
is, the abundance of ligands and consequent activity of cellular RAGE. 
RAGE inhibition in animal models of the sepsis syndromes has been reported to improve 
outcomes including mortality. Whether this might translate into clinical benefit in patients is 
not yet known and before such trials can be seriously contemplated there are fundamental 
questions that need to be answered. Primarily, does inhibition of RAGE-mediated signalling 
reduce excessive systemic inflammation without compromising vital anti-microbial defences 
in animals that are biologically closer to humans than mice, and in models that are more 
clinically relevant than caecal ligation and puncture? For example, inhibition of RAGE in 
established models of pneumonia in pigs would potentially provide more relevant 
information [736]. It may be that RAGE inhibition does compromise microbial defences and 
the benefits of inhibition are only seen in ‘sterile’ SIRS. Therefore investigation in models of 
‘sterile’ SIRS would also be valuable; for example, use of established porcine haemorrhagic 
shock and resuscitation models of systemic inflammation [737].  
Survivors of critical illness suffer not just increased morbidity, but also increased mortality 
compared to matched controls for years following hospital discharge [738]. Indeed, severity 
of acute illness (assessed by APACHE II score) and extent of organ failure are independently 
associated with increased risk of long term mortality [738, 739]. The physiological 
mechanisms that mediate this phenomenon remain undetermined. Although it is highly 
speculative, it is possible that episodes of acute systemic inflammation cause long-standing 
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alterations in immune responses that contribute towards these observations. Up-regulation 
of the RAGE axis could participate in this, with increased ligands during inflammatory 
episodes causing widespread up-regulation of RAGE that persists after resolution of the 
acute illness. 
Future work 
To determine the influence of age of the RAGE axis it would be desirable to measure RAGE 
expression on a variety of cells and tissues from patients across a wide range of ages. In 
addition to extent of expression, the inflammatory response consequent upon RAGE ligation 
and particularly its relation to the age of the leukocyte donor would further elucidate the 
influence of age on the RAGE axis. Measurements of AGE content of tissues as well as AGE-
modified plasma proteins would be novel and informative, particularly if paired with 
measures of RAGE expression and responsiveness. 
To establish the relationship between leukocyte RAGE expression before, during and after 
snCPB to both clinical characteristics and to sRAGE levels, the work presented in Section 12 
could be continued in a larger cohort of patients. Were such observations to be paired with 
measures of soluble RAGE forms it would be possible to gain further understanding of their 
relationship. Indeed, such studies would be valuable in other populations with acute 
systemic inflammation including trauma and severe sepsis.  
To further characterise the alterations in leukocyte function consequent upon RAGE ligand 
binding we could assay chemotaxis, phagocytosis, or intracellular killing instead of cytokine 
release. Inhibition experiments could be conducted in better-characterised models such as 
alveolar epithelial cell lines (A549 [715]) or endothelial cells (HUVEC [716]) prior to the use 
of novel inhibitors such as sRAGE fragments [713]. Moving from in vitro models to in vivo 
models but with greater relevance to the human immune response, ‘humanized’ mice could 
be used to study the effects of RAGE inhibition on outcomes from experimental SIRS [740]. 
Genetic association studies require large sample sizes to have adequate power to reject the 
null hypothesis. Therefore, a far larger cohort of patients would be required to take this 
work further. One approach would be to use DNA from a biobank of previously collected 
samples, such as the previously described GenoSept study. Furthermore, use of semi-
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automated sequencing technologies instead of SSP-PCR would permit genotyping of a wider 
range of SNPs more efficiently and accurately. 
Conclusions 
These investigations provide evidence supporting the role of the RAGE axis in acute systemic 
inflammation following snCPB. The implications of these findings reach beyond the immune 
response to cardiac surgery and are likely to apply similarly to other causes of SIRS. Further 
investigations are required to gain a deeper understanding of the role of RAGE and its 
soluble form sRAGE in human inflammatory disease, prior to the evaluation of RAGE 
inhibitors in this setting. 
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Abbreviations 
A549 cells Human Type II Alveolar Epithelial Cell Line 
ABG Arterial Blood Gases 
ACCP/SCCM American College Of Chest Physicians/Society Of Critical Care  
ACE Angiotensin Converting Enzyme 
ADAM A Disintegrin And Metalloprotease 
AECC American-European Consensus Conference 
AGE Advanced Glycation End-Products 
AKI Acute Kidney Injury 
ALI Acute Lung Injury 
ANOVA  Analysis Of Variance  
AP-1 Activator Protein-1 
APACHE Acute Physiology And Chronic Health Evaluation 
ARB Angiotension Receptor Blocker 
ARDS Acute Respiratory Distress Syndrome 
BAL  Bronchoalveolar Lavage  
BALF Bronchoalveolar Lavage Fluid 
BSA Bovine Serum Albumin 
CABG Coronary Artery Bypass Graft 
CAD Coronary Artery Disease 
CARS Compensatory Anti-Inflammatory Response Syndrome 
CD Cluster Of Differentiation 
cDNA Complementary DNA 
CF  Cystic Fibrosis  
CKD Chronic Kidney Disease 
CLP Caecal Ligation And Puncture 
CML Nε Carboxymethyl-Lysine 
COPD Chronic Obstructive Pulmonary Disease 
COX Cyclo-Oxygenase 
CPB  Cardiopulmonary Bypass  
CRP C-Reactive Protein 
Ct  Cycle Threshold  
CURB Confusion, Urea, Respiratory Rate, Blood Pressure 
CV Cardiovascular 
CXR  Chest X-Ray  
D(A-a) Alveolar-Oxygen Difference 
DAMP Damage Associated Molecular Pattern 
DM Diabetes Mellitus 
DMCT Dunn’s Multiple Comparisons Test 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethyl Sulphoxide 
DNA Deoxyribo Nucleic Acid 
DNA Deoxyribonucleic Acid 
ECMO  Extracorporeal Membrane Oxygenation  
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EDTA Ethylenediaminetetraacetic Acid 
ELISA Enzyme Linked Immunosorbent Assay 
EP Ethyl Pyruvate 
ERK Extracellular Signal Related Kinase 
esRAGE Endogenous Secretory Receptor For Advanced Glycation End-Products 
FC Flow Cytometer 
FCS Fetal Calf Serum 
FEV1  Forced Expiratory Volume In 1 Second  
FiO2 Inspiratory Oxygen Fraction 
FITC Fluorescein Isothiocyanate 
FITC Fluorescein Isothiocyanate 
FSC Forward Scatter 
G-CSF Granulocyte Colony-Stimulating Factor 
h Hour 
Hb Haemoglobin 
HFOV High Frequency Oscillatory Ventilation 
HLA Human Leukocyte Antigen 
HMGB1 High Mobility Group Box 1 
HMGB1 High Mobility Group Box 1 
HRP Horse Radish Peroxidase 
HV Healthy Volunteers 
IC Isotype Control 
ICAM  Intercellular Adhesion Molecule  
ICU Intensive Care Unit 
IFN Interferon 
IKK IB Kinase 
IL  Interleukin  
IQR Interquartile Range 
JNK C-Jun N-Terminal Kinase 
KS Kolmogorov-Smirnov 
KWT Kruskal-Wallis Test 
L3C Level 3 Care 
LAL Limulus Amoebocyte Lysate  
LOS Length Of Stay 
LPS Lipopolysaccharide 
LR Logistic Regression 
mins Minutes 
Mac-1 Macrophage-1 Antigen 
MAPK Mitogen Activated Protein Kinase 
MFI Mean Fluorescence Intensity 
MHC Major Histocompatibility Complex 
MMP Membrane Metalloprotease 
MODS Multiple Organ Dysfunction Score 
mRNA Messenger Ribonucleic Acid 
MSD Meso-Scale Discovery 
MV Mechanical Ventilation 
MW Molecular Weight  
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MWU Mann Whitney U 
NF-ĸB Nuclear Factor –ĸb 
NO Nitric Oxide 
OPCAB Off-Pump Coronary Artery Bypass 
PaCO2 Arterial Carbon Dioxide Tension 
PAMP Pathogen-Associated Molecular Patterns 
PaO2 Arterial Oxygen Tension 
PBMC Peripheral Blood Mononuclear Cells 
PBS Phosphate Buffered Saline 
PEEP Positive End-Expiratory Pressure 
PFR Pao2/Fio2 Ratio 
PRR Pattern Recognition Receptor 
PS Propensity Scoring 
qRT-PCR Quantitative Real Time Reverse Transcriptase -Polymerase Chain Reaction 
RA Rheumatoid Arthritis 
RAGE Receptor For Advanced Glycation End-Products 
RBH Royal Brompton Hospital 
RCT Randomised Controlled Trial 
RNA Ribo Nucleic Acid 
ROS Reactive Oxygen Species 
RPMI Roswell Park Memorial Institute 
RRT Renal Replacement Therapy 
SAPS Simplified Acute Physiology Score 
SD Standard Deviation 
SDD Selective Digestive Decontamination 
SEM Standard Error Of The Mean 
SIRS Systemic Inflammatory Response Syndrome 
snCPB Surgery Necessitating Cardiopulmonary Bypass 
SNP Single Nucleotide Polymorphism 
SOFA Sequential Organ Failure Assessment Score 
sRAGE Soluble Receptor For Advanced Glycation End-Products 
SSC Side Scatter 
SSP Sequence Specific Primer 
TLR Toll-Like Receptor 
TNF Tumour Necrosis Factor 
TNFR Tumour Necrosis Factor Receptor 
VAD Ventricular Assist Device 
VT Tidal Volume 
WB Whole Blood  
WBC White Blood Cell Count 
WMPT Wilcoxon Matched Pairs Test 
WT Wild Type 
y Year 
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Appendix 
Patient information sheets and consent forms for the patients in cohort C (“Does albumin 
reduce inflammation following cardiac surgery and reduce length of time patients spend on 
the intensive care unit?”); followed by the information sheets and consent forms for cohort 
B ("Cardiac surgery and the effect of haem release on the development of post operative 
lung related complications (Genetic polymorphisms in lung injury)"). 
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